Implant-based O
reconstruction O
is O
performed O
in O
the O
majority O
of O
women O
offered O
primary O
reconstruction O
for O
breast O
cancer O
. O

Two O
different O
expander O
implants O
were O
compared O
prospectively O
. O

The O
primary O
endpoint O
was O
the O
number O
of O
operations O
needed O
in O
each O
group O
to O
obtain O
patient O
satisfaction O
. O

Secondary O
endpoints O
were O
evaluation O
of O
breast O
volume O
and O
shape O
and O
aspects O
of O
quality O
of O
life O
. O

Seventy O
consecutive O
breast O
cancer O
patients O
were O
randomized O
to O
either O
a O
one-stage O
reconstruction O
with O
a O
round O
permanent O
expander O
implant O
( O
Becker O
25 O
";" O
n=35 O
) O
or O
a O
two-stage O
reconstruction O
with O
a O
crescent-shaped O
expander O
( O
LV O
133 O
";" O
n=35 O
) O
, O
later O
replaced O
by O
a O
form-stable O
anatomical O
implant O
. O

Thirty O
patients O
had O
to O
be O
excluded O
and O
40 O
patients O
, O
20 O
in O
each O
group O
, O
were O
evaluated O
. O

The O
median O
follow-up O
for O
both O
groups O
was O
3.5 O
years O
( O
range O
, O
1.5 O
to O
5 O
years O
) O
. O

Plastic O
cups O
, O
plastic O
casts O
, O
and O
two O
-and O
three-dimensional O
scanning O
techniques O
were O
used O
for O
objective O
assessment O
of O
breast O
volume O
and O
shape O
. O

The O
aesthetic O
outcome O
was O
evaluated O
by O
a O
panel O
of O
experts O
and O
lay O
people O
, O
and O
by O
the O
patients O
. O

Quality O
of O
life O
was O
evaluated O
with O
a O
validated O
questionnaire O
( O
36-Item O
Short O
Form O
Health O
Survey O
) O
. O

Of B-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
one-stage I-Premise
group I-Premise
, I-Premise
70 I-Premise
percent I-Premise
had I-Premise
revision I-Premise
surgery I-Premise
, I-Premise
mostly I-Premise
because I-Premise
of I-Premise
upper I-Premise
pole I-Premise
fullness I-Premise
and I-Premise
poor I-Premise
ptosis I-Premise
. I-Premise

These O
findings O
agreed O
with O
the O
data O
from O
the O
two-dimensional O
scanning O
and O
from O
the O
expert O
panel O
and O
the O
patients O
' O
subjective O
judgment O
. O

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

The B-Claim
permanent I-Claim
expander I-Claim
method I-Claim
failed I-Claim
significantly I-Claim
as I-Claim
a I-Claim
one-stage I-Claim
procedure I-Claim
. I-Claim

The B-Claim
crescent I-Claim
two-stage I-Claim
method I-Claim
gave I-Claim
the I-Claim
most I-Claim
acceptable I-Claim
results I-Claim
both I-Claim
objectively I-Claim
and I-Claim
subjectively I-Claim
. I-Claim

To O
analyze O
the O
clinical O
course O
, O
treatment O
, O
complications O
, O
outcome O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
perineal/perianal O
rhabdomyosarcoma O
( O
PRMS O
) O
treated O
within O
the O
CWS-86 O
, O
-91 O
, O
-96 O
, O
and O
-2002P O
trials O
. O

Although O
multiple O
international O
study O
trials O
exist O
for O
the O
treatment O
of O
rhabdomyosarcoma O
, O
only O
very O
limited O
information O
is O
given O
on O
treatment O
, O
outcome O
, O
and O
QOL O
in O
PRMS O
. O

A O
total O
of O
35 O
patients O
suffering O
from O
PRMS O
were O
treated O
with O
neoadjuvant O
chemotherapy O
. O

Local O
therapy O
with O
radiation O
and/or O
surgery O
was O
performed O
, O
followed O
by O
adjuvant O
chemotherapy O
. O

Functional O
long-term O
follow-up O
was O
evaluated O
by O
a O
gastrointestinal/QOL O
survey O
. O

Thirty-two O
patients O
were O
evaluated O
( O
exclusion O
n O
= O
3 O
) O
. O

Eight O
patients O
had O
embryonal O
histology O
, O
and O
24 O
patients O
had O
alveolar O
histology O
. O

The O
median O
age O
was O
108 O
months O
( O
median O
follow-up O
: O
5.8 O
years O
) O
. O

The O
5-year O
overall O
survival O
was O
47 O
% O
( O
95 O
% O
confidence O
interval O
: O
29-64 O
) O
. O

Sixteen O
IRS O
( O
Intergroup O
Rhabdomyosarcoma O
Study O
) O
III O
and O
IV O
patients O
had O
locoregional O
lymph O
node O
involvement O
at O
diagnosis O
. O

Seven O
patients O
were O
treated O
with O
chemotherapy/surgery O
alone O
[ O
5-year O
event-free O
survival O
( O
EFS O
) O
: O
85.7 O
% O
] O
. O

Eleven O
patients O
received O
only O
radiochemotherapy O
( O
5-year O
EFS O
: O
27.3 O
% O
) O
. O

Combined O
radiochemotherapy/surgery O
was O
used O
in O
12 O
patients O
( O
5-year O
EFS O
: O
63.6 O
% O
) O
. O

Two O
patients O
were O
treated O
only O
with O
chemotherapy O
and O
they O
died O
. O

Patients B-Premise
with I-Premise
embryonal I-Premise
histology I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
5-year I-Premise
EFS I-Premise
( I-Premise
87.5 I-Premise
% I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
alveolar I-Premise
histology I-Premise
( I-Premise
39.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Some B-Premise
patients I-Premise
reported I-Premise
symptoms I-Premise
of I-Premise
fecal I-Premise
incontinence I-Premise
. I-Premise

The B-Premise
median I-Premise
Wexner I-Premise
fecal I-Premise
incontinence I-Premise
score I-Premise
was I-Premise
9 I-Premise
( I-Premise
possible I-Premise
range I-Premise
: I-Premise
0-20 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
median I-Premise
QOL I-Premise
score I-Premise
was I-Premise
90.5 I-Premise
( I-Premise
applicable I-Premise
range I-Premise
: I-Premise
0-144 I-Premise
) I-Premise
. I-Premise

The B-Claim
outcome I-Claim
of I-Claim
these I-Claim
patients I-Claim
remains I-Claim
unsatisfactory I-Claim
. I-Claim

Prognostic B-Premise
factors I-Premise
for I-Premise
a I-Premise
favorable I-Premise
outcome I-Premise
are I-Premise
tumor I-Premise
size I-Premise
of I-Premise
smaller I-Premise
than I-Premise
5 I-Premise
cm I-Premise
, I-Premise
negative I-Premise
locoregional I-Premise
lymph I-Premise
nodes I-Premise
, I-Premise
age I-Premise
less I-Premise
than I-Premise
10 I-Premise
years I-Premise
, I-Premise
low I-Premise
IRS I-Premise
group I-Premise
, I-Premise
and I-Premise
embryonal I-Premise
histology I-Premise
. I-Premise

Fecal B-Claim
incontinence I-Claim
seems I-Claim
to I-Claim
be I-Claim
a I-Claim
problem I-Claim
. I-Claim

Phase B-Claim
II I-Claim
and I-Claim
III I-Claim
studies I-Claim
have I-Claim
shown I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
interleukin-2 I-Claim
( I-Claim
IL-2 I-Claim
) I-Claim
and I-Claim
interferon I-Claim
alpha-2b I-Claim
( I-Claim
IFN I-Claim
alpha-2b I-Claim
) I-Claim
in I-Claim
multiagent I-Claim
chemotherapy I-Claim
( I-Claim
CT I-Claim
) I-Claim
for I-Claim
advanced I-Claim
melanoma I-Claim
increases I-Claim
overall I-Claim
response I-Claim
( I-Claim
OR I-Claim
) I-Claim
, I-Claim
albeit I-Claim
without I-Claim
clear I-Claim
evidence I-Claim
of I-Claim
an I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
survival I-Claim
( I-Claim
OS I-Claim
) I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
high-dose I-Claim
IL-2 I-Claim
can I-Claim
cause I-Claim
severe I-Claim
toxicity I-Claim
and I-Claim
is I-Claim
normally I-Claim
administered I-Claim
in I-Claim
an I-Claim
inpatient I-Claim
setting I-Claim
. I-Claim

We O
conducted O
a O
multicenter O
prospective O
randomized O
clinical O
trial O
in O
outpatients O
with O
metastatic O
melanoma O
to O
compare O
CT O
with O
biochemotherapy O
( O
bioCT O
) O
using O
immunomodulant O
doses O
of O
IL-2 O
and O
IFN O
alpha-2b O
. O

One O
hundred O
seventy-six O
eligible O
patients O
with O
advanced O
melanoma O
were O
randomized O
to O
receive O
CT O
( O
cisplatin O
and O
dacarbazine O
with O
or O
without O
carmustine O
every O
21 O
days O
) O
or O
bioCT O
comprising O
the O
same O
CT O
regimen O
followed O
by O
low-dose O
subcutaneous O
IL-2 O
for O
8 O
days O
and O
IFN O
alpha-2b O
three O
times O
a O
week O
, O
both O
for O
six O
cycles O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
18 I-Premise
( I-Premise
CT I-Premise
) I-Premise
and I-Premise
16 I-Premise
( I-Premise
bioCT I-Premise
) I-Premise
months I-Premise
, I-Premise
median I-Premise
OS I-Premise
was I-Premise
9.5 I-Premise
versus I-Premise
11.0 I-Premise
months I-Premise
( I-Premise
P I-Premise
=.51 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
89 I-Premise
CT-arm I-Premise
patients I-Premise
, I-Premise
18 I-Premise
ORs I-Premise
( I-Premise
20.2 I-Premise
% I-Premise
) I-Premise
( I-Premise
three I-Premise
complete I-Premise
responders I-Premise
[ I-Premise
CRs I-Premise
] I-Premise
and I-Premise
15 I-Premise
partial I-Premise
responders I-Premise
[ I-Premise
PRs I-Premise
] I-Premise
) I-Premise
were I-Premise
observed I-Premise
according I-Premise
to I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
criteria I-Premise
. I-Premise

In B-Premise
the I-Premise
87 I-Premise
bioCT-arm I-Premise
patients I-Premise
, I-Premise
22 I-Premise
ORs I-Premise
( I-Premise
25.3 I-Premise
% I-Premise
) I-Premise
( I-Premise
three I-Premise
CRs I-Premise
and I-Premise
19 I-Premise
PRs I-Premise
) I-Premise
( I-Premise
P I-Premise
=.70 I-Premise
) I-Premise
were I-Premise
recorded I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
fairly I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
low-dose I-Claim
immunotherapy I-Claim
did I-Claim
not I-Claim
produce I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
advantage I-Claim
in I-Claim
OS I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
or I-Claim
OR I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
11-month I-Claim
median I-Claim
OS I-Claim
in I-Claim
the I-Claim
bioCT I-Claim
arm I-Claim
does I-Claim
not I-Claim
differ I-Claim
greatly I-Claim
from I-Claim
the I-Claim
best I-Claim
results I-Claim
with I-Claim
high-dose I-Claim
IL-2-containing I-Claim
regimens I-Claim
reported I-Claim
in I-Claim
the I-Claim
literature I-Claim
. I-Claim

Furthermore O
, O
our B-Claim
treatment I-Claim
schedule I-Claim
was I-Claim
carried I-Claim
out I-Claim
on I-Claim
outpatients I-Claim
and I-Claim
had I-Claim
an I-Claim
acceptable I-Claim
level I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

SIR-Spheres O
are O
radioactive O
yttrium90 O
microspheres O
( O
SIR-Spheres O
, O
Sirtex O
Medical O
Limited O
, O
Australia O
) O
used O
to O
selectively O
target O
high O
levels O
of O
ionising O
radiation O
to O
tumors O
within O
the O
liver O
. O

This O
trial O
was O
designed O
to O
measure O
any O
increased O
patient O
benefit O
by O
adding O
a O
single O
administration O
of O
SIR-Spheres O
to O
a O
regimen O
of O
regional O
hepatic O
artery O
chemotherapy O
( O
HAC O
) O
administered O
as O
a O
12 O
day O
infusion O
of O
floxuridine O
and O
repeated O
at O
monthly O
intervals O
, O
vs. O
the O
same O
chemotherapy O
alone O
. O

A O
phase O
III O
randomised O
clinical O
trial O
entering O
74 O
patients O
was O
undertaken O
on O
patients O
with O
bi-lobar O
non-resectable O
liver O
metastases O
from O
primary O
adenocarcinoma O
of O
the O
large O
bowel O
. O

Patient O
benefit O
criteria O
assessed O
in O
the O
trial O
were O
tumor O
response O
, O
time O
to O
disease O
progression O
in O
the O
liver O
, O
overall O
survival O
, O
quality O
of O
life O
, O
and O
treatment O
related O
toxicity O
. O

Tumor O
response O
was O
measured O
by O
serial O
changes O
in O
both O
cross-sectional O
tumor O
areas O
and O
total O
tumor O
volumes O
, O
provided O
any O
response O
lasted O
not O
less O
than O
three O
months O
as O
well O
as O
changes O
in O
serum O
carcino-embryonic O
antigen O
( O
CEA O
) O
. O

The B-Premise
partial I-Premise
and I-Premise
complete I-Premise
response I-Premise
rate I-Premise
( I-Premise
PR I-Premise
+ I-Premise
CR I-Premise
) I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
when I-Premise
measured I-Premise
by I-Premise
tumor I-Premise
areas I-Premise
( I-Premise
44 I-Premise
% I-Premise
) I-Premise
vs. I-Premise
17.6 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
tumor I-Premise
volumes I-Premise
( I-Premise
50 I-Premise
% I-Premise
vs. I-Premise
24 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
and I-Premise
CEA I-Premise
( I-Premise
72 I-Premise
% I-Premise
vs. I-Premise
47 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
in I-Premise
the I-Premise
liver I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
in I-Premise
comparison I-Premise
to I-Premise
patients I-Premise
receiving I-Premise
HAC I-Premise
alone I-Premise
when I-Premise
measured I-Premise
by I-Premise
either I-Premise
tumor I-Premise
areas I-Premise
( I-Premise
9.7 I-Premise
vs. I-Premise
15.9 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
tumor I-Premise
volumes I-Premise
( I-Premise
7.6 I-Premise
vs. I-Premise
12.0 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
or I-Premise
CEA I-Premise
( I-Premise
5.7 I-Premise
vs. I-Premise
6.7 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
. I-Premise

The B-Premise
one I-Premise
, I-Premise
two I-Premise
, I-Premise
three I-Premise
and I-Premise
five-year I-Premise
survival I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
was I-Premise
72 I-Premise
% I-Premise
, I-Premise
39 I-Premise
% I-Premise
, I-Premise
17 I-Premise
% I-Premise
and I-Premise
3.5 I-Premise
% I-Premise
, I-Premise
compared I-Premise
to I-Premise
68 I-Premise
% I-Premise
, I-Premise
29 I-Premise
% I-Premise
, I-Premise
6.5 I-Premise
% I-Premise
and I-Premise
0 I-Premise
% I-Premise
for I-Premise
HAC I-Premise
alone I-Premise
. I-Premise

Cox B-Premise
regression I-Premise
analysis I-Premise
suggests I-Premise
an I-Premise
improvement I-Premise
in I-Premise
survival I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
SIR-Spheres I-Premise
who I-Premise
survive I-Premise
more I-Premise
than I-Premise
15 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
increase I-Premise
in I-Premise
grade I-Premise
3-4 I-Premise
treatment I-Premise
related I-Premise
toxicity I-Premise
and I-Premise
no I-Premise
loss I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
SIR-Spheres I-Premise
in I-Premise
comparison I-Premise
to I-Premise
patients I-Premise
receiving I-Premise
HAC I-Premise
alone I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
a I-Claim
single I-Claim
injection I-Claim
of I-Claim
SIR-Spheres I-Claim
plus I-Claim
HAC I-Claim
is I-Claim
substantially I-Claim
more I-Claim
effective I-Claim
in I-Claim
increasing I-Claim
tumor I-Claim
responses I-Claim
and I-Claim
progression I-Claim
free I-Claim
survival I-Claim
than I-Claim
the I-Claim
same I-Claim
regimen I-Claim
of I-Claim
HAC I-Claim
alone I-Claim
. I-Claim

The O
purpose O
of O
the O
study O
was O
to O
assess O
response O
rate O
, O
clinical O
outcome O
, O
organ/function O
preservation O
and O
toxicity O
in O
head O
and O
neck O
cancer O
patients O
treated O
with O
induction O
chemotherapy O
followed O
by O
concomitant O
chemoradiotherapy O
and O
, O
when O
necessary O
, O
limited O
surgery O
. O

The O
study O
design O
was O
a O
phase O
II O
non-randomized O
trial O
in O
hospitalized O
patients O
setting O
. O

The O
treatment O
plan O
consisted O
of O
3 O
cycles O
of O
induction O
chemotherapy O
with O
cisplatin O
, O
fluorouracil O
( O
5-FU O
) O
, O
l-leucovorin O
and O
interferon O
alpha2b O
( O
PFL-IFN O
) O
followed O
by O
7 O
cycles O
of O
5-FU O
, O
hydroxyurea O
and O
concomitant O
radiation O
for O
5 O
days O
( O
FHX O
) O
for O
a O
total O
radiation O
dose O
of O
70 O
Gy O
. O

13 O
Cis-retinoic O
acid O
was O
added O
to O
treatment O
regimen O
for O
chemoprevention O
and O
a O
systematic O
prophylaxis O
of O
mucositis O
was O
administered O
to O
all O
patients O
during O
FHX O
. O

Conservative O
surgical O
resection O
was O
reserved O
to O
patients O
with O
no O
optimal O
response O
( O
PR O
> O
or O
70 O
% O
) O
, O
whereas O
radical O
surgery O
was O
performed O
as O
salvage O
treatment O
. O

Twenty-six O
patients O
were O
treated O
at O
one O
institution O
: O
more O
than O
90 O
% O
had O
stage O
IV O
disease O
and O
only O
19.2 O
% O
had O
laryngeal O
cancer O
. O

Eighty-one O
percent O
of O
patients O
had O
performance O
status O
0 O
and O
23.1 O
% O
of O
patients O
had O
> O
5 O
% O
weight O
loss O
at O
the O
start O
of O
treatment O
. O

Nineteen O
patients O
were O
analyzed O
for O
response O
to O
PFL-IFN O
: O
3/19 O
( O
15.8 O
% O
) O
patients O
achieved O
a O
CR O
and O
7/19 O
( O
36.8 O
% O
) O
achieved O
a O
PR O
for O
an O
ORR O
of O
52.6 O
% O
. O

FHX O
was O
administered O
on O
protocol O
to O
12 O
patients O
: O
6 O
patients O
( O
50 O
% O
) O
had O
CR O
, O
1 O
patient O
( O
8.3 O
% O
) O
had O
PR O
for O
an O
ORR O
of O
58.3 O
% O
, O
2 O
patients O
( O
16.7 O
% O
) O
had O
SD O
and O
3 O
patients O
( O
25 O
% O
) O
had O
PD O
. O

At O
the O
completion O
of O
FHX O
, O
no O
patient O
underwent O
local O
therapy O
according O
to O
treatment O
plan O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
13.5 I-Premise
months I-Premise
( I-Premise
range I-Premise
1-28+ I-Premise
) I-Premise
at I-Premise
June I-Premise
2001 I-Premise
, I-Premise
among I-Premise
26 I-Premise
patients I-Premise
enrolled I-Premise
12 I-Premise
( I-Premise
46.1 I-Premise
% I-Premise
) I-Premise
were I-Premise
still I-Premise
alive I-Premise
and I-Premise
9 I-Premise
( I-Premise
75 I-Premise
% I-Premise
) I-Premise
of I-Premise
them I-Premise
were I-Premise
progression-free I-Premise
. I-Premise

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
9 I-Premise
months I-Premise
( I-Premise
range I-Premise
0-25+ I-Premise
) I-Premise
, I-Premise
the I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
10.5 I-Premise
months I-Premise
( I-Premise
range I-Premise
0-28+ I-Premise
) I-Premise
, I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
was I-Premise
9 I-Premise
months I-Premise
( I-Premise
range I-Premise
1-22 I-Premise
) I-Premise
. I-Premise

The B-Premise
toxicity I-Premise
was I-Premise
significant I-Premise
and I-Premise
consisted I-Premise
mainly I-Premise
of I-Premise
mucositis I-Premise
and I-Premise
, I-Premise
to I-Premise
a I-Premise
lesser I-Premise
extent I-Premise
, I-Premise
neutropenia/thrombocytopenia I-Premise
. I-Premise

In O
the O
present O
study O
, O
the B-Claim
low I-Claim
serum I-Claim
levels I-Claim
of I-Claim
leptin I-Claim
and I-Claim
the I-Claim
high I-Claim
serum I-Claim
levels I-Claim
of I-Claim
proinflammatory I-Claim
cytokines I-Claim
in I-Claim
advanced I-Claim
stage I-Claim
cancer I-Claim
patients I-Claim
were I-Claim
confirmed I-Claim
. I-Claim

In O
conclusion O
, O
this B-Claim
sequential I-Claim
induction I-Claim
chemotherapy I-Claim
and I-Claim
chemoradiotherapy I-Claim
program I-Claim
has I-Claim
been I-Claim
found I-Claim
moderately I-Claim
active I-Claim
and I-Claim
significantly I-Claim
toxic I-Claim
";" I-Claim
moreover O
, O
the O
long O
overall O
treatment O
duration O
must O
be O
taken O
into O
consideration O
. O

For O
these O
reasons O
, O
this B-Claim
regimen I-Claim
could I-Claim
not I-Claim
be I-Claim
recommended I-Claim
for I-Claim
a I-Claim
phase I-Claim
III I-Claim
randomized I-Claim
study I-Claim
. I-Claim

Intermittent O
dosing O
may O
reduce O
the O
adverse O
events O
( O
AEs O
) O
of O
androgen-deprivation O
therapy O
( O
ADT O
) O
. O

To O
compare O
intermittent O
androgen O
deprivation O
( O
IAD O
) O
and O
continuous O
androgen O
deprivation O
( O
CAD O
) O
with O
regard O
to O
health-related O
quality O
of O
life O
( O
QoL O
) O
. O

A O
total O
of O
852 O
men O
with O
advanced O
prostate O
cancer O
( O
PCa O
) O
were O
enrolled O
to O
receive O
goserelin O
acetate O
3.6 O
mg O
every O
28 O
d O
for O
24 O
wk O
. O

A O
total O
of O
554 O
patients O
whose O
prostate-specific O
antigen O
( O
PSA O
) O
decreased O
to O
< O
10 O
ng/ml O
or O
by O
≥50 O
% O
( O
< O
20 O
ng/ml O
at O
baseline O
) O
were O
randomised O
to O
IAD O
or O
CAD O
. O

In O
the O
IAD O
arm O
, O
ADT O
was O
resumed O
for O
at O
least O
24 O
wk O
whenever O
PSA O
increased O
> O
20 O
ng/ml O
or O
above O
baseline O
. O

QoL O
was O
monitored O
with O
a O
validated O
Cleary O
30-item O
questionnaire O
and O
analysed O
by O
the O
Mann-Whitney O
U O
test O
, O
0.5 O
standard O
deviation O
rule O
, O
and O
repeated O
measures O
analysis O
of O
variance O
. O

AEs O
and O
adverse O
drug O
reactions O
( O
ADRs O
) O
were O
analysed O
by O
the O
chi-square O
test O
. O

Median O
follow-up O
was O
65 O
mo O
. O

Significant B-Premise
differences I-Premise
in I-Premise
QoL I-Premise
emerged I-Premise
in I-Premise
activity I-Premise
limitation I-Premise
, I-Premise
physical I-Premise
capacity I-Premise
, I-Premise
and I-Premise
sexual I-Premise
functioning I-Premise
, I-Premise
favouring I-Premise
IAD I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
emerged I-Premise
in I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
AEs I-Premise
: I-Premise
87 I-Premise
patients I-Premise
in I-Premise
the I-Premise
IAD I-Premise
arm I-Premise
( I-Premise
31.8 I-Premise
% I-Premise
) I-Premise
and I-Premise
95 I-Premise
in I-Premise
the I-Premise
CAD I-Premise
arm I-Premise
( I-Premise
33.9 I-Premise
% I-Premise
) I-Premise
had I-Premise
cardiovascular I-Premise
( I-Premise
CV I-Premise
) I-Premise
AEs I-Premise
( I-Premise
p=0.59 I-Premise
) I-Premise
, I-Premise
with I-Premise
25 I-Premise
( I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
29 I-Premise
( I-Premise
10.4 I-Premise
% I-Premise
) I-Premise
withdrawn I-Premise
( I-Premise
p=0.62 I-Premise
) I-Premise
, I-Premise
and I-Premise
21 I-Premise
( I-Premise
7.7 I-Premise
% I-Premise
) I-Premise
and I-Premise
24 I-Premise
( I-Premise
8.6 I-Premise
% I-Premise
) I-Premise
dying I-Premise
because I-Premise
of I-Premise
a I-Premise
CV I-Premise
event I-Premise
( I-Premise
p=0.70 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
bone B-Premise
fractures I-Premise
occurred I-Premise
in I-Premise
19 I-Premise
( I-Premise
6.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
15 I-Premise
( I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
patients I-Premise
( I-Premise
p=0.44 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Hot B-Premise
flushes I-Premise
or I-Premise
night I-Premise
sweats I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
ADRs I-Premise
( I-Premise
47.1 I-Premise
% I-Premise
vs I-Premise
50.4 I-Premise
% I-Premise
";" I-Premise
p=0.44 I-Premise
) I-Premise
. I-Premise

Erectile B-Premise
dysfunction I-Premise
( I-Premise
15.7 I-Premise
% I-Premise
vs I-Premise
7.9 I-Premise
% I-Premise
";" I-Premise
p=0.042 I-Premise
) I-Premise
and I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
2.2 I-Premise
vs I-Premise
0 I-Premise
% I-Premise
";" I-Premise
p=0.032 I-Premise
) I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IAD I-Premise
arm I-Premise
. I-Premise

IAD B-Claim
showed I-Claim
benefits I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
PCa I-Claim
with I-Claim
respect I-Claim
to I-Claim
QoL I-Claim
. I-Claim

The B-Claim
prevalence I-Claim
of I-Claim
AEs I-Claim
was I-Claim
not I-Claim
significantly I-Claim
lower I-Claim
with I-Claim
IAD I-Claim
. I-Claim

Quality O
of O
life O
( O
QoL O
) O
after O
breast O
cancer O
is O
nowadays O
a O
major O
challenge O
. O

Complementary O
interventions O
are O
necessary O
because O
of O
frequent O
depression O
symptoms O
after O
treatment O
and O
also O
to O
favour O
return O
to O
activity O
. O

Besides O
, O
radio-chemotherapy O
has O
side-effects O
like O
weight O
gain O
and O
fatigue O
. O

Several O
strategies O
including O
group O
behavioural-educational O
interventions O
, O
physical O
training O
and/or O
dietary O
education O
, O
have O
been O
tested O
to O
answer O
these O
difficulties O
with O
moderate O
success O
in O
the O
long O
run O
. O

Two O
hundred O
and O
fifty-one O
non-metastatic O
patients O
were O
accrued O
after O
chemotherapy O
in O
a O
prospective O
randomised O
multicenter O
trial O
between O
2008 O
and O
2010 O
, O
testing O
a O
2-week O
intervention O
in O
SPA O
centres O
. O

Intervention O
comprised O
group O
physical O
training O
, O
dietary O
education O
and O
physiotherapy O
. O

Selected O
patients O
were O
in O
complete O
remission O
. O

QoL O
was O
evaluated O
with O
SF36 O
questionnaire O
, O
anxiety O
and O
depression O
with O
the O
hospital O
anxiety O
and O
depression O
( O
HAD O
) O
one O
. O

Anthropometric O
measures O
and O
QoL O
evaluations O
were O
obtained O
before O
randomisation O
and O
every O
6 O
months O
during O
3 O
years O
. O

Two O
hundred O
and O
twenty O
patients O
were O
evaluable O
at O
1 O
year O
. O

Intervention B-Premise
increased I-Premise
SF36 I-Premise
score I-Premise
by I-Premise
9.5 I-Premise
points I-Premise
( I-Premise
p=0.000006 I-Premise
) I-Premise
, I-Premise
4.6 I-Premise
( I-Premise
p=0.032 I-Premise
) I-Premise
and I-Premise
6.2 I-Premise
( I-Premise
p=0.028 I-Premise
) I-Premise
respectively I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
. I-Premise

Effect B-Premise
size I-Premise
( I-Premise
ES I-Premise
) I-Premise
was I-Premise
0.63 I-Premise
[ I-Premise
0.37 I-Premise
";" I-Premise
0.90 I-Premise
] I-Premise
, I-Premise
0.29 I-Premise
[ I-Premise
0.03 I-Premise
";" I-Premise
0.55 I-Premise
] I-Premise
and I-Premise
0.41 I-Premise
[ I-Premise
0.04 I-Premise
";" I-Premise
0.78 I-Premise
] I-Premise
. I-Premise

Anxiety B-Premise
score I-Premise
was I-Premise
shortly I-Premise
minored I-Premise
by I-Premise
intervention I-Premise
( I-Premise
6-month I-Premise
ES=-0.24 I-Premise
[ I-Premise
-0.42 I-Premise
";" I-Premise
-0.05 I-Premise
] I-Premise
) I-Premise
and I-Premise
depression I-Premise
score I-Premise
more I-Premise
durably I-Premise
: I-Premise
ES=-0.45 I-Premise
[ I-Premise
-0.72 I-Premise
";" I-Premise
-0.18 I-Premise
] I-Premise
, I-Premise
-0.34 I-Premise
[ I-Premise
-61 I-Premise
";" I-Premise
-0.08 I-Premise
] I-Premise
, I-Premise
and I-Premise
-0.26 I-Premise
[ I-Premise
-0.63 I-Premise
";" I-Premise
0.11 I-Premise
] I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
. I-Premise

This B-Claim
2-week I-Claim
group I-Claim
intervention I-Claim
seemed I-Claim
to I-Claim
durably I-Claim
influence I-Claim
QoL I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
by I-Claim
chemotherapy I-Claim
. I-Claim

Differences B-Claim
, I-Claim
smaller I-Claim
at I-Claim
12 I-Claim
months I-Claim
than I-Claim
at I-Claim
six I-Claim
, I-Claim
suggest I-Claim
that I-Claim
a I-Claim
second I-Claim
but I-Claim
shorter I-Claim
intervention I-Claim
could I-Claim
help I-Claim
maintain I-Claim
the I-Claim
6-month I-Claim
benefits I-Claim
. I-Claim

To O
assess O
toxicities O
, O
functional O
outcomes O
, O
and O
health-related O
quality O
of O
life O
associated O
with O
concurrent O
chemoradiation O
therapy O
( O
CRT O
) O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Prospective O
and O
retrospective O
outcomes O
study O
. O

Tertiary O
care O
institution O
. O

Participants O
in O
the O
longitudinal O
Outcomes O
Assessment O
Project O
whose O
head O
and O
neck O
cancer O
was O
treated O
with O
CRT O
between O
February O
1 O
, O
2000 O
, O
and O
March O
1 O
, O
2007 O
( O
n O
= O
104 O
) O
. O

Patients O
prospectively O
provided O
functional O
and O
health-related O
quality O
of O
life O
information O
, O
including O
data O
from O
the O
1-year O
and O
most O
current O
follow-up O
visits O
. O

Medical O
records O
were O
reviewed O
to O
determine O
toxicity O
and O
survival O
rates O
. O

Well-defined O
acute O
and O
late O
toxicities O
";" O
functional O
outcomes O
( O
diet O
, O
dentition O
, O
tracheostomies O
) O
";" O
head O
and O
neck O
cancer-specific O
, O
general O
health O
, O
and O
depression O
outcomes O
";" O
and O
survival O
rates O
. O

Most O
patients O
had O
oropharyngeal O
or O
laryngeal O
tumors O
( O
87.5 O
% O
) O
and O
advanced-stage O
disease O
( O
75.0 O
% O
) O
. O

Approximately B-Premise
one-half I-Premise
had I-Premise
hematologic I-Premise
toxicities I-Premise
and I-Premise
toxicity-related I-Premise
treatment I-Premise
delays I-Premise
. I-Premise

Approximately B-Premise
one-quarter I-Premise
had I-Premise
neurotoxicities I-Premise
and/or I-Premise
ototoxicites I-Premise
, I-Premise
moist I-Premise
desquamation I-Premise
, I-Premise
pneumonia I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
requiring I-Premise
hospitalization I-Premise
or I-Premise
intravenous I-Premise
fluids I-Premise
, I-Premise
dehydration I-Premise
or I-Premise
malnutrition I-Premise
requiring I-Premise
hospitalization I-Premise
, I-Premise
and I-Premise
mild I-Premise
or I-Premise
moderate I-Premise
fever I-Premise
. I-Premise

Although B-Premise
patients I-Premise
receiving I-Premise
the I-Premise
current I-Premise
intensity-modulated I-Premise
radiation I-Premise
therapy I-Premise
( I-Premise
IMRT I-Premise
) I-Premise
protocol I-Premise
using I-Premise
the I-Premise
Pinnacle I-Premise
( I-Premise
3 I-Premise
) I-Premise
planning I-Premise
system I-Premise
had I-Premise
more I-Premise
toxicity-related I-Premise
treatment I-Premise
delays I-Premise
, I-Premise
they B-Premise
had I-Premise
fewer I-Premise
toxicities I-Premise
and I-Premise
better I-Premise
functional I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
outcomes I-Premise
compared I-Premise
with I-Premise
those I-Premise
receiving I-Premise
conventional I-Premise
lateral I-Premise
opposing-field I-Premise
radiation I-Premise
or I-Premise
the I-Premise
initial I-Premise
IMRT I-Premise
protocol I-Premise
using I-Premise
the I-Premise
Best I-Premise
nomos I-Premise
PEACOCK I-Premise
planning I-Premise
system I-Premise
. I-Premise

Patients B-Claim
receiving I-Claim
CRT I-Claim
experience I-Claim
a I-Claim
substantial I-Claim
number I-Claim
of I-Claim
treatment-related I-Claim
adverse I-Claim
events I-Claim
, I-Claim
primarily I-Claim
affecting I-Claim
oropharyngeal I-Claim
and I-Claim
laryngeal I-Claim
function I-Claim
, I-Claim
with I-Claim
improvement I-Claim
noted I-Claim
for I-Claim
the I-Claim
current I-Claim
IMRT I-Claim
protocol I-Claim
. I-Claim

Improving O
dental O
prosthetic O
rehabilitation O
and O
including O
evaluations O
with O
speech O
and O
swallowing O
pathologists O
before O
and O
during O
treatment O
may O
enhance O
patient O
outcomes O
. O

To O
evaluate O
the O
combination O
of O
the O
gastrin O
antagonist O
Z-360 O
and O
gemcitabine O
for O
advanced O
pancreatic O
cancer O
. O

Previously O
untreated O
patients O
with O
PC O
were O
randomly O
allocated O
to O
Z-360 O
120 O
mg O
, O
240 O
mg O
or O
placebo O
. O

Z-360/placebo O
was O
given O
on O
day O
-3 O
and O
gemcitabine O
1000 O
mg/m O
( O
2 O
) O
commenced O
on O
day O
1 O
followed O
by O
Z-360 O
on O
day O
2 O
. O

Thereafter O
Z-360/placebo O
was O
given O
twice O
daily O
concurrently O
with O
standard O
dose O
of O
gemcitabine O
. O

Pharmacokinetics O
for O
both O
drugs O
was O
measured O
alone O
and O
in O
combination O
. O

Toxicity O
, O
response O
and O
quality O
of O
life O
were O
also O
recorded O
. O

Thirty-three O
patients O
with O
a O
median O
age O
of O
62 O
years O
were O
randomised O
of O
which O
six O
had O
locally O
advanced O
disease O
and O
26 O
had O
metastatic O
disease O
. O

Analysis O
of O
the O
area O
under O
the O
plasma O
concentration O
versus O
time O
curve O
( O
AUC O
) O
, O
the O
maximum O
observed O
concentration O
( O
Cmax O
( O
obs O
) O
) O
and O
the O
time O
of O
the O
maximum O
observed O
concentration O
( O
Tmax O
( O
obs O
) O
) O
for O
Z-360 O
, O
gemcitabine O
and O
2,2-difluorodeoxyuridine O
( O
dFdU O
) O
, O
could O
not O
exclude O
an O
effect O
on O
the O
systemic O
exposure O
to O
Z-360 O
, O
gemcitabine O
and O
dFdU O
when O
co-administration O
of O
Z-360 O
and O
gemcitabine O
was O
compared O
with O
single O
agent O
administration O
. O

The B-Premise
most I-Premise
commonly I-Premise
reported I-Premise
adverse I-Premise
events I-Premise
were I-Premise
nausea I-Premise
, I-Premise
abdominal I-Premise
pain I-Premise
, I-Premise
vomiting I-Premise
and I-Premise
fatigue I-Premise
. I-Premise

At B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
62.5 I-Premise
% I-Premise
, I-Premise
25 I-Premise
% I-Premise
and I-Premise
60 I-Premise
% I-Premise
had I-Premise
stable I-Premise
disease I-Premise
in I-Premise
the I-Premise
120 I-Premise
mg I-Premise
, I-Premise
240 I-Premise
mg I-Premise
and I-Premise
placebo I-Premise
group I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
higher I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
in I-Premise
Z-360 I-Premise
groups I-Premise
reported I-Premise
improvement I-Premise
in I-Premise
pain I-Premise
. I-Premise

Z-360 B-Claim
is I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
when I-Claim
combined I-Claim
with I-Claim
gemcitabine I-Claim
. I-Claim

A O
Phase O
III O
trial O
is O
needed O
to O
determine O
whether O
the O
combination O
of O
Z-360 O
and O
gemcitabine O
is O
superior O
to O
gemcitabine O
alone O
in O
advanced O
PC O
. O

Oral O
etoposide O
is O
an O
active O
single O
agent O
in O
small-cell O
lung O
cancer O
( O
SCLC O
) O
and O
is O
widely O
prescribed O
as O
first-line O
treatment O
as O
an O
alternative O
to O
intravenous O
combination O
chemotherapy O
in O
patients O
with O
extensive O
disease O
. O

The O
intention O
of O
this O
study O
was O
to O
determine O
if O
the O
effects O
of O
oral O
etoposide O
therapy O
on O
survival O
and O
quality O
of O
life O
are O
equivalent O
to O
those O
of O
intravenous O
chemotherapy O
. O

In O
a O
randomized O
trial O
of O
palliative O
treatment O
in O
advanced O
SCLC O
, O
oral O
etoposide O
( O
100 O
mg O
given O
twice O
daily O
for O
5 O
days O
) O
was O
compared O
with O
intravenous O
chemotherapy O
consisting O
of O
alternating O
cycles O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
and O
cyclophosphamide O
, O
doxorubicin O
, O
and O
vincristine O
( O
CAV O
) O
. O

Six O
cycles O
of O
chemotherapy O
were O
administered O
every O
21 O
days O
in O
both O
regimens O
. O

Symptom O
control O
and O
quality O
of O
life O
were O
measured O
with O
the O
Rotterdam O
Symptom O
Checklist O
and O
a O
daily O
diary O
card O
. O

In O
January O
1996 O
, O
after O
155 O
patients O
had O
been O
randomly O
assigned O
from O
a O
projected O
intake O
of O
365 O
patients O
, O
an O
independent O
Data O
Monitoring O
Committee O
examined O
the O
interim O
results O
. O

Survival O
was O
determined O
by O
the O
Kaplan-Meier O
method O
, O
and O
the O
logrank O
test O
was O
used O
to O
compare O
treatments O
. O

For O
quality-of-life O
comparisons O
, O
average O
scores O
were O
calculated O
for O
each O
time O
point O
. O

The O
Mann-Whitney O
U O
test O
was O
used O
to O
determine O
any O
significant O
overall O
differences O
between O
treatments O
. O

For O
the O
Rotterdam O
Symptom O
Checklist O
, O
separate O
analyses O
were O
done O
for O
each O
subset O
( O
psychological O
well-being O
, O
physical O
symptoms O
, O
lung O
cancer O
symptoms O
, O
treatment O
symptoms O
, O
activity O
, O
and O
quality O
of O
life O
) O
. O

Response O
rates O
and O
toxicity O
scores O
were O
compared O
by O
using O
chi2 O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Survival B-Premise
was I-Premise
inferior I-Premise
at I-Premise
1 I-Premise
year I-Premise
in I-Premise
the I-Premise
oral I-Premise
etoposide I-Premise
group I-Premise
compared I-Premise
with I-Premise
intravenous I-Premise
therapy I-Premise
( I-Premise
9.8 I-Premise
% I-Premise
for I-Premise
oral I-Premise
versus I-Premise
19.3 I-Premise
% I-Premise
for I-Premise
intravenous I-Premise
";" I-Premise
difference I-Premise
= I-Premise
9.5 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
of I-Premise
difference I-Premise
= I-Premise
0.3 I-Premise
% I-Premise
-18.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
there I-Premise
was I-Premise
a I-Premise
trend I-Premise
toward I-Premise
inferior I-Premise
overall I-Premise
survival I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
4.8 I-Premise
months I-Premise
for I-Premise
oral I-Premise
treatment I-Premise
and I-Premise
5.9 I-Premise
months I-Premise
for I-Premise
intravenous I-Premise
therapy I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
oral I-Premise
etoposide I-Premise
arm I-Premise
( I-Premise
median I-Premise
= I-Premise
3.6 I-Premise
months I-Premise
versus I-Premise
5.6 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
32.9 I-Premise
% I-Premise
versus I-Premise
46.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

With B-Premise
the I-Premise
exception I-Premise
of I-Premise
acute I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
associated I-Premise
with I-Premise
intravenous I-Premise
chemotherapy I-Premise
, I-Premise
all B-Premise
aspects I-Premise
of I-Premise
symptom I-Premise
control I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
either I-Premise
the I-Premise
same I-Premise
or I-Premise
worse I-Premise
in I-Premise
the I-Premise
oral I-Premise
etoposide I-Premise
group I-Premise
. I-Premise

Study O
closure O
was O
recommended O
. O

These B-Claim
interim I-Claim
results I-Claim
show I-Claim
that I-Claim
this I-Claim
schedule I-Claim
of I-Claim
oral I-Claim
etoposide I-Claim
is I-Claim
inferior I-Claim
to I-Claim
intravenous I-Claim
chemotherapy I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
SCLC I-Claim
and I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
this I-Claim
disease I-Claim
. I-Claim

To O
evaluate O
the O
effects O
of O
the O
Chinese O
medicine O
( O
CM O
) O
five-element O
music O
on O
quality O
of O
life O
for O
senior O
and O
non-senior O
advanced O
cancer O
patients O
. O

With O
a O
randomized O
controlled O
trial O
, O
170 O
advanced O
cancer O
patients O
were O
randomly O
assigned O
to O
three O
groups O
: O
the O
CM O
five-element O
music O
group O
( O
68 O
patients O
) O
, O
the O
Western O
music O
therapy O
group O
( O
68 O
cases O
) O
, O
and O
the O
no O
music O
therapy O
group O
( O
34 O
cases O
) O
. O

All O
patients O
of O
70 O
years O
old O
or O
older O
were O
considered O
seniors O
and O
the O
remaining O
patients O
younger O
than O
70 O
years O
were O
considered O
nonseniors O
. O

Patients O
in O
the O
CM O
five-element O
music O
group O
listened O
to O
CM O
five-element O
music O
, O
the O
patients O
in O
the O
Western O
music O
group O
listened O
to O
Western O
music O
, O
and O
the O
patients O
in O
the O
no O
music O
group O
did O
not O
listen O
to O
music O
. O

A O
course O
of O
treatment O
was O
3 O
weeks O
, O
with O
30 O
min O
each O
day O
, O
5 O
days O
a O
week O
. O

The O
Hospice O
Quality O
of O
Life O
Index-Revised O
( O
HQOLI-R O
) O
and O
Karnofsky O
performance O
score O
( O
KPS O
) O
were O
measured O
in O
the O
three O
groups O
before O
and O
after O
treatment O
. O

The O
symptom O
diary O
score O
was O
measured O
in O
the O
three O
groups O
every O
3 O
days O
, O
7 O
times O
in O
total O
. O

CM B-Premise
five-element I-Premise
music I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
difference I-Premise
of I-Premise
HQOLI-R I-Premise
, I-Premise
KPS I-Premise
and I-Premise
symptom I-Premise
diary I-Premise
score I-Premise
with I-Premise
other I-Premise
groups I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
significant I-Premise
differences I-Premise
of I-Premise
HQOLI-R I-Premise
, I-Premise
symptom I-Premise
diary I-Premise
score I-Premise
, I-Premise
and I-Premise
KPS I-Premise
after I-Premise
treatment I-Premise
in I-Premise
CM I-Premise
five-element I-Premise
music I-Premise
group I-Premise
and I-Premise
other I-Premise
groups I-Premise
in I-Premise
the I-Premise
non-senior I-Premise
subgroup I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Additionally O
, O
there B-Premise
were I-Premise
significant I-Premise
differences I-Premise
in I-Premise
HQOLI-R I-Premise
and I-Premise
KPS I-Premise
after I-Premise
treatment I-Premise
among I-Premise
the I-Premise
three I-Premise
groups I-Premise
in I-Premise
the I-Premise
senior I-Premise
subgroup I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

CM B-Claim
five-element I-Claim
music I-Claim
therapy I-Claim
could I-Claim
improve I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
KPS I-Claim
for I-Claim
senior I-Claim
and I-Claim
non I-Claim
senior I-Claim
advanced I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
improve I-Claim
subjective I-Claim
symptoms I-Claim
for I-Claim
non-senior I-Claim
advanced I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Bacillus B-Claim
Calmette-Guérin I-Claim
and I-Claim
intravesical I-Claim
chemotherapy I-Claim
represent I-Claim
viable I-Claim
adjuvant I-Claim
options I-Claim
for I-Claim
intermediate I-Claim
risk I-Claim
nonmuscle I-Claim
invasive I-Claim
bladder I-Claim
cancer I-Claim
. I-Claim

Although O
bacillus O
Calmette-Guérin O
is O
perceived O
as O
less O
tolerable O
than O
intravesical O
chemotherapy O
, O
to O
our O
knowledge O
no O
comparative O
studies O
have O
addressed O
quality O
of O
life O
issues O
. O

We O
compared O
the O
quality O
of O
life O
of O
patients O
with O
nonmuscle O
invasive O
bladder O
cancer O
who O
received O
adjuvant O
intravesical O
gemcitabine O
or O
1/3 O
dose O
bacillus O
Calmette-Guérin O
. O

Our O
multicenter O
, O
prospective O
, O
randomized O
, O
phase O
II O
study O
included O
120 O
patients O
with O
intermediate O
risk O
nonmuscle O
invasive O
bladder O
cancer O
. O

Of O
these O
patients O
88 O
remained O
assessable O
at O
1-year O
followup O
. O

Only O
1 O
patient O
was O
withdrawn O
because O
of O
adverse O
events O
. O

Overall O
61 O
patients O
received O
2,000 O
mg/50 O
cc O
gemcitabine O
weekly O
for O
6 O
weeks O
( O
maintenance O
monthly O
for O
1 O
year O
) O
while O
59 O
received O
1/3 O
dose O
bacillus O
Calmette-Guérin O
Connaught O
weekly O
for O
6 O
weeks O
( O
maintenance O
3 O
weekly O
instillations O
at O
3 O
, O
6 O
and O
12 O
months O
) O
. O

Quality O
of O
life O
was O
measured O
by O
the O
EORTC O
QLQ-C30 O
( O
European O
Organization O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
30 O
version O
3.0 O
) O
and O
QLQ-BLS24 O
( O
Quality O
of O
Life O
Superficial O
Bladder O
Cancer-Specific O
24 O
) O
questionnaires O
. O

Group O
differences O
were O
calculated O
using O
ANOVA O
( O
ANOVA/MANOVA O
) O
. O

Treatment B-Premise
was I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
local I-Premise
and I-Premise
systemic I-Premise
side I-Premise
effects I-Premise
were I-Premise
more I-Premise
frequently I-Premise
reported I-Premise
in I-Premise
the I-Premise
bacillus I-Premise
Calmette-Guérin I-Premise
arm I-Premise
. I-Premise

Multivariate B-Premise
analyses I-Premise
showed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
in I-Premise
all I-Premise
quality I-Premise
of I-Premise
life I-Premise
dimensions I-Premise
. I-Premise

No B-Premise
significant I-Premise
changes I-Premise
over I-Premise
time I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
domains I-Premise
were I-Premise
detected I-Premise
for I-Premise
patients I-Premise
on I-Premise
bacillus I-Premise
Calmette-Guérin I-Premise
and I-Premise
gemcitabine I-Premise
except I-Premise
for I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
which I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
detected I-Premise
in I-Premise
terms I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
progression I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
at I-Premise
1-year I-Premise
followup I-Premise
. I-Premise

While O
a B-Claim
higher I-Claim
rate I-Claim
of I-Claim
side I-Claim
effects I-Claim
, I-Claim
albeit I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
, I-Claim
was I-Claim
detected I-Claim
with I-Claim
1/3 I-Claim
dose I-Claim
bacillus I-Claim
Calmette-Guérin I-Claim
compared I-Claim
to I-Claim
gemcitabine I-Claim
, I-Claim
our B-Claim
study I-Claim
failed I-Claim
to I-Claim
show I-Claim
significant I-Claim
differences I-Claim
between I-Claim
the I-Claim
2 I-Claim
drugs I-Claim
in I-Claim
terms I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
safety O
of O
first-line O
, O
single-agent O
trastuzumab O
in O
women O
with O
HER2-overexpressing O
metastatic O
breast O
cancer O
. O

One O
hundred O
fourteen O
women O
with O
HER2-overexpressing O
metastatic O
breast O
cancer O
were O
randomized O
to O
receive O
first-line O
treatment O
with O
trastuzumab O
4 O
mg/kg O
loading O
dose O
, O
followed O
by O
2 O
mg/kg O
weekly O
, O
or O
a O
higher O
8 O
mg/kg O
loading O
dose O
, O
followed O
by O
4 O
mg/kg O
weekly O
. O

The B-Premise
objective I-Premise
response I-Premise
rate I-Premise
was I-Premise
26 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
18.2 I-Premise
% I-Premise
to I-Premise
34.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
with I-Premise
seven I-Premise
complete I-Premise
and I-Premise
23 I-Premise
partial I-Premise
responses I-Premise
. I-Premise

Response B-Premise
rates I-Premise
in I-Premise
111 I-Premise
assessable I-Premise
patients I-Premise
with I-Premise
3 I-Premise
and I-Premise
2 I-Premise
HER2 I-Premise
overexpression I-Premise
by I-Premise
immunohistochemistry I-Premise
( I-Premise
IHC I-Premise
) I-Premise
were I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
24.4 I-Premise
% I-Premise
to I-Premise
44.7 I-Premise
% I-Premise
) I-Premise
and I-Premise
none I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
% I-Premise
to I-Premise
15.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
clinical I-Premise
benefit I-Premise
rates I-Premise
in I-Premise
assessable I-Premise
patients I-Premise
with I-Premise
3 I-Premise
and I-Premise
2 I-Premise
HER2 I-Premise
overexpression I-Premise
were I-Premise
48 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
response I-Premise
rates I-Premise
in I-Premise
108 I-Premise
assessable I-Premise
patients I-Premise
with I-Premise
and I-Premise
without I-Premise
HER2 I-Premise
gene I-Premise
amplification I-Premise
by I-Premise
fluorescence I-Premise
in I-Premise
situ I-Premise
hybridization I-Premise
( I-Premise
FISH I-Premise
) I-Premise
analysis I-Premise
were I-Premise
34 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
23.9 I-Premise
% I-Premise
to I-Premise
45.7 I-Premise
% I-Premise
) I-Premise
and I-Premise
7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.8 I-Premise
% I-Premise
to I-Premise
22.8 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Seventeen B-Premise
( I-Premise
57 I-Premise
% I-Premise
) I-Premise
of I-Premise
30 I-Premise
patients I-Premise
with I-Premise
an I-Premise
objective I-Premise
response I-Premise
and I-Premise
22 I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
of I-Premise
43 I-Premise
patients I-Premise
with I-Premise
clinical I-Premise
benefit I-Premise
had I-Premise
not I-Premise
experienced I-Premise
disease I-Premise
progression I-Premise
at I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
or I-Premise
later I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
chills I-Premise
( I-Premise
25 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
, I-Premise
asthenia I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
fever I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
, I-Premise
pain I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
nausea I-Premise
( I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Cardiac B-Premise
dysfunction I-Premise
occurred I-Premise
in I-Premise
two I-Premise
patients I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
";" I-Premise
both I-Premise
had I-Premise
histories I-Premise
of I-Premise
cardiac I-Premise
disease I-Premise
and I-Premise
did I-Premise
not I-Premise
require I-Premise
additional I-Premise
intervention I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
trastuzumab I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
clear I-Claim
evidence I-Claim
of I-Claim
a I-Claim
dose-response I-Claim
relationship I-Claim
for I-Claim
response I-Claim
, I-Claim
survival I-Claim
, I-Claim
or I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Single-agent B-Claim
trastuzumab I-Claim
is I-Claim
active I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
women I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
with I-Claim
HER2 I-Claim
3 I-Claim
overexpression I-Claim
by I-Claim
IHC I-Claim
or I-Claim
gene I-Claim
amplification I-Claim
by I-Claim
FISH I-Claim
. I-Claim

We O
investigated O
the O
influence O
of O
bladder O
neck O
preservation O
on O
urinary O
continence O
, O
quality O
of O
life O
and O
surgical O
margins O
after O
radical O
prostatectomy O
. O

A O
total O
of O
208 O
men O
who O
presented O
for O
radical O
prostatectomy O
were O
randomized O
to O
complete O
bladder O
neck O
preservation O
with O
subsequent O
urethro-urethral O
anastomosis O
or O
to O
no O
preservation O
as O
controls O
. O

Patients O
with O
failed O
bladder O
neck O
preservation O
were O
not O
included O
in O
study O
. O

We O
documented O
objective O
continence O
by O
the O
24-hour O
pad O
test O
, O
social O
continence O
by O
the O
number O
of O
pads O
per O
day O
and O
quality O
of O
life O
outcomes O
by O
the O
validated O
Incontinence O
Quality O
of O
Life O
questionnaire O
in O
a O
single O
blind O
setting O
. O

Cancer O
resection O
was O
assessed O
by O
surgical O
margin O
status O
. O

At B-Premise
0 I-Premise
, I-Premise
3 I-Premise
, I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
mean I-Premise
urine I-Premise
loss I-Premise
in I-Premise
the I-Premise
control I-Premise
vs I-Premise
the I-Premise
bladder I-Premise
neck I-Premise
preservation I-Premise
group I-Premise
was I-Premise
713.3 I-Premise
vs I-Premise
237.0 I-Premise
, I-Premise
49.6 I-Premise
vs I-Premise
15.6 I-Premise
, I-Premise
44.4 I-Premise
vs I-Premise
5.5 I-Premise
and I-Premise
25.4 I-Premise
vs I-Premise
3.1 I-Premise
gm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
each I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
, I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
control I-Premise
vs I-Premise
the I-Premise
preservation I-Premise
group I-Premise
the I-Premise
social I-Premise
continence I-Premise
rate I-Premise
was I-Premise
55.3 I-Premise
% I-Premise
vs I-Premise
84.2 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
74.8 I-Premise
% I-Premise
vs I-Premise
89.5 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
81.4 I-Premise
% I-Premise
vs I-Premise
94.7 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0.027 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
80.4 I-Premise
vs I-Premise
90.3 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
85.4 I-Premise
vs I-Premise
91.7 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
and I-Premise
86.0 I-Premise
vs I-Premise
93.8 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

We B-Premise
noted I-Premise
significantly I-Premise
less I-Premise
urine I-Premise
loss I-Premise
, I-Premise
higher I-Premise
objective I-Premise
and I-Premise
social I-Premise
continence I-Premise
rates I-Premise
, I-Premise
and I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
after I-Premise
complete I-Premise
bladder I-Premise
neck I-Premise
preservation I-Premise
at I-Premise
all I-Premise
followup I-Premise
points I-Premise
. I-Premise

On O
multiple O
logistic O
regression O
analysis O
complete O
bladder O
neck O
preservation O
was O
an O
independent O
positive O
predictor O
of O
continence O
. O

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
in I-Premise
surgical I-Premise
margin I-Premise
status I-Premise
between I-Premise
the I-Premise
control I-Premise
and I-Premise
bladder I-Premise
neck I-Premise
preservation I-Premise
groups I-Premise
( I-Premise
12.5 I-Premise
% I-Premise
vs I-Premise
14.7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

In B-Claim
what I-Claim
is I-Claim
to I-Claim
our I-Claim
knowledge I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
, I-Claim
controlled I-Claim
, I-Claim
single I-Claim
blind I-Claim
trial I-Claim
complete I-Claim
bladder I-Claim
neck I-Claim
preservation I-Claim
during I-Claim
radical I-Claim
prostatectomy I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
significantly I-Claim
higher I-Claim
urinary I-Claim
continence I-Claim
rate I-Claim
and I-Claim
increased I-Claim
patient I-Claim
satisfaction I-Claim
without I-Claim
compromising I-Claim
resection I-Claim
margins I-Claim
. I-Claim

Docetaxel O
administered O
every O
3 O
weeks O
is O
a O
standard O
treatment O
for O
castration-resistant O
advanced O
prostate O
cancer O
. O

We O
hypothesised O
that O
2-weekly O
administration O
of O
docetaxel O
would O
be O
better O
tolerated O
than O
3-weekly O
docetaxel O
in O
patients O
with O
castration-resistant O
advanced O
prostate O
cancer O
, O
and O
did O
a O
prospective O
, O
multicentre O
, O
randomised O
, O
phase O
3 O
study O
to O
compare O
efficacy O
and O
safety O
. O

Eligible O
patients O
had O
advanced O
prostate O
cancer O
( O
metastasis O
, O
a O
prostate-specific-antigen O
test O
result O
of O
more O
than O
10·0 O
ng/mL O
, O
and O
WHO O
performance O
status O
score O
of O
0-2 O
) O
, O
had O
received O
no O
chemotherapy O
( O
except O
with O
estramustine O
) O
, O
had O
undergone O
surgical O
or O
chemical O
castration O
, O
and O
had O
been O
referred O
to O
a O
treatment O
centre O
in O
Finland O
, O
Ireland O
, O
or O
Sweden O
. O

Enrolment O
and O
treatment O
were O
done O
between O
March O
1 O
, O
2004 O
, O
and O
May O
31 O
, O
2009 O
. O

Randomisation O
was O
done O
centrally O
and O
stratified O
by O
centre O
and O
WHO O
performance O
status O
score O
of O
0-1 O
vs O
2 O
. O

Patients O
were O
assigned O
75 O
mg/m O
( O
2 O
) O
docetaxel O
intravenously O
on O
day O
1 O
of O
a O
3-week O
cycle O
, O
or O
50 O
mg/m O
( O
2 O
) O
docetaxel O
intravenously O
on O
days O
1 O
and O
15 O
of O
a O
4-week O
cycle O
. O

10 O
mg O
oral O
prednisolone O
was O
administered O
daily O
to O
all O
patients O
. O

The O
primary O
endpoint O
was O
time O
to O
treatment O
failure O
( O
TTTF O
) O
. O

We O
assessed O
data O
in O
the O
per-protocol O
population O
. O

177 O
patients O
were O
randomly O
assigned O
to O
the O
2-weekly O
docetaxel O
group O
and O
184 O
to O
the O
3-weekly O
group O
. O

170 O
patients O
in O
the O
2-weekly O
group O
and O
176 O
in O
the O
3-weekly O
group O
were O
included O
in O
the O
analysis O
. O

The B-Premise
2-weekly I-Premise
administration I-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
longer I-Premise
TTTF I-Premise
than I-Premise
was I-Premise
3-weekly I-Premise
administration I-Premise
( I-Premise
5·6 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5·0-6·2 I-Premise
vs I-Premise
4·9 I-Premise
months I-Premise
, I-Premise
4·5-5·4 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
1·3 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1·1-1·6 I-Premise
, I-Premise
p=0·014 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3-4 I-Premise
adverse I-Premise
events I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
3-weekly I-Premise
than I-Premise
in I-Premise
the I-Premise
2-weekly I-Premise
administration I-Premise
group I-Premise
, I-Premise
including I-Premise
neutropenia I-Premise
( I-Premise
93 I-Premise
[ I-Premise
53 I-Premise
% I-Premise
] I-Premise
vs I-Premise
61 I-Premise
[ I-Premise
36 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
( I-Premise
51 I-Premise
[ I-Premise
29 I-Premise
% I-Premise
] I-Premise
vs I-Premise
22 I-Premise
[ I-Premise
13 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
25 I-Premise
[ I-Premise
14 I-Premise
% I-Premise
] I-Premise
vs I-Premise
six I-Premise
[ I-Premise
4 I-Premise
% I-Premise
] I-Premise
) I-Premise
. I-Premise

Neutropenic B-Premise
infections I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
docetaxel I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
43 I-Premise
[ I-Premise
24 I-Premise
% I-Premise
] I-Premise
vs I-Premise
11 I-Premise
[ I-Premise
6 I-Premise
% I-Premise
] I-Premise
, I-Premise
p=0·002 I-Premise
) I-Premise
. I-Premise

Administration B-Claim
of I-Claim
docetaxel I-Claim
every I-Claim
2 I-Claim
weeks I-Claim
seems I-Claim
to I-Claim
be I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
patients I-Claim
with I-Claim
castration-resistant I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
and I-Claim
could I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
when I-Claim
3-weekly I-Claim
single-dose I-Claim
administration I-Claim
is I-Claim
unlikely I-Claim
to I-Claim
be I-Claim
tolerated I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
cancer I-Claim
( I-Claim
AGGEC I-Claim
) I-Claim
providing I-Claim
clinical I-Claim
benefit I-Claim
with I-Claim
improved I-Claim
palliation I-Claim
is I-Claim
highly I-Claim
desirable I-Claim
. I-Claim

However O
, O
a O
prospective O
evaluation O
of O
clinical O
benefit O
in O
AGGEC O
patients O
has O
never O
before O
been O
reported O
in O
a O
phase O
III O
setting O
. O

In O
a O
multinational O
trial O
( O
V325 O
) O
, O
445 O
patients O
were O
randomly O
assigned O
and O
treated O
with O
either O
docetaxel O
plus O
cisplatin O
and O
fluorouracil O
( O
DCF O
) O
or O
cisplatin O
and O
fluorouracil O
( O
CF O
) O
. O

Clinical O
benefit O
was O
prospectively O
evaluated O
in O
this O
trial O
as O
a O
secondary O
end O
point O
. O

The O
primary O
measure O
for O
clinical O
benefit O
analysis O
was O
time O
to O
definitive O
worsening O
by O
one O
or O
more O
categories O
of O
Karnofsky O
performance O
status O
( O
KPS O
) O
. O

Secondary O
clinical O
benefit O
end O
points O
included O
time O
to O
5 O
% O
definitive O
weight O
loss O
, O
time O
to O
definitive O
worsening O
of O
appetite O
by O
one O
grade O
, O
pain-free O
survival O
( O
defined O
as O
time O
to O
first O
appearance O
of O
pain O
) O
, O
and O
time O
to O
first O
cancer O
pain-related O
opioid O
intake O
. O

Clinical O
benefit O
assessments O
were O
recorded O
at O
each O
clinic O
visit O
. O

Clinical O
benefit O
assessments O
were O
performed O
in O
more O
than O
75 O
% O
of O
patients O
throughout O
V325 O
. O

DCF B-Premise
significantly I-Premise
prolonged I-Premise
time I-Premise
to I-Premise
definitive I-Premise
worsening I-Premise
of I-Premise
KPS I-Premise
compared I-Premise
with I-Premise
CF I-Premise
( I-Premise
median I-Premise
, I-Premise
6.1 I-Premise
v I-Premise
4.8 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.38 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.08 I-Premise
to I-Premise
1.76 I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
. I-Premise

Although B-Premise
time I-Premise
to I-Premise
definitive I-Premise
weight I-Premise
loss I-Premise
and I-Premise
time I-Premise
to I-Premise
definitive I-Premise
worsening I-Premise
of I-Premise
appetite I-Premise
favored I-Premise
DCF I-Premise
, I-Premise
the B-Premise
results I-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Pain-free B-Premise
survival I-Premise
and I-Premise
time I-Premise
to I-Premise
first I-Premise
cancer I-Premise
pain-related I-Premise
opioid I-Premise
intake I-Premise
were I-Premise
comparable I-Premise
. I-Premise

To O
our O
knowledge O
, O
V325 O
is O
the O
first O
phase O
III O
trial O
to O
report O
clinical O
benefit O
in O
AGGEC O
patients O
. O

Clinical O
benefit O
was O
assessed O
beyond O
protocol-specific O
chemotherapy O
. O

The B-Claim
addition I-Claim
of I-Claim
D I-Claim
to I-Claim
CF I-Claim
not I-Claim
only I-Claim
significantly I-Claim
improved I-Claim
clinical I-Claim
benefit I-Claim
but I-Claim
also I-Claim
improved I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
and I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
CF I-Claim
. I-Claim

The O
addition O
of O
mTOR O
inhibitor O
everolimus O
( O
EVE O
) O
to O
exemestane O
( O
EXE O
) O
was O
evaluated O
in O
an O
international O
, O
phase O
3 O
study O
( O
BOLERO-2 O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
breast O
cancer O
refractory O
to O
letrozole O
or O
anastrozole O
. O

The O
safety O
and O
efficacy O
of O
anticancer O
treatments O
may O
be O
influenced O
by O
ethnicity O
( O
Sekine O
et O
al O
. O

in O
Br O
J O
Cancer O
99:1757-62 O
, O
2008 O
) O
. O

Safety O
and O
efficacy O
results O
from O
Asian O
versus O
non-Asian O
patients O
in O
BOLERO-2 O
are O
reported O
. O

Patients O
were O
randomized O
( O
2:1 O
) O
to O
10 O
mg/day O
EVE O
+ O
EXE O
or O
placebo O
( O
PBO O
) O
+ O
EXE O
. O

Primary O
endpoint O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Secondary O
endpoints O
included O
overall O
survival O
, O
response O
rate O
, O
clinical O
benefit O
rate O
, O
and O
safety O
. O

Of O
143 O
Asian O
patients O
, O
98 O
received O
EVE O
+ O
EXE O
and O
45 O
received O
PBO O
+ O
EXE O
. O

Treatment B-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
significantly I-Premise
improved I-Premise
median I-Premise
PFS I-Premise
versus I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
among I-Premise
Asian I-Premise
patients I-Premise
by I-Premise
38 I-Premise
% I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.62 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.41-0.94 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
also I-Premise
improved I-Premise
among I-Premise
non-Asian I-Premise
patients I-Premise
by I-Premise
59 I-Premise
% I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.41 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.33-0.50 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
duration I-Premise
among I-Premise
EVE-treated I-Premise
Asian I-Premise
patients I-Premise
was I-Premise
8.48 I-Premise
versus I-Premise
4.14 I-Premise
months I-Premise
for I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
, I-Premise
and I-Premise
7.33 I-Premise
versus I-Premise
2.83 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
non-Asian I-Premise
patients I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3/4 I-Premise
adverse I-Premise
events I-Premise
( I-Premise
stomatitis I-Premise
, I-Premise
anemia I-Premise
, I-Premise
elevated I-Premise
liver I-Premise
enzymes I-Premise
, I-Premise
hyperglycemia I-Premise
, I-Premise
and I-Premise
dyspnea I-Premise
) I-Premise
occurred I-Premise
at I-Premise
similar I-Premise
frequencies I-Premise
in I-Premise
Asian I-Premise
and I-Premise
non-Asian I-Premise
patients I-Premise
. I-Premise

Grade B-Premise
1/2 I-Premise
interstitial I-Premise
lung I-Premise
disease I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
Asian I-Premise
patients I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
Asian I-Premise
patients I-Premise
. I-Premise

Adding B-Claim
EVE I-Claim
to I-Claim
EXE I-Claim
provided I-Claim
substantial I-Claim
clinical I-Claim
benefit I-Claim
in I-Claim
both I-Claim
Asian I-Claim
and I-Claim
non-Asian I-Claim
patients I-Claim
with I-Claim
similar I-Claim
safety I-Claim
profiles I-Claim
. I-Claim

This B-Claim
combination I-Claim
represents I-Claim
an I-Claim
improvement I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
HR I-Claim
( I-Claim
+ I-Claim
) I-Claim
/HER2 I-Claim
( I-Claim
- I-Claim
) I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
progressing I-Claim
on I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
regardless I-Claim
of I-Claim
ethnicity I-Claim
. I-Claim

Older B-Claim
patients I-Claim
, I-Claim
even I-Claim
if I-Claim
fit I-Claim
, I-Claim
are I-Claim
often I-Claim
considered I-Claim
incapable I-Claim
of I-Claim
tolerating I-Claim
platinum-based I-Claim
systemic I-Claim
therapy I-Claim
. I-Claim

We O
performed O
a O
retrospective O
analysis O
of O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
5592 O
, O
a O
phase O
III O
randomized O
trial O
of O
platinum-based O
chemotherapy O
regimens O
for O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
, O
and O
compared O
outcomes O
in O
enrollees O
70 O
years O
of O
age O
and O
older O
with O
those O
in O
younger O
patients O
. O

ECOG O
carried O
out O
a O
randomized O
phase O
III O
trial O
of O
cisplatin O
plus O
either O
etoposide O
or O
paclitaxel O
in O
chemotherapy-naïve O
NSCLC O
patients O
with O
stages O
III O
( O
B O
) O
or O
IV O
disease O
. O

Toxic O
effects O
, O
response O
rates O
, O
and O
survival O
rates O
were O
compared O
between O
age O
groups O
. O

All O
P O
values O
were O
two-sided O
. O

A O
total O
of O
574 O
patients O
enrolled O
from O
August O
1993 O
through O
December O
1994 O
were O
evaluable O
. O

Eighty-six O
( O
15 O
% O
) O
were O
70 O
years O
old O
or O
older O
. O

Older B-Premise
patients I-Premise
had I-Premise
a I-Premise
higher I-Premise
incidence I-Premise
of I-Premise
cardiovascular I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
and I-Premise
respiratory I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
comorbidities I-Premise
and I-Premise
nonanalgesic I-Premise
medication I-Premise
use I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
. I-Premise

Leukopenia B-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
neuropsychiatric I-Premise
toxicity I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
elderly I-Premise
men I-Premise
than I-Premise
in I-Premise
younger I-Premise
men I-Premise
. I-Premise

Elderly B-Premise
women I-Premise
lost I-Premise
more I-Premise
weight I-Premise
than I-Premise
younger I-Premise
women I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

Other B-Premise
toxic I-Premise
effects I-Premise
were I-Premise
similar I-Premise
in I-Premise
older I-Premise
and I-Premise
younger I-Premise
patients I-Premise
. I-Premise

The B-Premise
proportions I-Premise
with I-Premise
clinical I-Premise
partial I-Premise
or I-Premise
complete I-Premise
response I-Premise
( I-Premise
21.5 I-Premise
% I-Premise
versus I-Premise
23.3 I-Premise
% I-Premise
";" I-Premise
Fisher I-Premise
's I-Premise
exact I-Premise
test I-Premise
, I-Premise
P I-Premise
=.66 I-Premise
) I-Premise
, I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
4.37 I-Premise
versus I-Premise
4.30 I-Premise
months I-Premise
";" I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.29 I-Premise
) I-Premise
, I-Premise
and I-Premise
survival I-Premise
distribution I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.29 I-Premise
";" I-Premise
median I-Premise
survival I-Premise
, I-Premise
9.05 I-Premise
versus I-Premise
8.53 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
, I-Premise
38 I-Premise
% I-Premise
versus I-Premise
29 I-Premise
% I-Premise
";" I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
, I-Premise
14 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
) I-Premise
were I-Premise
similar I-Premise
in I-Premise
patients I-Premise
younger I-Premise
than I-Premise
70 I-Premise
years I-Premise
and I-Premise
70 I-Premise
years I-Premise
old I-Premise
or I-Premise
older I-Premise
. I-Premise

Baseline B-Premise
quality-of-life I-Premise
and I-Premise
treatment-outcome I-Premise
indices I-Premise
were I-Premise
similar I-Premise
. I-Premise

Equivalent B-Premise
declines I-Premise
over I-Premise
time I-Premise
in I-Premise
functional I-Premise
well-being I-Premise
occurred I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Response B-Claim
rate I-Claim
, I-Claim
toxicity I-Claim
, I-Claim
and I-Claim
survival I-Claim
in I-Claim
fit I-Claim
, I-Claim
elderly I-Claim
NSCLC I-Claim
patients I-Claim
receiving I-Claim
platinum-based I-Claim
treatment I-Claim
appear I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
those I-Claim
in I-Claim
younger I-Claim
patients I-Claim
, I-Claim
although B-Claim
patients I-Claim
70 I-Claim
years I-Claim
old I-Claim
or I-Claim
older I-Claim
have I-Claim
more I-Claim
comorbidities I-Claim
and I-Claim
can I-Claim
expect I-Claim
more I-Claim
leukopenia I-Claim
and I-Claim
neuropsychiatric I-Claim
toxicity I-Claim
. I-Claim

Advanced B-Claim
age I-Claim
alone I-Claim
should I-Claim
not I-Claim
preclude I-Claim
appropriate I-Claim
NSCLC I-Claim
treatment I-Claim
. I-Claim

To O
investigate O
the O
effect O
of O
two O
doses O
of O
megestrol O
acetate O
( O
MA O
) O
compared O
with O
placebo O
on O
quality O
of O
life O
( O
QoL O
) O
and O
nutritional O
status O
( O
NS O
) O
in O
patients O
with O
advanced O
endocrine-insensitive O
cancer O
. O

Two O
hundred O
forty O
patients O
were O
randomised O
to O
double-blind O
MA O
480 O
mg/day O
, O
MA O
160 O
mg/day O
, O
or O
matching O
placebo O
for O
12 O
weeks O
. O

Nutritional O
status O
( O
including O
weight O
, O
skinfold O
thickness O
and O
midarm O
circumference O
) O
and O
QoL O
( O
using O
6 O
linear O
analogue O
self-assessment O
( O
LASA O
) O
scales O
) O
were O
assessed O
at O
randomisation O
and O
after O
four O
, O
eight O
and O
12 O
weeks O
. O

A O
QoL O
ranking O
incorporating O
QoL O
and O
death O
was O
also O
used O
ranging O
from O
1 O
= O
dead O
to O
5 O
= O
much O
better O
QoL O
. O

One O
hundred O
seventy-four O
patients O
were O
assessable O
at O
week O
four O
, O
136 O
at O
week O
eight O
and O
103 O
patients O
at O
week O
12 O
. O

Patients B-Premise
receiving I-Premise
MA I-Premise
reported I-Premise
substantially I-Premise
better I-Premise
appetite I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
possibly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
than I-Premise
patients I-Premise
receiving I-Premise
placebo I-Premise
, I-Premise
based I-Premise
on I-Premise
a I-Premise
test I-Premise
for I-Premise
trend I-Premise
. I-Premise

A B-Premise
larger I-Premise
benefit I-Premise
was I-Premise
seen I-Premise
with I-Premise
the I-Premise
higher I-Premise
dose I-Premise
which I-Premise
( I-Premise
unlike I-Premise
the I-Premise
lower I-Premise
dose I-Premise
) I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
pairwise I-Premise
comparisons I-Premise
with I-Premise
placebo I-Premise
for I-Premise
appetite I-Premise
, I-Premise
mood I-Premise
and I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
each I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Despite B-Premise
some I-Premise
missing I-Premise
data I-Premise
on I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
QoL I-Premise
ranking I-Premise
was I-Premise
available I-Premise
on I-Premise
227 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
of I-Premise
patients I-Premise
with I-Premise
significantly I-Premise
higher I-Premise
QoL I-Premise
ranking I-Premise
associated I-Premise
with I-Premise
MA I-Premise
( I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
QoL I-Premise
occurred I-Premise
early I-Premise
within I-Premise
four I-Premise
weeks I-Premise
and I-Premise
were I-Premise
sustained I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
NS I-Premise
measurements I-Premise
, I-Premise
including I-Premise
weight I-Premise
( I-Premise
P I-Premise
= I-Premise
0.29 I-Premise
) I-Premise
. I-Premise

Side B-Premise
effects I-Premise
of I-Premise
therapy I-Premise
were I-Premise
minor I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
across I-Premise
treatments I-Premise
. I-Premise

Megestrol B-Claim
acetate I-Claim
given I-Claim
at I-Claim
480 I-Claim
mg/day I-Claim
is I-Claim
useful I-Claim
palliation I-Claim
in I-Claim
patients I-Claim
with I-Claim
endocrine-insensitive I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

It B-Claim
improves I-Claim
appetite I-Claim
, I-Claim
mood I-Claim
and I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
these I-Claim
patients I-Claim
, I-Claim
although B-Claim
not I-Claim
through I-Claim
a I-Claim
direct I-Claim
effect I-Claim
on I-Claim
nutritional I-Claim
status I-Claim
. I-Claim

Suramin B-Claim
is I-Claim
a I-Claim
novel I-Claim
agent I-Claim
that I-Claim
has I-Claim
demonstrated I-Claim
preliminary I-Claim
evidence I-Claim
of I-Claim
antitumor I-Claim
activity I-Claim
in I-Claim
hormone-refractory I-Claim
prostate I-Claim
cancer I-Claim
( I-Claim
HRPC I-Claim
) I-Claim
. I-Claim

A O
prospective O
randomized O
clinical O
trial O
was O
designed O
to O
evaluate O
pain O
and O
opioid O
analgesic O
intake O
as O
surrogates O
for O
antitumor O
response O
in O
HRPC O
patients O
with O
significant O
, O
opioid O
analgesic-dependent O
pain O
. O

A O
double-blind O
, O
placebo-controlled O
trial O
randomized O
patients O
to O
receive O
a O
78-day O
, O
outpatient O
regimen O
of O
either O
suramin O
plus O
hydrocortisone O
( O
HC O
, O
40 O
mg/d O
) O
or O
placebo O
plus O
HC O
. O

Treatment O
assignment O
was O
unblinded O
when O
either O
disease O
progression O
or O
dose-limiting O
toxicity O
occurred O
";" O
placebo O
patients O
were O
allowed O
to O
cross-over O
to O
open-label O
suramin O
plus O
HC O
. O

In O
addition O
to O
pain O
and O
opioid O
analgesic O
intake O
, O
prostate-specific O
antigen O
( O
PSA O
) O
response O
, O
time O
to O
disease O
progression O
, O
quality O
of O
life O
, O
performance O
status O
, O
and O
survival O
were O
compared O
. O

Overall B-Premise
mean I-Premise
reductions I-Premise
in I-Premise
combined I-Premise
pain I-Premise
and I-Premise
opioid I-Premise
analgesic I-Premise
intake I-Premise
were I-Premise
greater I-Premise
for I-Premise
suramin I-Premise
plus I-Premise
HC I-Premise
( I-Premise
rank I-Premise
sum I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
response I-Premise
was I-Premise
achieved I-Premise
in I-Premise
a I-Premise
higher I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
suramin I-Premise
than I-Premise
placebo I-Premise
( I-Premise
43 I-Premise
% I-Premise
v I-Premise
28 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
, I-Premise
and O
duration B-Premise
of I-Premise
response I-Premise
was I-Premise
longer I-Premise
for I-Premise
suramin I-Premise
responders I-Premise
( I-Premise
median I-Premise
, I-Premise
240 I-Premise
v I-Premise
69 I-Premise
days I-Premise
";" I-Premise
P I-Premise
=.0027 I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
disease I-Premise
progression I-Premise
was I-Premise
longer I-Premise
( I-Premise
relative I-Premise
risk I-Premise
= I-Premise
1.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.2 I-Premise
to I-Premise
1.9 I-Premise
) I-Premise
and O
the B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
with I-Premise
a I-Premise
greater I-Premise
than I-Premise
50 I-Premise
% I-Premise
decline I-Premise
in I-Premise
PSA I-Premise
was I-Premise
higher I-Premise
( I-Premise
33 I-Premise
% I-Premise
v I-Premise
16 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
suramin I-Premise
. I-Premise

Neither B-Premise
quality I-Premise
of I-Premise
life I-Premise
nor I-Premise
performance I-Premise
status I-Premise
was I-Premise
decreased I-Premise
by I-Premise
suramin I-Premise
treatment I-Premise
, I-Premise
and O
overall B-Premise
survival I-Premise
was I-Premise
similar I-Premise
. I-Premise

Most B-Premise
adverse I-Premise
events I-Premise
were I-Premise
of I-Premise
mild I-Premise
or I-Premise
moderate I-Premise
intensity I-Premise
and I-Premise
were I-Premise
easily I-Premise
managed I-Premise
medically I-Premise
. I-Premise

Outpatient B-Claim
treatment I-Claim
with I-Claim
suramin I-Claim
plus I-Claim
HC I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
provides I-Claim
moderate I-Claim
palliative I-Claim
benefit I-Claim
and I-Claim
delay I-Claim
in I-Claim
disease I-Claim
progression I-Claim
for I-Claim
patients I-Claim
with I-Claim
symptomatic I-Claim
HRPC I-Claim
. I-Claim

To O
compare O
vinflunine O
( O
VFL O
) O
to O
docetaxel O
in O
patients O
with O
stage O
IIIB/IV O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
who O
have O
experienced O
treatment O
failure O
with O
first-line O
platinum-based O
chemotherapy O
. O

Randomized O
, O
multicenter O
, O
phase O
III O
study O
, O
551 O
patients O
received O
either O
vinflunine O
320 O
mg/m O
( O
2 O
) O
or O
docetaxel O
75 O
mg/m O
( O
2 O
) O
every O
21 O
days O
until O
disease O
progression O
or O
serious O
toxicity O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

The O
noninferiority O
analysis O
was O
based O
on O
a O
10 O
% O
difference O
( O
types O
I/II O
error O
rates O
: O
5 O
% O
/20 O
% O
) O
. O

Secondary O
end O
points O
included O
response O
rate O
( O
ORR O
) O
, O
response O
duration O
, O
overall O
survival O
( O
OS O
) O
, O
clinical O
benefit O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
safety O
. O

Median B-Premise
PFS I-Premise
was I-Premise
2.3 I-Premise
months I-Premise
for I-Premise
each I-Premise
arm I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.004 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.841 I-Premise
to I-Premise
1.199 I-Premise
) I-Premise
. I-Premise

ORR B-Premise
, I-Premise
stable I-Premise
disease I-Premise
, I-Premise
median I-Premise
OS I-Premise
, I-Premise
were I-Premise
4.4 I-Premise
% I-Premise
versus I-Premise
5.5 I-Premise
% I-Premise
, I-Premise
36.0 I-Premise
% I-Premise
versus I-Premise
39.6 I-Premise
% I-Premise
, I-Premise
6.7 I-Premise
versus I-Premise
7.2 I-Premise
months I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.973 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.805 I-Premise
to I-Premise
1.176 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
patient I-Premise
benefit I-Premise
and I-Premise
QOL I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
) I-Premise
. I-Premise

No B-Premise
unexpected I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
. I-Premise

Grade B-Premise
higher I-Premise
than I-Premise
0 I-Premise
( I-Premise
vinflunine I-Premise
v I-Premise
docetaxel I-Premise
) I-Premise
anemia I-Premise
( I-Premise
82.1 I-Premise
% I-Premise
v I-Premise
79.8 I-Premise
% I-Premise
) I-Premise
, I-Premise
neutropenia I-Premise
( I-Premise
49.3 I-Premise
v I-Premise
39.02 I-Premise
% I-Premise
) I-Premise
, I-Premise
thrombocytopenia I-Premise
( I-Premise
30.6 I-Premise
% I-Premise
v I-Premise
14.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3.3 I-Premise
% I-Premise
v I-Premise
4.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
39.2 I-Premise
% I-Premise
v I-Premise
11.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
36.6 I-Premise
% I-Premise
v I-Premise
33.9 I-Premise
% I-Premise
) I-Premise
, I-Premise
injection I-Premise
site I-Premise
reaction I-Premise
( I-Premise
31.9 I-Premise
% I-Premise
v I-Premise
0.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
nausea I-Premise
( I-Premise
26.7 I-Premise
% I-Premise
v I-Premise
23.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
23.8 I-Premise
% I-Premise
v I-Premise
14.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
alopecia I-Premise
( I-Premise
19.8 I-Premise
% I-Premise
v I-Premise
35.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatis I-Premise
( I-Premise
19.4 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
abdominal I-Premise
pain I-Premise
( I-Premise
20.1 I-Premise
% I-Premise
v I-Premise
3.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
myalgia I-Premise
( I-Premise
14.7 I-Premise
% I-Premise
v I-Premise
6.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
10.7 I-Premise
% I-Premise
v I-Premise
15.0 I-Premise
% I-Premise
) I-Premise
, I-Premise
arthralgia I-Premise
( I-Premise
7.0 I-Premise
% I-Premise
v I-Premise
7.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
6.2 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
edema I-Premise
( I-Premise
1.5 I-Premise
% I-Premise
v I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
nail I-Premise
disorders I-Premise
( I-Premise
1.1 I-Premise
% I-Premise
v I-Premise
5 I-Premise
";" I-Premise
1 I-Premise
% I-Premise
) I-Premise
were I-Premise
observed I-Premise
. I-Premise

This B-Claim
noninferiority I-Claim
phase I-Claim
III I-Claim
study I-Claim
showed I-Claim
similar I-Claim
efficacy I-Claim
end I-Claim
points I-Claim
for I-Claim
vinflunine I-Claim
and I-Claim
docetaxel I-Claim
. I-Claim

Despite B-Claim
higher I-Claim
rates I-Claim
of I-Claim
some I-Claim
adverse I-Claim
effects I-Claim
( I-Claim
anemia I-Claim
, I-Claim
abdominal I-Claim
pain I-Claim
, I-Claim
constipation I-Claim
, I-Claim
fatigue I-Claim
) I-Claim
the B-Claim
overall I-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
vinflunine I-Claim
was I-Claim
manageable I-Claim
. I-Claim

Therefore O
, O
VFL B-Claim
may I-Claim
be I-Claim
another I-Claim
option I-Claim
in I-Claim
the I-Claim
second-line I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

This O
randomised O
, O
placebo-controlled O
single-blind O
trial O
investigated O
the O
safety O
and O
efficacy O
of O
SAMITAL® O
, O
a O
formulation O
of O
highly O
standardised O
botanical O
extracts O
, O
in O
the O
treatment O
of O
chemo/radiotherapy-induced O
oral O
mucositis O
( O
OM O
) O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Patients O
received O
SAMITAL® O
or O
placebo O
four O
times O
daily O
for O
up O
to O
50 O
days O
during O
scheduled O
chemo/radiotherapy O
. O

Severity O
of O
OM O
was O
monitored O
according O
to O
a O
modified O
WHO O
severity O
scale O
, O
and O
pain O
and O
quality-of-life O
assessments O
were O
based O
on O
the O
effect O
of O
symptoms O
of O
OM O
on O
relevant O
daily O
activities O
, O
according O
to O
a O
visual O
analogue O
scale O
. O

Mean B-Premise
scores I-Premise
for I-Premise
the I-Premise
severity I-Premise
of I-Premise
OM I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
versus I-Premise
baseline I-Premise
) I-Premise
reduced I-Premise
from I-Premise
day I-Premise
31 I-Premise
until I-Premise
the I-Premise
end I-Premise
of I-Premise
treatment I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
SAMITAL® I-Premise
( I-Premise
n I-Premise
= I-Premise
20 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
10 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
reduction I-Premise
was I-Premise
significant I-Premise
from I-Premise
day I-Premise
4 I-Premise
till I-Premise
end I-Premise
of I-Premise
treatment I-Premise
with I-Premise
SAMITAL® I-Premise
and I-Premise
from I-Premise
days I-Premise
7 I-Premise
to I-Premise
21 I-Premise
in I-Premise
placebo I-Premise
patients I-Premise
. I-Premise

SAMITAL® B-Premise
also I-Premise
significantly I-Premise
improved I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
as I-Premise
shown I-Premise
by I-Premise
improvements I-Premise
in I-Premise
scores I-Premise
for I-Premise
relevant I-Premise
daily I-Premise
activities I-Premise
including I-Premise
eating I-Premise
, I-Premise
drinking I-Premise
and I-Premise
sleeping I-Premise
. I-Premise

All O
SAMITAL® O
patients O
completed O
the O
treatment O
period O
, O
but O
no O
placebo O
recipients O
completed O
treatment O
. O

No B-Premise
severe I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
with I-Premise
SAMITAL® I-Premise
, I-Premise
and I-Premise
systemic I-Premise
absorption I-Premise
of I-Premise
relevant I-Premise
active I-Premise
ingredients I-Premise
was I-Premise
undetectable I-Premise
. I-Premise

SAMITAL® B-Claim
significantly I-Claim
decreased I-Claim
the I-Claim
severity I-Claim
of I-Claim
chemo/radiotherapy-induced I-Claim
OM I-Claim
in I-Claim
patients I-Claim
with I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
, I-Claim
with I-Claim
no I-Claim
treatment-related I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Pain B-Claim
relief I-Claim
lasted I-Claim
through I-Claim
the I-Claim
treatment I-Claim
period I-Claim
, I-Claim
and I-Claim
improvements I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
were I-Claim
reflected I-Claim
by I-Claim
the I-Claim
significant I-Claim
benefits I-Claim
of I-Claim
SAMITAL® I-Claim
on I-Claim
activities I-Claim
like I-Claim
drinking I-Claim
, I-Claim
eating I-Claim
and I-Claim
speaking I-Claim
. I-Claim

Patients O
who O
develop O
castration-resistant O
prostate O
cancer O
( O
CRPCa O
) O
typically O
continue O
on O
androgen O
deprivation O
therapy O
( O
ADT O
) O
. O

Whether O
these O
patients O
need O
to O
remain O
on O
ADT O
has O
not O
been O
well O
studied O
. O

We O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
an O
intermittent O
versus O
continuous O
approach O
to O
ADT O
in O
CRPCa O
patients O
. O

Overall O
survival O
, O
health-related O
quality O
of O
life O
( O
QOL O
) O
, O
and O
cost O
were O
the O
main O
endpoints O
. O

CRPCa O
patients O
were O
randomized O
2:1 O
to O
intermittent O
or O
continuous O
luteinizing O
hormone-releasing O
hormone O
agonists O
( O
LHRHa O
) O
. O

Patients O
were O
followed O
with O
clinical O
assessments O
, O
laboratory O
investigations O
, O
and O
QOL O
questionnaires O
( O
EORTC O
QLQ-C30 O
or O
PROSQOLI O
) O
every O
2 O
months O
. O

If O
the O
serum O
testosterone O
rose O
above O
castrate O
levels O
( O
1.75 O
nmol/L O
) O
, O
LHRHa O
were O
reinitiated O
. O

The O
study O
was O
designed O
to O
close O
if O
> O
50 O
% O
of O
patients O
needed O
to O
restart O
ADT O
in O
the O
intermittent O
arm O
. O

Thirty-one O
patients O
were O
followed O
with O
a O
median O
follow-up O
of O
26.8 O
months-18 O
in O
the O
intermittent O
arm O
and O
13 O
in O
the O
continuous O
. O

Twelve O
of O
18 O
patients O
on O
the O
intermittent O
arm O
were O
reinitiated O
on O
LHRHa O
at O
a O
median O
time O
of O
17.9 O
months O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
or I-Premise
cancer-specific I-Premise
survival I-Premise
between I-Premise
the I-Premise
2 I-Premise
arms I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
between I-Premise
the I-Premise
2 I-Premise
arms I-Premise
at I-Premise
0 I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

The B-Premise
total I-Premise
mean I-Premise
costs I-Premise
at I-Premise
24 I-Premise
months I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
intermittent I-Premise
arm I-Premise
( I-Premise
$ I-Premise
3135 I-Premise
vs. I-Premise
$ I-Premise
8253 I-Premise
Canadian I-Premise
dollars I-Premise
, I-Premise
P=0.0167 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
continuous I-Premise
. I-Premise

The B-Premise
main I-Premise
limitation I-Premise
of I-Premise
this I-Premise
study I-Premise
is I-Premise
the I-Premise
small I-Premise
sample I-Premise
size I-Premise
. I-Premise

We B-Claim
have I-Claim
observed I-Claim
that I-Claim
intermittent I-Claim
ADT I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPCa I-Claim
, I-Claim
using I-Claim
a I-Claim
testosterone I-Claim
of I-Claim
> I-Claim
1.75 I-Claim
ngmol/L I-Claim
as I-Claim
a I-Claim
trigger I-Claim
to I-Claim
reinitiate I-Claim
LHRHa I-Claim
, I-Claim
results I-Claim
in I-Claim
a I-Claim
substantial I-Claim
cost I-Claim
savings I-Claim
with I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
oncologic I-Claim
and I-Claim
QOL I-Claim
outcomes I-Claim
. I-Claim

Menopausal O
hormone O
therapy O
continues O
in O
clinical O
use O
but O
questions O
remain O
regarding O
its O
risks O
and O
benefits O
for O
chronic O
disease O
prevention O
. O

To O
report O
a O
comprehensive O
, O
integrated O
overview O
of O
findings O
from O
the O
2 O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
hormone O
therapy O
trials O
with O
extended O
postintervention O
follow-up O
. O

A O
total O
of O
27,347 O
postmenopausal O
women O
aged O
50 O
to O
79 O
years O
were O
enrolled O
at O
40 O
US O
centers O
. O

Women O
with O
an O
intact O
uterus O
received O
conjugated O
equine O
estrogens O
( O
CEE O
";" O
0.625 O
mg/d O
) O
plus O
medroxyprogesterone O
acetate O
( O
MPA O
";" O
2.5 O
mg/d O
) O
( O
n O
= O
8506 O
) O
or O
placebo O
( O
n O
= O
8102 O
) O
. O

Women O
with O
prior O
hysterectomy O
received O
CEE O
alone O
( O
0.625 O
mg/d O
) O
( O
n O
= O
5310 O
) O
or O
placebo O
( O
n O
= O
5429 O
) O
. O

The O
intervention O
lasted O
a O
median O
of O
5.6 O
years O
in O
CEE O
plus O
MPA O
trial O
and O
7.2 O
years O
in O
CEE O
alone O
trial O
with O
13 O
years O
of O
cumulative O
follow-up O
until O
September O
30 O
, O
2010 O
. O

Primary O
efficacy O
and O
safety O
outcomes O
were O
coronary O
heart O
disease O
( O
CHD O
) O
and O
invasive O
breast O
cancer O
, O
respectively O
. O

A O
global O
index O
also O
included O
stroke O
, O
pulmonary O
embolism O
, O
colorectal O
cancer O
, O
endometrial O
cancer O
, O
hip O
fracture O
, O
and O
death O
. O

During B-Premise
the I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
intervention I-Premise
phase I-Premise
, I-Premise
the I-Premise
numbers I-Premise
of I-Premise
CHD I-Premise
cases I-Premise
were I-Premise
196 I-Premise
for I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
vs I-Premise
159 I-Premise
for I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.95-1.45 I-Premise
) I-Premise
and I-Premise
206 I-Premise
vs I-Premise
155 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.24 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.01-1.53 I-Premise
) I-Premise
. I-Premise

Other B-Premise
risks I-Premise
included I-Premise
increased I-Premise
stroke I-Premise
, I-Premise
pulmonary I-Premise
embolism I-Premise
, I-Premise
dementia I-Premise
( I-Premise
in I-Premise
women I-Premise
aged I-Premise
≥65 I-Premise
years I-Premise
) I-Premise
, I-Premise
gallbladder I-Premise
disease I-Premise
, I-Premise
and I-Premise
urinary I-Premise
incontinence I-Premise
";" I-Premise
benefits I-Premise
included I-Premise
decreased I-Premise
hip I-Premise
fractures I-Premise
, I-Premise
diabetes I-Premise
, I-Premise
and I-Premise
vasomotor I-Premise
symptoms I-Premise
. I-Premise

Most B-Premise
risks I-Premise
and I-Premise
benefits I-Premise
dissipated I-Premise
postintervention I-Premise
, I-Premise
although B-Premise
some I-Premise
elevation I-Premise
in I-Premise
breast I-Premise
cancer I-Premise
risk I-Premise
persisted I-Premise
during I-Premise
cumulative I-Premise
follow-up I-Premise
( I-Premise
434 I-Premise
cases I-Premise
for I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
vs I-Premise
323 I-Premise
for I-Premise
placebo I-Premise
";" I-Premise
HR I-Premise
, I-Premise
1.28 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.11-1.48 I-Premise
] I-Premise
) I-Premise
. I-Premise

The B-Premise
risks I-Premise
and I-Premise
benefits I-Premise
were I-Premise
more I-Premise
balanced I-Premise
during I-Premise
the I-Premise
CEE I-Premise
alone I-Premise
intervention I-Premise
with I-Premise
204 I-Premise
CHD I-Premise
cases I-Premise
for I-Premise
CEE I-Premise
alone I-Premise
vs I-Premise
222 I-Premise
cases I-Premise
for I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.94 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.78-1.14 I-Premise
) I-Premise
and I-Premise
104 I-Premise
vs I-Premise
135 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.79 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.61-1.02 I-Premise
) I-Premise
";" I-Premise
cumulatively I-Premise
, I-Premise
there I-Premise
were I-Premise
168 I-Premise
vs I-Premise
216 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
cases I-Premise
of I-Premise
breast I-Premise
cancer I-Premise
diagnosed I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.79 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.65-0.97 I-Premise
) I-Premise
. I-Premise

Results O
for O
other O
outcomes O
were O
similar O
to O
CEE O
plus O
MPA O
. O

Neither O
regimen O
affected O
all-cause O
mortality O
. O

For B-Premise
CEE I-Premise
alone I-Premise
, I-Premise
younger I-Premise
women I-Premise
( I-Premise
aged I-Premise
50-59 I-Premise
years I-Premise
) I-Premise
had I-Premise
more I-Premise
favorable I-Premise
results I-Premise
for I-Premise
all-cause I-Premise
mortality I-Premise
, I-Premise
myocardial I-Premise
infarction I-Premise
, I-Premise
and I-Premise
the I-Premise
global I-Premise
index I-Premise
( I-Premise
nominal I-Premise
P I-Premise
< I-Premise
.05 I-Premise
for I-Premise
trend I-Premise
by I-Premise
age I-Premise
) I-Premise
. I-Premise

Absolute B-Premise
risks I-Premise
of I-Premise
adverse I-Premise
events I-Premise
( I-Premise
measured I-Premise
by I-Premise
the I-Premise
global I-Premise
index I-Premise
) I-Premise
per I-Premise
10,000 I-Premise
women I-Premise
annually I-Premise
taking I-Premise
CEE I-Premise
plus I-Premise
MPA I-Premise
ranged I-Premise
from I-Premise
12 I-Premise
excess I-Premise
cases I-Premise
for I-Premise
ages I-Premise
of I-Premise
50-59 I-Premise
years I-Premise
to I-Premise
38 I-Premise
for I-Premise
ages I-Premise
of I-Premise
70-79 I-Premise
years I-Premise
";" I-Premise
for I-Premise
women I-Premise
taking I-Premise
CEE I-Premise
alone I-Premise
, I-Premise
from I-Premise
19 I-Premise
fewer I-Premise
cases I-Premise
for I-Premise
ages I-Premise
of I-Premise
50-59 I-Premise
years I-Premise
to I-Premise
51 I-Premise
excess I-Premise
cases I-Premise
for I-Premise
ages I-Premise
of I-Premise
70-79 I-Premise
years I-Premise
. I-Premise

Quality-of-life O
outcomes O
had O
mixed O
results O
in O
both O
trials O
. O

Menopausal B-Claim
hormone I-Claim
therapy I-Claim
has I-Claim
a I-Claim
complex I-Claim
pattern I-Claim
of I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
. I-Claim

Findings B-Claim
from I-Claim
the I-Claim
intervention I-Claim
and I-Claim
extended I-Claim
postintervention I-Claim
follow-up I-Claim
of I-Claim
the I-Claim
2 I-Claim
WHI I-Claim
hormone I-Claim
therapy I-Claim
trials I-Claim
do I-Claim
not I-Claim
support I-Claim
use I-Claim
of I-Claim
this I-Claim
therapy I-Claim
for I-Claim
chronic I-Claim
disease I-Claim
prevention I-Claim
, I-Claim
although B-Claim
it I-Claim
is I-Claim
appropriate I-Claim
for I-Claim
symptom I-Claim
management I-Claim
in I-Claim
some I-Claim
women I-Claim
. I-Claim

Colorectal O
cancer O
survivors O
are O
at O
risk O
for O
poor O
health O
outcomes O
because O
of O
unhealthy O
lifestyles O
, O
but O
few O
studies O
have O
developed O
translatable O
health O
behavior O
change O
interventions O
. O

This O
study O
aimed O
to O
determine O
the O
effects O
of O
a O
telephone-delivered O
multiple O
health O
behavior O
change O
intervention O
( O
CanChange O
) O
on O
health O
and O
behavioral O
outcomes O
among O
colorectal O
cancer O
survivors O
. O

In O
this O
two-group O
randomized O
controlled O
trial O
, O
410 O
colorectal O
cancer O
survivors O
were O
randomly O
assigned O
to O
the O
health O
coaching O
intervention O
( O
11 O
theory-based O
telephone-delivered O
health O
coaching O
sessions O
delivered O
over O
6 O
months O
focusing O
on O
physical O
activity O
, O
weight O
management O
, O
dietary O
habits O
, O
alcohol O
, O
and O
smoking O
) O
or O
usual O
care O
. O

Assessment O
of O
primary O
( O
ie O
, O
physical O
activity O
[ O
Godin O
Leisure O
Time O
Index O
] O
, O
health-related O
quality O
of O
life O
[ O
HRQoL O
";" O
Short O
Form-36 O
] O
, O
and O
cancer-related O
fatigue O
[ O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Fatigue O
Scale O
] O
) O
and O
secondary O
outcomes O
( O
ie O
, O
body O
mass O
index O
[ O
kg/m O
( O
2 O
) O
] O
, O
diet O
and O
alcohol O
intake O
[ O
Food O
Frequency O
Questionnaire O
] O
, O
and O
smoking O
) O
were O
conducted O
at O
baseline O
and O
6 O
and O
12 O
months O
. O

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
significant I-Premise
intervention I-Premise
effects I-Premise
were I-Premise
observed I-Premise
for I-Premise
moderate I-Premise
physical I-Premise
activity I-Premise
( I-Premise
28.5 I-Premise
minutes I-Premise
";" I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
-0.9 I-Premise
kg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
energy I-Premise
from I-Premise
total I-Premise
fat I-Premise
( I-Premise
-7.0 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
and I-Premise
energy I-Premise
from I-Premise
saturated I-Premise
fat I-Premise
( I-Premise
-2.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.016 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
intervention I-Premise
effect I-Premise
was I-Premise
reported I-Premise
for I-Premise
vegetable I-Premise
intake I-Premise
( I-Premise
0.4 I-Premise
servings I-Premise
per I-Premise
day I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

No B-Premise
significant I-Premise
group I-Premise
differences I-Premise
were I-Premise
found I-Premise
at I-Premise
6 I-Premise
or I-Premise
12 I-Premise
months I-Premise
for I-Premise
HRQoL I-Premise
, I-Premise
cancer-related I-Premise
fatigue I-Premise
, I-Premise
fruit I-Premise
, I-Premise
fiber I-Premise
, I-Premise
or I-Premise
alcohol I-Premise
intake I-Premise
, I-Premise
or I-Premise
smoking I-Premise
. I-Premise

The B-Claim
CanChange I-Claim
intervention I-Claim
was I-Claim
effective I-Claim
for I-Claim
improving I-Claim
physical I-Claim
activity I-Claim
, I-Claim
dietary I-Claim
habits I-Claim
, I-Claim
and I-Claim
body I-Claim
mass I-Claim
index I-Claim
in I-Claim
colorectal I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

The O
intervention O
is O
translatable O
through O
existing O
telephone O
cancer O
support O
and O
information O
services O
in O
Australia O
and O
other O
countries O
. O

Evaluation O
of O
health-related O
quality-of-life O
( O
HRQoL O
) O
and O
symptom O
improvement O
were O
preplanned O
secondary O
objectives O
for O
the O
overall O
population O
and O
posthoc O
analyses O
for O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
mutation-positive/negative O
subgroups O
in O
IPASS O
. O

HRQoL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
( O
FACT-L O
) O
and O
Trial O
Outcome O
Index O
( O
TOI O
) O
";" O
symptom O
improvement O
by O
the O
Lung O
Cancer O
Subscale O
( O
LCS O
) O
. O

Improvements O
defined O
as O
: O
6 O
or O
more O
( O
FACT-L O
";" O
TOI O
) O
, O
2 O
or O
more O
( O
LCS O
) O
points O
increase O
maintained O
for O
21 O
or O
more O
days O
. O

Overall O
( O
n O
= O
1151/1217 O
evaluable O
) O
, O
HRQoL O
improvement O
rates O
were O
significantly O
greater O
with O
gefitinib O
versus O
carboplatin/paclitaxel O
";" O
symptom O
improvement O
rates O
were O
similar O
for O
both O
treatments O
. O

Significantly B-Premise
more I-Premise
patients I-Premise
recorded I-Premise
improvements I-Premise
in I-Premise
HRQoL I-Premise
and I-Premise
symptoms I-Premise
with I-Premise
gefitinib I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
mutation-positive I-Premise
subgroup I-Premise
( I-Premise
n I-Premise
= I-Premise
259 I-Premise
";" I-Premise
FACT-L I-Premise
70.2 I-Premise
% I-Premise
versus I-Premise
44.5 I-Premise
% I-Premise
";" I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
3.01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.79-5.07 I-Premise
] I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
";" I-Premise
TOI I-Premise
70.2 I-Premise
% I-Premise
versus I-Premise
38.3 I-Premise
% I-Premise
";" I-Premise
3.96 I-Premise
[ I-Premise
2.33-6.71 I-Premise
] I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
";" I-Premise
LCS I-Premise
75.6 I-Premise
% I-Premise
versus I-Premise
53.9 I-Premise
% I-Premise
";" I-Premise
2.70 I-Premise
[ I-Premise
1.58-4.62 I-Premise
] I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
with I-Premise
carboplatin/paclitaxel I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
mutation-negative I-Premise
subgroup I-Premise
( I-Premise
n I-Premise
= I-Premise
169 I-Premise
";" I-Premise
FACT-L I-Premise
14.6 I-Premise
% I-Premise
versus I-Premise
36.3 I-Premise
% I-Premise
";" I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
0.31 I-Premise
[ I-Premise
0.15-0.65 I-Premise
] I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
";" I-Premise
TOI I-Premise
12.4 I-Premise
% I-Premise
versus I-Premise
28.8 I-Premise
% I-Premise
";" I-Premise
0.35 I-Premise
[ I-Premise
0.16-0.79 I-Premise
] I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.011 I-Premise
";" I-Premise
LCS I-Premise
20.2 I-Premise
% I-Premise
versus I-Premise
47.5 I-Premise
% I-Premise
";" I-Premise
0.28 I-Premise
[ I-Premise
0.14-0.55 I-Premise
] I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time-to-worsening I-Premise
( I-Premise
months I-Premise
) I-Premise
FACT-L I-Premise
score I-Premise
was I-Premise
longer I-Premise
with I-Premise
gefitinib I-Premise
versus I-Premise
carboplatin/paclitaxel I-Premise
for I-Premise
the I-Premise
overall I-Premise
population I-Premise
( I-Premise
8.3 I-Premise
versus I-Premise
2.5 I-Premise
) I-Premise
and I-Premise
EGFR I-Premise
mutation-positive I-Premise
subgroup I-Premise
( I-Premise
15.6 I-Premise
versus I-Premise
3.0 I-Premise
) I-Premise
, I-Premise
and I-Premise
similar I-Premise
for I-Premise
both I-Premise
treatments I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
mutation-negative I-Premise
subgroup I-Premise
( I-Premise
1.4 I-Premise
versus I-Premise
1.4 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time-to-improvement I-Premise
with I-Premise
gefitinib I-Premise
was I-Premise
8 I-Premise
days I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
mutation-positive I-Premise
tumors I-Premise
who I-Premise
improved I-Premise
. I-Premise

HRQoL B-Claim
and I-Claim
symptom I-Claim
endpoints I-Claim
were I-Claim
consistent I-Claim
with I-Claim
efficacy I-Claim
outcomes I-Claim
in I-Claim
IPASS I-Claim
and I-Claim
favored I-Claim
gefitinib I-Claim
in I-Claim
patients I-Claim
with I-Claim
EGFR I-Claim
mutation-positive I-Claim
tumors I-Claim
and I-Claim
carboplatin/paclitaxel I-Claim
in I-Claim
patients I-Claim
with I-Claim
EGFR I-Claim
mutation-negative I-Claim
tumors I-Claim
. I-Claim

In B-Claim
a I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
infusion I-Claim
with I-Claim
adenosine I-Claim
5'-triphosphate I-Claim
( I-Claim
ATP I-Claim
) I-Claim
inhibited I-Claim
loss I-Claim
of I-Claim
body I-Claim
weight I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

In O
the O
present O
article O
, O
the O
effects O
of O
ATP O
on O
body O
composition O
, O
energy O
intake O
, O
and O
energy O
expenditure O
as O
secondary O
outcome O
measures O
in O
the O
same O
patients O
are O
reported O
. O

Patients O
with O
NSCLC O
, O
stage O
IIIB O
or O
IV O
, O
were O
randomized O
to O
receive O
either O
10 O
intravenous O
, O
30-hour O
ATP O
infusions O
every O
2 O
to O
4 O
weeks O
or O
no O
ATP O
. O

Fat O
mass O
( O
FM O
) O
, O
fat-free O
mass O
( O
FFM O
) O
, O
and O
arm O
muscle O
area O
were O
assessed O
at O
4-week O
intervals O
for O
28 O
weeks O
. O

Food O
intake O
, O
body O
cell O
mass O
( O
BCM O
) O
, O
and O
resting O
energy O
expenditure O
( O
REE O
) O
were O
assessed O
at O
8-week O
intervals O
for O
16 O
weeks O
. O

Between-group O
differences O
were O
tested O
for O
statistical O
significance O
by O
repeated-measures O
analysis O
of O
covariance O
. O

Fifty-eight O
patients O
were O
randomized O
( O
28 O
ATP O
, O
30 O
control O
) O
. O

No B-Premise
change I-Premise
in I-Premise
body I-Premise
composition I-Premise
over I-Premise
the I-Premise
28-week I-Premise
follow-up I-Premise
period I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
, I-Premise
whereas I-Premise
, I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
, I-Premise
the I-Premise
control I-Premise
group I-Premise
lost I-Premise
0.6 I-Premise
kg I-Premise
of I-Premise
FM I-Premise
( I-Premise
P I-Premise
=.004 I-Premise
) I-Premise
, I-Premise
0.5 I-Premise
kg I-Premise
of I-Premise
FFM I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
, I-Premise
1.8 I-Premise
% I-Premise
of I-Premise
arm I-Premise
muscle I-Premise
area I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
0.6 I-Premise
% I-Premise
of I-Premise
BCM/kg I-Premise
body I-Premise
weight I-Premise
( I-Premise
P I-Premise
=.054 I-Premise
) I-Premise
and I-Premise
decreased I-Premise
568 I-Premise
KJ/d I-Premise
in I-Premise
energy I-Premise
intake I-Premise
( I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

Appetite B-Premise
also I-Premise
remained I-Premise
stable I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
but I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
in I-Premise
REE I-Premise
between I-Premise
the I-Premise
ATP I-Premise
and I-Premise
control I-Premise
groups I-Premise
were I-Premise
observed I-Premise
. I-Premise

The B-Claim
inhibition I-Claim
of I-Claim
weight I-Claim
loss I-Claim
by I-Claim
ATP I-Claim
infusions I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
is I-Claim
attributed I-Claim
to I-Claim
counteracting I-Claim
the I-Claim
loss I-Claim
of I-Claim
both I-Claim
metabolically I-Claim
active I-Claim
and I-Claim
inactive I-Claim
tissues I-Claim
. I-Claim

These B-Premise
effects I-Premise
are I-Premise
partly I-Premise
ascribed I-Premise
to I-Premise
maintenance I-Premise
of I-Premise
energy I-Premise
intake I-Premise
. I-Premise

To O
evaluate O
whether O
treatment O
with O
single-agent O
docetaxel O
would O
result O
in O
longer O
survival O
than O
would O
best O
supportive O
care O
in O
patients O
with O
non-small-cell O
lung O
cancer O
who O
had O
previously O
been O
treated O
with O
platinum-based O
chemotherapy O
. O

Secondary O
end O
points O
included O
assessment O
of O
response O
( O
docetaxel O
arm O
only O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Patients O
with O
performance O
statuses O
of O
0 O
to O
2 O
and O
stage O
IIIB/IV O
non-small-cell O
lung O
cancer O
with O
either O
measurable O
or O
evaluable O
lesions O
were O
eligible O
for O
entry O
onto O
the O
study O
if O
they O
had O
undergone O
one O
or O
more O
platinum-based O
chemotherapy O
regimens O
and O
if O
they O
had O
adequate O
hematology O
and O
biochemistry O
parameters O
. O

They O
were O
excluded O
if O
they O
had O
symptomatic O
brain O
metastases O
or O
if O
they O
had O
previously O
been O
treated O
with O
paclitaxel O
. O

Patients O
were O
stratified O
by O
performance O
status O
and O
best O
response O
to O
cisplatin O
chemotherapy O
and O
were O
then O
randomized O
to O
treatment O
with O
docetaxel O
100 O
mg/m O
( O
2 O
) O
( O
49 O
patients O
) O
or O
75 O
mg/m O
( O
2 O
) O
( O
55 O
patients O
) O
or O
best O
supportive O
care O
. O

Patients O
in O
both O
arms O
were O
assessed O
every O
3 O
weeks O
. O

One O
hundred O
four O
patients O
( O
103 O
of O
whom O
were O
eligible O
for O
entry O
onto O
the O
study O
) O
were O
well O
balanced O
for O
prognostic O
factors O
. O

Of O
84 O
patients O
with O
measurable O
lesions O
, O
six O
( O
7 O
. O

1 O
% O
) O
achieved O
partial O
responses O
( O
three O
patients O
at O
each O
dose O
level O
) O
. O

Time B-Premise
to I-Premise
progression I-Premise
was I-Premise
longer I-Premise
for I-Premise
docetaxel I-Premise
patients I-Premise
than I-Premise
for I-Premise
best I-Premise
supportive I-Premise
care I-Premise
patients I-Premise
( I-Premise
10.6 I-Premise
v I-Premise
6.7 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
survival I-Premise
( I-Premise
7.0 I-Premise
v I-Premise
4.6 I-Premise
months I-Premise
";" I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.047 I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
was I-Premise
more I-Premise
significant I-Premise
for I-Premise
docetaxel I-Premise
75 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
patients I-Premise
, I-Premise
compared I-Premise
with I-Premise
corresponding I-Premise
best I-Premise
supportive I-Premise
care I-Premise
patients I-Premise
( I-Premise
7.5 I-Premise
v I-Premise
4.6 I-Premise
months I-Premise
";" I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
=.010 I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
, I-Premise
37 I-Premise
% I-Premise
v I-Premise
11 I-Premise
% I-Premise
";" I-Premise
chi I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
, I-Premise
P I-Premise
=.003 I-Premise
) I-Premise
. I-Premise

Febrile B-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
11 I-Premise
patients I-Premise
treated I-Premise
with I-Premise
docetaxel I-Premise
100 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
, I-Premise
three I-Premise
of I-Premise
whom I-Premise
died I-Premise
, I-Premise
and I-Premise
in I-Premise
one I-Premise
patient I-Premise
treated I-Premise
with I-Premise
docetaxel I-Premise
75 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
nonhematologic I-Premise
toxicity I-Premise
, I-Premise
with I-Premise
the I-Premise
exception I-Premise
of I-Premise
diarrhea I-Premise
, I-Premise
occurred I-Premise
at I-Premise
a I-Premise
similar I-Premise
rate I-Premise
in I-Premise
both I-Premise
the I-Premise
docetaxel I-Premise
and I-Premise
best I-Premise
supportive I-Premise
care I-Premise
groups I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
docetaxel I-Claim
is I-Claim
associated I-Claim
with I-Claim
significant I-Claim
prolongation I-Claim
of I-Claim
survival I-Claim
, I-Claim
and O
at B-Claim
a I-Claim
dose I-Claim
of I-Claim
75 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
the I-Claim
benefits I-Claim
of I-Claim
docetaxel I-Claim
therapy I-Claim
outweigh I-Claim
the I-Claim
risks I-Claim
. I-Claim

Enhanced O
recovery O
programmes O
( O
ERPs O
) O
have O
been O
shown O
to O
reduce O
length O
of O
hospital O
stay O
( O
LOS O
) O
and O
complications O
in O
colorectal O
surgery O
. O

Whether O
ERPs O
have O
the O
same O
benefits O
in O
open O
liver O
resection O
surgery O
is O
unclear O
, O
and O
randomized O
clinical O
trials O
are O
lacking O
. O

Consecutive O
patients O
scheduled O
for O
open O
liver O
resection O
were O
randomized O
to O
an O
ERP O
group O
or O
standard O
care O
. O

Primary O
endpoints O
were O
time O
until O
medically O
fit O
for O
discharge O
( O
MFD O
) O
and O
LOS O
. O

Secondary O
endpoints O
were O
postoperative O
morbidity O
, O
pain O
scores O
, O
readmission O
rate O
, O
mortality O
, O
quality O
of O
life O
( O
QoL O
) O
and O
patient O
satisfaction O
. O

ERP O
elements O
included O
greater O
preoperative O
education O
, O
preoperative O
oral O
carbohydrate O
loading O
, O
postoperative O
goal-directed O
fluid O
therapy O
, O
early O
mobilization O
and O
physiotherapy O
. O

Both O
groups O
received O
standardized O
anaesthesia O
with O
epidural O
analgesia O
. O

The O
analysis O
included O
46 O
patients O
in O
the O
ERP O
group O
and O
45 O
in O
the O
standard O
care O
group O
. O

Median B-Premise
MFD I-Premise
time I-Premise
was I-Premise
reduced I-Premise
in I-Premise
the I-Premise
ERP I-Premise
group I-Premise
( I-Premise
3 I-Premise
days I-Premise
versus I-Premise
6 I-Premise
days I-Premise
with I-Premise
standard I-Premise
care I-Premise
";" I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
LOS I-Premise
( I-Premise
4 I-Premise
days I-Premise
versus I-Premise
7 I-Premise
days I-Premise
";" I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

The B-Premise
ERP I-Premise
significantly I-Premise
reduced I-Premise
the I-Premise
rate I-Premise
of I-Premise
medical I-Premise
complications I-Premise
( I-Premise
7 I-Premise
versus I-Premise
27 I-Premise
per I-Premise
cent I-Premise
";" I-Premise
P I-Premise
= I-Premise
0·020 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
surgical I-Premise
complications I-Premise
( I-Premise
15 I-Premise
versus I-Premise
11 I-Premise
per I-Premise
cent I-Premise
";" I-Premise
P I-Premise
= I-Premise
0·612 I-Premise
) I-Premise
, I-Premise
readmissions I-Premise
( I-Premise
4 I-Premise
versus I-Premise
0 I-Premise
per I-Premise
cent I-Premise
";" I-Premise
P I-Premise
= I-Premise
0·153 I-Premise
) I-Premise
or I-Premise
mortality I-Premise
( I-Premise
both I-Premise
2 I-Premise
per I-Premise
cent I-Premise
";" I-Premise
P I-Premise
= I-Premise
0·987 I-Premise
) I-Premise
. I-Premise

QoL B-Premise
over I-Premise
28 I-Premise
days I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
ERP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0·002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
. I-Premise

ERPs B-Claim
for I-Claim
open I-Claim
liver I-Claim
resection I-Claim
surgery I-Claim
are I-Claim
safe I-Claim
and I-Claim
effective I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
in I-Claim
the I-Claim
ERP I-Claim
recovered I-Claim
faster I-Claim
, I-Claim
were I-Claim
discharged I-Claim
sooner I-Claim
, I-Claim
and I-Claim
had I-Claim
fewer I-Claim
medical-related I-Claim
complications I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
. I-Claim

Although O
chemotherapy-induced O
cognitive O
impairment O
is O
common O
among O
breast O
cancer O
patients O
, O
evidence O
for O
effective O
interventions O
addressing O
cognitive O
deficits O
is O
limited O
. O

This O
randomized O
controlled O
trial O
examined O
the O
feasibility O
and O
preliminary O
efficacy O
of O
a O
Tibetan O
Sound O
Meditation O
( O
TSM O
) O
program O
to O
improve O
cognitive O
function O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
. O

Forty-seven O
breast O
cancer O
patients O
( O
mean O
age O
56.3 O
years O
) O
, O
who O
were O
staged O
I-III O
at O
diagnosis O
, O
6-60 O
months O
post-chemotherapy O
, O
and O
reported O
cognitive O
impairment O
at O
study O
entry O
were O
recruited O
. O

Participants O
were O
randomized O
to O
either O
two O
weekly O
TSM O
sessions O
for O
6 O
weeks O
or O
a O
wait O
list O
control O
group O
. O

Neuropsychological O
assessments O
were O
completed O
at O
baseline O
and O
1 O
month O
post-treatment O
. O

Self-report O
measures O
of O
cognitive O
function O
( O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Cog O
) O
, O
quality O
of O
life O
( O
SF-36 O
) O
, O
depressive O
symptoms O
( O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
) O
, O
sleep O
disturbance O
( O
Pittsburgh O
Sleep O
Quality O
Index O
) O
, O
fatigue O
( O
Brief O
Fatigue O
Inventory O
) O
, O
and O
spirituality O
( O
FACT-Sp O
) O
were O
completed O
at O
baseline O
, O
the O
end O
of O
treatment O
, O
and O
1 O
month O
later O
. O

Relative B-Premise
to I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
women I-Premise
in I-Premise
the I-Premise
TSM I-Premise
group I-Premise
performed I-Premise
better I-Premise
on I-Premise
the I-Premise
verbal I-Premise
memory I-Premise
test I-Premise
( I-Premise
Rey I-Premise
Auditory I-Premise
Verbal I-Premise
Learning I-Premise
Test I-Premise
trial I-Premise
1 I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
and I-Premise
the I-Premise
short-term I-Premise
memory I-Premise
and I-Premise
processing I-Premise
speed I-Premise
task I-Premise
( I-Premise
Digit I-Premise
Symbol I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
and I-Premise
reported I-Premise
improved I-Premise
cognitive I-Premise
function I-Premise
( I-Premise
p I-Premise
= I-Premise
0.06 I-Premise
) I-Premise
, I-Premise
cognitive I-Premise
abilities I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
, I-Premise
mental I-Premise
health I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
spirituality I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
treatment I-Premise
but I-Premise
not I-Premise
1 I-Premise
month I-Premise
later I-Premise
. I-Premise

This B-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
revealed I-Claim
that I-Claim
TSM I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
intervention I-Claim
and I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
short-term I-Claim
improvements I-Claim
in I-Claim
objective I-Claim
and I-Claim
subjective I-Claim
cognitive I-Claim
function I-Claim
as I-Claim
well I-Claim
as I-Claim
mental I-Claim
health I-Claim
and I-Claim
spirituality I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
choice I-Claim
of I-Claim
reconstruction I-Claim
after I-Claim
gastrectomy I-Claim
and I-Claim
the I-Claim
significance I-Claim
of I-Claim
remaining I-Claim
reservoir I-Claim
function I-Claim
is I-Claim
a I-Claim
matter I-Claim
of I-Claim
controversy I-Claim
. I-Claim

To O
broaden O
the O
criteria O
for O
choice O
of O
treatment O
, O
we O
conducted O
a O
prospective O
randomized O
clinical O
trial O
to O
determine O
the O
impact O
of O
various O
gastrectomy O
procedures O
on O
quality O
of O
life O
. O

Consecutive O
patients O
( O
n O
= O
64 O
) O
eligible O
for O
curative O
gastric O
cancer O
surgery O
were O
randomized O
to O
have O
either O
a O
total O
( O
n O
= O
31 O
) O
or O
subtotal O
( O
n O
= O
13 O
) O
gastrectomy O
or O
a O
jejunal O
S-shaped O
pouch O
( O
n O
= O
20 O
) O
implanted O
as O
a O
gastric O
substitute O
. O

The O
quality-of-life O
evaluation O
was O
based O
on O
a O
battery O
of O
questionnaires O
covering O
both O
general O
and O
specific O
aspects O
of O
life O
. O

The O
patients O
were O
rated O
by O
one O
of O
two O
psychiatrists O
who O
were O
blinded O
to O
the O
patients O
' O
group O
affiliation O
. O

Assessments O
were O
made O
on O
three O
occasions O
: O
during O
the O
week O
prior O
to O
surgery O
and O
3 O
and O
12 O
months O
after O
the O
surgical O
intervention O
. O

The B-Premise
postoperative I-Premise
complication I-Premise
and I-Premise
mortality I-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
with I-Premise
few I-Premise
serious I-Premise
complications I-Premise
recorded I-Premise
. I-Premise

Irrespective B-Premise
of I-Premise
type I-Premise
of I-Premise
treatment I-Premise
, I-Premise
the I-Premise
patients I-Premise
suffered I-Premise
from I-Premise
alimentary I-Premise
symptoms I-Premise
and I-Premise
functional I-Premise
limitations I-Premise
in I-Premise
everyday I-Premise
life I-Premise
, I-Premise
whereas B-Premise
their I-Premise
mental I-Premise
well-being I-Premise
improved I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Patients B-Premise
who I-Premise
underwent I-Premise
subtotal I-Premise
gastrectomy I-Premise
had I-Premise
the I-Premise
best I-Premise
outcome I-Premise
, I-Premise
especially I-Premise
with I-Premise
respect I-Premise
to I-Premise
complaints I-Premise
of I-Premise
diarrhea I-Premise
. I-Premise

Patients B-Premise
given I-Premise
a I-Premise
gastric I-Premise
substitute I-Premise
after I-Premise
gastrectomy I-Premise
showed I-Premise
no I-Premise
difference I-Premise
from I-Premise
those I-Premise
who I-Premise
had I-Premise
only I-Premise
a I-Premise
total I-Premise
gastrectomy I-Premise
. I-Premise

We B-Claim
conclude I-Claim
that I-Claim
despite I-Claim
significant I-Claim
unfavorable I-Claim
consequences I-Claim
that I-Claim
follow I-Claim
gastrectomy I-Claim
, I-Claim
patients I-Claim
recover I-Claim
with I-Claim
an I-Claim
improved I-Claim
mental I-Claim
status I-Claim
. I-Claim

A B-Claim
pouch I-Claim
reconstruction I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
does I-Claim
not I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
but O
a B-Claim
subtotal I-Claim
gastrectomy I-Claim
has I-Claim
advantages I-Claim
that I-Claim
must I-Claim
be I-Claim
considered I-Claim
when I-Claim
the I-Claim
procedure I-Claim
is I-Claim
clinically I-Claim
feasible I-Claim
. I-Claim

To O
evaluate O
the O
effect O
of O
epoetin O
alfa O
on O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
solid O
tumors O
and O
mild-to-moderate O
anemia O
receiving O
platinum-based O
chemotherapy O
relative O
to O
population O
norms O
. O

In O
the O
original O
study O
, O
patients O
( O
n O
= O
316 O
) O
with O
hemoglobin O
( O
Hb O
) O
levels O
< O
or O
=12.1 O
g/dl O
were O
randomized O
2:1 O
to O
receive O
either O
epoetin O
alfa O
at O
a O
dose O
of O
10,000 O
U O
thrice O
weekly O
s.c. O
or O
best O
supportive O
care O
( O
BSC O
) O
to O
compare O
the O
effects O
on O
transfusion O
use O
, O
hematologic O
response O
, O
and O
QOL O
( O
measured O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
[ O
FACT-An O
] O
and O
Cancer O
Linear O
Analogue O
Scale O
[ O
CLAS O
] O
) O
. O

The O
QOL O
data O
from O
this O
previously O
reported O
trial O
were O
reanalyzed O
here O
relative O
to O
population O
norms O
. O

Mean O
baseline O
QOL O
scores O
were O
similar O
between O
groups O
. O

At O
study O
completion O
, O
mean O
CLAS O
, O
FACT-An O
, O
FACT-An O
Anemia O
subscale O
, O
and O
FACT-An O
Fatigue O
subscale O
scores O
were O
significantly O
higher O
for O
patients O
given O
epoetin O
alfa O
than O
for O
those O
treated O
with O
BSC O
. O

Compared O
with O
population O
norms O
, O
both O
groups O
had O
impaired O
QOL O
at O
baseline O
. O

Differences B-Premise
in I-Premise
mean I-Premise
QOL I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
study I-Premise
end I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
versus I-Premise
BSC I-Premise
were I-Premise
3.17 I-Premise
points I-Premise
for I-Premise
the I-Premise
FACT-General I-Premise
Total I-Premise
, I-Premise
9.90 I-Premise
for I-Premise
the I-Premise
FACT-An I-Premise
Fatigue I-Premise
subscale I-Premise
, I-Premise
and I-Premise
7.30 I-Premise
for I-Premise
the I-Premise
FACT-An I-Premise
Anemia I-Premise
subscale I-Premise
. I-Premise

This B-Premise
was I-Premise
equivalent I-Premise
to I-Premise
corrections I-Premise
in I-Premise
QOL I-Premise
deficits I-Premise
attributable I-Premise
to I-Premise
epoetin I-Premise
alfa I-Premise
of I-Premise
97.3 I-Premise
% I-Premise
, I-Premise
40.7 I-Premise
% I-Premise
, I-Premise
and I-Premise
38.0 I-Premise
% I-Premise
for I-Premise
the I-Premise
FACT-General I-Premise
Total I-Premise
, I-Premise
FACT-An I-Premise
Fatigue I-Premise
, I-Premise
and I-Premise
FACT-An I-Premise
Anemia I-Premise
subscale I-Premise
scores I-Premise
, I-Premise
respectively I-Premise
, I-Premise
versus I-Premise
BSC I-Premise
. I-Premise

A B-Premise
somewhat I-Premise
greater I-Premise
QOL I-Premise
benefit I-Premise
was I-Premise
observed I-Premise
for I-Premise
the I-Premise
FACT-An I-Premise
Fatigue I-Premise
and I-Premise
FACT-An I-Premise
Anemia I-Premise
subscales I-Premise
in I-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
10.5 I-Premise
g/dl I-Premise
. I-Premise

Patients B-Premise
in I-Premise
this I-Premise
study I-Premise
had I-Premise
impaired I-Premise
QOL I-Premise
compared I-Premise
with I-Premise
population I-Premise
norms I-Premise
. I-Premise

Early B-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
to I-Claim
correct I-Claim
anemia I-Claim
improved I-Claim
QOL I-Claim
in I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
way I-Claim
, I-Claim
and I-Claim
improvements I-Claim
were I-Claim
greater I-Claim
in I-Claim
patients I-Claim
with I-Claim
baseline I-Claim
Hb I-Claim
levels I-Claim
> I-Claim
10.5 I-Claim
g/dl I-Claim
. I-Claim

To O
observe O
the O
effect O
of O
Chinese O
medicine O
( O
CM O
) O
comprehensive O
regimen O
as O
the O
maintenance O
therapy O
( O
MT O
) O
on O
time O
to O
progression O
( O
TTP O
) O
and O
quality O
of O
life O
( O
QOL O
) O
of O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
study O
was O
a O
prospective O
, O
randomized O
and O
controlled O
clinical O
trial O
. O

Fifty O
non-progressive O
patients O
with O
advanced O
NSCLC O
who O
responded O
to O
first-line O
therapy O
were O
randomized O
into O
the O
test O
group O
( O
25 O
cases O
, O
treated O
with O
CM O
comprehensive O
regimen O
: O
intravenous O
dripping O
of O
Chinese O
herbal O
preparation O
, O
oral O
administration O
of O
Chinese O
herbal O
decoction O
, O
and O
point O
application O
) O
and O
the O
control O
group O
[ O
25 O
cases O
, O
treated O
with O
one O
of O
three O
single-agent O
maintenance O
chemotherapy O
regimens O
: O
pemetrexed O
( O
500 O
mg/m2 O
, O
day O
1 O
) O
, O
docetaxel O
( O
75 O
mg/m2 O
, O
day O
1 O
) O
, O
and O
gemcitabine O
( O
1000 O
mg/mi O
, O
day O
1 O
and O
day O
8 O
) O
in O
the O
ratio O
of O
1:1 O
] O
. O

Each O
cycle O
consisted O
of O
21 O
days O
. O

Cycles O
were O
repeated O
until O
the O
disease O
progressed O
, O
or O
intolerable O
toxic O
or O
adverse O
reaction O
occurred O
, O
or O
patients O
refused O
to O
continue O
the O
treatment O
. O

The O
primary O
end O
point O
was O
TTP O
and O
the O
secondary O
end O
point O
was O
QOL O
. O

QOL O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire O
QLQ-LC43 O
( O
EORTC O
QLQ-LC43 O
) O
. O

TTP O
of O
fifty O
patients O
and O
QOL O
of O
43 O
patients O
had O
been O
statistically O
analyzed O
. O

( O
1 O
) O
The B-Premise
TTP I-Premise
in I-Premise
the I-Premise
test I-Premise
group I-Premise
was I-Premise
prolonged I-Premise
for I-Premise
23 I-Premise
days I-Premise
when I-Premise
compared I-Premise
with I-Premise
that I-Premise
of I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
with I-Premise
insignificant I-Premise
difference I-Premise
( I-Premise
87 I-Premise
days I-Premise
vs I-Premise
64 I-Premise
days I-Premise
, I-Premise
P=0.063 I-Premise
) I-Premise
. I-Premise

( O
2 O
) O
The B-Premise
scores I-Premise
of I-Premise
domains I-Premise
in I-Premise
EORTC I-Premise
QLQ-LC43 I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
test I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
except B-Premise
cognitive I-Premise
and I-Premise
social I-Premise
functions I-Premise
, I-Premise
the I-Premise
symptoms I-Premise
of I-Premise
dysphagia I-Premise
and I-Premise
pain I-Premise
in I-Premise
other I-Premise
parts I-Premise
. I-Premise

( O
1 O
) O
The B-Claim
CM I-Claim
comprehensive I-Claim
regimen I-Claim
as I-Claim
MT I-Claim
had I-Claim
equivalent I-Claim
efficacy I-Claim
on I-Claim
TTP I-Claim
when I-Claim
compared I-Claim
with I-Claim
single-agent I-Claim
maintenance I-Claim
chemotherapy I-Claim
regimen I-Claim
. I-Claim

It B-Claim
was I-Claim
advantageous I-Claim
over I-Claim
improving I-Claim
the I-Claim
QOL I-Claim
. I-Claim

( O
2 O
) O
It B-Claim
is I-Claim
necessary I-Claim
to I-Claim
enlarge I-Claim
the I-Claim
sample I-Claim
size I-Claim
to I-Claim
further I-Claim
confirm I-Claim
the I-Claim
therapeutic I-Claim
efficacy I-Claim
of I-Claim
CM I-Claim
comprehensive I-Claim
regimen I-Claim
as I-Claim
MT I-Claim
in I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Restorative O
proctocolectomy O
with O
ileal O
pouch-anal O
anastomosis O
( O
IPAA O
) O
is O
the O
standard O
surgical O
procedure O
for O
ulcerative O
colitis O
( O
UC O
) O
and O
familial O
adenomatous O
polyposis O
( O
FAP O
) O
. O

While O
minimal O
invasive O
techniques O
have O
been O
applied O
increasingly O
, O
clear O
evidence O
of O
superiority O
for O
laparoscopic O
pouch O
procedures O
is O
not O
yet O
available O
. O

The O
aim O
of O
the O
LapConPouch O
Trial O
was O
to O
compare O
the O
effectiveness O
of O
laparoscopic O
( O
LAP O
) O
versus O
conventional O
( O
CON O
) O
ileoanal O
pouch O
procedure O
in O
patients O
undergoing O
elective O
restorative O
proctocolectomy O
. O

The O
trial O
was O
designed O
as O
a O
single-centre O
, O
pre-operatively O
randomized O
, O
controlled O
trial O
using O
a O
two-group O
parallel O
superiority O
design O
. O

Eligible O
for O
participation O
were O
patients O
scheduled O
for O
restorative O
proctocolectomy O
either O
for O
FAP O
or O
for O
UC O
. O

Patients O
and O
outcome O
assessors O
were O
blinded O
to O
group O
assignment O
. O

The O
primary O
endpoint O
was O
defined O
as O
the O
amount O
of O
blood O
loss O
. O

Statistical O
analyses O
were O
explorative O
since O
the O
trial O
had O
to O
be O
stopped O
prematurely O
. O

A O
total O
of O
42 O
patients O
( O
21 O
LAP O
( O
50.0 O
% O
) O
";" O
21 O
CON O
( O
50.0 O
% O
) O
) O
were O
randomized O
. O

The B-Premise
trial I-Premise
had I-Premise
to I-Premise
be I-Premise
stopped I-Premise
prematurely I-Premise
due I-Premise
to I-Premise
insufficient I-Premise
patient I-Premise
recruitment I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
amount I-Premise
of I-Premise
blood I-Premise
loss I-Premise
between I-Premise
both I-Premise
groups I-Premise
: I-Premise
LAP I-Premise
261.5 I-Premise
± I-Premise
195.4 I-Premise
ml I-Premise
, I-Premise
CON I-Premise
228.1 I-Premise
± I-Premise
119.5 I-Premise
ml I-Premise
. I-Premise

Secondary O
endpoints O
differ O
in O
both O
groups O
. O

Laparoscopic B-Claim
surgery I-Claim
was I-Claim
superior I-Claim
regarding I-Claim
the I-Claim
length I-Claim
of I-Claim
skin I-Claim
incision I-Claim
";" I-Claim
in O
contrast O
, O
the B-Claim
conventional I-Claim
approach I-Claim
was I-Claim
superior I-Claim
in I-Claim
duration I-Claim
of I-Claim
operation I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
discrepancies I-Premise
in I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
postoperative I-Premise
pain I-Premise
, I-Premise
bowel I-Premise
function I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
both I-Premise
approaches I-Premise
. I-Premise

The O
conversion O
rate O
from O
LAP O
to O
CON O
approach O
was O
23.8 O
% O
. O

There B-Claim
was I-Claim
no I-Claim
difference I-Claim
with I-Claim
respect I-Claim
to I-Claim
blood I-Claim
loss I-Claim
between I-Claim
the I-Claim
LAP I-Claim
and I-Claim
the I-Claim
CON I-Claim
group I-Claim
. I-Claim

The B-Claim
LAP I-Claim
approach I-Claim
is I-Claim
feasible I-Claim
for I-Claim
restorative I-Claim
proctocolectomy I-Claim
, I-Claim
and I-Claim
IPAA I-Claim
seems I-Claim
at I-Claim
least I-Claim
as I-Claim
safe I-Claim
as I-Claim
CON I-Claim
surgery I-Claim
. I-Claim

The O
most O
obvious O
advantage O
of O
the O
minimal O
invasive O
technique O
is O
the O
improved O
cosmesis O
. O

This O
analysis O
of O
the O
results O
of O
a O
randomized O
, O
controlled O
trial O
evaluating O
the O
effects O
of O
epoetin O
alfa O
( O
EPO O
) O
therapy O
on O
transfusion O
requirements O
, O
hemoglobin O
( O
Hb O
) O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
cancer O
receiving O
platinum-based O
chemotherapy O
was O
conducted O
to O
evaluate O
the O
effect O
of O
initial O
Hb O
level O
on O
study O
outcomes O
. O

Patients O
with O
Hb O
levels O
< O
or O
=12.1 O
g/dl O
were O
randomized O
2:1 O
to O
receive O
EPO O
, O
10,000 O
U O
three O
times O
weekly O
s.c. O
or O
best O
supportive O
care O
( O
BSC O
) O
until O
4 O
weeks O
after O
their O
last O
chemotherapy O
cycle O
. O

For O
this O
analysis O
, O
patients O
were O
stratified O
by O
baseline O
Hb O
level O
( O
< O
or O
=9.7 O
g/dl O
, O
> O
9.7 O
g/dl O
to O
< O
or O
=10.5 O
g/dl O
, O
> O
10.5 O
g/dl O
to O
< O
or O
=11.3 O
g/dl O
, O
and O
> O
11.3 O
g/dl O
to O
< O
or O
=12.1 O
g/dl O
) O
, O
and O
study O
results O
were O
reanalyzed O
. O

Significantly B-Premise
fewer I-Premise
EPO I-Premise
patients I-Premise
than I-Premise
BSC I-Premise
patients I-Premise
with I-Premise
initial I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
9.7 I-Premise
g/dl I-Premise
to I-Premise
< I-Premise
or I-Premise
=12.1 I-Premise
g/dl I-Premise
required I-Premise
transfusions I-Premise
. I-Premise

EPO B-Premise
maintained I-Premise
Hb I-Premise
levels I-Premise
throughout I-Premise
the I-Premise
study I-Premise
for I-Premise
patients I-Premise
with I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
11.3 I-Premise
g/dl I-Premise
to I-Premise
< I-Premise
or I-Premise
=12.1 I-Premise
g/dl I-Premise
, I-Premise
compared I-Premise
with I-Premise
a I-Premise
decrease I-Premise
with I-Premise
BSC I-Premise
. I-Premise

For B-Premise
patients I-Premise
with I-Premise
baseline I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
10.5 I-Premise
g/dl I-Premise
, I-Premise
for I-Premise
whom I-Premise
the I-Premise
mean I-Premise
changes I-Premise
from I-Premise
baseline I-Premise
to I-Premise
last I-Premise
assessment I-Premise
were I-Premise
measured I-Premise
by I-Premise
the I-Premise
Cancer I-Premise
Linear I-Premise
Analogue I-Premise
Scale I-Premise
assessments I-Premise
of I-Premise
energy I-Premise
and I-Premise
overall I-Premise
QOL I-Premise
as I-Premise
well I-Premise
as I-Premise
by I-Premise
the I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
( I-Premise
FACT I-Premise
) I-Premise
-Fatigue I-Premise
and I-Premise
FACT-An I-Premise
Anemia I-Premise
subscale I-Premise
, I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
with I-Premise
EPO I-Premise
than I-Premise
with I-Premise
BSC I-Premise
. I-Premise

QOL B-Premise
declined I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
BSC I-Premise
, I-Premise
and O
the B-Premise
mean I-Premise
decreases I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
greater I-Premise
for I-Premise
BSC I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
Hb I-Premise
levels I-Premise
> I-Premise
10.5 I-Premise
g/dl I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
overall I-Premise
BSC I-Premise
group I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
receiving I-Claim
platinum-based I-Claim
chemotherapy I-Claim
and I-Claim
with I-Claim
baseline I-Claim
Hb I-Claim
levels I-Claim
> I-Claim
10.5 I-Claim
g/dl I-Claim
, I-Claim
early I-Claim
intervention I-Claim
with I-Claim
EPO I-Claim
reduces I-Claim
transfusions I-Claim
, I-Claim
maintains I-Claim
Hb I-Claim
level I-Claim
, I-Claim
and I-Claim
maintains I-Claim
or I-Claim
improves I-Claim
QOL I-Claim
. I-Claim

This B-Claim
study I-Claim
supports I-Claim
the I-Claim
positive I-Claim
effects I-Claim
of I-Claim
early I-Claim
intervention I-Claim
when I-Claim
analyzed I-Claim
according I-Claim
to I-Claim
initial I-Claim
Hb I-Claim
value I-Claim
. I-Claim

The B-Claim
extent I-Claim
to I-Claim
which I-Claim
chemotherapy I-Claim
may I-Claim
relieve I-Claim
tumour-related I-Claim
symptoms I-Claim
, I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
gastric I-Claim
cancer I-Claim
is I-Claim
not I-Claim
known I-Claim
in I-Claim
spite I-Claim
of I-Claim
the I-Claim
extensive I-Claim
use I-Claim
of I-Claim
this I-Claim
treatment I-Claim
modality I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
estimate O
any O
gain O
in O
the O
quantity O
and O
quality O
of O
life O
produced O
by O
chemotherapy O
in O
these O
patients O
. O

Between O
January O
1991 O
and O
February O
1995 O
, O
61 O
patients O
with O
gastric O
cancer O
were O
randomized O
to O
either O
chemotherapy O
in O
addition O
to O
best O
supportive O
care O
or O
to O
best O
supportive O
care O
. O

Chemotherapy O
was O
allowed O
in O
the O
latter O
group O
if O
the O
supportive O
measures O
did O
not O
lead O
to O
palliation O
. O

Chemotherapy O
was O
the O
ELF-regimen O
consisting O
of O
5-fluorouracil O
, O
leucovorin O
and O
etoposide O
, O
or O
, O
in O
elderly O
patients O
with O
poor O
performance O
, O
a O
5-fluorouracil/leucovorin O
regimen O
( O
FLv O
) O
. O

Quality O
of O
life O
was O
evaluated O
with O
the O
EORTC-QLQ-C30 O
instrument O
. O

More B-Premise
patients I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
( I-Premise
45 I-Premise
% I-Premise
, I-Premise
14/31 I-Premise
) I-Premise
had I-Premise
an I-Premise
improved I-Premise
or I-Premise
prolonged I-Premise
high I-Premise
quality I-Premise
of I-Premise
life I-Premise
for I-Premise
a I-Premise
minimum I-Premise
period I-Premise
of I-Premise
4 I-Premise
months I-Premise
compared I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
best I-Premise
supportive I-Premise
care I-Premise
group I-Premise
( I-Premise
20 I-Premise
% I-Premise
, I-Premise
6/30 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

A B-Premise
similar I-Premise
difference I-Premise
was I-Premise
seen I-Premise
in I-Premise
the I-Premise
treating I-Premise
physician I-Premise
's I-Premise
evaluation I-Premise
of I-Premise
whether I-Premise
the I-Premise
patient I-Premise
was I-Premise
subjectively I-Premise
improved I-Premise
or I-Premise
continued I-Premise
to I-Premise
do I-Premise
well I-Premise
for I-Premise
at I-Premise
least I-Premise
4 I-Premise
months I-Premise
( I-Premise
17/31 I-Premise
, I-Premise
55 I-Premise
% I-Premise
versus I-Premise
6/30 I-Premise
, I-Premise
20 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
( I-Premise
median I-Premise
8 I-Premise
vs. I-Premise
5 I-Premise
months I-Premise
) I-Premise
although B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.12 I-Premise
) I-Premise
. I-Premise

After B-Premise
corrections I-Premise
for I-Premise
imbalances I-Premise
in I-Premise
pretreatment I-Premise
characteristics I-Premise
, I-Premise
chemotherapy I-Premise
treatment I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
associated I-Premise
with I-Premise
a I-Premise
survival I-Premise
benefit I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

Also B-Premise
, I-Premise
the I-Premise
quality-adjusted I-Premise
survival I-Premise
time I-Premise
and I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
were I-Premise
longer I-Premise
for I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
chemotherapy I-Premise
( I-Premise
median I-Premise
5 I-Premise
vs. I-Premise
2 I-Premise
months I-Premise
, I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

The B-Claim
results I-Claim
show I-Claim
that I-Claim
chemotherapy I-Claim
can I-Claim
add I-Claim
to I-Claim
both I-Claim
quantity I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

The B-Claim
number I-Claim
of I-Claim
patients I-Claim
who I-Claim
benefit I-Claim
from I-Claim
treatment I-Claim
is I-Claim
, I-Claim
however I-Claim
, I-Claim
still I-Claim
rather I-Claim
limited I-Claim
. I-Claim

Laparoscopic-assisted B-Claim
colectomy I-Claim
( I-Claim
LAC I-Claim
) I-Claim
has I-Claim
emerged I-Claim
as I-Claim
the I-Claim
preferred I-Claim
minimally I-Claim
invasive I-Claim
surgical I-Claim
strategy I-Claim
for I-Claim
diseases I-Claim
of I-Claim
the I-Claim
colon I-Claim
. I-Claim

The B-Claim
safety I-Claim
and I-Claim
efficacy I-Claim
of I-Claim
LAC I-Claim
for I-Claim
colon I-Claim
cancer I-Claim
are I-Claim
unknown I-Claim
, I-Claim
and O
the B-Claim
nature I-Claim
and I-Claim
magnitude I-Claim
of I-Claim
any I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
benefit I-Claim
resulting I-Claim
from I-Claim
LAC I-Claim
for I-Claim
colon I-Claim
cancer I-Claim
is I-Claim
also I-Claim
unknown I-Claim
. I-Claim

To O
compare O
short-term O
QOL O
outcomes O
after O
LAC O
vs O
open O
colectomy O
for O
colon O
cancer O
. O

Multicenter O
, O
randomized O
controlled O
trial O
( O
Clinical O
Outcomes O
of O
Surgical O
Therapy O
[ O
COST O
] O
) O
. O

Between O
September O
1994 O
and O
February O
1999 O
, O
37 O
of O
48 O
centers O
provided O
data O
for O
the O
QOL O
component O
of O
the O
trial O
for O
449 O
consecutive O
patients O
with O
clinically O
resectable O
colon O
cancer O
. O

Scores O
on O
the O
Symptoms O
Distress O
Scale O
( O
SDS O
) O
, O
Quality O
of O
Life O
Index O
, O
and O
a O
single-item O
global O
rating O
scale O
at O
2 O
days O
, O
2 O
weeks O
, O
and O
2 O
months O
postoperative O
";" O
duration O
of O
postoperative O
in-hospital O
analgesic O
use O
";" O
and O
length O
of O
stay O
. O

Of O
449 O
patients O
, O
428 O
provided O
QOL O
data O
. O

In B-Premise
an I-Premise
intention-to-treat I-Premise
analysis I-Premise
comparing I-Premise
SDS I-Premise
pain I-Premise
intensity I-Premise
, I-Premise
SDS I-Premise
summary I-Premise
, I-Premise
QOL I-Premise
Index I-Premise
summary I-Premise
, I-Premise
and I-Premise
global I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
at I-Premise
each I-Premise
time I-Premise
point I-Premise
, I-Premise
the I-Premise
only I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
observed I-Premise
between I-Premise
groups I-Premise
was I-Premise
the I-Premise
global I-Premise
rating I-Premise
scale I-Premise
score I-Premise
for I-Premise
2 I-Premise
weeks I-Premise
postsurgery I-Premise
. I-Premise

The B-Premise
mean I-Premise
( I-Premise
median I-Premise
) I-Premise
global I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
2 I-Premise
weeks I-Premise
postsurgery I-Premise
were I-Premise
76.9 I-Premise
( I-Premise
80 I-Premise
) I-Premise
for I-Premise
LAC I-Premise
vs I-Premise
74.4 I-Premise
( I-Premise
75 I-Premise
) I-Premise
for I-Premise
open I-Premise
colectomy I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
. I-Premise

While B-Premise
in I-Premise
the I-Premise
hospital I-Premise
, I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
LAC I-Premise
required I-Premise
fewer I-Premise
days I-Premise
of I-Premise
both I-Premise
parenteral I-Premise
analgesics I-Premise
compared I-Premise
with I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
open I-Premise
colectomy I-Premise
( I-Premise
mean I-Premise
[ I-Premise
median I-Premise
] I-Premise
, I-Premise
3.2 I-Premise
[ I-Premise
3 I-Premise
] I-Premise
vs I-Premise
4.0 I-Premise
[ I-Premise
4 I-Premise
] I-Premise
days I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
oral I-Premise
analgesics I-Premise
( I-Premise
mean I-Premise
[ I-Premise
median I-Premise
] I-Premise
, I-Premise
1.9 I-Premise
[ I-Premise
1 I-Premise
] I-Premise
vs I-Premise
2.2 I-Premise
[ I-Premise
2 I-Premise
] I-Premise
days I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
. I-Premise

Only B-Claim
minimal I-Claim
short-term I-Claim
QOL I-Claim
benefits I-Claim
were I-Claim
found I-Claim
with I-Claim
LAC I-Claim
for I-Claim
colon I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
standard I-Claim
open I-Claim
colectomy I-Claim
. I-Claim

Until B-Claim
ongoing I-Claim
trials I-Claim
establish I-Claim
that I-Claim
LAC I-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
open I-Claim
colectomy I-Claim
in I-Claim
preventing I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
from I-Claim
colon I-Claim
cancer I-Claim
, I-Claim
this I-Claim
procedure I-Claim
should I-Claim
not I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
colon I-Claim
cancer I-Claim
. I-Claim

The B-Claim
impact I-Claim
of I-Claim
prolonged I-Claim
subclinical I-Claim
hyperthyroidism I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
is I-Claim
unclear I-Claim
. I-Claim

Therefore O
, O
we O
evaluated O
quality O
of O
life O
in O
patients O
with O
differentiated O
thyroid O
carcinoma O
( O
DTC O
) O
on O
TSH-suppressive O
thyroxine O
therapy O
as O
a O
model O
for O
subclinical O
hyperthyroidism O
and O
we O
investigated O
whether O
restoration O
to O
euthyroidism O
affects O
quality O
of O
life O
. O

We O
performed O
a O
prospective O
, O
single-blinded O
, O
placebo-controlled O
, O
randomized O
trial O
of O
6 O
months O
' O
duration O
with O
two O
parallel O
groups O
. O

Twenty-four O
subjects O
with O
a O
history O
of O
differentiated O
thyroid O
carcinoma O
with O
> O
10 O
years O
TSH-suppressive O
therapy O
with O
L-thyroxine O
completed O
the O
study O
. O

L-thyroxine O
dose O
was O
replaced O
by O
study O
medication O
containing O
L-thyroxine O
or O
L-thyroxine O
plus O
placebo O
. O

Medication O
was O
titrated O
to O
establish O
continuation O
of O
TSH O
suppression O
( O
low-TSH O
group O
) O
and O
euthyroidism O
( O
euthyroid O
group O
) O
. O

Both O
groups O
consisted O
of O
12 O
patients O
. O

We O
evaluated O
quality O
of O
life O
using O
five O
validated O
questionnaires O
. O

At O
baseline O
, O
the O
somatic O
disorder O
questionnaire O
( O
SDQ O
) O
indicated O
more O
somatic O
dysfunction O
in O
patients O
as O
compared O
with O
reference O
values O
, O
whereas O
the O
depression O
score O
( O
HADS O
) O
revealed O
a O
better O
score O
than O
the O
reference O
group O
. O

All O
other O
quality O
of O
life O
parameters O
were O
normal O
. O

At O
baseline O
, O
no O
significant O
differences O
between O
the O
low-TSH O
and O
the O
euthyroidism O
groups O
were O
observed O
. O

After B-Premise
6 I-Premise
months I-Premise
, I-Premise
none I-Premise
of I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
parameters I-Premise
in I-Premise
the I-Premise
low-TSH I-Premise
group I-Premise
was I-Premise
different I-Premise
from I-Premise
baseline I-Premise
values I-Premise
. I-Premise

In B-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
motivation I-Premise
was I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
Multidimensional I-Premise
Fatigue I-Premise
Index-20 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
, I-Premise
although B-Premise
this I-Premise
parameter I-Premise
did I-Premise
not I-Premise
differ I-Premise
from I-Premise
the I-Premise
reference I-Premise
group I-Premise
at I-Premise
baseline I-Premise
. I-Premise

A B-Premise
probable I-Premise
worsening I-Premise
in I-Premise
role I-Premise
limitations I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
physical I-Premise
problems I-Premise
( I-Premise
Short I-Premise
Form-36 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.050 I-Premise
) I-Premise
was I-Premise
observed I-Premise
. I-Premise

No B-Premise
improvement I-Premise
in I-Premise
the I-Premise
SDQ I-Premise
score I-Premise
was I-Premise
observed I-Premise
. I-Premise

In B-Claim
summary I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
DTC I-Claim
and I-Claim
long-term I-Claim
subclinical I-Claim
hyperthyroidism I-Claim
in I-Claim
general I-Claim
is I-Claim
preserved I-Claim
. I-Claim

Restoration B-Claim
of I-Claim
euthyroidism I-Claim
in I-Claim
general I-Claim
does I-Claim
not I-Claim
affect I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Most O
patients O
with O
glioblastoma O
are O
older O
than O
60 O
years O
, O
but O
treatment O
guidelines O
are O
based O
on O
trials O
in O
patients O
aged O
only O
up O
to O
70 O
years O
. O

We O
did O
a O
randomised O
trial O
to O
assess O
the O
optimum O
palliative O
treatment O
in O
patients O
aged O
60 O
years O
and O
older O
with O
glioblastoma O
. O

Patients O
with O
newly O
diagnosed O
glioblastoma O
were O
recruited O
from O
Austria O
, O
Denmark O
, O
France O
, O
Norway O
, O
Sweden O
, O
Switzerland O
, O
and O
Turkey O
. O

They O
were O
assigned O
by O
a O
computer-generated O
randomisation O
schedule O
, O
stratified O
by O
centre O
, O
to O
receive O
temozolomide O
( O
200 O
mg/m O
( O
2 O
) O
on O
days O
1-5 O
of O
every O
28 O
days O
for O
up O
to O
six O
cycles O
) O
, O
hypofractionated O
radiotherapy O
( O
34·0 O
Gy O
administered O
in O
3·4 O
Gy O
fractions O
over O
2 O
weeks O
) O
, O
or O
standard O
radiotherapy O
( O
60·0 O
Gy O
administered O
in O
2·0 O
Gy O
fractions O
over O
6 O
weeks O
) O
. O

Patients O
and O
study O
staff O
were O
aware O
of O
treatment O
assignment O
. O

The O
primary O
endpoint O
was O
overall O
survival O
. O

Analyses O
were O
done O
by O
intention O
to O
treat O
. O

This O
trial O
is O
registered O
, O
number O
ISRCTN81470623 O
. O

342 O
patients O
were O
enrolled O
, O
of O
whom O
291 O
were O
randomised O
across O
three O
treatment O
groups O
( O
temozolomide O
n=93 O
, O
hypofractionated O
radiotherapy O
n=98 O
, O
standard O
radiotherapy O
n=100 O
) O
and O
51 O
of O
whom O
were O
randomised O
across O
only O
two O
groups O
( O
temozolomide O
n=26 O
, O
hypofractionated O
radiotherapy O
n=25 O
) O
. O

In B-Premise
the I-Premise
three-group I-Premise
randomisation I-Premise
, I-Premise
in I-Premise
comparison I-Premise
with I-Premise
standard I-Premise
radiotherapy I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
temozolomide I-Premise
( I-Premise
8·3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
7·1-9·5 I-Premise
";" I-Premise
n=93 I-Premise
] I-Premise
vs I-Premise
6·0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5·1-6·8 I-Premise
";" I-Premise
n=100 I-Premise
] I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0·70 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·52-0·93 I-Premise
, I-Premise
p=0·01 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
hypofractionated I-Premise
radiotherapy I-Premise
( I-Premise
7·5 I-Premise
months I-Premise
[ I-Premise
6·5-8·6 I-Premise
";" I-Premise
n=98 I-Premise
] I-Premise
, I-Premise
HR I-Premise
0·85 I-Premise
[ I-Premise
0·64-1·12 I-Premise
] I-Premise
, I-Premise
p=0·24 I-Premise
) I-Premise
. I-Premise

For B-Premise
all I-Premise
patients I-Premise
who I-Premise
received I-Premise
temozolomide I-Premise
or I-Premise
hypofractionated I-Premise
radiotherapy I-Premise
( I-Premise
n=242 I-Premise
) I-Premise
overall I-Premise
survival I-Premise
was I-Premise
similar I-Premise
( I-Premise
8·4 I-Premise
months I-Premise
[ I-Premise
7·3-9·4 I-Premise
";" I-Premise
n=119 I-Premise
] I-Premise
vs I-Premise
7·4 I-Premise
months I-Premise
[ I-Premise
6·4-8·4 I-Premise
";" I-Premise
n=123 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·63-1·06 I-Premise
";" I-Premise
p=0·12 I-Premise
) I-Premise
. I-Premise

For B-Premise
age I-Premise
older I-Premise
than I-Premise
70 I-Premise
years I-Premise
, I-Premise
survival I-Premise
was I-Premise
better I-Premise
with I-Premise
temozolomide I-Premise
and I-Premise
with I-Premise
hypofractionated I-Premise
radiotherapy I-Premise
than I-Premise
with I-Premise
standard I-Premise
radiotherapy I-Premise
( I-Premise
HR I-Premise
for I-Premise
temozolomide I-Premise
vs I-Premise
standard I-Premise
radiotherapy I-Premise
0·35 I-Premise
[ I-Premise
0·21-0·56 I-Premise
] I-Premise
, I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
";" I-Premise
HR I-Premise
for I-Premise
hypofractionated I-Premise
vs I-Premise
standard I-Premise
radiotherapy I-Premise
0·59 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·37-0·93 I-Premise
] I-Premise
, I-Premise
p=0·02 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
temozolomide I-Premise
who I-Premise
had I-Premise
tumour I-Premise
MGMT I-Premise
promoter I-Premise
methylation I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
survival I-Premise
than I-Premise
those I-Premise
without I-Premise
MGMT I-Premise
promoter I-Premise
methylation I-Premise
( I-Premise
9·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
8·0-11·4 I-Premise
] I-Premise
vs I-Premise
6·8 I-Premise
months I-Premise
[ I-Premise
5·9-7·7 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·56 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·34-0·93 I-Premise
] I-Premise
, I-Premise
p=0·02 I-Premise
) I-Premise
, I-Premise
but I-Premise
no I-Premise
difference I-Premise
was I-Premise
noted I-Premise
between I-Premise
those I-Premise
with I-Premise
methylated I-Premise
and I-Premise
unmethylated I-Premise
MGMT I-Premise
promoter I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
( I-Premise
HR I-Premise
0·97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·69-1·38 I-Premise
] I-Premise
";" I-Premise
p=0·81 I-Premise
) I-Premise
. I-Premise

As O
expected O
, O
the B-Premise
most I-Premise
common I-Premise
grade I-Premise
3-4 I-Premise
adverse I-Premise
events I-Premise
in I-Premise
the I-Premise
temozolomide I-Premise
group I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
n=12 I-Premise
) I-Premise
and I-Premise
thrombocytopenia I-Premise
( I-Premise
n=18 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3-5 I-Premise
infections I-Premise
in I-Premise
all I-Premise
randomisation I-Premise
groups I-Premise
were I-Premise
reported I-Premise
in I-Premise
18 I-Premise
patients I-Premise
. I-Premise

Two B-Premise
patients I-Premise
had I-Premise
fatal I-Premise
infections I-Premise
( I-Premise
one I-Premise
in I-Premise
the I-Premise
temozolomide I-Premise
group I-Premise
and I-Premise
one I-Premise
in I-Premise
the I-Premise
standard I-Premise
radiotherapy I-Premise
group I-Premise
) I-Premise
and I-Premise
one I-Premise
in I-Premise
the I-Premise
temozolomide I-Premise
group I-Premise
with I-Premise
grade I-Premise
2 I-Premise
thrombocytopenia I-Premise
died I-Premise
from I-Premise
complications I-Premise
after I-Premise
surgery I-Premise
for I-Premise
a I-Premise
gastrointestinal I-Premise
bleed I-Premise
. I-Premise

Standard B-Claim
radiotherapy I-Claim
was I-Claim
associated I-Claim
with I-Claim
poor I-Claim
outcomes I-Claim
, I-Claim
especially I-Claim
in I-Claim
patients I-Claim
older I-Claim
than I-Claim
70 I-Claim
years I-Claim
. I-Claim

Both B-Claim
temozolomide I-Claim
and I-Claim
hypofractionated I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
standard I-Claim
treatment I-Claim
options I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
glioblastoma I-Claim
. I-Claim

MGMT B-Claim
promoter I-Claim
methylation I-Claim
status I-Claim
might I-Claim
be I-Claim
a I-Claim
useful I-Claim
predictive I-Claim
marker I-Claim
for I-Claim
benefit I-Claim
from I-Claim
temozolomide I-Claim
. I-Claim

To O
evaluate O
the O
difference O
of O
efficacy O
, O
side-effects O
and O
quality O
of O
life O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
patients O
treated O
with O
oxaliplatin O
plus O
vinorelbine O
or O
cisplatin O
plus O
vinorelbine O
. O

Eligible O
patients O
were O
randomly O
assigned O
to O
NL O
( O
oxaliplatin O
+ O
vinorelbine O
) O
group O
and O
NP O
( O
cisplatin O
+ O
vinorelbine O
) O
group O
in O
a O
2:1 O
ratio O
. O

In O
the O
NL O
group O
, O
70 O
evaluable O
cases O
were O
treated O
with O
oxaliplatin O
130 O
mg/m O
( O
2 O
) O
i.v O
. O

on O
day O
2 O
, O
and O
vinorelbine O
25 O
mg/m O
( O
2 O
) O
i.v O
. O

on O
days O
1 O
and O
8 O
in O
21 O
days O
per O
cycle O
. O

In O
the O
NP O
group O
, O
32 O
evaluable O
cases O
were O
treated O
with O
cisplatin O
80 O
mg/m O
( O
2 O
) O
i.v O
. O

divided O
to O
2 O
- O
3 O
days O
dosing O
, O
21 O
days O
per O
cycle O
, O
and O
vinorelbine O
administered O
by O
the O
same O
way O
as O
in O
the O
NL O
group O
. O

The O
response O
rate O
, O
time O
to O
progression O
( O
TTP O
) O
, O
one-year O
survival O
, O
side-effects O
and O
the O
quality O
of O
life O
were O
observed O
. O

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
35.7 I-Premise
% I-Premise
vs. I-Premise
43.8 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.4 I-Premise
) I-Premise
, I-Premise
median I-Premise
TTP I-Premise
was I-Premise
4.7 I-Premise
months I-Premise
vs. I-Premise
5.5 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.6 I-Premise
) I-Premise
, I-Premise
one-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
38.5 I-Premise
% I-Premise
vs. I-Premise
58.6 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.07 I-Premise
) I-Premise
in I-Premise
the I-Premise
NL I-Premise
and I-Premise
NP I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Grade B-Premise
I-II I-Premise
neuro-sensory I-Premise
toxicity I-Premise
occurred I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
NL I-Premise
group I-Premise
than I-Premise
in I-Premise
NP I-Premise
group I-Premise
( I-Premise
68.4 I-Premise
% I-Premise
vs. I-Premise
36.4 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0017 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
Grade I-Premise
I-II I-Premise
granulocytopenia I-Premise
was I-Premise
significantly I-Premise
less I-Premise
occurred I-Premise
in I-Premise
NL I-Premise
group I-Premise
than I-Premise
in I-Premise
NP I-Premise
group I-Premise
( I-Premise
49.4 I-Premise
% I-Premise
vs. I-Premise
70.6 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Due B-Claim
to I-Claim
good I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
, I-Claim
the I-Claim
NL I-Claim
regimen I-Claim
offered I-Claim
a I-Claim
new I-Claim
candidate I-Claim
for I-Claim
treating I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Restoring O
sensory O
innervation O
may O
be O
a O
useful O
adjunct O
in O
free O
flap O
head O
and O
neck O
reconstruction O
but O
, O
as O
yet O
, O
has O
not O
been O
shown O
to O
improve O
outcomes O
of O
breast O
reconstruction O
. O

The O
authors O
' O
previous O
study O
demonstrated O
objectively O
improved O
sensation O
in O
a O
group O
of O
innervated O
transverse O
rectus O
abdominis O
musculocutaneous O
( O
TRAM O
) O
flap O
breast O
reconstruction O
patients O
relative O
to O
noninnervated O
flaps O
. O

This O
study O
compared O
patient-rated O
outcomes O
of O
free O
TRAM O
breast O
reconstruction O
in O
innervated O
versus O
noninnervated O
flaps O
. O

Twenty-seven O
women O
were O
randomized O
prospectively O
to O
undergo O
either O
innervated O
or O
noninnervated O
free O
TRAM O
flap O
breast O
reconstruction O
. O

For O
innervated O
flaps O
, O
the O
T10 O
intercostal O
nerve O
was O
harvested O
with O
the O
TRAM O
flap O
and O
neurotized O
to O
the O
T4 O
sensory O
nerve O
at O
the O
recipient O
site O
. O

Three O
validated O
outcome O
tools O
were O
administered O
after O
surgery O
: O
the O
Medical O
Outcomes O
Study O
36-Item O
Short O
Form O
Health O
Survey O
, O
the O
Body O
Image O
after O
Breast O
Cancer O
Questionnaire O
, O
and O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
. O

Results B-Premise
were I-Premise
correlated I-Premise
with I-Premise
previously I-Premise
reported I-Premise
objective I-Premise
sensibility I-Premise
outcomes I-Premise
. I-Premise

Eighteen O
of O
27 O
women O
returned O
their O
questionnaires O
a O
mean O
48 O
months O
after O
free O
TRAM O
flap O
reconstruction O
. O

Demographic O
analysis O
revealed O
no O
significant O
differences O
in O
patient O
age O
, O
height O
, O
smoking O
, O
radiation O
therapy O
, O
and O
nipple-areola O
complex O
reconstruction O
between O
randomized O
patient O
groups O
. O

There B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
all I-Premise
three I-Premise
measures I-Premise
in I-Premise
patients I-Premise
who I-Premise
were I-Premise
randomized I-Premise
to I-Premise
receive I-Premise
innervated I-Premise
free I-Premise
TRAM I-Premise
flaps I-Premise
compared I-Premise
with I-Premise
those I-Premise
receiving I-Premise
noninnervated I-Premise
flaps I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
innervation I-Claim
of I-Claim
free I-Claim
TRAM I-Claim
flaps I-Claim
used I-Claim
for I-Claim
breast I-Claim
reconstruction I-Claim
not I-Claim
only I-Claim
improves I-Claim
sensibility I-Claim
but I-Claim
also I-Claim
has I-Claim
a I-Claim
positive I-Claim
effect I-Claim
on I-Claim
patient-rated I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Despite O
improvements O
in O
surgical O
techniques O
, O
urinary O
incontinence O
( O
UI O
) O
is O
not O
uncommon O
after O
radical O
prostatectomy O
( O
RP O
) O
, O
and O
it O
may O
dramatically O
worsen O
quality O
of O
life O
( O
QoL O
) O
. O

To O
determine O
the O
benefit O
of O
starting O
pelvic O
floor O
muscle O
exercise O
( O
PFME O
) O
30d O
before O
RP O
and O
of O
continuing O
PFME O
postoperatively O
for O
early O
recovery O
of O
continence O
. O

A O
randomised O
, O
prospective O
study O
was O
designed O
. O

Men O
with O
localised O
prostate O
cancer O
( O
PCa O
) O
who O
underwent O
an O
open O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
at O
our O
department O
of O
urology O
were O
included O
. O

Patients O
were O
randomised O
to O
start O
PFME O
preoperatively O
and O
continue O
postoperatively O
( O
active O
group O
: O
A O
) O
or O
to O
start O
PFME O
postoperatively O
alone O
( O
control O
group O
: O
B O
) O
. O

The O
primary O
outcome O
measure O
was O
self-reported O
continence O
after O
surgery O
. O

Secondary O
outcome O
measures O
were O
assessed O
by O
degree O
of O
UI O
based O
on O
a O
24-h O
pad O
test O
and O
QoL O
instruments O
( O
International O
Continence O
Society O
[ O
ICS O
] O
male O
short O
form O
[ O
SF O
] O
) O
. O

Of O
143 O
men O
evaluated O
for O
the O
study O
, O
118 O
were O
randomised O
either O
to O
start O
PFME O
preoperatively O
and O
continue O
postoperatively O
( O
group O
A O
";" O
n=59 O
) O
or O
to O
start O
postoperative O
PFME O
( O
group O
B O
";" O
n=59 O
) O
. O

After B-Premise
1 I-Premise
mo I-Premise
, I-Premise
44.1 I-Premise
% I-Premise
( I-Premise
26 I-Premise
of I-Premise
59 I-Premise
) I-Premise
of I-Premise
patients I-Premise
were I-Premise
continent I-Premise
in I-Premise
group I-Premise
A I-Premise
, I-Premise
while I-Premise
20.3 I-Premise
% I-Premise
( I-Premise
12 I-Premise
of I-Premise
59 I-Premise
) I-Premise
were I-Premise
continent I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
mo I-Premise
, I-Premise
59.3 I-Premise
% I-Premise
( I-Premise
35 I-Premise
of I-Premise
59 I-Premise
) I-Premise
and I-Premise
37.3 I-Premise
% I-Premise
( I-Premise
22 I-Premise
of I-Premise
59 I-Premise
) I-Premise
patients I-Premise
were I-Premise
continent I-Premise
in I-Premise
group I-Premise
A I-Premise
and I-Premise
group I-Premise
B I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p=0.028 I-Premise
) I-Premise
. I-Premise

The B-Premise
ICS I-Premise
male I-Premise
SF I-Premise
mean I-Premise
score I-Premise
showed I-Premise
better I-Premise
results I-Premise
in I-Premise
group I-Premise
A I-Premise
than I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
at I-Premise
both I-Premise
1 I-Premise
mo I-Premise
( I-Premise
14.6 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
and I-Premise
3 I-Premise
mo I-Premise
( I-Premise
8.1 I-Premise
vs I-Premise
12.2 I-Premise
) I-Premise
after I-Premise
RP I-Premise
( I-Premise
p=0.002 I-Premise
) I-Premise
. I-Premise

In B-Premise
age-adjusted I-Premise
logistic I-Premise
regression I-Premise
analyses I-Premise
, I-Premise
patients I-Premise
who I-Premise
performed I-Premise
preoperative I-Premise
PFME I-Premise
had I-Premise
a I-Premise
0.41-fold I-Premise
lower I-Premise
risk I-Premise
of I-Premise
being I-Premise
incontinent I-Premise
1 I-Premise
mo I-Premise
after I-Premise
RP I-Premise
and I-Premise
a I-Premise
0.38-fold I-Premise
lower I-Premise
risk I-Premise
of I-Premise
being I-Premise
incontinent I-Premise
3 I-Premise
mo I-Premise
after I-Premise
RP I-Premise
( I-Premise
p≤0.001 I-Premise
) I-Premise
. I-Premise

Preoperative B-Claim
PFME I-Claim
may I-Claim
improve I-Claim
early I-Claim
continence I-Claim
and I-Claim
QoL I-Claim
outcomes I-Claim
after I-Claim
RP I-Claim
. I-Claim

Further B-Claim
studies I-Claim
are I-Claim
needed I-Claim
to I-Claim
corroborate I-Claim
our I-Claim
results I-Claim
. I-Claim

The O
role O
of O
chemotherapy O
for O
advanced O
NSCLC O
patients O
and O
ECOG O
PS2 O
remains O
controversial O
. O

We O
evaluated O
4 O
doses O
of O
3-weekly O
docetaxel O
to O
identify O
a O
less O
toxic O
, O
clinically O
effective O
dose O
. O

Seventy-three O
patients O
with O
stage O
III O
( O
22 O
% O
) O
( O
unsuitable O
for O
radical O
surgery/radiotherapy O
) O
and O
IV O
( O
78 O
% O
) O
NSCLC O
were O
randomized O
to O
receive O
4 O
doses O
of O
3-weekly O
docetaxel O
, O
for O
4 O
cycles O
: O
arm O
( O
A O
) O
40 O
mg/m O
( O
2 O
) O
( O
n=17 O
) O
, O
arm O
( O
B O
) O
50 O
mg/m O
( O
2 O
) O
( O
n=17 O
) O
, O
arm O
( O
C O
) O
60 O
mg/m O
( O
2 O
) O
( O
n=19 O
) O
, O
arm O
( O
D O
) O
50 O
mg/m O
( O
2 O
) O
escalated O
by O
10 O
mg/m O
( O
2 O
) O
to O
a O
maximum O
of O
70 O
mg/m O
( O
2 O
) O
( O
n=19 O
) O
. O

Primary O
endpoints O
: O
maximum O
tolerated O
dose O
, O
RR O
, O
duration O
of O
response O
, O
symptom O
improvement O
, O
toxicity O
and O
QoL O
. O

Secondary O
endpoint O
: O
overall O
survival O
( O
OS O
) O
. O

Patients O
and O
disease O
characteristics O
were O
well O
balanced O
. O

Median O
age O
was O
67 O
( O
range O
45-81 O
) O
, O
there O
were O
32 O
male O
and O
41 O
female O
, O
histology O
subtype O
: O
squamous/adenocarcinoma/mixed/NOS=42 O
% O
/49 O
% O
/4 O
% O
/5 O
% O
. O

Seven O
patients O
did O
not O
receive O
any O
treatment O
because O
of O
deterioration O
in O
PS O
or O
death O
. O

50 O
% O
of O
patients O
in O
arm O
D O
, O
who O
received O
more O
than O
one O
cycle O
, O
received O
dose O
escalation O
. O

There B-Premise
was I-Premise
no I-Premise
statistical I-Premise
difference I-Premise
in I-Premise
the I-Premise
number I-Premise
of I-Premise
cycles I-Premise
administered I-Premise
( I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
and I-Premise
D I-Premise
: I-Premise
median I-Premise
2 I-Premise
cycles I-Premise
and I-Premise
arm I-Premise
C I-Premise
: I-Premise
median I-Premise
3 I-Premise
cycles I-Premise
) I-Premise
and I-Premise
no I-Premise
difference I-Premise
in I-Premise
RR I-Premise
: I-Premise
arm I-Premise
A=6 I-Premise
% I-Premise
, I-Premise
arm I-Premise
B=6 I-Premise
% I-Premise
, I-Premise
arm I-Premise
C=10 I-Premise
% I-Premise
, I-Premise
and I-Premise
arm I-Premise
D=0 I-Premise
% I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
between I-Premise
the I-Premise
four I-Premise
arms I-Premise
. I-Premise

No B-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
hospitalization I-Premise
rate I-Premise
, I-Premise
blood I-Premise
transfusions I-Premise
, I-Premise
antibiotics I-Premise
administration I-Premise
and I-Premise
non-haematological I-Premise
toxicity I-Premise
. I-Premise

QoL O
: O
no O
difference O
in O
total O
scores O
between O
baseline O
and O
cycles O
1-4 O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pain I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
post I-Premise
cycles I-Premise
2 I-Premise
and I-Premise
3 I-Premise
( I-Premise
p=0.025 I-Premise
and I-Premise
p=0.002 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
OS I-Premise
( I-Premise
p=0.992 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
and I-Premise
6-month I-Premise
survival I-Premise
were I-Premise
61 I-Premise
, I-Premise
86 I-Premise
, I-Premise
88 I-Premise
and I-Premise
97 I-Premise
days I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
33 I-Premise
% I-Premise
, I-Premise
21 I-Premise
% I-Premise
and I-Premise
26 I-Premise
% I-Premise
for I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
C I-Premise
, I-Premise
and I-Premise
D I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Clinical B-Claim
efficacy I-Claim
of I-Claim
docetaxel I-Claim
was I-Claim
observed I-Claim
at I-Claim
all I-Claim
dose I-Claim
levels I-Claim
. I-Claim

Higher B-Claim
dose I-Claim
levels I-Claim
were I-Claim
not I-Claim
associated I-Claim
with I-Claim
increased I-Claim
toxicities I-Claim
, I-Claim
use I-Claim
of I-Claim
IV I-Claim
antibiotics I-Claim
or I-Claim
hospitalization I-Claim
rates I-Claim
. I-Claim

However O
, O
the B-Premise
median I-Premise
survival I-Premise
observed I-Premise
is I-Premise
shorter I-Premise
than I-Premise
historical I-Premise
data I-Premise
and I-Premise
do I-Premise
not I-Premise
support I-Premise
further I-Premise
evaluation I-Premise
of I-Premise
these I-Premise
doses I-Premise
of I-Premise
single I-Premise
agent I-Premise
docetaxel I-Premise
in I-Premise
this I-Premise
population I-Premise
. I-Premise

Somatostatin O
analogs O
are O
indicated O
for O
symptom O
control O
in O
patients O
with O
gastroenteropancreatic O
neuroendocrine O
tumors O
( O
NETs O
) O
. O

The O
ability O
of O
somatostatin O
analogs O
to O
control O
the O
growth O
of O
well-differentiated O
metastatic O
NETs O
is O
a O
matter O
of O
debate O
. O

We O
performed O
a O
placebo-controlled O
, O
double-blind O
, O
phase O
IIIB O
study O
in O
patients O
with O
well-differentiated O
metastatic O
midgut O
NETs O
. O

The O
hypothesis O
was O
that O
octreotide O
LAR O
prolongs O
time O
to O
tumor O
progression O
and O
survival O
. O

Treatment-naive O
patients O
were O
randomly O
assigned O
to O
either O
placebo O
or O
octreotide O
LAR O
30 O
mg O
intramuscularly O
in O
monthly O
intervals O
until O
tumor O
progression O
or O
death O
. O

The O
primary O
efficacy O
end O
point O
was O
time O
to O
tumor O
progression O
. O

Secondary O
end O
points O
were O
survival O
time O
and O
tumor O
response O
. O

This O
report O
is O
based O
on O
67 O
tumor O
progressions O
and O
16 O
observed O
deaths O
in O
85 O
patients O
at O
the O
time O
of O
the O
planned O
interim O
analysis O
. O

Median B-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
LAR I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
14.3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.34 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.20 I-Premise
to I-Premise
0.59 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.000072 I-Premise
) I-Premise
. I-Premise

After B-Premise
6 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
, I-Premise
stable I-Premise
disease I-Premise
was I-Premise
observed I-Premise
in I-Premise
66.7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
LAR I-Premise
group I-Premise
and I-Premise
37.2 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Functionally O
active O
and O
inactive O
tumors O
responded O
similarly O
. O

The B-Premise
most I-Premise
favorable I-Premise
effect I-Premise
was I-Premise
observed I-Premise
in I-Premise
patients I-Premise
with I-Premise
low I-Premise
hepatic I-Premise
tumor I-Premise
load I-Premise
and I-Premise
resected I-Premise
primary I-Premise
tumor I-Premise
. I-Premise

Seven B-Premise
and I-Premise
nine I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
LAR I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.81 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.30 I-Premise
to I-Premise
2.18 I-Premise
) I-Premise
. I-Premise

Octreotide B-Claim
LAR I-Claim
significantly I-Claim
lengthens I-Claim
time I-Claim
to I-Claim
tumor I-Claim
progression I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
patients I-Claim
with I-Claim
functionally I-Claim
active I-Claim
and I-Claim
inactive I-Claim
metastatic I-Claim
midgut I-Claim
NETs I-Claim
. I-Claim

Because B-Premise
of I-Premise
the I-Premise
low I-Premise
number I-Premise
of I-Premise
observed I-Premise
deaths I-Premise
, I-Premise
survival I-Premise
analysis I-Premise
was I-Premise
not I-Premise
confirmatory I-Premise
. I-Premise

In B-Claim
the I-Claim
context I-Claim
of I-Claim
chronic I-Claim
physical I-Claim
illness I-Claim
, I-Claim
such I-Claim
as I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
depression I-Claim
is I-Claim
associated I-Claim
with I-Claim
increased I-Claim
morbidity I-Claim
, I-Claim
longer I-Claim
periods I-Claim
of I-Claim
hospitalization I-Claim
, I-Claim
and I-Claim
greater I-Claim
overall I-Claim
disability I-Claim
. I-Claim

Prompt B-Claim
diagnosis I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
is I-Claim
, I-Claim
therefore I-Claim
, I-Claim
essential I-Claim
. I-Claim

Several O
small O
studies O
have O
established O
the O
efficacy O
of O
tricyclic O
antidepressants O
( O
TCAs O
) O
in O
this O
setting O
, O
and O
the O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
would O
appear O
to O
be O
an O
alternative O
therapeutic O
option O
because O
of O
their O
established O
efficacy O
and O
better O
tolerability O
profile O
. O

This O
was O
a O
multicenter O
. O

double-blind O
, O
parallel-group O
study O
in O
which O
179 O
women O
with O
breast O
cancer O
were O
randomized O
to O
treatment O
with O
either O
the O
SSRI O
paroxetine O
( O
20-40 O
mg/day O
) O
, O
or O
the O
TCA O
, O
amitriptyline O
( O
75-150 O
mg/day O
) O
. O

After B-Premise
8-weeks I-Premise
treatment I-Premise
, I-Premise
depressive I-Premise
symptomatology I-Premise
had I-Premise
improved I-Premise
markedly I-Premise
and I-Premise
to I-Premise
a I-Premise
similar I-Premise
extent I-Premise
in I-Premise
both I-Premise
groups I-Premise
on I-Premise
the I-Premise
Montgomery I-Premise
Asberg I-Premise
Depression I-Premise
Rating I-Premise
Scale I-Premise
. I-Premise

Clinical B-Premise
global I-Premise
impression I-Premise
( I-Premise
CGI I-Premise
) I-Premise
Global I-Premise
improvement I-Premise
and I-Premise
Patient I-Premise
global I-Premise
evaluation I-Premise
scales I-Premise
indicated I-Premise
that I-Premise
patients I-Premise
were I-Premise
minimally I-Premise
to I-Premise
much I-Premise
improved I-Premise
at I-Premise
study I-Premise
endpoint I-Premise
: I-Premise
a I-Premise
change I-Premise
from I-Premise
moderately/mildly I-Premise
ill I-Premise
to I-Premise
borderline I-Premise
ill I-Premise
on I-Premise
the I-Premise
CGI I-Premise
severity I-Premise
of I-Premise
Illness I-Premise
scale I-Premise
. I-Premise

A B-Claim
steady I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
also I-Claim
observed I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
clinically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

In B-Premise
total I-Premise
, I-Premise
47 I-Premise
( I-Premise
53.4 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
paroxetine I-Premise
group I-Premise
and I-Premise
53 I-Premise
( I-Premise
59.6 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
amitriptyline I-Premise
group I-Premise
had I-Premise
adverse I-Premise
experiences I-Premise
, I-Premise
the I-Premise
most I-Premise
common I-Premise
of I-Premise
which I-Premise
were I-Premise
the I-Premise
well-recognized I-Premise
side-effects I-Premise
of I-Premise
the I-Premise
antidepressant I-Premise
medications I-Premise
or I-Premise
chemotherapy I-Premise
. I-Premise

Anticholinergic B-Premise
effects I-Premise
were I-Premise
almost I-Premise
twice I-Premise
as I-Premise
frequent I-Premise
in I-Premise
the I-Premise
amitriptyline I-Premise
group I-Premise
( I-Premise
19.1 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
paroxetine I-Premise
( I-Premise
11.4 I-Premise
% I-Premise
) I-Premise
. I-Premise

This O
study O
has O
demonstrated O
that O
paroxetine B-Claim
is I-Claim
a I-Claim
suitable I-Claim
alternative I-Claim
to I-Claim
amitriptyline I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
depression I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

In O
anorectal O
cancer O
patients O
, O
an O
acute O
side O
effect O
of O
chemoradiotherapy O
is O
gastrointestinal O
toxicity O
, O
which O
often O
impedes O
treatment O
delivery O
. O

Based O
on O
previous O
trials O
, O
octreotide O
acetate O
is O
widely O
recommended O
for O
the O
control O
of O
chemotherapy-induced O
diarrhea O
. O

However O
, O
the O
effectiveness O
of O
octreotide O
in O
preventing O
or O
controlling O
radiation- O
and O
chemoradiation-induced O
diarrhea O
is O
not O
known O
. O

A O
randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
was O
designed O
to O
determine O
the O
efficacy O
of O
long-acting O
octreotide O
acetate O
( O
LAO O
) O
in O
preventing O
the O
onset O
of O
acute O
diarrhea O
in O
patients O
undergoing O
chemoradiation O
therapy O
for O
rectal O
or O
anal O
cancer O
. O

Between O
4 O
and O
7 O
days O
before O
the O
start O
of O
radiation O
therapy O
, O
patients O
received O
a O
30-mg O
dose O
of O
LAO O
( O
109 O
patients O
) O
or O
placebo O
( O
106 O
patients O
) O
via O
intramuscular O
injection O
. O

A O
second O
dose O
was O
given O
on O
day O
22 O
( O
+/-3 O
days O
) O
of O
radiation O
treatment O
. O

A O
total O
of O
215 O
patients O
were O
included O
in O
the O
final O
analysis O
. O

The O
primary O
endpoint O
was O
the O
incidence O
of O
grade O
2-4 O
acute O
diarrhea O
";" O
secondary O
endpoints O
included O
treatment O
compliance O
, O
medical O
resource O
utilization O
, O
patient-reported O
bowel O
function O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Statistical O
tests O
were O
one- O
or O
two-sided O
, O
as O
specified O
. O

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
9.64 I-Premise
months I-Premise
, I-Premise
incidence I-Premise
rates I-Premise
of I-Premise
grades I-Premise
2-4 I-Premise
acute I-Premise
diarrhea I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
( I-Premise
49 I-Premise
% I-Premise
placebo I-Premise
vs I-Premise
44 I-Premise
% I-Premise
LAO I-Premise
";" I-Premise
P I-Premise
= I-Premise
.21 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
treatment I-Premise
differences I-Premise
in I-Premise
chemotherapy I-Premise
or I-Premise
radiation I-Premise
delivery I-Premise
, I-Premise
medical I-Premise
resource I-Premise
utilization I-Premise
, I-Premise
patient-reported I-Premise
bowel I-Premise
function I-Premise
, I-Premise
or I-Premise
QoL I-Premise
were I-Premise
observed I-Premise
. I-Premise

In B-Claim
this I-Claim
study I-Claim
, I-Claim
the I-Claim
prophylactic I-Claim
use I-Claim
of I-Claim
LAO I-Claim
did I-Claim
not I-Claim
prevent I-Claim
the I-Claim
incidence I-Claim
or I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
diarrhea I-Claim
and I-Claim
had I-Claim
no I-Claim
notable I-Claim
impact I-Claim
on I-Claim
patient-reported I-Claim
bowel I-Claim
function I-Claim
or I-Claim
QoL I-Claim
. I-Claim

A O
significant O
proportion O
of O
patients O
develop O
urinary O
incontinence O
early O
after O
radical O
prostatectomy O
. O

Posterior O
reconstruction O
of O
supporting O
tissues O
has O
been O
found O
to O
reduce O
incontinence O
in O
open O
and O
conventional O
laparoscopic O
prostatectomy O
series O
. O

To O
investigate O
whether O
our O
version O
of O
a O
posterior O
musculofascial O
reconstruction O
will O
reduce O
early O
incontinence O
and O
have O
a O
beneficial O
effect O
on O
patients O
' O
quality O
of O
life O
( O
QoL O
) O
. O

One O
hundred O
seven O
consecutive O
patients O
undergoing O
primary O
robot-assisted O
radical O
laparoscopic O
prostatectomy O
( O
RALP O
) O
performed O
by O
a O
single O
surgeon O
at O
one O
tertiary O
referral O
oncology O
institution O
were O
alternately O
assigned O
( O
not O
randomised O
) O
to O
intervention O
( O
n=53 O
) O
or O
control O
groups O
( O
n=54 O
) O
. O

RALP O
with O
median O
fibrous O
raphe O
reconstruction O
( O
MFRR O
) O
followed O
by O
formation O
of O
the O
urethrovesical O
anastomosis O
( O
intervention O
group O
) O
versus O
standard O
anastomosis O
without O
posterior O
reconstruction O
( O
control O
group O
) O
. O

Measurements O
included O
incontinence O
at O
baseline O
and O
3-mo O
intervals O
";" O
QoL O
as O
measured O
by O
a O
simple O
questionnaire O
, O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life-Core O
30 O
( O
QLQ-C30 O
) O
, O
and O
Prostate O
Cancer O
Module O
( O
PR25 O
) O
questionnaires O
preoperatively O
and O
at O
6 O
mo O
postprocedure O
";" O
tumour O
characteristics O
";" O
operative O
time O
";" O
fascial O
preservation O
score O
";" O
duration O
of O
catheterisation O
";" O
and O
anastomotic O
leakage O
on O
cystogram O
. O

For B-Premise
intervention I-Premise
and I-Premise
control I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
mean I-Premise
catheter I-Premise
duration I-Premise
was I-Premise
11.74 I-Premise
d I-Premise
and I-Premise
12.74 I-Premise
d I-Premise
( I-Premise
p=0.451 I-Premise
) I-Premise
";" I-Premise
leakage I-Premise
on I-Premise
cystogram I-Premise
was I-Premise
present I-Premise
in I-Premise
six I-Premise
and I-Premise
eight I-Premise
cases I-Premise
( I-Premise
p=0.28 I-Premise
) I-Premise
";" I-Premise
and I-Premise
incontinence I-Premise
( I-Premise
any I-Premise
involuntary I-Premise
urine I-Premise
loss I-Premise
) I-Premise
at I-Premise
3 I-Premise
mo I-Premise
was I-Premise
75 I-Premise
% I-Premise
and I-Premise
69 I-Premise
% I-Premise
( I-Premise
p=0.391 I-Premise
) I-Premise
and I-Premise
at I-Premise
6 I-Premise
mo I-Premise
was I-Premise
51 I-Premise
% I-Premise
and I-Premise
43 I-Premise
% I-Premise
( I-Premise
p=0.686 I-Premise
) I-Premise
. I-Premise

Urinary B-Premise
retention I-Premise
occurred I-Premise
only I-Premise
in I-Premise
one I-Premise
case I-Premise
( I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

The B-Premise
percentage I-Premise
of I-Premise
cases I-Premise
returning I-Premise
to I-Premise
baseline I-Premise
in I-Premise
all I-Premise
QoL I-Premise
domains I-Premise
( I-Premise
except I-Premise
insomnia I-Premise
) I-Premise
was I-Premise
similar I-Premise
at I-Premise
6 I-Premise
mo I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Short B-Premise
follow-up I-Premise
, I-Premise
lack I-Premise
of I-Premise
blinding I-Premise
, I-Premise
and I-Premise
probable I-Premise
small I-Premise
differences I-Premise
in I-Premise
our I-Premise
method I-Premise
of I-Premise
MFRR I-Premise
performed I-Premise
compared I-Premise
with I-Premise
other I-Premise
studies I-Premise
were I-Premise
identified I-Premise
as I-Premise
significant I-Premise
limitations I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
analysed I-Premise
outcome I-Premise
measures I-Premise
was I-Premise
observed I-Premise
. I-Premise

Posterior B-Claim
reconstruction I-Claim
of I-Claim
the I-Claim
musculofascial I-Claim
complex I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
improve I-Claim
early I-Claim
urinary I-Claim
incontinence I-Claim
after I-Claim
RALP I-Claim
. I-Claim

In O
the O
Gynecologic O
Cancer O
Intergroup O
International O
Collaboration O
on O
Ovarian O
Neoplasms O
7 O
( O
ICON7 O
) O
trial O
, O
bevacizumab O
improved O
progression-free O
survival O
in O
patients O
with O
ovarian O
cancer O
when O
used O
in O
combination O
with O
first-line O
chemotherapy O
and O
as O
a O
single-drug O
continuation O
treatment O
for O
18 O
cycles O
. O

In O
a O
preliminary O
analysis O
of O
a O
high-risk O
subset O
of O
patients O
, O
there O
was O
also O
an O
improvement O
in O
overall O
survival O
. O

This O
study O
aims O
to O
describe O
the O
health-related O
quality-of-life O
( O
QoL O
) O
outcomes O
from O
ICON7 O
. O

ICON7 O
is O
a O
randomised O
, O
multicentre O
, O
open-label O
phase O
3 O
trial O
. O

Between O
Dec O
18 O
, O
2006 O
, O
and O
Feb O
16 O
, O
2009 O
, O
after O
a O
surgical O
procedure O
aiming O
to O
debulk O
the O
disease O
, O
women O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
( O
FIGO O
) O
high-risk O
stage O
I-IV O
epithelial O
ovarian O
cancer O
were O
randomly O
allocated O
( O
1:1 O
) O
by O
computer O
program O
and O
block O
randomisation O
to O
receive O
either O
six O
cycles O
of O
standard O
chemotherapy O
( O
total O
18 O
weeks O
) O
with O
carboplatin O
( O
area O
under O
the O
curve O
5 O
or O
6 O
) O
and O
paclitaxel O
( O
175 O
mg/m O
( O
2 O
) O
) O
alone O
or O
with O
bevacizumab O
( O
7·5 O
mg/kg O
) O
given O
intravenously O
with O
chemotherapy O
and O
continued O
as O
a O
single O
drug O
thereafter O
( O
total O
54 O
weeks O
) O
. O

The O
primary O
QoL O
endpoint O
was O
global O
QoL O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire-core O
30 O
at O
week O
54 O
, O
analysed O
by O
ANOVA O
and O
adjusted O
for O
baseline O
score O
. O

Analyses O
were O
by O
intention O
to O
treat O
. O

The O
ICON7 O
trial O
has O
completed O
recruitment O
and O
remains O
in O
follow-up O
. O

This O
study O
is O
registered O
, O
number O
ISRCTN91273375 O
. O

764 O
women O
were O
randomly O
assigned O
to O
the O
standard O
chemotherapy O
group O
and O
764 O
to O
the O
bevacizumab O
group O
. O

At O
baseline O
, O
684 O
( O
90 O
% O
) O
of O
women O
in O
the O
standard O
chemotherapy O
group O
and O
691 O
( O
90 O
% O
) O
of O
those O
in O
the O
bevacizumab O
group O
had O
completed O
QoL O
questionnaires O
. O

At O
week O
54 O
, O
502 O
( O
66 O
% O
) O
women O
in O
the O
bevacizumab O
group O
and O
388 O
( O
51 O
% O
) O
women O
in O
the O
standard O
chemotherapy O
group O
provided O
QoL O
data O
. O

Overall B-Premise
, I-Premise
the I-Premise
mean I-Premise
global I-Premise
QoL I-Premise
score I-Premise
improved I-Premise
during I-Premise
chemotherapy I-Premise
by I-Premise
7·2 I-Premise
points I-Premise
( I-Premise
SD I-Premise
24·4 I-Premise
) I-Premise
when I-Premise
analysed I-Premise
for I-Premise
all I-Premise
women I-Premise
with I-Premise
data I-Premise
at I-Premise
baseline I-Premise
and I-Premise
week I-Premise
18 I-Premise
. I-Premise

The B-Premise
mean I-Premise
global I-Premise
QoL I-Premise
score I-Premise
at I-Premise
54 I-Premise
weeks I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
standard I-Premise
chemotherapy I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
( I-Premise
76·1 I-Premise
[ I-Premise
SD I-Premise
18·2 I-Premise
] I-Premise
vs I-Premise
69·7 I-Premise
[ I-Premise
19·1 I-Premise
] I-Premise
points I-Premise
";" I-Premise
difference I-Premise
6·4 I-Premise
points I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3·7-9·0 I-Premise
, I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

Bevacizumab B-Claim
continuation I-Claim
treatment I-Claim
seems I-Claim
to I-Claim
be I-Claim
associated I-Claim
with I-Claim
a I-Claim
small I-Claim
but I-Claim
clinically I-Claim
significant I-Claim
decrement I-Claim
in I-Claim
QoL I-Claim
compared I-Claim
with I-Claim
standard I-Claim
treatment I-Claim
for I-Claim
women I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

The O
trade-off O
between O
the O
prolongation O
of O
progression-free O
survival O
and O
the O
quality O
of O
that O
period O
of O
time O
needs O
to O
be O
considered O
in O
clinical O
practice O
when O
making O
treatment O
decisions O
. O

Mediating O
mechanisms O
of O
a O
12-week O
group-based O
exercise O
intervention O
on O
cancer O
survivors O
' O
quality O
of O
life O
( O
QoL O
) O
were O
examined O
to O
inform O
future O
exercise O
intervention O
development O
. O

Two O
hundred O
nine O
cancer O
survivors O
≥ O
3 O
months O
posttreatment O
( O
57 O
% O
breast O
cancer O
) O
aged O
49.5 O
( O
± O
10.4 O
) O
years O
were O
assigned O
to O
physical O
exercise O
( O
n O
= O
147 O
) O
or O
wait-list O
control O
( O
n O
= O
62 O
) O
. O

QoL O
, O
fatigue O
, O
emotional O
distress O
, O
physical O
activity O
, O
general O
self-efficacy O
and O
mastery O
were O
assessed O
at O
baseline O
and O
post-intervention O
using O
questionnaires O
. O

Path O
analysis O
was O
conducted O
using O
Mplus O
to O
explore O
whether O
improved O
physical O
activity O
, O
general O
self-efficacy O
and O
mastery O
mediated O
the O
effects O
of O
exercise O
on O
fatigue O
and O
distress O
and O
consequently O
QoL O
. O

The B-Premise
intervention I-Premise
was I-Premise
associated I-Premise
with I-Premise
increased I-Premise
physical I-Premise
activity I-Premise
( I-Premise
β I-Premise
= I-Premise
0.46 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
= I-Premise
0.14 I-Premise
";" I-Premise
0.59 I-Premise
) I-Premise
, I-Premise
general I-Premise
self-efficacy I-Premise
( I-Premise
β I-Premise
= I-Premise
2.41 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.35 I-Premise
";" I-Premise
4.73 I-Premise
) I-Premise
, I-Premise
and I-Premise
mastery I-Premise
( I-Premise
β I-Premise
= I-Premise
1.75 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.36 I-Premise
";" I-Premise
2.78 I-Premise
) I-Premise
. I-Premise

Further O
, O
the B-Premise
intervention I-Premise
had I-Premise
both I-Premise
a I-Premise
direct I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.09 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.12 I-Premise
";" I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
indirect I-Premise
effect I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.54 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.00 I-Premise
";" I-Premise
-0.21 I-Premise
) I-Premise
via I-Premise
physical I-Premise
activity I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.29 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.64 I-Premise
";" I-Premise
-0.07 I-Premise
) I-Premise
and I-Premise
general I-Premise
self-efficacy I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.25 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.61 I-Premise
";" I-Premise
-0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
intervention I-Premise
had I-Premise
a I-Premise
borderline I-Premise
significant I-Premise
direct I-Premise
effect I-Premise
on I-Premise
reduced I-Premise
distress I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.32 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.68 I-Premise
";" I-Premise
0.11 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
indirect I-Premise
effect I-Premise
via I-Premise
increased I-Premise
general I-Premise
self-efficacy I-Premise
and I-Premise
mastery I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.06 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.89 I-Premise
";" I-Premise
-0.38 I-Premise
) I-Premise
. I-Premise

Reductions B-Premise
in I-Premise
fatigue I-Premise
( I-Premise
β I-Premise
= I-Premise
-1.33 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
=-1.85 I-Premise
";" I-Premise
-0.83 I-Premise
) I-Premise
and I-Premise
distress I-Premise
( I-Premise
β I-Premise
= I-Premise
-0.86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.25 I-Premise
";" I-Premise
-0.52 I-Premise
) I-Premise
were I-Premise
associated I-Premise
with I-Premise
improved I-Premise
QoL I-Premise
. I-Premise

Further O
, O
increased B-Premise
physical I-Premise
activity I-Premise
was I-Premise
directly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
QoL I-Premise
( I-Premise
β I-Premise
= I-Premise
3.37 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.01 I-Premise
";" I-Premise
5.54 I-Premise
) I-Premise
. I-Premise

The B-Claim
beneficial I-Claim
effect I-Claim
of I-Claim
group-based I-Claim
physical I-Claim
exercise I-Claim
on I-Claim
QoL I-Claim
was I-Claim
mediated I-Claim
by I-Claim
increased I-Claim
physical I-Claim
activity I-Claim
, I-Claim
general I-Claim
self-efficacy I-Claim
and I-Claim
mastery I-Claim
, I-Claim
and I-Claim
subsequent I-Claim
reductions I-Claim
in I-Claim
fatigue I-Claim
and I-Claim
distress I-Claim
. I-Claim

In B-Claim
addition I-Claim
to I-Claim
physical I-Claim
activity I-Claim
, I-Claim
future I-Claim
interventions I-Claim
should I-Claim
target I-Claim
self-efficacy I-Claim
and I-Claim
mastery I-Claim
. I-Claim

This B-Claim
may I-Claim
lead I-Claim
to I-Claim
reduced I-Claim
distress I-Claim
and I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
consequently I-Claim
improved I-Claim
QoL I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

To O
assess O
whether O
omission O
of O
post-operative O
radiotherapy O
( O
RT O
) O
in O
women O
with O
'low-risk O
' O
axillary O
node-negative O
breast O
cancer O
[ O
tumour O
size O
of O
less O
than O
5 O
cm O
( O
T0-2 O
) O
although O
the O
eligibility O
criteria O
further O
reduce O
the O
eligible O
size O
to O
a O
maximum O
of O
3 O
cm O
] O
treated O
by O
breast-conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost-effective O
. O

A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphovascular O
invasion O
and O
preoperative O
endocrine O
therapy O
was O
performed O
. O

Breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
UK O
. O

Patients O
aged O
≥ O
65 O
years O
were O
eligible O
provided O
that O
their O
breast O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
they O
were O
suitable O
for O
breast O
conservation O
surgery O
, O
they O
were O
receiving O
endocrine O
therapy O
and O
they O
were O
willing O
and O
able O
to O
give O
informed O
consent O
. O

The O
standard O
treatment O
of O
post-operative O
whole O
breast O
irradiation O
or O
the O
omission O
of O
RT O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost-effectiveness O
. O

Secondary O
outcome O
measures O
were O
recurrence O
rates O
and O
survival O
, O
and O
treatment-related O
morbidity O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
on O
four O
occasions O
over O
15 O
months O
, O
then O
by O
postal O
questionnaire O
at O
3 O
and O
5 O
years O
after O
surgery O
. O

The O
hypothesised O
improvement O
in O
overall O
quality O
of O
life O
with O
the O
omission O
of O
RT O
was O
not O
seen O
in O
the O
summary O
domains O
of O
the O
European O
Organisation O
for O
Research O
in O
the O
Treatment O
of O
Cancer O
( O
EORTC O
) O
scales O
. O

Some O
differences O
were O
apparent O
within O
subscales O
of O
the O
EORTC O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open-ended O
questions O
added O
by O
the O
trial O
team O
. O

Differences O
were O
most O
apparent O
shortly O
after O
the O
time O
of O
completion O
of O
RT O
. O

RT B-Premise
was I-Premise
then I-Premise
associated I-Premise
with I-Premise
increased I-Premise
breast I-Premise
symptoms I-Premise
and I-Premise
with I-Premise
greater I-Premise
( I-Premise
self-reported I-Premise
) I-Premise
fatigue I-Premise
, I-Premise
but I-Premise
with I-Premise
lower I-Premise
levels I-Premise
of I-Premise
insomnia I-Premise
and I-Premise
endocrine I-Premise
side I-Premise
effects I-Premise
. I-Premise

These B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
breast I-Premise
symptoms I-Premise
persisted I-Premise
for I-Premise
up I-Premise
to I-Premise
5 I-Premise
years I-Premise
after I-Premise
RT I-Premise
[ I-Premise
mean I-Premise
difference I-Premise
, I-Premise
RT I-Premise
was I-Premise
5.27 I-Premise
units I-Premise
greater I-Premise
than I-Premise
no I-Premise
RT I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
of I-Premise
1.46 I-Premise
to I-Premise
9.07 I-Premise
] I-Premise
, I-Premise
with I-Premise
similar I-Premise
, I-Premise
though I-Premise
non-significant I-Premise
, I-Premise
trends I-Premise
in I-Premise
insomnia I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
measure I-Premise
, I-Premise
with I-Premise
the I-Premise
no I-Premise
RT I-Premise
group I-Premise
having I-Premise
0.36 I-Premise
units I-Premise
greater I-Premise
quality I-Premise
of I-Premise
life I-Premise
than I-Premise
the I-Premise
RT I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-5.09 I-Premise
to I-Premise
5.81 I-Premise
) I-Premise
. I-Premise

Breast B-Claim
RT I-Claim
is I-Claim
tolerated I-Claim
well I-Claim
by I-Claim
most I-Claim
older I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
without I-Claim
impairing I-Claim
their I-Claim
overall I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQoL I-Claim
) I-Claim
. I-Claim

Although O
HRQoL O
should O
always O
be O
taken O
into O
account O
when O
determining O
treatment O
, O
our B-Claim
results I-Claim
show I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
RT I-Claim
does I-Claim
not I-Claim
impair I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Further B-Claim
economic I-Claim
modelling I-Claim
on I-Claim
the I-Claim
longer-term I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
RT I-Claim
is I-Claim
required I-Claim
. I-Claim

La O -
reconstrucción O -
con O -
implantes O -
se O -
realiza O -
en O -
la O -
mayoría O -
de O -
las O -
mujeres O -
a O -
las O -
que O -
se O -
les O -
ofrece O -
una O -
reconstrucción O -
primaria O -
por O -
cáncer O -
de O -
mama O -
. O -

Se O -
compararon O -
prospectivamente O -
dos O -
implantes O -
de O -
expansores O -
diferentes. O -

El O -
criterio O -
de O -
valoración O -
principal O -
fue O -
el O -
número O -
de O -
operaciones O -
necesarias O -
en O -
cada O -
grupo O -
para O -
obtener O -
la O -
satisfacción O -
del O -
paciente O -
. O -

Los O -
criterios O -
de O -
valoración O -
secundarios O -
fueron O -
la O -
evaluación O -
del O -
volumen O -
y O -
la O -
forma O -
de O -
las O -
mamas O -
y O -
aspectos O -
de O -
la O -
calidad O -
de O -
vida O -
. O -

Setenta O -
pacientes O -
consecutivas O -
con O -
cáncer O -
de O -
mama O -
fueron O -
aleatorizadas O -
a O -
una O -
reconstrucción O -
en O -
una O -
fase O -
con O -
un O -
implante O -
expansor O -
permanente O -
redondo O -
( O -
Becker O -
25 O -
; O -
n=35 O -
) O -
o O -
a O -
una O -
reconstrucción O -
en O -
dos O -
fases O -
con O -
un O -
expansor O -
en O -
forma O -
de O -
media O -
luna O -
( O -
LV O -
133 O -
; O -
n=35 O -
) O -
, O -
sustituido O -
posteriormente O -
por O -
un O -
implante O -
anatómico O -
de O -
forma O -
estable O -
. O -

Hubo O -
que O -
excluir O -
a O -
30 O -
pacientes O -
y O -
se O -
evaluaron O -
40, O -
20 O -
en O -
cada O -
grupo. O -

La O -
mediana O -
de O -
seguimiento O -
para O -
ambos O -
grupos O -
fue O -
de O -
3,5 O -
años O -
( O -
rango O -
, O -
1,5 O -
a O -
5 O -
años O -
) O -
. O -

Se O -
utilizaron O -
copas O -
de O -
plástico, O -
moldes O -
de O -
plástico O -
y O -
técnicas O -
de O -
escaneo O -
bidimensional O -
y O -
tridimensional O -
para O -
la O -
evaluación O -
objetiva O -
del O -
volumen O -
y O -
la O -
forma O -
de O -
las O -
mamas. O -

El O -
resultado O -
estético O -
fue O -
evaluado O -
por O -
un O -
panel O -
de O -
expertos O -
y O -
legos O -
, O -
y O -
por O -
los O -
pacientes O -
. O -

La O -
calidad O -
de O -
vida O -
se O -
evaluó O -
con O -
un O -
cuestionario O -
validado O -
( O -
36-Item O -
Short O -
Form O -
Health O -
Survey O -
) O -
. O -

De B-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
una I-Premise HighQuality
etapa I-Premise HighQuality
, I-Premise HighQuality
el I-Premise HighQuality
70 I-Premise HighQuality
por I-Premise HighQuality
ciento I-Premise HighQuality
se I-Premise HighQuality
sometió I-Premise HighQuality
a I-Premise HighQuality
una I-Premise HighQuality
cirugía I-Premise HighQuality
de I-Premise HighQuality
revisión I-Premise HighQuality
, I-Premise HighQuality
en I-Premise HighQuality
su I-Premise HighQuality
mayoría I-Premise HighQuality
debido I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
plenitud I-Premise HighQuality
del I-Premise HighQuality
polo I-Premise HighQuality
superior I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
mala I-Premise HighQuality
ptosis I-Premise HighQuality
. I-Premise HighQuality

Estos O -
resultados O -
concuerdan O -
con O -
los O -
datos O -
de O -
la O -
exploración O -
bidimensional O -
y O -
del O -
panel O -
de O -
expertos O -
y O -
el O -
juicio O -
subjetivo O -
de O -
los O -
pacientes. O -

La B-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
fue I-Premise HighQuality
similar I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
dos I-Premise HighQuality
grupos. I-Premise HighQuality

El B-Claim HighQuality
método I-Claim HighQuality
del I-Claim HighQuality
expansor I-Claim HighQuality
permanente I-Claim HighQuality
fracasó I-Claim HighQuality
significativamente I-Claim HighQuality
como I-Claim HighQuality
procedimiento I-Claim HighQuality
de I-Claim HighQuality
una I-Claim HighQuality
sola I-Claim HighQuality
etapa I-Claim HighQuality
. I-Claim HighQuality

El B-Claim HighQuality
método I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
media I-Claim HighQuality
luna I-Claim HighQuality
en I-Claim HighQuality
dos I-Claim HighQuality
etapas I-Claim HighQuality
dio I-Claim HighQuality
los I-Claim HighQuality
resultados I-Claim HighQuality
más I-Claim HighQuality
aceptables I-Claim HighQuality
tanto I-Claim HighQuality
objetiva I-Claim HighQuality
como I-Claim HighQuality
subjetivamente I-Claim HighQuality
. I-Claim HighQuality

Analizar O -
el O -
curso O -
clínico, O -
el O -
tratamiento, O -
las O -
complicaciones, O -
el O -
resultado O -
y O -
la O -
calidad O -
de O -
vida O -
( O -
QOL O -
) O -
en O -
pacientes O -
con O -
rabdomiosarcoma O -
perineal/perianal O -
( O -
PRMS O -
) O -
tratados O -
dentro O -
de O -
los O -
ensayos O -
CWS-86 O -
, O -
-91 O -
, O -
-96 O -
, O -
y O -
-2002P O -
. O -

Aunque O -
existen O -
múltiples O -
ensayos O -
de O -
estudios O -
internacionales O -
para O -
el O -
tratamiento O -
del O -
rabdomiosarcoma, O -
sólo O -
se O -
ofrece O -
una O -
información O -
muy O -
limitada O -
sobre O -
el O -
tratamiento, O -
los O -
resultados O -
y O -
la O -
calidad O -
de O -
vida O -
en O -
el O -
EMRP. O -

Un O -
total O -
de O -
35 O -
pacientes O -
que O -
padecían O -
EMRP O -
fueron O -
tratados O -
con O -
quimioterapia O -
neoadyuvante O -
. O -

Se O -
realizó O -
una O -
terapia O -
local O -
con O -
radiación O -
y/o O -
cirugía, O -
seguida O -
de O -
quimioterapia O -
adyuvante. O -

El O -
seguimiento O -
funcional O -
a O -
largo O -
plazo O -
se O -
evaluó O -
mediante O -
una O -
encuesta O -
gastrointestinal/de O -
calidad O -
de O -
vida. O -

Se O -
evaluaron O -
32 O -
pacientes O -
( O -
exclusión O -
n O -
= O -
3 O -
) O -
. O -

Ocho O -
pacientes O -
presentaban O -
una O -
histología O -
embrionaria O -
y O -
24 O -
una O -
histología O -
alveolar. O -

La O -
mediana O -
de O -
edad O -
era O -
de O -
108 O -
meses O -
( O -
mediana O -
de O -
seguimiento O -
: O -
5,8 O -
años O -
) O -
. O -

La O -
supervivencia O -
global O -
a O -
los O -
5 O -
años O -
fue O -
del O -
47 O -
% O -
( O -
intervalo O -
de O -
confianza O -
del O -
95 O -
% O -
: O -
29-64 O -
) O -
. O -

Dieciséis O -
pacientes O -
del O -
IRS O -
( O -
Intergroup O -
Rhabdomyosarcoma O -
Study O -
) O -
III O -
y O -
IV O -
tenían O -
afectación O -
ganglionar O -
locorregional O -
en O -
el O -
momento O -
del O -
diagnóstico O -
. O -

Siete O -
pacientes O -
fueron O -
tratados O -
sólo O -
con O -
quimioterapia/cirugía O -
[supervivencia O -
libre O -
de O -
eventos O -
a O -
5 O -
años O -
( O -
EFS O -
) O -
: O -
85,7 O -
% O -
] O -
. O -

Once O -
pacientes O -
recibieron O -
sólo O -
radioquimioterapia O -
( O -
SFE O -
a O -
5 O -
años O -
: O -
27,3 O -
% O -
) O -
. O -

En O -
12 O -
pacientes O -
se O -
utilizó O -
la O -
radioquimioterapia/cirugía O -
combinada O -
( O -
SFE O -
a O -
5 O -
años O -
: O -
63,6 O -
% O -
) O -
. O -

Dos O -
pacientes O -
fueron O -
tratados O -
sólo O -
con O -
quimioterapia O -
y O -
murieron. O -

Los B-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
histología I-Premise HighQuality
embrionaria I-Premise HighQuality
tuvieron I-Premise HighQuality
una I-Premise HighQuality
SSC I-Premise HighQuality
a I-Premise HighQuality
5 I-Premise HighQuality
años I-Premise HighQuality
significativamente I-Premise HighQuality
mejor I-Premise HighQuality
( I-Premise HighQuality
87,5% I-Premise HighQuality
) I-Premise HighQuality
que I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
histología I-Premise HighQuality
alveolar I-Premise HighQuality
( I-Premise HighQuality
39,1% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,013 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Algunos B-Premise HighQuality
pacientes I-Premise HighQuality
informaron I-Premise HighQuality
de I-Premise HighQuality
síntomas I-Premise HighQuality
de I-Premise HighQuality
incontinencia I-Premise HighQuality
fecal. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
de I-Premise HighQuality
incontinencia I-Premise HighQuality
fecal I-Premise HighQuality
de I-Premise HighQuality
Wexner I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
9 I-Premise HighQuality
( I-Premise HighQuality
rango I-Premise HighQuality
posible I-Premise HighQuality
: I-Premise HighQuality
0-20 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
90,5 I-Premise HighQuality
( I-Premise HighQuality
rango I-Premise HighQuality
aplicable I-Premise HighQuality
: I-Premise HighQuality
0-144 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

El B-Claim HighQuality
resultado I-Claim HighQuality
de I-Claim HighQuality
estos I-Claim HighQuality
pacientes I-Claim HighQuality
sigue I-Claim HighQuality
siendo I-Claim HighQuality
insatisfactorio. I-Claim HighQuality

Los B-Premise HighQuality
factores I-Premise HighQuality
pronósticos I-Premise HighQuality
para I-Premise HighQuality
un I-Premise HighQuality
resultado I-Premise HighQuality
favorable I-Premise HighQuality
son I-Premise HighQuality
el I-Premise HighQuality
tamaño I-Premise HighQuality
del I-Premise HighQuality
tumor I-Premise HighQuality
menor I-Premise HighQuality
de I-Premise HighQuality
5 I-Premise HighQuality
cm I-Premise HighQuality
, I-Premise HighQuality
los I-Premise HighQuality
ganglios I-Premise HighQuality
linfáticos I-Premise HighQuality
locorregionales I-Premise HighQuality
negativos I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
edad I-Premise HighQuality
menor I-Premise HighQuality
de I-Premise HighQuality
10 I-Premise HighQuality
años I-Premise HighQuality
, I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
IRS I-Premise HighQuality
bajo I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
histología I-Premise HighQuality
embrionaria I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
incontinencia I-Claim HighQuality
fecal I-Claim HighQuality
parece I-Claim HighQuality
ser I-Claim HighQuality
un I-Claim HighQuality
problema. I-Claim HighQuality

Los B-Claim HighQuality
estudios I-Claim HighQuality
de I-Claim HighQuality
fase I-Claim HighQuality
II I-Claim HighQuality
y I-Claim HighQuality
III I-Claim HighQuality
han I-Claim HighQuality
demostrado I-Claim HighQuality
que I-Claim HighQuality
la I-Claim HighQuality
adición I-Claim HighQuality
de I-Claim HighQuality
interleucina-2 I-Claim HighQuality
( I-Claim HighQuality
IL-2 I-Claim HighQuality
) I-Claim HighQuality
e I-Claim HighQuality
interferón I-Claim HighQuality
alfa-2b I-Claim HighQuality
( I-Claim HighQuality
IFN I-Claim HighQuality
alfa-2b I-Claim HighQuality
) I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
quimioterapia I-Claim HighQuality
multiagente I-Claim HighQuality
( I-Claim HighQuality
CT I-Claim HighQuality
) I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
melanoma I-Claim HighQuality
avanzado I-Claim HighQuality
aumenta I-Claim HighQuality
la I-Claim HighQuality
respuesta I-Claim HighQuality
global I-Claim HighQuality
( I-Claim HighQuality
OR I-Claim HighQuality
) I-Claim HighQuality
, I-Claim HighQuality
aunque I-Claim HighQuality
sin I-Claim HighQuality
evidencia I-Claim HighQuality
clara I-Claim HighQuality
de I-Claim HighQuality
una I-Claim HighQuality
mejora I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
supervivencia I-Claim HighQuality
global I-Claim HighQuality
( I-Claim HighQuality
OS I-Claim HighQuality
) I-Claim HighQuality
. I-Claim HighQuality

El B-Claim HighQuality
tratamiento I-Claim HighQuality
con I-Claim HighQuality
altas I-Claim HighQuality
dosis I-Claim HighQuality
de I-Claim HighQuality
IL-2 I-Claim HighQuality
puede I-Claim HighQuality
causar I-Claim HighQuality
una I-Claim HighQuality
toxicidad I-Claim HighQuality
grave I-Claim HighQuality
y I-Claim HighQuality
normalmente I-Claim HighQuality
se I-Claim HighQuality
administra I-Claim HighQuality
en I-Claim HighQuality
un I-Claim HighQuality
entorno I-Claim HighQuality
de I-Claim HighQuality
hospitalización. I-Claim HighQuality

Realizamos O -
un O -
ensayo O -
clínico O -
prospectivo O -
y O -
aleatorio O -
multicéntrico O -
en O -
pacientes O -
ambulatorios O -
con O -
melanoma O -
metastásico O -
para O -
comparar O -
la O -
TC O -
con O -
la O -
bioquimioterapia O -
( O -
bioCT O -
) O -
utilizando O -
dosis O -
inmunomoduladoras O -
de O -
IL-2 O -
e O -
IFN O -
alfa-2b O -
. O -

Ciento O -
setenta O -
y O -
seis O -
pacientes O -
elegibles O -
con O -
melanoma O -
avanzado O -
fueron O -
aleatorizados O -
para O -
recibir O -
CT O -
( O -
cisplatino O -
y O -
dacarbazina O -
con O -
o O -
sin O -
carmustina O -
cada O -
21 O -
días O -
) O -
o O -
bioCT O -
que O -
comprende O -
el O -
mismo O -
régimen O -
de O -
CT O -
seguido O -
de O -
IL-2 O -
subcutánea O -
a O -
dosis O -
bajas O -
durante O -
8 O -
días O -
y O -
IFN O -
alfa-2b O -
tres O -
veces O -
por O -
semana O -
, O -
ambos O -
durante O -
seis O -
ciclos O -
. O -

En B-Premise HighQuality
una I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
seguimiento I-Premise HighQuality
de I-Premise HighQuality
18 I-Premise HighQuality
( I-Premise HighQuality
TC I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
16 I-Premise HighQuality
( I-Premise HighQuality
bioCT I-Premise HighQuality
) I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SG I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
9,5 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
11,0 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,51 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
. I-Premise HighQuality

En B-Premise HighQuality
los I-Premise HighQuality
89 I-Premise HighQuality
pacientes I-Premise HighQuality
del I-Premise HighQuality
brazo I-Premise HighQuality
CT, I-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
18 I-Premise HighQuality
OR I-Premise HighQuality
( I-Premise HighQuality
20,2 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
( I-Premise HighQuality
tres I-Premise HighQuality
respondedores I-Premise HighQuality
completos I-Premise HighQuality
[ I-Premise HighQuality
CR I-Premise HighQuality
] I-Premise HighQuality
y I-Premise HighQuality
15 I-Premise HighQuality
respondedores I-Premise HighQuality
parciales I-Premise HighQuality
[ I-Premise HighQuality
PR I-Premise HighQuality
] I-Premise HighQuality
) I-Premise HighQuality
según I-Premise HighQuality
los I-Premise HighQuality
criterios I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
Organización I-Premise HighQuality
Mundial I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
Salud I-Premise HighQuality
. I-Premise HighQuality

En B-Premise HighQuality
los I-Premise HighQuality
87 I-Premise HighQuality
pacientes I-Premise HighQuality
del I-Premise HighQuality
brazo I-Premise HighQuality
de I-Premise HighQuality
bioCT, I-Premise HighQuality
se I-Premise HighQuality
registraron I-Premise HighQuality
22 I-Premise HighQuality
OR I-Premise HighQuality
( I-Premise HighQuality
25,3 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
( I-Premise HighQuality
tres I-Premise HighQuality
RC I-Premise HighQuality
y I-Premise HighQuality
19 I-Premise HighQuality
RP I-Premise HighQuality
) I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,70 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
toxicidad I-Premise HighQuality
relacionada I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
fue I-Premise HighQuality
bastante I-Premise HighQuality
similar I-Premise HighQuality
en I-Premise HighQuality
ambos I-Premise HighQuality
brazos. I-Premise HighQuality

La B-Claim HighQuality
adición I-Claim HighQuality
de I-Claim HighQuality
una I-Claim HighQuality
dosis I-Claim HighQuality
baja I-Claim HighQuality
de I-Claim HighQuality
inmunoterapia I-Claim HighQuality
no I-Claim HighQuality
produjo I-Claim HighQuality
una I-Claim HighQuality
ventaja I-Claim HighQuality
estadísticamente I-Claim HighQuality
significativa I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
SG, I-Claim HighQuality
el I-Claim HighQuality
tiempo I-Claim HighQuality
hasta I-Claim HighQuality
la I-Claim HighQuality
progresión I-Claim HighQuality
o I-Claim HighQuality
la I-Claim HighQuality
OR. I-Claim HighQuality

Sin B-Claim HighQuality
embargo, I-Claim HighQuality
la I-Claim HighQuality
mediana I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
SG I-Claim HighQuality
de I-Claim HighQuality
11 I-Claim HighQuality
meses I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
brazo I-Claim HighQuality
del I-Claim HighQuality
bioCT I-Claim HighQuality
no I-Claim HighQuality
difiere I-Claim HighQuality
en I-Claim HighQuality
gran I-Claim HighQuality
medida I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
mejores I-Claim HighQuality
resultados I-Claim HighQuality
con I-Claim HighQuality
regímenes I-Claim HighQuality
que I-Claim HighQuality
contienen I-Claim HighQuality
altas I-Claim HighQuality
dosis I-Claim HighQuality
de I-Claim HighQuality
IL-2 I-Claim HighQuality
que I-Claim HighQuality
se I-Claim HighQuality
han I-Claim HighQuality
reportado I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
literatura. I-Claim HighQuality

Además, O -
nuestro B-Claim HighQuality
programa I-Claim HighQuality
de I-Claim HighQuality
tratamiento I-Claim HighQuality
se I-Claim HighQuality
llevó I-Claim HighQuality
a I-Claim HighQuality
cabo I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
ambulatorios I-Claim HighQuality
y I-Claim HighQuality
tuvo I-Claim HighQuality
un I-Claim HighQuality
nivel I-Claim HighQuality
de I-Claim HighQuality
toxicidad I-Claim HighQuality
aceptable. I-Claim HighQuality

Las O -
microesferas O -
SIR O -
son O -
microesferas O -
radiactivas O -
de O -
itrio O -
90 O -
(SIR-Spheres, O -
Sirtex O -
Medical O -
Limited, O -
Australia) O -
que O -
se O -
utilizan O -
para O -
dirigir O -
selectivamente O -
altos O -
niveles O -
de O -
radiación O -
ionizante O -
a O -
los O -
tumores O -
del O -
hígado. O -

Este O -
ensayo O -
se O -
diseñó O -
para O -
medir O -
cualquier O -
aumento O -
del O -
beneficio O -
para O -
el O -
paciente O -
al O -
añadir O -
una O -
única O -
administración O -
de O -
microesferas O -
SIR O -
a O -
un O -
régimen O -
de O -
quimioterapia O -
regional O -
en O -
la O -
arteria O -
hepática O -
( O -
HAC O -
) O -
administrada O -
como O -
una O -
infusión O -
de O -
12 O -
días O -
de O -
floxuridina O -
y O -
repetida O -
a O -
intervalos O -
mensuales O -
, O -
frente O -
a O -
la O -
misma O -
quimioterapia O -
sola O -
. O -

Se O -
llevó O -
a O -
cabo O -
un O -
ensayo O -
clínico O -
aleatorizado O -
de O -
fase O -
III O -
en O -
el O -
que O -
participaron O -
74 O -
pacientes O -
con O -
metástasis O -
hepáticas O -
bi-lobulares O -
no O -
resecables O -
de O -
adenocarcinoma O -
primario O -
de O -
intestino O -
grueso. O -

Los O -
criterios O -
de O -
beneficio O -
para O -
los O -
pacientes O -
evaluados O -
en O -
el O -
ensayo O -
fueron O -
la O -
respuesta O -
tumoral, O -
el O -
tiempo O -
de O -
progresión O -
de O -
la O -
enfermedad O -
en O -
el O -
hígado, O -
la O -
supervivencia O -
global, O -
la O -
calidad O -
de O -
vida O -
y O -
la O -
toxicidad O -
relacionada O -
con O -
el O -
tratamiento. O -

La O -
respuesta O -
del O -
tumor O -
se O -
midió O -
mediante O -
cambios O -
seriados O -
tanto O -
en O -
las O -
áreas O -
transversales O -
del O -
tumor O -
como O -
en O -
los O -
volúmenes O -
totales O -
del O -
mismo, O -
siempre O -
que O -
cualquier O -
respuesta O -
durara O -
no O -
menos O -
de O -
tres O -
meses, O -
así O -
como O -
los O -
cambios O -
en O -
el O -
antígeno O -
carcinoembrionario O -
( O -
CEA O -
) O -
en O -
suero. O -

La B-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
respuesta I-Premise HighQuality
parcial I-Premise HighQuality
y I-Premise HighQuality
completa I-Premise HighQuality
( I-Premise HighQuality
PR I-Premise HighQuality
+ I-Premise HighQuality
CR I-Premise HighQuality
) I-Premise HighQuality
fue I-Premise HighQuality
significativamente I-Premise HighQuality
mayor I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
microesferas I-Premise HighQuality
SIR I-Premise HighQuality
cuando I-Premise HighQuality
se I-Premise HighQuality
midió I-Premise HighQuality
por I-Premise HighQuality
áreas I-Premise HighQuality
tumorales I-Premise HighQuality
( I-Premise HighQuality
44 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
17,6 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,01 I-Premise HighQuality
) I-Premise HighQuality
volúmenes I-Premise HighQuality
tumorales I-Premise HighQuality
( I-Premise HighQuality
50 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
24 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,03 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
CEA I-Premise HighQuality
( I-Premise HighQuality
72 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
47 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,004 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
progresión I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
hígado I-Premise HighQuality
fue I-Premise HighQuality
significativamente I-Premise HighQuality
más I-Premise HighQuality
larga I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
microesferas I-Premise HighQuality
SIR I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
sólo I-Premise HighQuality
HAC I-Premise HighQuality
cuando I-Premise HighQuality
se I-Premise HighQuality
midió I-Premise HighQuality
por I-Premise HighQuality
áreas I-Premise HighQuality
tumorales I-Premise HighQuality
( I-Premise HighQuality
9,7 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
15,9 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
volúmenes I-Premise HighQuality
tumorales I-Premise HighQuality
( I-Premise HighQuality
7,6 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
12,0 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,04 I-Premise HighQuality
) I-Premise HighQuality
o I-Premise HighQuality
CEA I-Premise HighQuality
( I-Premise HighQuality
5,7 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
6,7 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,06 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
supervivencia I-Premise HighQuality
a I-Premise HighQuality
uno, I-Premise HighQuality
dos, I-Premise HighQuality
tres I-Premise HighQuality
y I-Premise HighQuality
cinco I-Premise HighQuality
años I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
microesferas I-Premise HighQuality
SIR I-Premise HighQuality
fue I-Premise HighQuality
del I-Premise HighQuality
72 I-Premise HighQuality
%, I-Premise HighQuality
39 I-Premise HighQuality
%, I-Premise HighQuality
17 I-Premise HighQuality
% I-Premise HighQuality
y I-Premise HighQuality
3,5 I-Premise HighQuality
%, I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
68 I-Premise HighQuality
%, I-Premise HighQuality
29 I-Premise HighQuality
%, I-Premise HighQuality
6,5 I-Premise HighQuality
% I-Premise HighQuality
y I-Premise HighQuality
0 I-Premise HighQuality
% I-Premise HighQuality
del I-Premise HighQuality
HAC I-Premise HighQuality
solo. I-Premise HighQuality

El B-Premise HighQuality
análisis I-Premise HighQuality
de I-Premise HighQuality
regresión I-Premise HighQuality
de I-Premise HighQuality
Cox I-Premise HighQuality
sugiere I-Premise HighQuality
una I-Premise HighQuality
mejora I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
tratados I-Premise HighQuality
con I-Premise HighQuality
Esferas I-Premise HighQuality
SIR I-Premise HighQuality
que I-Premise HighQuality
sobreviven I-Premise HighQuality
más I-Premise HighQuality
de I-Premise HighQuality
15 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,06 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
produjo I-Premise HighQuality
un I-Premise HighQuality
aumento I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
toxicidad I-Premise HighQuality
relacionada I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
3-4 I-Premise HighQuality
ni I-Premise HighQuality
una I-Premise HighQuality
pérdida I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
SIR-Spheres I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
sólo I-Premise HighQuality
recibieron I-Premise HighQuality
HAC I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
combinación I-Claim HighQuality
de I-Claim HighQuality
una I-Claim HighQuality
única I-Claim HighQuality
inyección I-Claim HighQuality
de I-Claim HighQuality
microesferas I-Claim HighQuality
SIR I-Claim HighQuality
más I-Claim HighQuality
HAC I-Claim HighQuality
es I-Claim HighQuality
sustancialmente I-Claim HighQuality
más I-Claim HighQuality
eficaz I-Claim HighQuality
para I-Claim HighQuality
aumentar I-Claim HighQuality
las I-Claim HighQuality
respuestas I-Claim HighQuality
tumorales I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
supervivencia I-Claim HighQuality
libre I-Claim HighQuality
de I-Claim HighQuality
progresión I-Claim HighQuality
que I-Claim HighQuality
el I-Claim HighQuality
mismo I-Claim HighQuality
régimen I-Claim HighQuality
de I-Claim HighQuality
HAC I-Claim HighQuality
solo I-Claim HighQuality
. I-Claim HighQuality

El O -
objetivo O -
del O -
estudio O -
era O -
evaluar O -
la O -
tasa O -
de O -
respuesta, O -
el O -
resultado O -
clínico, O -
la O -
preservación O -
de O -
órganos/funciones O -
y O -
la O -
toxicidad O -
en O -
pacientes O -
con O -
cáncer O -
de O -
cabeza O -
y O -
cuello O -
tratados O -
con O -
quimioterapia O -
de O -
inducción O -
seguida O -
de O -
quimiorradioterapia O -
concomitante O -
y, O -
cuando O -
fuera O -
necesario, O -
cirugía O -
limitada. O -

El O -
diseño O -
del O -
estudio O -
fue O -
un O -
ensayo O -
no O -
aleatorio O -
de O -
fase O -
II O -
en O -
pacientes O -
hospitalizados. O -

El O -
plan O -
de O -
tratamiento O -
consistió O -
en O -
3 O -
ciclos O -
de O -
quimioterapia O -
de O -
inducción O -
con O -
cisplatino O -
, O -
fluorouracilo O -
( O -
5-FU O -
) O -
, O -
l-leucovorina O -
e O -
interferón O -
alfa2b O -
( O -
PFL-IFN O -
) O -
seguido O -
de O -
7 O -
ciclos O -
de O -
5-FU O -
, O -
hidroxiurea O -
y O -
radiación O -
concomitante O -
durante O -
5 O -
días O -
( O -
FHX O -
) O -
para O -
una O -
dosis O -
total O -
de O -
radiación O -
de O -
70 O -
Gy O -
. O -

13 O -
Se O -
añadió O -
ácido O -
cis-retinoico O -
al O -
régimen O -
de O -
tratamiento O -
para O -
la O -
quimioprevención O -
y O -
se O -
administró O -
una O -
profilaxis O -
sistemática O -
de O -
la O -
mucositis O -
a O -
todos O -
los O -
pacientes O -
durante O -
el O -
FHX O -
. O -

La O -
resección O -
quirúrgica O -
conservadora O -
se O -
reservó O -
a O -
los O -
pacientes O -
sin O -
respuesta O -
óptima O -
( O -
PR O -
> O -
o O -
=70 O -
% O -
) O -
, O -
mientras O -
que O -
la O -
cirugía O -
radical O -
se O -
realizó O -
como O -
tratamiento O -
de O -
rescate O -
. O -

Veintiséis O -
pacientes O -
fueron O -
tratados O -
en O -
una O -
institución: O -
más O -
del O -
90 O -
% O -
tenían O -
la O -
enfermedad O -
en O -
estadio O -
IV O -
y O -
sólo O -
el O -
19,2 O -
% O -
tenían O -
cáncer O -
de O -
laringe O -
. O -

El O -
81% O -
de O -
los O -
pacientes O -
tenía O -
un O -
estado O -
de O -
rendimiento O -
0 O -
y O -
el O -
23,1% O -
de O -
los O -
pacientes O -
tenía O -
una O -
pérdida O -
de O -
peso O -
superior O -
al O -
5% O -
al O -
inicio O -
del O -
tratamiento. O -

Se O -
analizaron O -
diecinueve O -
pacientes O -
para O -
determinar O -
la O -
respuesta O -
al O -
PFL-IFN: O -
3/19 O -
( O -
15,8 O -
% O -
) O -
pacientes O -
lograron O -
una O -
RC O -
y O -
7/19 O -
( O -
36,8 O -
% O -
) O -
lograron O -
una O -
RP O -
para O -
una O -
ORR O -
del O -
52,6 O -
% O -
. O -

Se O -
administró O -
FHX O -
según O -
el O -
protocolo O -
a O -
12 O -
pacientes: O -
6 O -
pacientes O -
( O -
50 O -
% O -
) O -
tuvieron O -
RC O -
, O -
1 O -
paciente O -
( O -
8,3 O -
% O -
) O -
tuvo O -
RP O -
para O -
una O -
ORR O -
del O -
58,3 O -
% O -
, O -
2 O -
pacientes O -
( O -
16,7 O -
% O -
) O -
tuvieron O -
SD O -
y O -
3 O -
pacientes O -
( O -
25 O -
% O -
) O -
tuvieron O -
PD O -
. O -

Al O -
finalizar O -
el O -
FHX O -
, O -
ningún O -
paciente O -
fue O -
sometido O -
a O -
terapia O -
local O -
según O -
el O -
plan O -
de O -
tratamiento. O -

En B-Premise HighQuality
una I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
seguimiento I-Premise HighQuality
de I-Premise HighQuality
13,5 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
rango I-Premise HighQuality
1-28+ I-Premise HighQuality
) I-Premise HighQuality
en I-Premise HighQuality
junio I-Premise HighQuality
de I-Premise HighQuality
2001 I-Premise HighQuality
, I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
26 I-Premise HighQuality
pacientes I-Premise HighQuality
inscritos I-Premise HighQuality
12 I-Premise HighQuality
( I-Premise HighQuality
46,1 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
seguían I-Premise HighQuality
vivos I-Premise HighQuality
y I-Premise HighQuality
9 I-Premise HighQuality
( I-Premise HighQuality
75 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
ellos I-Premise HighQuality
estaban I-Premise HighQuality
libres I-Premise HighQuality
de I-Premise HighQuality
progresión I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
duración I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
respuesta I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
9 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
rango I-Premise HighQuality
0-25+ I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
libre I-Premise HighQuality
de I-Premise HighQuality
progresión I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
10,5 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
rango I-Premise HighQuality
0-28+ I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
del I-Premise HighQuality
tiempo I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
9 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
rango I-Premise HighQuality
1-22 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
toxicidad I-Premise HighQuality
fue I-Premise HighQuality
significativa I-Premise HighQuality
y I-Premise HighQuality
consistió I-Premise HighQuality
principalmente I-Premise HighQuality
en I-Premise HighQuality
mucositis I-Premise HighQuality
y, I-Premise HighQuality
en I-Premise HighQuality
menor I-Premise HighQuality
medida, I-Premise HighQuality
en I-Premise HighQuality
neutropenia/trombocitopenia. I-Premise HighQuality

En O -
el O -
presente O -
estudio, O -
se B-Claim HighQuality
confirmaron I-Claim HighQuality
los I-Claim HighQuality
bajos I-Claim HighQuality
niveles I-Claim HighQuality
séricos I-Claim HighQuality
de I-Claim HighQuality
leptina I-Claim HighQuality
y I-Claim HighQuality
los I-Claim HighQuality
altos I-Claim HighQuality
niveles I-Claim HighQuality
séricos I-Claim HighQuality
de I-Claim HighQuality
citoquinas I-Claim HighQuality
proinflamatorias I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
en I-Claim HighQuality
fase I-Claim HighQuality
avanzada. I-Claim HighQuality

En O -
conclusión, O -
este B-Claim HighQuality
programa I-Claim HighQuality
secuencial I-Claim HighQuality
de I-Claim HighQuality
quimioterapia I-Claim HighQuality
de I-Claim HighQuality
inducción I-Claim HighQuality
y I-Claim HighQuality
quimiorradioterapia I-Claim HighQuality
ha I-Claim HighQuality
resultado I-Claim HighQuality
ser I-Claim HighQuality
moderadamente I-Claim HighQuality
activo I-Claim HighQuality
y I-Claim HighQuality
significativamente I-Claim HighQuality
tóxico; I-Claim HighQuality
además, O -
hay O -
que O -
tener O -
en O -
cuenta O -
la O -
larga O -
duración O -
global O -
del O -
tratamiento. O -

Por O -
estas O -
razones O -
, O -
este B-Claim HighQuality
régimen I-Claim HighQuality
no I-Claim HighQuality
pudo I-Claim HighQuality
ser I-Claim HighQuality
recomendado I-Claim HighQuality
para I-Claim HighQuality
un I-Claim HighQuality
estudio I-Claim HighQuality
aleatorio I-Claim HighQuality
de I-Claim HighQuality
fase I-Claim HighQuality
III I-Claim HighQuality
. I-Claim HighQuality

La O -
dosificación O -
intermitente O -
puede O -
reducir O -
los O -
efectos O -
adversos O -
(EA) O -
de O -
la O -
terapia O -
de O -
privación O -
de O -
andrógenos O -
(TDA). O -

Comparar O -
la O -
privación O -
intermitente O -
de O -
andrógenos O -
( O -
IAD O -
) O -
y O -
la O -
privación O -
continua O -
de O -
andrógenos O -
( O -
CAD O -
) O -
con O -
respecto O -
a O -
la O -
calidad O -
de O -
vida O -
relacionada O -
con O -
la O -
salud O -
( O -
QoL O -
) O -
. O -

Un O -
total O -
de O -
852 O -
hombres O -
con O -
cáncer O -
de O -
próstata O -
avanzado O -
(CaP) O -
se O -
inscribieron O -
para O -
recibir O -
acetato O -
de O -
goserelina O -
3,6 O -
mg O -
cada O -
28 O -
días O -
durante O -
24 O -
semanas. O -

Un O -
total O -
de O -
554 O -
pacientes O -
cuyo O -
antígeno O -
prostático O -
específico O -
( O -
PSA O -
) O -
disminuyó O -
a O -
< O -
10 O -
ng/ml O -
o O -
en O -
≥50 O -
% O -
( O -
< O -
20 O -
ng/ml O -
en O -
la O -
línea O -
de O -
base O -
) O -
fueron O -
asignados O -
al O -
azar O -
a O -
IAD O -
o O -
CAD O -
. O -

En O -
el O -
brazo O -
de O -
IAD, O -
la O -
ADT O -
se O -
reanudó O -
durante O -
al O -
menos O -
24 O -
semanas O -
siempre O -
que O -
el O -
PSA O -
aumentara O -
> O -
20 O -
ng/ml O -
o O -
por O -
encima O -
del O -
valor O -
inicial. O -

La O -
CdV O -
se O -
controló O -
con O -
un O -
cuestionario O -
Cleary O -
validado O -
de O -
30 O -
ítems O -
y O -
se O -
analizó O -
mediante O -
la O -
prueba O -
U O -
de O -
Mann-Whitney O -
, O -
la O -
regla O -
de O -
la O -
desviación O -
estándar O -
de O -
0,5 O -
y O -
el O -
análisis O -
de O -
varianza O -
de O -
medidas O -
repetidas. O -

Los O -
EA O -
y O -
las O -
reacciones O -
adversas O -
a O -
los O -
medicamentos O -
(RAM) O -
se O -
analizaron O -
mediante O -
la O -
prueba O -
de O -
chi-cuadrado. O -

La O -
mediana O -
de O -
seguimiento O -
fue O -
de O -
65 O -
meses. O -

Surgieron B-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
limitación I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
actividad I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
capacidad I-Premise HighQuality
física I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
funcionamiento I-Premise HighQuality
sexual I-Premise HighQuality
, I-Premise HighQuality
favoreciendo I-Premise HighQuality
la I-Premise HighQuality
DAI I-Premise HighQuality
. I-Premise HighQuality

No B-Premise LowQuality
se I-Premise LowQuality
observaron I-Premise LowQuality
diferencias I-Premise LowQuality
significativas I-Premise LowQuality
en I-Premise LowQuality
la I-Premise LowQuality
prevalencia I-Premise LowQuality
de I-Premise LowQuality
los I-Premise LowQuality
EA: I-Premise LowQuality
87 I-Premise LowQuality
pacientes I-Premise LowQuality
del I-Premise LowQuality
brazo I-Premise LowQuality
IAD I-Premise LowQuality
( I-Premise LowQuality
31,8 I-Premise LowQuality
% I-Premise LowQuality
) I-Premise LowQuality
y I-Premise LowQuality
95 I-Premise LowQuality
del I-Premise LowQuality
brazo I-Premise LowQuality
CAD I-Premise LowQuality
( I-Premise LowQuality
33,9 I-Premise LowQuality
% I-Premise LowQuality
) I-Premise LowQuality
tuvieron I-Premise LowQuality
EA I-Premise LowQuality
cardiovasculares I-Premise LowQuality
( I-Premise LowQuality
p=0,59 I-Premise LowQuality
) I-Premise LowQuality
, I-Premise LowQuality
con I-Premise LowQuality
25 I-Premise LowQuality
( I-Premise LowQuality
9,1 I-Premise LowQuality
% I-Premise LowQuality
) I-Premise LowQuality
y I-Premise LowQuality
29 I-Premise LowQuality
( I-Premise LowQuality
10.4 I-Premise LowQuality
% I-Premise LowQuality
) I-Premise LowQuality
que I-Premise LowQuality
se I-Premise LowQuality
retiraron I-Premise LowQuality
( I-Premise LowQuality
p=0,62 I-Premise LowQuality
) I-Premise LowQuality
, I-Premise LowQuality
y I-Premise LowQuality
21 I-Premise LowQuality
( I-Premise LowQuality
7,7 I-Premise LowQuality
% I-Premise LowQuality
) I-Premise LowQuality
y I-Premise LowQuality
24 I-Premise LowQuality
( I-Premise LowQuality
8,6 I-Premise LowQuality
% I-Premise LowQuality
) I-Premise LowQuality
que I-Premise LowQuality
murieron I-Premise LowQuality
a I-Premise LowQuality
causa I-Premise LowQuality
de I-Premise LowQuality
un I-Premise LowQuality
evento I-Premise LowQuality
CV I-Premise LowQuality
( I-Premise LowQuality
p=0,70 I-Premise LowQuality
) I-Premise LowQuality
, I-Premise LowQuality
respectivamente I-Premise LowQuality
; I-Premise LowQuality
se B-Premise HighQuality
produjeron I-Premise HighQuality
fracturas I-Premise HighQuality
óseas I-Premise HighQuality
en I-Premise HighQuality
19 I-Premise HighQuality
( I-Premise HighQuality
6,9 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
15 I-Premise HighQuality
( I-Premise HighQuality
5,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
pacientes I-Premise HighQuality
( I-Premise HighQuality
p=0,44 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
. O -

Los B-Premise HighQuality
sofocos I-Premise HighQuality
o I-Premise HighQuality
los I-Premise HighQuality
sudores I-Premise HighQuality
nocturnos I-Premise HighQuality
fueron I-Premise HighQuality
las I-Premise HighQuality
reacciones I-Premise HighQuality
adversas I-Premise HighQuality
más I-Premise HighQuality
frecuentes I-Premise HighQuality
( I-Premise HighQuality
47,1 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
50,4 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
p=0,44 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
disfunción I-Premise HighQuality
eréctil I-Premise HighQuality
( I-Premise HighQuality
15,7 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
7,9 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
p=0,042 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
estado I-Premise HighQuality
de I-Premise HighQuality
ánimo I-Premise HighQuality
deprimido I-Premise HighQuality
( I-Premise HighQuality
2,2 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
0 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
p=0,032 I-Premise HighQuality
) I-Premise HighQuality
fueron I-Premise HighQuality
más I-Premise HighQuality
frecuentes I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
brazo I-Premise HighQuality
de I-Premise HighQuality
DAI I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
DAI I-Claim HighQuality
mostró I-Claim HighQuality
beneficios I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
del I-Claim HighQuality
CaP I-Claim HighQuality
avanzado I-Claim HighQuality
con I-Claim HighQuality
respecto I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida. I-Claim HighQuality

La B-Claim HighQuality
prevalencia I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
EA I-Claim HighQuality
no I-Claim HighQuality
fue I-Claim HighQuality
significativamente I-Claim HighQuality
menor I-Claim HighQuality
con I-Claim HighQuality
la I-Claim HighQuality
DAI I-Claim HighQuality
. I-Claim HighQuality

La O -
calidad O -
de O -
vida O -
( O -
QoL O -
) O -
después O -
del O -
cáncer O -
de O -
mama O -
es O -
hoy O -
en O -
día O -
un O -
gran O -
desafío O -
. O -

Las O -
intervenciones O -
complementarias O -
son O -
necesarias O -
debido O -
a O -
los O -
frecuentes O -
síntomas O -
de O -
depresión O -
después O -
del O -
tratamiento O -
y O -
también O -
para O -
favorecer O -
la O -
vuelta O -
a O -
la O -
actividad O -
. O -

Además, O -
la O -
radioquimioterapia O -
tiene O -
efectos O -
secundarios O -
como O -
el O -
aumento O -
de O -
peso O -
y O -
la O -
fatiga. O -

Se O -
han O -
probado O -
varias O -
estrategias, O -
como O -
las O -
intervenciones O -
conductuales-educativas O -
de O -
grupo, O -
el O -
entrenamiento O -
físico O -
y/o O -
la O -
educación O -
dietética, O -
para O -
responder O -
a O -
estas O -
dificultades O -
con O -
un O -
éxito O -
moderado O -
a O -
largo O -
plazo. O -

Doscientos O -
cincuenta O -
y O -
un O -
pacientes O -
no O -
metastásicos O -
fueron O -
reclutados O -
después O -
de O -
la O -
quimioterapia O -
en O -
un O -
ensayo O -
prospectivo O -
multicéntrico O -
aleatorio O -
entre O -
2008 O -
y O -
2010 O -
, O -
probando O -
una O -
intervención O -
de O -
2 O -
semanas O -
en O -
centros O -
de O -
SPA O -
. O -

La O -
intervención O -
consistió O -
en O -
entrenamiento O -
físico O -
en O -
grupo, O -
educación O -
dietética O -
y O -
fisioterapia. O -

Los O -
pacientes O -
seleccionados O -
estaban O -
en O -
remisión O -
completa. O -

La O -
calidad O -
de O -
vida O -
se O -
evaluó O -
con O -
el O -
cuestionario O -
SF36 O -
y O -
la O -
ansiedad O -
y O -
la O -
depresión O -
con O -
el O -
cuestionario O -
de O -
ansiedad O -
y O -
depresión O -
hospitalaria O -
(HAD). O -

Se O -
obtuvieron O -
medidas O -
antropométricas O -
y O -
evaluaciones O -
de O -
la O -
calidad O -
de O -
vida O -
antes O -
de O -
la O -
aleatorización O -
y O -
cada O -
6 O -
meses O -
durante O -
3 O -
años. O -

Doscientos O -
veinte O -
pacientes O -
fueron O -
evaluables O -
al O -
año. O -

La B-Premise HighQuality
intervención I-Premise HighQuality
aumentó I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
SF36 I-Premise HighQuality
en I-Premise HighQuality
9,5 I-Premise HighQuality
puntos I-Premise HighQuality
( I-Premise HighQuality
p=0,000006 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
4,6 I-Premise HighQuality
( I-Premise HighQuality
p=0,032 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
6,2 I-Premise HighQuality
( I-Premise HighQuality
p=0,028 I-Premise HighQuality
) I-Premise HighQuality
respectivamente I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
, I-Premise HighQuality
12 I-Premise HighQuality
y I-Premise HighQuality
24 I-Premise HighQuality
meses I-Premise HighQuality
. I-Premise HighQuality

El B-Premise HighQuality
tamaño I-Premise HighQuality
del I-Premise HighQuality
efecto I-Premise HighQuality
( I-Premise HighQuality
ES I-Premise HighQuality
) I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
0,63 I-Premise HighQuality
[ I-Premise HighQuality
0,37 I-Premise HighQuality
; I-Premise HighQuality
0,90 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
0,29 I-Premise HighQuality
[ I-Premise HighQuality
0,03 I-Premise HighQuality
; I-Premise HighQuality
0,55 I-Premise HighQuality
] I-Premise HighQuality
y I-Premise HighQuality
0,41 I-Premise HighQuality
[ I-Premise HighQuality
0,04 I-Premise HighQuality
; I-Premise HighQuality
0,78 I-Premise HighQuality
] I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
puntuación I-Premise HighQuality
de I-Premise HighQuality
ansiedad I-Premise HighQuality
se I-Premise HighQuality
redujo I-Premise HighQuality
brevemente I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
intervención I-Premise HighQuality
( I-Premise HighQuality
ES=-0,24 I-Premise HighQuality
[ I-Premise HighQuality
-0,42 I-Premise HighQuality
; I-Premise HighQuality
-0,05 I-Premise HighQuality
] I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
meses I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
de I-Premise HighQuality
depresión I-Premise HighQuality
de I-Premise HighQuality
forma I-Premise HighQuality
más I-Premise HighQuality
duradera I-Premise HighQuality
: I-Premise HighQuality
ES=-0,45 I-Premise HighQuality
[ I-Premise HighQuality
-0,72 I-Premise HighQuality
; I-Premise HighQuality
-0,18 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
-0,34 I-Premise HighQuality
[ I-Premise HighQuality
-061 I-Premise HighQuality
; I-Premise HighQuality
-0,08 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
-0,26 I-Premise HighQuality
[ I-Premise HighQuality
-0,63 I-Premise HighQuality
; I-Premise HighQuality
0,11 I-Premise HighQuality
] I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
, I-Premise HighQuality
12 I-Premise HighQuality
y I-Premise HighQuality
24 I-Premise HighQuality
meses I-Premise HighQuality
. I-Premise HighQuality

Esta B-Claim HighQuality
intervención I-Claim HighQuality
grupal I-Claim HighQuality
de I-Claim HighQuality
2 I-Claim HighQuality
semanas I-Claim HighQuality
pareció I-Claim HighQuality
influir I-Claim HighQuality
de I-Claim HighQuality
forma I-Claim HighQuality
duradera I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
CdV I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
mama I-Claim HighQuality
tratadas I-Claim HighQuality
con I-Claim HighQuality
quimioterapia I-Claim HighQuality
. I-Claim HighQuality

Las B-Claim HighQuality
diferencias, I-Claim HighQuality
más I-Claim HighQuality
pequeñas I-Claim HighQuality
a I-Claim HighQuality
los I-Claim HighQuality
12 I-Claim HighQuality
meses I-Claim HighQuality
que I-Claim HighQuality
a I-Claim HighQuality
los I-Claim HighQuality
seis, I-Claim HighQuality
sugieren I-Claim HighQuality
que I-Claim HighQuality
una I-Claim HighQuality
segunda I-Claim HighQuality
intervención, I-Claim HighQuality
pero I-Claim HighQuality
más I-Claim HighQuality
corta, I-Claim HighQuality
podría I-Claim HighQuality
ayudar I-Claim HighQuality
a I-Claim HighQuality
mantener I-Claim HighQuality
los I-Claim HighQuality
beneficios I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
6 I-Claim HighQuality
meses. I-Claim HighQuality

Evaluar O -
las O -
toxicidades, O -
los O -
resultados O -
funcionales O -
y O -
la O -
calidad O -
de O -
vida O -
relacionada O -
con O -
la O -
salud O -
asociados O -
a O -
la O -
quimiorradioterapia O -
( O -
CRT O -
) O -
concurrente O -
en O -
pacientes O -
con O -
cáncer O -
de O -
cabeza O -
y O -
cuello O -
. O -

Estudio O -
de O -
resultados O -
prospectivo O -
y O -
retrospectivo O -
. O -

Institución O -
de O -
atención O -
terciaria O -
. O -

Participantes O -
en O -
el O -
Proyecto O -
de O -
Evaluación O -
de O -
Resultados O -
longitudinales O -
cuyo O -
cáncer O -
de O -
cabeza O -
y O -
cuello O -
fue O -
tratado O -
con O -
TRC O -
entre O -
el O -
1 O -
de O -
febrero O -
de O -
2000 O -
y O -
el O -
1 O -
de O -
marzo O -
de O -
2007 O -
( O -
n O -
= O -
104 O -
) O -
. O -

Los O -
pacientes O -
proporcionaron O -
de O -
forma O -
prospectiva O -
información O -
sobre O -
la O -
calidad O -
de O -
vida O -
funcional O -
y O -
relacionada O -
con O -
la O -
salud O -
, O -
incluidos O -
los O -
datos O -
de O -
las O -
visitas O -
de O -
seguimiento O -
de O -
un O -
año O -
y O -
de O -
las O -
más O -
recientes. O -

Se O -
revisaron O -
las O -
historias O -
clínicas O -
para O -
determinar O -
la O -
toxicidad O -
y O -
las O -
tasas O -
de O -
supervivencia. O -

Toxicidades O -
agudas O -
y O -
tardías O -
bien O -
definidas O -
; O -
resultados O -
funcionales O -
( O -
dieta O -
, O -
dentición O -
, O -
traqueostomías O -
) O -
; O -
resultados O -
específicos O -
del O -
cáncer O -
de O -
cabeza O -
y O -
cuello O -
, O -
salud O -
general O -
y O -
depresión O -
; O -
y O -
tasas O -
de O -
supervivencia O -
. O -

La O -
mayoría O -
de O -
los O -
pacientes O -
tenían O -
tumores O -
orofaríngeos O -
o O -
laríngeos O -
( O -
87,5 O -
% O -
) O -
y O -
enfermedad O -
en O -
estado O -
avanzado O -
( O -
75,0 O -
% O -
) O -
. O -

Aproximadamente B-Premise HighQuality
la I-Premise HighQuality
mitad I-Premise HighQuality
tuvo I-Premise HighQuality
toxicidades I-Premise HighQuality
hematológicas I-Premise HighQuality
y I-Premise HighQuality
retrasos I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
relacionados I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
toxicidad. I-Premise HighQuality

Aproximadamente B-Premise HighQuality
una I-Premise HighQuality
cuarta I-Premise HighQuality
parte I-Premise HighQuality
tuvo I-Premise HighQuality
neurotoxicidades I-Premise HighQuality
y/o I-Premise HighQuality
ototoxicidades I-Premise HighQuality
, I-Premise HighQuality
descamación I-Premise HighQuality
húmeda I-Premise HighQuality
, I-Premise HighQuality
neumonía I-Premise HighQuality
, I-Premise HighQuality
náuseas I-Premise HighQuality
y I-Premise HighQuality
vómitos I-Premise HighQuality
que I-Premise HighQuality
requirieron I-Premise HighQuality
hospitalización I-Premise HighQuality
o I-Premise HighQuality
líquidos I-Premise HighQuality
intravenosos I-Premise HighQuality
, I-Premise HighQuality
deshidratación I-Premise HighQuality
o I-Premise HighQuality
desnutrición I-Premise HighQuality
que I-Premise HighQuality
requirieron I-Premise HighQuality
hospitalización I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
fiebre I-Premise HighQuality
leve I-Premise HighQuality
o I-Premise HighQuality
moderada I-Premise HighQuality
. I-Premise HighQuality

Aunque B-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
el I-Premise HighQuality
protocolo I-Premise HighQuality
actual I-Premise HighQuality
de I-Premise HighQuality
radioterapia I-Premise HighQuality
de I-Premise HighQuality
intensidad I-Premise HighQuality
modulada I-Premise HighQuality
( I-Premise HighQuality
IMRT I-Premise HighQuality
) I-Premise HighQuality
utilizando I-Premise HighQuality
el I-Premise HighQuality
sistema I-Premise HighQuality
de I-Premise HighQuality
planificación I-Premise HighQuality
Pinnacle I-Premise HighQuality
( I-Premise HighQuality
3 I-Premise HighQuality
) I-Premise HighQuality
tuvieron I-Premise HighQuality
más I-Premise HighQuality
retrasos I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
relacionados I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
toxicidad I-Premise HighQuality
, I-Premise HighQuality
tuvieron B-Premise HighQuality
menos I-Premise HighQuality
toxicidades I-Premise HighQuality
y I-Premise HighQuality
mejores I-Premise HighQuality
resultados I-Premise HighQuality
funcionales I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
relacionados I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
salud I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
radiación I-Premise HighQuality
lateral I-Premise HighQuality
convencional I-Premise HighQuality
de I-Premise HighQuality
campo I-Premise HighQuality
opuesto I-Premise HighQuality
o I-Premise HighQuality
el I-Premise HighQuality
protocolo I-Premise HighQuality
inicial I-Premise HighQuality
de I-Premise HighQuality
IMRT I-Premise HighQuality
utilizando I-Premise HighQuality
el I-Premise HighQuality
sistema I-Premise HighQuality
de I-Premise HighQuality
planificación I-Premise HighQuality
Best I-Premise HighQuality
nomos I-Premise HighQuality
PEACOCK I-Premise HighQuality
. I-Premise HighQuality

Los B-Claim HighQuality
pacientes I-Claim HighQuality
que I-Claim HighQuality
reciben I-Claim HighQuality
TRC I-Claim HighQuality
experimentan I-Claim HighQuality
un I-Claim HighQuality
número I-Claim HighQuality
considerable I-Claim HighQuality
de I-Claim HighQuality
acontecimientos I-Claim HighQuality
adversos I-Claim HighQuality
relacionados I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
tratamiento, I-Claim HighQuality
que I-Claim HighQuality
afectan I-Claim HighQuality
principalmente I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
función I-Claim HighQuality
orofaríngea I-Claim HighQuality
y I-Claim HighQuality
laríngea, I-Claim HighQuality
y I-Claim HighQuality
se I-Claim HighQuality
ha I-Claim HighQuality
observado I-Claim HighQuality
una I-Claim HighQuality
mejora I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
protocolo I-Claim HighQuality
actual I-Claim HighQuality
de I-Claim HighQuality
RIM. I-Claim HighQuality

Mejorar O -
la O -
rehabilitación O -
protésica O -
dental O -
e O -
incluir O -
evaluaciones O -
con O -
patólogos O -
del O -
habla O -
y O -
la O -
deglución O -
antes O -
y O -
durante O -
el O -
tratamiento O -
puede O -
mejorar O -
los O -
resultados O -
de O -
los O -
pacientes O -
. O -

Evaluar O -
la O -
combinación O -
del O -
antagonista O -
de O -
la O -
gastrina O -
Z-360 O -
y O -
la O -
gemcitabina O -
para O -
el O -
cáncer O -
de O -
páncreas O -
avanzado. O -

Los O -
pacientes O -
con O -
CP O -
no O -
tratados O -
previamente O -
fueron O -
asignados O -
aleatoriamente O -
a O -
Z-360 O -
120 O -
mg O -
, O -
240 O -
mg O -
o O -
placebo O -
. O -

Se O -
administró O -
Z-360/placebo O -
el O -
día O -
-3 O -
y O -
se O -
comenzó O -
con O -
gemcitabina O -
1000 O -
mg/m O -
( O -
2 O -
) O -
el O -
día O -
1 O -
seguido O -
de O -
Z-360 O -
el O -
día O -
2 O -
. O -

A O -
partir O -
de O -
entonces, O -
Z-360/placebo O -
se O -
administró O -
dos O -
veces O -
al O -
día O -
junto O -
con O -
la O -
dosis O -
estándar O -
de O -
gemcitabina. O -

Se O -
midió O -
la O -
farmacocinética O -
de O -
ambos O -
fármacos O -
solos O -
y O -
en O -
combinación. O -

También O -
se O -
registraron O -
la O -
toxicidad, O -
la O -
respuesta O -
y O -
la O -
calidad O -
de O -
vida. O -

Se O -
asignaron O -
al O -
azar O -
33 O -
pacientes O -
con O -
una O -
edad O -
media O -
de O -
62 O -
años, O -
de O -
los O -
cuales O -
6 O -
tenían O -
enfermedad O -
localmente O -
avanzada O -
y O -
26 O -
tenían O -
enfermedad O -
metastásica. O -

El O -
análisis O -
del O -
área O -
bajo O -
la O -
curva O -
de O -
concentración O -
plasmática O -
en O -
función O -
del O -
tiempo O -
( O -
AUC O -
) O -
, O -
la O -
concentración O -
máxima O -
observada O -
( O -
Cmáx O -
( O -
obs O -
) O -
) O -
y O -
el O -
tiempo O -
de O -
la O -
concentración O -
máxima O -
observada O -
( O -
Tmáx O -
( O -
obs O -
) O -
) O -
para O -
Z-360 O -
, O -
gemcitabina O -
y O -
2,2-difluorodeoxiuridina O -
( O -
dFdU O -
) O -
, O -
no O -
pudo O -
excluir O -
un O -
efecto O -
sobre O -
la O -
exposición O -
sistémica O -
a O -
Z-360 O -
, O -
gemcitabina O -
y O -
dFdU O -
cuando O -
se O -
comparó O -
la O -
administración O -
conjunta O -
de O -
Z-360 O -
y O -
gemcitabina O -
con O -
la O -
administración O -
de O -
un O -
solo O -
agente O -
. O -

Los B-Premise HighQuality
efectos I-Premise HighQuality
adversos I-Premise HighQuality
más I-Premise HighQuality
frecuentes I-Premise HighQuality
fueron I-Premise HighQuality
náuseas, I-Premise HighQuality
dolor I-Premise HighQuality
abdominal, I-Premise HighQuality
vómitos I-Premise HighQuality
y I-Premise HighQuality
fatiga. I-Premise HighQuality

Al B-Premise HighQuality
final I-Premise HighQuality
del I-Premise HighQuality
estudio, I-Premise HighQuality
el I-Premise HighQuality
62,5 I-Premise HighQuality
%, I-Premise HighQuality
el I-Premise HighQuality
25 I-Premise HighQuality
% I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
60 I-Premise HighQuality
% I-Premise HighQuality
tenían I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
estable I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
120 I-Premise HighQuality
mg, I-Premise HighQuality
240 I-Premise HighQuality
mg I-Premise HighQuality
y I-Premise HighQuality
placebo, I-Premise HighQuality
respectivamente. I-Premise HighQuality

Una B-Premise HighQuality
mayor I-Premise HighQuality
proporción I-Premise HighQuality
de I-Premise HighQuality
pacientes I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
Z-360 I-Premise HighQuality
informó I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
mejora I-Premise HighQuality
del I-Premise HighQuality
dolor I-Premise HighQuality
. I-Premise HighQuality

Z-360 B-Claim HighQuality
es I-Claim HighQuality
seguro I-Claim HighQuality
y I-Claim HighQuality
bien I-Claim HighQuality
tolerado I-Claim HighQuality
cuando I-Claim HighQuality
se I-Claim HighQuality
combina I-Claim HighQuality
con I-Claim HighQuality
gemcitabina I-Claim HighQuality
. I-Claim HighQuality

Se O -
necesita O -
un O -
ensayo O -
de O -
fase O -
III O -
para O -
determinar O -
si O -
la O -
combinación O -
de O -
Z-360 O -
y O -
gemcitabina O -
es O -
superior O -
a O -
la O -
gemcitabina O -
sola O -
en O -
el O -
CP O -
avanzado. O -

El O -
etopósido O -
oral O -
es O -
un O -
agente O -
único O -
activo O -
en O -
el O -
cáncer O -
de O -
pulmón O -
de O -
células O -
pequeñas O -
( O -
SCLC O -
) O -
y O -
se O -
prescribe O -
ampliamente O -
como O -
tratamiento O -
de O -
primera O -
línea O -
como O -
alternativa O -
a O -
la O -
quimioterapia O -
combinada O -
intravenosa O -
en O -
pacientes O -
con O -
enfermedad O -
extensa O -
. O -

La O -
intención O -
de O -
este O -
estudio O -
era O -
determinar O -
si O -
los O -
efectos O -
del O -
tratamiento O -
con O -
etopósido O -
oral O -
sobre O -
la O -
supervivencia O -
y O -
la O -
calidad O -
de O -
vida O -
son O -
equivalentes O -
a O -
los O -
de O -
la O -
quimioterapia O -
intravenosa O -
. O -

En O -
un O -
ensayo O -
aleatorio O -
de O -
tratamiento O -
paliativo O -
en O -
el O -
CPCP O -
avanzado, O -
se O -
comparó O -
el O -
etopósido O -
oral O -
( O -
100 O -
mg O -
administrados O -
dos O -
veces O -
al O -
día O -
durante O -
5 O -
días O -
) O -
con O -
la O -
quimioterapia O -
intravenosa O -
consistente O -
en O -
ciclos O -
alternados O -
de O -
cisplatino O -
y O -
etopósido O -
( O -
PE O -
) O -
y O -
ciclofosfamida O -
, O -
doxorrubicina O -
y O -
vincristina O -
( O -
CAV O -
) O -
. O -

Se O -
administraron O -
seis O -
ciclos O -
de O -
quimioterapia O -
cada O -
21 O -
días O -
en O -
ambos O -
regímenes. O -

El O -
control O -
de O -
los O -
síntomas O -
y O -
la O -
calidad O -
de O -
vida O -
se O -
midieron O -
con O -
la O -
lista O -
de O -
control O -
de O -
síntomas O -
de O -
Rotterdam O -
y O -
una O -
tarjeta O -
de O -
diario. O -

En O -
enero O -
de O -
1996, O -
después O -
de O -
que O -
se O -
asignaran O -
aleatoriamente O -
155 O -
pacientes O -
de O -
un O -
total O -
previsto O -
de O -
365, O -
un O -
Comité O -
de O -
Seguimiento O -
de O -
Datos O -
independiente O -
examinó O -
los O -
resultados O -
provisionales. O -

La O -
supervivencia O -
se O -
determinó O -
mediante O -
el O -
método O -
de O -
Kaplan-Meier O -
y O -
se O -
utilizó O -
el O -
test O -
de O -
logrank O -
para O -
comparar O -
los O -
tratamientos. O -

Para O -
las O -
comparaciones O -
de O -
la O -
calidad O -
de O -
vida, O -
se O -
calcularon O -
las O -
puntuaciones O -
medias O -
para O -
cada O -
punto O -
temporal. O -

Se O -
utilizó O -
la O -
prueba O -
U O -
de O -
Mann-Whitney O -
para O -
determinar O -
cualquier O -
diferencia O -
global O -
significativa O -
entre O -
los O -
tratamientos. O -

Para O -
la O -
lista O -
de O -
control O -
de O -
síntomas O -
de O -
Rotterdam, O -
se O -
realizaron O -
análisis O -
separados O -
para O -
cada O -
subconjunto O -
( O -
bienestar O -
psicológico, O -
síntomas O -
físicos, O -
síntomas O -
de O -
cáncer O -
de O -
pulmón, O -
síntomas O -
de O -
tratamiento, O -
actividad O -
y O -
calidad O -
de O -
vida O -
) O -
. O -

Las O -
tasas O -
de O -
respuesta O -
y O -
las O -
puntuaciones O -
de O -
toxicidad O -
se O -
compararon O -
mediante O -
chi2 O -
. O -

Todas O -
las O -
pruebas O -
estadísticas O -
fueron O -
de O -
dos O -
caras. O -

La B-Premise HighQuality
supervivencia I-Premise HighQuality
a I-Premise HighQuality
un I-Premise HighQuality
año I-Premise HighQuality
fue I-Premise HighQuality
inferior I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
etopósido I-Premise HighQuality
oral I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
terapia I-Premise HighQuality
intravenosa I-Premise HighQuality
( I-Premise HighQuality
9,8 I-Premise HighQuality
% I-Premise HighQuality
para I-Premise HighQuality
el I-Premise HighQuality
oral I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
19,3 I-Premise HighQuality
% I-Premise HighQuality
para I-Premise HighQuality
el I-Premise HighQuality
intravenoso; I-Premise HighQuality
diferencia I-Premise HighQuality
= I-Premise HighQuality
9,5 I-Premise HighQuality
%; I-Premise HighQuality
intervalo I-Premise HighQuality
de I-Premise HighQuality
confianza I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
diferencia I-Premise HighQuality
= I-Premise HighQuality
0,3 I-Premise HighQuality
% I-Premise HighQuality
-18,7 I-Premise HighQuality
%; I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,05 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
hubo I-Premise HighQuality
una I-Premise HighQuality
tendencia I-Premise HighQuality
hacia I-Premise HighQuality
una I-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
inferior I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
4,8 I-Premise HighQuality
meses I-Premise HighQuality
para I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
oral I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
5,9 I-Premise HighQuality
meses I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
terapia I-Premise HighQuality
intravenosa I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
supervivencia I-Premise HighQuality
sin I-Premise HighQuality
progresión I-Premise HighQuality
fue I-Premise HighQuality
peor I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
brazo I-Premise HighQuality
de I-Premise HighQuality
etopósido I-Premise HighQuality
oral I-Premise HighQuality
( I-Premise HighQuality
mediana I-Premise HighQuality
= I-Premise HighQuality
3,6 I-Premise HighQuality
meses I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
5,6 I-Premise HighQuality
meses I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
así I-Premise HighQuality
como I-Premise HighQuality
la I-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
respuesta I-Premise HighQuality
global I-Premise HighQuality
( I-Premise HighQuality
32,9 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
46,3 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,01 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

A B-Premise HighQuality
excepción I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
náuseas I-Premise HighQuality
y I-Premise HighQuality
vómitos I-Premise HighQuality
agudos I-Premise HighQuality
asociados I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
quimioterapia I-Premise HighQuality
intravenosa I-Premise HighQuality
, I-Premise HighQuality
todos B-Premise HighQuality
los I-Premise HighQuality
aspectos I-Premise HighQuality
del I-Premise HighQuality
control I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
síntomas I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
fueron I-Premise HighQuality
iguales I-Premise HighQuality
o I-Premise HighQuality
peores I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
etopósido I-Premise HighQuality
oral I-Premise HighQuality
. I-Premise HighQuality

Se O -
recomendó O -
el O -
cierre O -
del O -
estudio. O -

Estos B-Claim HighQuality
resultados I-Claim HighQuality
provisionales I-Claim HighQuality
muestran I-Claim HighQuality
que I-Claim HighQuality
esta I-Claim HighQuality
pauta I-Claim HighQuality
de I-Claim HighQuality
etopósido I-Claim HighQuality
oral I-Claim HighQuality
es I-Claim HighQuality
inferior I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
quimioterapia I-Claim HighQuality
intravenosa I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
del I-Claim HighQuality
CPCP I-Claim HighQuality
avanzado I-Claim HighQuality
y I-Claim HighQuality
no I-Claim HighQuality
debe I-Claim HighQuality
utilizarse I-Claim HighQuality
como I-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
primera I-Claim HighQuality
línea I-Claim HighQuality
de I-Claim HighQuality
esta I-Claim HighQuality
enfermedad. I-Claim HighQuality

Evaluar O -
los O -
efectos O -
de O -
la O -
música O -
de O -
cinco O -
elementos O -
de O -
la O -
medicina O -
china O -
( O -
CM O -
) O -
en O -
la O -
calidad O -
de O -
vida O -
de O -
los O -
pacientes O -
de O -
cáncer O -
avanzado, O -
tanto O -
mayores O -
como O -
no O -
mayores O -
. O -

Con O -
un O -
ensayo O -
controlado O -
aleatorio O -
, O -
170 O -
pacientes O -
con O -
cáncer O -
avanzado O -
fueron O -
asignados O -
al O -
azar O -
a O -
tres O -
grupos O -
: O -
el O -
grupo O -
de O -
música O -
de O -
cinco O -
elementos O -
CM O -
( O -
68 O -
pacientes O -
) O -
, O -
el O -
grupo O -
de O -
musicoterapia O -
occidental O -
( O -
68 O -
casos O -
) O -
, O -
y O -
el O -
grupo O -
de O -
no O -
musicoterapia O -
( O -
34 O -
casos O -
) O -
. O -

Todos O -
los O -
pacientes O -
de O -
70 O -
años O -
o O -
más O -
se O -
consideraron O -
mayores O -
y O -
el O -
resto O -
de O -
pacientes O -
menores O -
de O -
70 O -
años O -
se O -
consideraron O -
no O -
mayores. O -

Los O -
pacientes O -
del O -
grupo O -
de O -
música O -
de O -
cinco O -
elementos O -
CM O -
escucharon O -
música O -
de O -
cinco O -
elementos O -
CM O -
, O -
los O -
pacientes O -
del O -
grupo O -
de O -
música O -
occidental O -
escucharon O -
música O -
occidental O -
, O -
y O -
los O -
pacientes O -
del O -
grupo O -
sin O -
música O -
no O -
escucharon O -
música O -
. O -

El O -
curso O -
del O -
tratamiento O -
fue O -
de O -
3 O -
semanas, O -
con O -
30 O -
minutos O -
cada O -
día, O -
5 O -
días O -
a O -
la O -
semana. O -

Se O -
midieron O -
el O -
Índice O -
de O -
Calidad O -
de O -
Vida O -
en O -
Hospicio-Revisado O -
( O -
HQOLI-R O -
) O -
y O -
la O -
puntuación O -
de O -
rendimiento O -
de O -
Karnofsky O -
( O -
KPS O -
) O -
en O -
los O -
tres O -
grupos O -
antes O -
y O -
después O -
del O -
tratamiento O -
. O -

La O -
puntuación O -
del O -
diario O -
de O -
síntomas O -
se O -
midió O -
en O -
los O -
tres O -
grupos O -
cada O -
3 O -
días, O -
7 O -
veces O -
en O -
total. O -

El B-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
música I-Premise HighQuality
de I-Premise HighQuality
cinco I-Premise HighQuality
elementos I-Premise HighQuality
CM I-Premise HighQuality
mostró I-Premise HighQuality
una I-Premise HighQuality
diferencia I-Premise HighQuality
significativa I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
del I-Premise HighQuality
HQOLI-R I-Premise HighQuality
, I-Premise HighQuality
el I-Premise HighQuality
KPS I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
diario I-Premise HighQuality
de I-Premise HighQuality
síntomas I-Premise HighQuality
con I-Premise HighQuality
otros I-Premise HighQuality
grupos I-Premise HighQuality
( I-Premise HighQuality
todos I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,01 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Hubo B-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
del I-Premise HighQuality
HQOLI-R I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
del I-Premise HighQuality
diario I-Premise HighQuality
de I-Premise HighQuality
síntomas I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
KPS I-Premise HighQuality
después I-Premise HighQuality
del I-Premise HighQuality
tratamiento I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
música I-Premise HighQuality
de I-Premise HighQuality
cinco I-Premise HighQuality
elementos I-Premise HighQuality
de I-Premise HighQuality
CM I-Premise HighQuality
y I-Premise HighQuality
otros I-Premise HighQuality
grupos I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
subgrupo I-Premise HighQuality
de I-Premise HighQuality
no I-Premise HighQuality
ancianos I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,05 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Además, O -
hubo B-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
HQOLI-R I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
KPS I-Premise HighQuality
después I-Premise HighQuality
del I-Premise HighQuality
tratamiento I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
tres I-Premise HighQuality
grupos I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
subgrupo I-Premise HighQuality
de I-Premise HighQuality
mayores I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,05 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
musicoterapia I-Claim HighQuality
de I-Claim HighQuality
cinco I-Claim HighQuality
elementos I-Claim HighQuality
CM I-Claim HighQuality
podría I-Claim HighQuality
mejorar I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
y I-Claim HighQuality
el I-Claim HighQuality
KPS I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
de I-Claim HighQuality
cáncer I-Claim HighQuality
avanzado I-Claim HighQuality
senior I-Claim HighQuality
y I-Claim HighQuality
no I-Claim HighQuality
senior I-Claim HighQuality
, I-Claim HighQuality
y I-Claim HighQuality
podría I-Claim HighQuality
mejorar I-Claim HighQuality
los I-Claim HighQuality
síntomas I-Claim HighQuality
subjetivos I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
de I-Claim HighQuality
cáncer I-Claim HighQuality
avanzado I-Claim HighQuality
no I-Claim HighQuality
senior I-Claim HighQuality
. I-Claim HighQuality

El B-Claim HighQuality
bacilo I-Claim HighQuality
de I-Claim HighQuality
Calmette-Guérin I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
quimioterapia I-Claim HighQuality
intravesical I-Claim HighQuality
representan I-Claim HighQuality
opciones I-Claim HighQuality
adyuvantes I-Claim HighQuality
viables I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
vejiga I-Claim HighQuality
no I-Claim HighQuality
músculo-invasivo I-Claim HighQuality
de I-Claim HighQuality
riesgo I-Claim HighQuality
intermedio. I-Claim HighQuality

Aunque O -
el O -
bacilo O -
de O -
Calmette-Guérin O -
se O -
percibe O -
como O -
menos O -
tolerable O -
que O -
la O -
quimioterapia O -
intravesical O -
, O -
hasta O -
donde O -
sabemos, O -
ningún O -
estudio O -
comparativo O -
ha O -
abordado O -
cuestiones O -
de O -
calidad O -
de O -
vida O -
. O -

Se O -
comparó O -
la O -
calidad O -
de O -
vida O -
de O -
los O -
pacientes O -
con O -
cáncer O -
de O -
vejiga O -
no O -
músculo-invasivo O -
que O -
recibieron O -
gemcitabina O -
intravesical O -
adyuvante O -
o O -
1/3 O -
de O -
dosis O -
de O -
bacilo O -
de O -
Calmette-Guérin O -
. O -

Nuestro O -
estudio O -
multicéntrico, O -
prospectivo, O -
aleatorizado O -
y O -
de O -
fase O -
II O -
incluyó O -
a O -
120 O -
pacientes O -
con O -
cáncer O -
de O -
vejiga O -
no O -
músculo-invasivo O -
de O -
riesgo O -
intermedio. O -

De O -
estos O -
pacientes, O -
88 O -
seguían O -
siendo O -
evaluables O -
al O -
año O -
de O -
seguimiento. O -

Sólo O -
se O -
retiró O -
a O -
1 O -
paciente O -
por O -
efectos O -
adversos. O -

En O -
total, O -
61 O -
pacientes O -
recibieron O -
2.000 O -
mg/50 O -
cc O -
de O -
gemcitabina O -
semanalmente O -
durante O -
6 O -
semanas O -
( O -
mantenimiento O -
mensual O -
durante O -
1 O -
año O -
) O -
mientras O -
que O -
59 O -
recibieron O -
1/3 O -
de O -
dosis O -
de O -
bacilo O -
de O -
Calmette-Guérin O -
Connaught O -
semanalmente O -
durante O -
6 O -
semanas O -
( O -
mantenimiento O -
3 O -
instilaciones O -
semanales O -
a O -
los O -
3 O -
, O -
6 O -
y O -
12 O -
meses O -
) O -
. O -

La O -
calidad O -
de O -
vida O -
se O -
midió O -
con O -
los O -
cuestionarios O -
EORTC O -
QLQ-C30 O -
( O -
European O -
Organization O -
for O -
the O -
Research O -
and O -
Treatment O -
of O -
Cancer O -
Quality O -
of O -
Life O -
Questionnaire O -
Core O -
30 O -
version O -
3.0 O -
) O -
y O -
QLQ-BLS24 O -
( O -
Quality O -
of O -
Life O -
Superficial O -
Bladder O -
Cancer-Specific O -
24 O -
) O -
. O -

Las O -
diferencias O -
de O -
grupo O -
se O -
calcularon O -
mediante O -
ANOVA O -
( O -
ANOVA/MANOVA O -
) O -
. O -

El B-Premise HighQuality
tratamiento I-Premise HighQuality
fue I-Premise HighQuality
bien I-Premise HighQuality
tolerado I-Premise HighQuality
en I-Premise HighQuality
ambos I-Premise HighQuality
grupos, I-Premise HighQuality
aunque B-Premise HighQuality
los I-Premise HighQuality
efectos I-Premise HighQuality
secundarios I-Premise HighQuality
locales I-Premise HighQuality
y I-Premise HighQuality
sistémicos I-Premise HighQuality
fueron I-Premise HighQuality
más I-Premise HighQuality
frecuentes I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
brazo I-Premise HighQuality
del I-Premise HighQuality
bacilo I-Premise HighQuality
de I-Premise HighQuality
Calmette-Guérin. I-Premise HighQuality

Los B-Premise HighQuality
análisis I-Premise HighQuality
multivariantes I-Premise HighQuality
no I-Premise HighQuality
mostraron I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
dos I-Premise HighQuality
grupos I-Premise HighQuality
en I-Premise HighQuality
todas I-Premise HighQuality
las I-Premise HighQuality
dimensiones I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
detectaron I-Premise HighQuality
cambios I-Premise HighQuality
significativos I-Premise HighQuality
a I-Premise HighQuality
lo I-Premise HighQuality
largo I-Premise HighQuality
del I-Premise HighQuality
tiempo I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
dominios I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
bacilo I-Premise HighQuality
de I-Premise HighQuality
Calmette-Guérin I-Premise HighQuality
y I-Premise HighQuality
gemcitabina, I-Premise HighQuality
excepto I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
funcionamiento I-Premise HighQuality
físico I-Premise HighQuality
, I-Premise HighQuality
que I-Premise HighQuality
disminuyó I-Premise HighQuality
significativamente I-Premise HighQuality
en I-Premise HighQuality
ambos I-Premise HighQuality
grupos I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,002 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
detectaron I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
cuanto I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
recidiva I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
progresión I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
2 I-Premise HighQuality
grupos I-Premise HighQuality
a I-Premise HighQuality
1 I-Premise HighQuality
año I-Premise HighQuality
de I-Premise HighQuality
seguimiento. I-Premise HighQuality

Aunque O -
se B-Claim HighQuality
detectó I-Claim HighQuality
una I-Claim HighQuality
mayor I-Claim HighQuality
tasa I-Claim HighQuality
de I-Claim HighQuality
efectos I-Claim HighQuality
secundarios, I-Claim HighQuality
aunque I-Claim HighQuality
de I-Claim HighQuality
leves I-Claim HighQuality
a I-Claim HighQuality
moderados, I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
bacilo I-Claim HighQuality
de I-Claim HighQuality
Calmette-Guérin I-Claim HighQuality
de I-Claim HighQuality
1/3 I-Claim HighQuality
de I-Claim HighQuality
dosis I-Claim HighQuality
en I-Claim HighQuality
comparación I-Claim HighQuality
con I-Claim HighQuality
la I-Claim HighQuality
gemcitabina, I-Claim HighQuality
nuestro B-Claim HighQuality
estudio I-Claim HighQuality
no I-Claim HighQuality
logró I-Claim HighQuality
mostrar I-Claim HighQuality
diferencias I-Claim HighQuality
significativas I-Claim HighQuality
entre I-Claim HighQuality
los I-Claim HighQuality
2 I-Claim HighQuality
fármacos I-Claim HighQuality
en I-Claim HighQuality
términos I-Claim HighQuality
de I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida. I-Claim HighQuality

Evaluar O -
la O -
eficacia O -
y O -
seguridad O -
del O -
trastuzumab O -
de O -
primera O -
línea, O -
como O -
agente O -
único, O -
en O -
mujeres O -
con O -
cáncer O -
de O -
mama O -
metastásico O -
con O -
sobreexpresión O -
de O -
HER2. O -

Ciento O -
catorce O -
mujeres O -
con O -
cáncer O -
de O -
mama O -
metastásico O -
con O -
sobreexpresión O -
de O -
HER2 O -
fueron O -
aleatorizadas O -
para O -
recibir O -
un O -
tratamiento O -
de O -
primera O -
línea O -
con O -
trastuzumab O -
de O -
4 O -
mg/kg O -
de O -
dosis O -
de O -
carga, O -
seguido O -
de O -
2 O -
mg/kg O -
semanales, O -
o O -
una O -
dosis O -
de O -
carga O -
mayor O -
de O -
8 O -
mg/kg, O -
seguida O -
de O -
4 O -
mg/kg O -
semanales. O -

La B-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
respuesta I-Premise HighQuality
objetiva I-Premise HighQuality
fue I-Premise HighQuality
del I-Premise HighQuality
26 I-Premise HighQuality
% I-Premise HighQuality
( I-Premise HighQuality
intervalo I-Premise HighQuality
de I-Premise HighQuality
confianza I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
[ I-Premise HighQuality
CI I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
18,2 I-Premise HighQuality
% I-Premise HighQuality
a I-Premise HighQuality
34,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
con I-Premise HighQuality
siete I-Premise HighQuality
respuestas I-Premise HighQuality
completas I-Premise HighQuality
y I-Premise HighQuality
23 I-Premise HighQuality
parciales I-Premise HighQuality
. I-Premise HighQuality

Las B-Premise HighQuality
tasas I-Premise HighQuality
de I-Premise HighQuality
respuesta I-Premise HighQuality
en I-Premise HighQuality
111 I-Premise HighQuality
pacientes I-Premise HighQuality
evaluables I-Premise HighQuality
con I-Premise HighQuality
sobreexpresión I-Premise HighQuality
3+ I-Premise HighQuality
y I-Premise HighQuality
2+ I-Premise HighQuality
de I-Premise HighQuality
HER2 I-Premise HighQuality
por I-Premise HighQuality
inmunohistoquímica I-Premise HighQuality
( I-Premise HighQuality
IHC I-Premise HighQuality
) I-Premise HighQuality
fueron I-Premise HighQuality
del I-Premise HighQuality
35 I-Premise HighQuality
% I-Premise HighQuality
( I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
24,4 I-Premise HighQuality
% I-Premise HighQuality
a I-Premise HighQuality
44,7 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
ninguna I-Premise HighQuality
( I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
0 I-Premise HighQuality
% I-Premise HighQuality
a I-Premise HighQuality
15,5 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
. I-Premise HighQuality

Las B-Premise HighQuality
tasas I-Premise HighQuality
de I-Premise HighQuality
beneficio I-Premise HighQuality
clínico I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
evaluables I-Premise HighQuality
con I-Premise HighQuality
sobreexpresión I-Premise HighQuality
3+ I-Premise HighQuality
y I-Premise HighQuality
2+ I-Premise HighQuality
de I-Premise HighQuality
HER2 I-Premise HighQuality
fueron I-Premise HighQuality
del I-Premise HighQuality
48 I-Premise HighQuality
% I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
7 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
respectivamente. I-Premise HighQuality

Las B-Premise HighQuality
tasas I-Premise HighQuality
de I-Premise HighQuality
respuesta I-Premise HighQuality
en I-Premise HighQuality
108 I-Premise HighQuality
pacientes I-Premise HighQuality
evaluables I-Premise HighQuality
con I-Premise HighQuality
y I-Premise HighQuality
sin I-Premise HighQuality
amplificación I-Premise HighQuality
del I-Premise HighQuality
gen I-Premise HighQuality
HER2 I-Premise HighQuality
mediante I-Premise HighQuality
análisis I-Premise HighQuality
de I-Premise HighQuality
hibridación I-Premise HighQuality
fluorescente I-Premise HighQuality
in I-Premise HighQuality
situ I-Premise HighQuality
( I-Premise HighQuality
FISH I-Premise HighQuality
) I-Premise HighQuality
fueron I-Premise HighQuality
del I-Premise HighQuality
34 I-Premise HighQuality
% I-Premise HighQuality
( I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
23,9 I-Premise HighQuality
% I-Premise HighQuality
a I-Premise HighQuality
45,7 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
del I-Premise HighQuality
7 I-Premise HighQuality
% I-Premise HighQuality
( I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
0,8 I-Premise HighQuality
% I-Premise HighQuality
a I-Premise HighQuality
22,8 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
respectivamente. I-Premise HighQuality

Diecisiete B-Premise HighQuality
( I-Premise HighQuality
57 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
30 I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
una I-Premise HighQuality
respuesta I-Premise HighQuality
objetiva I-Premise HighQuality
y I-Premise HighQuality
22 I-Premise HighQuality
( I-Premise HighQuality
51 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
43 I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
beneficio I-Premise HighQuality
clínico I-Premise HighQuality
no I-Premise HighQuality
habían I-Premise HighQuality
experimentado I-Premise HighQuality
progresión I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
seguimiento I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
12 I-Premise HighQuality
meses I-Premise HighQuality
o I-Premise HighQuality
más I-Premise HighQuality
tarde I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
efectos I-Premise HighQuality
adversos I-Premise HighQuality
más I-Premise HighQuality
frecuentes I-Premise HighQuality
relacionados I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
fueron I-Premise HighQuality
escalofríos I-Premise HighQuality
( I-Premise HighQuality
25 I-Premise HighQuality
% I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
astenia I-Premise HighQuality
( I-Premise HighQuality
23 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
fiebre I-Premise HighQuality
( I-Premise HighQuality
22 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
dolor I-Premise HighQuality
( I-Premise HighQuality
18 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
náuseas I-Premise HighQuality
( I-Premise HighQuality
14 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
produjo I-Premise HighQuality
una I-Premise HighQuality
disfunción I-Premise HighQuality
cardíaca I-Premise HighQuality
en I-Premise HighQuality
dos I-Premise HighQuality
pacientes I-Premise HighQuality
( I-Premise HighQuality
2 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
; I-Premise HighQuality
ambos I-Premise HighQuality
tenían I-Premise HighQuality
antecedentes I-Premise HighQuality
de I-Premise HighQuality
enfermedad I-Premise HighQuality
cardíaca I-Premise HighQuality
y I-Premise HighQuality
no I-Premise HighQuality
requirieron I-Premise HighQuality
una I-Premise HighQuality
intervención I-Premise HighQuality
adicional I-Premise HighQuality
tras I-Premise HighQuality
la I-Premise HighQuality
interrupción I-Premise HighQuality
del I-Premise HighQuality
trastuzumab I-Premise HighQuality
. I-Premise HighQuality

No B-Claim HighQuality
hubo I-Claim HighQuality
pruebas I-Claim HighQuality
claras I-Claim HighQuality
de I-Claim HighQuality
una I-Claim HighQuality
relación I-Claim HighQuality
dosis-respuesta I-Claim HighQuality
para I-Claim HighQuality
la I-Claim HighQuality
respuesta, I-Claim HighQuality
la I-Claim HighQuality
supervivencia I-Claim HighQuality
o I-Claim HighQuality
los I-Claim HighQuality
acontecimientos I-Claim HighQuality
adversos. I-Claim HighQuality

El B-Claim HighQuality
trastuzumab I-Claim HighQuality
como I-Claim HighQuality
agente I-Claim HighQuality
único I-Claim HighQuality
es I-Claim HighQuality
activo I-Claim HighQuality
y I-Claim HighQuality
bien I-Claim HighQuality
tolerado I-Claim HighQuality
como I-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
primera I-Claim HighQuality
línea I-Claim HighQuality
en I-Claim HighQuality
mujeres I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
mama I-Claim HighQuality
metastásico I-Claim HighQuality
con I-Claim HighQuality
sobreexpresión I-Claim HighQuality
de I-Claim HighQuality
HER2 I-Claim HighQuality
3+ I-Claim HighQuality
por I-Claim HighQuality
IHC I-Claim HighQuality
o I-Claim HighQuality
amplificación I-Claim HighQuality
del I-Claim HighQuality
gen I-Claim HighQuality
por I-Claim HighQuality
FISH I-Claim HighQuality
. I-Claim HighQuality

Se O -
investigó O -
la O -
influencia O -
de O -
la O -
preservación O -
del O -
cuello O -
de O -
la O -
vejiga O -
en O -
la O -
continencia O -
urinaria, O -
la O -
calidad O -
de O -
vida O -
y O -
los O -
márgenes O -
quirúrgicos O -
tras O -
la O -
prostatectomía O -
radical. O -

Un O -
total O -
de O -
208 O -
hombres O -
que O -
se O -
presentaron O -
para O -
una O -
prostatectomía O -
radical O -
fueron O -
asignados O -
al O -
azar O -
a O -
la O -
preservación O -
completa O -
del O -
cuello O -
de O -
la O -
vejiga O -
con O -
anastomosis O -
uretro-uretral O -
posterior O -
o O -
a O -
la O -
no O -
preservación O -
como O -
controles O -
. O -

No O -
se O -
incluyeron O -
en O -
el O -
estudio O -
los O -
pacientes O -
con O -
preservación O -
fallida O -
del O -
cuello O -
de O -
la O -
vejiga. O -

Se O -
documentó O -
la O -
continencia O -
objetiva O -
mediante O -
la O -
prueba O -
de O -
la O -
compresa O -
de O -
24 O -
horas, O -
la O -
continencia O -
social O -
mediante O -
el O -
número O -
de O -
compresas O -
al O -
día O -
y O -
los O -
resultados O -
de O -
la O -
calidad O -
de O -
vida O -
mediante O -
el O -
cuestionario O -
validado O -
de O -
calidad O -
de O -
vida O -
de O -
la O -
incontinencia O -
en O -
un O -
entorno O -
de O -
ciego O -
único. O -

La O -
resección O -
del O -
cáncer O -
se O -
evaluó O -
por O -
el O -
estado O -
del O -
margen O -
quirúrgico O -
. O -

A B-Premise HighQuality
los I-Premise HighQuality
0, I-Premise HighQuality
3, I-Premise HighQuality
6 I-Premise HighQuality
y I-Premise HighQuality
12 I-Premise HighQuality
meses, I-Premise HighQuality
la I-Premise HighQuality
pérdida I-Premise HighQuality
media I-Premise HighQuality
de I-Premise HighQuality
orina I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
de I-Premise HighQuality
preservación I-Premise HighQuality
del I-Premise HighQuality
cuello I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
vejiga I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
713,3 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
237,0, I-Premise HighQuality
49,6 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
15,6, I-Premise HighQuality
44,4 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
5,5 I-Premise HighQuality
y I-Premise HighQuality
25,4 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
3,1 I-Premise HighQuality
gm, I-Premise HighQuality
respectivamente I-Premise HighQuality
( I-Premise HighQuality
cada I-Premise HighQuality
uno I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

A B-Premise HighQuality
los I-Premise HighQuality
3, I-Premise HighQuality
6 I-Premise HighQuality
y I-Premise HighQuality
12 I-Premise HighQuality
meses, I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
de I-Premise HighQuality
preservación, I-Premise HighQuality
la I-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
continencia I-Premise HighQuality
social I-Premise HighQuality
fue I-Premise HighQuality
del I-Premise HighQuality
55,3% I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
84,2% I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
del I-Premise HighQuality
74,8% I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
89,5% I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,05 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
del I-Premise HighQuality
81,4% I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
94,7% I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,027 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
fue I-Premise HighQuality
del I-Premise HighQuality
80,4 I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
90,3 I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
del I-Premise HighQuality
85,4 I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
91,7 I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,016 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
del I-Premise HighQuality
86,0 I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
93,8 I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
. I-Premise HighQuality

Observamos B-Premise HighQuality
una I-Premise HighQuality
pérdida I-Premise HighQuality
de I-Premise HighQuality
orina I-Premise HighQuality
significativamente I-Premise HighQuality
menor, I-Premise HighQuality
tasas I-Premise HighQuality
de I-Premise HighQuality
continencia I-Premise HighQuality
objetiva I-Premise HighQuality
y I-Premise HighQuality
social I-Premise HighQuality
más I-Premise HighQuality
altas I-Premise HighQuality
y I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
más I-Premise HighQuality
altas I-Premise HighQuality
tras I-Premise HighQuality
la I-Premise HighQuality
preservación I-Premise HighQuality
completa I-Premise HighQuality
del I-Premise HighQuality
cuello I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
vejiga I-Premise HighQuality
en I-Premise HighQuality
todos I-Premise HighQuality
los I-Premise HighQuality
puntos I-Premise HighQuality
de I-Premise HighQuality
seguimiento. I-Premise HighQuality

En O -
el O -
análisis O -
de O -
regresión O -
logística O -
múltiple, O -
la O -
preservación O -
completa O -
del O -
cuello O -
de O -
la O -
vejiga O -
fue O -
un O -
predictor O -
positivo O -
independiente O -
de O -
la O -
continencia. O -

No B-Premise HighQuality
se I-Premise HighQuality
encontraron I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
estado I-Premise HighQuality
del I-Premise HighQuality
margen I-Premise HighQuality
quirúrgico I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
preservación I-Premise HighQuality
del I-Premise HighQuality
cuello I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
vejiga I-Premise HighQuality
( I-Premise HighQuality
12,5 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
14,7 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,65 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

En B-Claim HighQuality
lo I-Claim HighQuality
que I-Claim HighQuality
es, I-Claim HighQuality
hasta I-Claim HighQuality
donde I-Claim HighQuality
sabemos, I-Claim HighQuality
el I-Claim HighQuality
primer I-Claim HighQuality
ensayo I-Claim HighQuality
prospectivo, I-Claim HighQuality
aleatorizado, I-Claim HighQuality
controlado I-Claim HighQuality
y I-Claim HighQuality
a I-Claim HighQuality
ciegas, I-Claim HighQuality
la I-Claim HighQuality
preservación I-Claim HighQuality
completa I-Claim HighQuality
del I-Claim HighQuality
cuello I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
vejiga I-Claim HighQuality
durante I-Claim HighQuality
la I-Claim HighQuality
prostatectomía I-Claim HighQuality
radical I-Claim HighQuality
se I-Claim HighQuality
asoció I-Claim HighQuality
a I-Claim HighQuality
una I-Claim HighQuality
tasa I-Claim HighQuality
de I-Claim HighQuality
continencia I-Claim HighQuality
urinaria I-Claim HighQuality
significativamente I-Claim HighQuality
mayor I-Claim HighQuality
y I-Claim HighQuality
a I-Claim HighQuality
un I-Claim HighQuality
aumento I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
satisfacción I-Claim HighQuality
del I-Claim HighQuality
paciente I-Claim HighQuality
sin I-Claim HighQuality
comprometer I-Claim HighQuality
los I-Claim HighQuality
márgenes I-Claim HighQuality
de I-Claim HighQuality
resección. I-Claim HighQuality

Docetaxel O -
administrado O -
cada O -
3 O -
semanas O -
es O -
un O -
tratamiento O -
estándar O -
para O -
el O -
cáncer O -
de O -
próstata O -
avanzado O -
resistente O -
a O -
la O -
castración O -
. O -

Se O -
planteó O -
la O -
hipótesis O -
de O -
que O -
la O -
administración O -
de O -
docetaxel O -
cada O -
dos O -
semanas O -
sería O -
mejor O -
tolerada O -
que O -
la O -
de O -
tres O -
semanas O -
en O -
pacientes O -
con O -
cáncer O -
de O -
próstata O -
avanzado O -
resistente O -
a O -
la O -
castración, O -
y O -
se O -
realizó O -
un O -
estudio O -
prospectivo, O -
multicéntrico, O -
aleatorizado O -
y O -
de O -
fase O -
3 O -
para O -
comparar O -
la O -
eficacia O -
y O -
la O -
seguridad. O -

Los O -
pacientes O -
elegibles O -
tenían O -
cáncer O -
de O -
próstata O -
avanzado O -
( O -
metástasis O -
, O -
un O -
resultado O -
de O -
la O -
prueba O -
del O -
antígeno O -
específico O -
de O -
la O -
próstata O -
de O -
más O -
de O -
10-0 O -
ng/mL O -
y O -
una O -
puntuación O -
del O -
estado O -
de O -
rendimiento O -
de O -
la O -
OMS O -
de O -
0-2 O -
) O -
no O -
habían O -
recibido O -
quimioterapia O -
(excepto O -
con O -
estramustina), O -
se O -
habían O -
sometido O -
a O -
una O -
castración O -
quirúrgica O -
o O -
química O -
y O -
habían O -
sido O -
remitidos O -
a O -
un O -
centro O -
de O -
tratamiento O -
en O -
Finlandia, O -
Irlanda O -
o O -
Suecia. O -

La O -
inscripción O -
y O -
el O -
tratamiento O -
se O -
realizaron O -
entre O -
el O -
1 O -
de O -
marzo O -
de O -
2004 O -
y O -
el O -
31 O -
de O -
mayo O -
de O -
2009. O -

La O -
aleatorización O -
se O -
realizó O -
de O -
forma O -
centralizada O -
y O -
se O -
estratificó O -
por O -
centro O -
y O -
por O -
la O -
puntuación O -
del O -
estado O -
funcional O -
de O -
la O -
OMS O -
de O -
0-1 O -
frente O -
a O -
2 O -
. O -

A O -
los O -
pacientes O -
se O -
les O -
asignó O -
75 O -
mg/m O -
( O -
2 O -
) O -
de O -
docetaxel O -
por O -
vía O -
intravenosa O -
el O -
día O -
1 O -
de O -
un O -
ciclo O -
de O -
3 O -
semanas O -
, O -
o O -
50 O -
mg/m O -
( O -
2 O -
) O -
de O -
docetaxel O -
por O -
vía O -
intravenosa O -
los O -
días O -
1 O -
y O -
15 O -
de O -
un O -
ciclo O -
de O -
4 O -
semanas O -
. O -

Se O -
administraron O -
10 O -
mg O -
de O -
prednisolona O -
oral O -
diariamente O -
a O -
todos O -
los O -
pacientes. O -

El O -
criterio O -
de O -
valoración O -
principal O -
fue O -
el O -
tiempo O -
hasta O -
el O -
fracaso O -
del O -
tratamiento O -
( O -
TTTF O -
) O -
. O -

Se O -
evaluaron O -
los O -
datos O -
de O -
la O -
población O -
por O -
protocolo. O -

177 O -
pacientes O -
fueron O -
asignados O -
aleatoriamente O -
al O -
grupo O -
de O -
docetaxel O -
de O -
2 O -
semanas O -
y O -
184 O -
al O -
grupo O -
de O -
3 O -
semanas. O -

Se O -
incluyeron O -
en O -
el O -
análisis O -
170 O -
pacientes O -
en O -
el O -
grupo O -
de O -
2 O -
semanas O -
y O -
176 O -
en O -
el O -
de O -
3 O -
semanas. O -

La B-Premise HighQuality
administración I-Premise HighQuality
bisemanal I-Premise HighQuality
se I-Premise HighQuality
asoció I-Premise HighQuality
con I-Premise HighQuality
una I-Premise HighQuality
TTTF I-Premise HighQuality
significativamente I-Premise HighQuality
más I-Premise HighQuality
larga I-Premise HighQuality
que I-Premise HighQuality
la I-Premise HighQuality
administración I-Premise HighQuality
bisemanal I-Premise HighQuality
( I-Premise HighQuality
5-6 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
5-0-6-2 I-Premise HighQuality
vs I-Premise HighQuality
4-9 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
4-5-5-4 I-Premise HighQuality
; I-Premise HighQuality
hazard I-Premise HighQuality
ratio I-Premise HighQuality
1-3 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
1-1-1-6 I-Premise HighQuality
, I-Premise HighQuality
p=0-014 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
acontecimientos I-Premise HighQuality
adversos I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
3-4 I-Premise HighQuality
se I-Premise HighQuality
produjeron I-Premise HighQuality
con I-Premise HighQuality
mayor I-Premise HighQuality
frecuencia I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
administración I-Premise HighQuality
de I-Premise HighQuality
3 I-Premise HighQuality
semanas I-Premise HighQuality
que I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
de I-Premise HighQuality
2 I-Premise HighQuality
semanas, I-Premise HighQuality
incluyendo I-Premise HighQuality
neutropenia I-Premise HighQuality
( I-Premise HighQuality
93 I-Premise HighQuality
[ I-Premise HighQuality
53 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
61 I-Premise HighQuality
[ I-Premise HighQuality
36 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
leucopenia I-Premise HighQuality
( I-Premise HighQuality
51 I-Premise HighQuality
[ I-Premise HighQuality
29 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
22 I-Premise HighQuality
[ I-Premise HighQuality
13 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
neutropenia I-Premise HighQuality
febril I-Premise HighQuality
( I-Premise HighQuality
25 I-Premise HighQuality
[ I-Premise HighQuality
14 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
seis I-Premise HighQuality
[ I-Premise HighQuality
4 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
notificaron I-Premise HighQuality
infecciones I-Premise HighQuality
neutropénicas I-Premise HighQuality
con I-Premise HighQuality
mayor I-Premise HighQuality
frecuencia I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
docetaxel I-Premise HighQuality
cada I-Premise HighQuality
3 I-Premise HighQuality
semanas I-Premise HighQuality
( I-Premise HighQuality
43 I-Premise HighQuality
[ I-Premise HighQuality
24 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
11 I-Premise HighQuality
[ I-Premise HighQuality
6 I-Premise HighQuality
% I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
p=0-002 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
administración I-Claim HighQuality
de I-Claim HighQuality
docetaxel I-Claim HighQuality
cada I-Claim HighQuality
2 I-Claim HighQuality
semanas I-Claim HighQuality
parece I-Claim HighQuality
ser I-Claim HighQuality
bien I-Claim HighQuality
tolerada I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
próstata I-Claim HighQuality
avanzado I-Claim HighQuality
resistente I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
castración I-Claim HighQuality
y I-Claim HighQuality
podría I-Claim HighQuality
ser I-Claim HighQuality
una I-Claim HighQuality
opción I-Claim HighQuality
útil I-Claim HighQuality
cuando I-Claim HighQuality
es I-Claim HighQuality
poco I-Claim HighQuality
probable I-Claim HighQuality
que I-Claim HighQuality
se I-Claim HighQuality
tolere I-Claim HighQuality
la I-Claim HighQuality
administración I-Claim HighQuality
de I-Claim HighQuality
una I-Claim HighQuality
dosis I-Claim HighQuality
única I-Claim HighQuality
cada I-Claim HighQuality
3 I-Claim HighQuality
semanas I-Claim HighQuality
. I-Claim HighQuality

Para B-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
gástrico I-Claim HighQuality
o I-Claim HighQuality
gastroesofágico I-Claim HighQuality
avanzado I-Claim HighQuality
( I-Claim HighQuality
AGGEC I-Claim HighQuality
) I-Claim HighQuality
proporcionar I-Claim HighQuality
un I-Claim HighQuality
beneficio I-Claim HighQuality
clínico I-Claim HighQuality
con I-Claim HighQuality
una I-Claim HighQuality
mejor I-Claim HighQuality
paliación I-Claim HighQuality
es I-Claim HighQuality
altamente I-Claim HighQuality
deseable I-Claim HighQuality
. I-Claim HighQuality

Sin O -
embargo, O -
nunca O -
antes O -
se O -
había O -
informado O -
de O -
una O -
evaluación O -
prospectiva O -
del O -
beneficio O -
clínico O -
en O -
pacientes O -
con O -
AGGEC O -
en O -
un O -
entorno O -
de O -
fase O -
III. O -

En O -
un O -
ensayo O -
multinacional O -
( O -
V325 O -
) O -
, O -
445 O -
pacientes O -
fueron O -
asignados O -
al O -
azar O -
y O -
tratados O -
con O -
docetaxel O -
más O -
cisplatino O -
y O -
fluorouracilo O -
( O -
DCF O -
) O -
o O -
cisplatino O -
y O -
fluorouracilo O -
( O -
CF O -
) O -
. O -

El O -
beneficio O -
clínico O -
se O -
evaluó O -
prospectivamente O -
en O -
este O -
ensayo O -
como O -
punto O -
final O -
secundario O -
. O -

La O -
medida O -
principal O -
para O -
el O -
análisis O -
del O -
beneficio O -
clínico O -
fue O -
el O -
tiempo O -
hasta O -
el O -
empeoramiento O -
definitivo O -
en O -
una O -
o O -
más O -
categorías O -
del O -
estado O -
de O -
rendimiento O -
de O -
Karnofsky O -
( O -
KPS O -
) O -
. O -

Los O -
puntos O -
finales O -
de O -
beneficio O -
clínico O -
secundarios O -
incluyeron O -
el O -
tiempo O -
hasta O -
la O -
pérdida O -
de O -
peso O -
definitiva O -
del O -
5 O -
% O -
, O -
el O -
tiempo O -
hasta O -
el O -
empeoramiento O -
definitivo O -
del O -
apetito O -
en O -
un O -
grado O -
, O -
la O -
supervivencia O -
sin O -
dolor O -
( O -
definida O -
como O -
el O -
tiempo O -
hasta O -
la O -
primera O -
aparición O -
del O -
dolor O -
) O -
y O -
el O -
tiempo O -
hasta O -
la O -
primera O -
ingesta O -
de O -
opioides O -
relacionados O -
con O -
el O -
dolor O -
del O -
cáncer O -
. O -

Las O -
evaluaciones O -
de O -
los O -
beneficios O -
clínicos O -
se O -
registraron O -
en O -
cada O -
visita O -
clínica O -
. O -

Las O -
evaluaciones O -
del O -
beneficio O -
clínico O -
se O -
realizaron O -
en O -
más O -
del O -
75 O -
% O -
de O -
los O -
pacientes O -
a O -
lo O -
largo O -
de O -
V325 O -
. O -

El B-Premise HighQuality
DCF I-Premise HighQuality
prolongó I-Premise HighQuality
significativamente I-Premise HighQuality
el I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
el I-Premise HighQuality
empeoramiento I-Premise HighQuality
definitivo I-Premise HighQuality
del I-Premise HighQuality
KPS I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
FC I-Premise HighQuality
( I-Premise HighQuality
mediana I-Premise HighQuality
, I-Premise HighQuality
6,1 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
4,8 I-Premise HighQuality
meses I-Premise HighQuality
; I-Premise HighQuality
hazard I-Premise HighQuality
ratio I-Premise HighQuality
, I-Premise HighQuality
1,38 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
1,08 I-Premise HighQuality
a I-Premise HighQuality
1,76 I-Premise HighQuality
; I-Premise HighQuality
log-rank I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
.009 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Aunque B-Premise HighQuality
el I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
pérdida I-Premise HighQuality
de I-Premise HighQuality
peso I-Premise HighQuality
definitiva I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
el I-Premise HighQuality
empeoramiento I-Premise HighQuality
definitivo I-Premise HighQuality
del I-Premise HighQuality
apetito I-Premise HighQuality
favorecieron I-Premise HighQuality
al I-Premise HighQuality
DCF I-Premise HighQuality
, I-Premise HighQuality
los B-Premise HighQuality
resultados I-Premise HighQuality
no I-Premise HighQuality
fueron I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativos. I-Premise HighQuality

La B-Premise HighQuality
supervivencia I-Premise HighQuality
sin I-Premise HighQuality
dolor I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
primera I-Premise HighQuality
toma I-Premise HighQuality
de I-Premise HighQuality
opioides I-Premise HighQuality
relacionada I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
dolor I-Premise HighQuality
del I-Premise HighQuality
cáncer I-Premise HighQuality
fueron I-Premise HighQuality
comparables I-Premise HighQuality
. I-Premise HighQuality

Hasta O -
donde O -
sabemos, O -
el O -
V325 O -
es O -
el O -
primer O -
ensayo O -
de O -
fase O -
III O -
que O -
informa O -
de O -
un O -
beneficio O -
clínico O -
en O -
pacientes O -
con O -
AGGEC. O -

El O -
beneficio O -
clínico O -
se O -
evaluó O -
más O -
allá O -
de O -
la O -
quimioterapia O -
específica O -
del O -
protocolo O -
. O -

La B-Claim HighQuality
adición I-Claim HighQuality
de I-Claim HighQuality
D I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
CF I-Claim HighQuality
no I-Claim HighQuality
sólo I-Claim HighQuality
mejoró I-Claim HighQuality
significativamente I-Claim HighQuality
el I-Claim HighQuality
beneficio I-Claim HighQuality
clínico I-Claim HighQuality
sino I-Claim HighQuality
que I-Claim HighQuality
también I-Claim HighQuality
mejoró I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
, I-Claim HighQuality
el I-Claim HighQuality
tiempo I-Claim HighQuality
hasta I-Claim HighQuality
la I-Claim HighQuality
progresión I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
supervivencia I-Claim HighQuality
global I-Claim HighQuality
en I-Claim HighQuality
comparación I-Claim HighQuality
con I-Claim HighQuality
la I-Claim HighQuality
CF I-Claim HighQuality
. I-Claim HighQuality

La O -
adición O -
del O -
inhibidor O -
de O -
mTOR O -
everolimus O -
( O -
EVE O -
) O -
al O -
exemestano O -
( O -
EXE O -
) O -
se O -
evaluó O -
en O -
un O -
estudio O -
internacional O -
de O -
fase O -
3 O -
( O -
BOLERO-2 O -
) O -
en O -
pacientes O -
con O -
cáncer O -
de O -
mama O -
con O -
receptores O -
hormonales O -
positivos O -
( O -
HR O -
( O -
+ O -
) O -
) O -
refractario O -
a O -
letrozol O -
o O -
anastrozol O -
. O -

La O -
seguridad O -
y O -
la O -
eficacia O -
de O -
los O -
tratamientos O -
contra O -
el O -
cáncer O -
pueden O -
verse O -
influidas O -
por O -
el O -
origen O -
étnico O -
( O -
Sekine O -
et O -
al O -
. O -

En O -
Br O -
J O -
Cancer O -
99:1757-62 O -
, O -
2008 O -
). O -

Se O -
presentan O -
los O -
resultados O -
de O -
seguridad O -
y O -
eficacia O -
de O -
los O -
pacientes O -
asiáticos O -
frente O -
a O -
los O -
no O -
asiáticos O -
en O -
BOLERO-2. O -

Los O -
pacientes O -
fueron O -
aleatorizados O -
( O -
2:1 O -
) O -
a O -
10 O -
mg/día O -
de O -
EVE O -
+ O -
EXE O -
o O -
a O -
placebo O -
( O -
PBO O -
) O -
+ O -
EXE O -
. O -

El O -
criterio O -
de O -
valoración O -
primario O -
fue O -
la O -
supervivencia O -
sin O -
progresión O -
( O -
PFS O -
) O -
. O -

Los O -
criterios O -
de O -
valoración O -
secundarios O -
fueron O -
la O -
supervivencia O -
global, O -
la O -
tasa O -
de O -
respuesta, O -
la O -
tasa O -
de O -
beneficio O -
clínico O -
y O -
la O -
seguridad. O -

De O -
los O -
143 O -
pacientes O -
asiáticos, O -
98 O -
recibieron O -
EVE O -
+ O -
EXE O -
y O -
45 O -
recibieron O -
PBO O -
+ O -
EXE. O -

El B-Premise HighQuality
tratamiento I-Premise HighQuality
con I-Premise HighQuality
EVE I-Premise HighQuality
+ I-Premise HighQuality
EXE I-Premise HighQuality
mejoró I-Premise HighQuality
significativamente I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SLP I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
PBO I-Premise HighQuality
+ I-Premise HighQuality
EXE I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asiáticos I-Premise HighQuality
en I-Premise HighQuality
un I-Premise HighQuality
38 I-Premise HighQuality
% I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
= I-Premise HighQuality
0,62 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,41-0,94 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SLP I-Premise HighQuality
también I-Premise HighQuality
mejoró I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
no I-Premise HighQuality
asiáticos I-Premise HighQuality
en I-Premise HighQuality
un I-Premise HighQuality
59% I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
= I-Premise HighQuality
0,41 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,33-0,50 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
duración I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SLP I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asiáticos I-Premise HighQuality
tratados I-Premise HighQuality
con I-Premise HighQuality
EVE I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
8,48 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
4,14 I-Premise HighQuality
meses I-Premise HighQuality
para I-Premise HighQuality
PBO I-Premise HighQuality
+ I-Premise HighQuality
EXE I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
7,33 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
2,83 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
, I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
no I-Premise HighQuality
asiáticos I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
efectos I-Premise HighQuality
adversos I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
3/4 I-Premise HighQuality
más I-Premise HighQuality
comunes I-Premise HighQuality
( I-Premise HighQuality
estomatitis I-Premise HighQuality
, I-Premise HighQuality
anemia I-Premise HighQuality
, I-Premise HighQuality
elevación I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
enzimas I-Premise HighQuality
hepáticas I-Premise HighQuality
, I-Premise HighQuality
hiperglucemia I-Premise HighQuality
y I-Premise HighQuality
disnea I-Premise HighQuality
) I-Premise HighQuality
se I-Premise HighQuality
produjeron I-Premise HighQuality
con I-Premise HighQuality
una I-Premise HighQuality
frecuencia I-Premise HighQuality
similar I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asiáticos I-Premise HighQuality
y I-Premise HighQuality
no I-Premise HighQuality
asiáticos I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
enfermedad I-Premise HighQuality
pulmonar I-Premise HighQuality
intersticial I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
1/2 I-Premise HighQuality
fue I-Premise HighQuality
más I-Premise HighQuality
frecuente I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asiáticos. I-Premise HighQuality

La B-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
fue I-Premise HighQuality
similar I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
brazos I-Premise HighQuality
de I-Premise HighQuality
tratamiento I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asiáticos I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
adición I-Claim HighQuality
de I-Claim HighQuality
EVE I-Claim HighQuality
a I-Claim HighQuality
EXE I-Claim HighQuality
proporcionó I-Claim HighQuality
un I-Claim HighQuality
beneficio I-Claim HighQuality
clínico I-Claim HighQuality
sustancial I-Claim HighQuality
tanto I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
asiáticos I-Claim HighQuality
como I-Claim HighQuality
no I-Claim HighQuality
asiáticos I-Claim HighQuality
con I-Claim HighQuality
perfiles I-Claim HighQuality
de I-Claim HighQuality
seguridad I-Claim HighQuality
similares I-Claim HighQuality
. I-Claim HighQuality

Esta B-Claim HighQuality
combinación I-Claim HighQuality
representa I-Claim HighQuality
una I-Claim HighQuality
mejora I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
mujeres I-Claim HighQuality
posmenopáusicas I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
mama I-Claim HighQuality
avanzado I-Claim HighQuality
HR I-Claim HighQuality
( I-Claim HighQuality
+ I-Claim HighQuality
) I-Claim HighQuality
/HER2 I-Claim HighQuality
( I-Claim HighQuality
- I-Claim HighQuality
) I-Claim HighQuality
que I-Claim HighQuality
progresan I-Claim HighQuality
con I-Claim HighQuality
inhibidores I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
aromatasa I-Claim HighQuality
no I-Claim HighQuality
esteroideos, I-Claim HighQuality
independientemente I-Claim HighQuality
de I-Claim HighQuality
su I-Claim HighQuality
origen I-Claim HighQuality
étnico. I-Claim HighQuality

Los B-Claim HighQuality
pacientes I-Claim HighQuality
de I-Claim HighQuality
edad I-Claim HighQuality
avanzada, I-Claim HighQuality
aunque I-Claim HighQuality
estén I-Claim HighQuality
en I-Claim HighQuality
forma, I-Claim HighQuality
suelen I-Claim HighQuality
considerarse I-Claim HighQuality
incapaces I-Claim HighQuality
de I-Claim HighQuality
tolerar I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
sistémico I-Claim HighQuality
con I-Claim HighQuality
platino. I-Claim HighQuality

Se O -
realizó O -
un O -
análisis O -
retrospectivo O -
del O -
Eastern O -
Cooperative O -
Oncology O -
Group O -
( O -
ECOG O -
) O -
5592 O -
, O -
un O -
ensayo O -
aleatorio O -
de O -
fase O -
III O -
de O -
regímenes O -
de O -
quimioterapia O -
basados O -
en O -
platino O -
para O -
el O -
cáncer O -
de O -
pulmón O -
no O -
microcítico O -
( O -
CPNM O -
) O -
, O -
y O -
se O -
compararon O -
los O -
resultados O -
en O -
los O -
inscritos O -
de O -
70 O -
años O -
o O -
más O -
con O -
los O -
de O -
los O -
pacientes O -
más O -
jóvenes O -
. O -

El O -
ECOG O -
llevó O -
a O -
cabo O -
un O -
ensayo O -
aleatorio O -
de O -
fase O -
III O -
de O -
cisplatino O -
más O -
etopósido O -
o O -
paclitaxel O -
en O -
pacientes O -
de O -
CPNM O -
no O -
tratados O -
con O -
quimioterapia O -
y O -
con O -
enfermedad O -
en O -
estadios O -
III O -
( O -
B O -
) O -
o O -
IV O -
. O -

Se O -
compararon O -
los O -
efectos O -
tóxicos, O -
las O -
tasas O -
de O -
respuesta O -
y O -
las O -
tasas O -
de O -
supervivencia O -
entre O -
los O -
grupos O -
de O -
edad. O -

Todos O -
los O -
valores O -
P O -
fueron O -
de O -
dos O -
caras. O -

Un O -
total O -
de O -
574 O -
pacientes O -
inscritos O -
desde O -
agosto O -
de O -
1993 O -
hasta O -
diciembre O -
de O -
1994 O -
fueron O -
evaluables O -
. O -

Ochenta O -
y O -
seis O -
( O -
15 O -
% O -
) O -
tenían O -
70 O -
años O -
o O -
más. O -

Los B-Premise HighQuality
pacientes I-Premise HighQuality
de I-Premise HighQuality
mayor I-Premise HighQuality
edad I-Premise HighQuality
tenían I-Premise HighQuality
una I-Premise HighQuality
mayor I-Premise HighQuality
incidencia I-Premise HighQuality
de I-Premise HighQuality
comorbilidades I-Premise HighQuality
cardiovasculares I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,009 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
respiratorias I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,04 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
uso I-Premise HighQuality
de I-Premise HighQuality
medicación I-Premise HighQuality
no I-Premise HighQuality
analgésica I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,02 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
leucopenia I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
toxicidad I-Premise HighQuality
neuropsiquiátrica I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,002 I-Premise HighQuality
) I-Premise HighQuality
fueron I-Premise HighQuality
más I-Premise HighQuality
frecuentes I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
hombres I-Premise HighQuality
de I-Premise HighQuality
edad I-Premise HighQuality
avanzada I-Premise HighQuality
que I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
más I-Premise HighQuality
jóvenes. I-Premise HighQuality

Las B-Premise HighQuality
mujeres I-Premise HighQuality
mayores I-Premise HighQuality
perdieron I-Premise HighQuality
más I-Premise HighQuality
peso I-Premise HighQuality
que I-Premise HighQuality
las I-Premise HighQuality
más I-Premise HighQuality
jóvenes I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,006 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Otros B-Premise HighQuality
efectos I-Premise HighQuality
tóxicos I-Premise HighQuality
fueron I-Premise HighQuality
similares I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
de I-Premise HighQuality
mayor I-Premise HighQuality
y I-Premise HighQuality
menor I-Premise HighQuality
edad. I-Premise HighQuality

Las B-Premise HighQuality
proporciones I-Premise HighQuality
con I-Premise HighQuality
respuesta I-Premise HighQuality
clínica I-Premise HighQuality
parcial I-Premise HighQuality
o I-Premise HighQuality
completa I-Premise HighQuality
( I-Premise HighQuality
21,5 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
23,3 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
prueba I-Premise HighQuality
exacta I-Premise HighQuality
de I-Premise HighQuality
Fisher I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
=0,66 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
progresión I-Premise HighQuality
( I-Premise HighQuality
4,37 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
4,30 I-Premise HighQuality
meses I-Premise HighQuality
; I-Premise HighQuality
prueba I-Premise HighQuality
de I-Premise HighQuality
rango I-Premise HighQuality
logarítmico I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
=0,29 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
distribución I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
( I-Premise HighQuality
prueba I-Premise HighQuality
de I-Premise HighQuality
rango I-Premise HighQuality
logarítmico I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
=0,29 I-Premise HighQuality
; I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
, I-Premise HighQuality
9,05 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
8,53 I-Premise HighQuality
meses I-Premise HighQuality
; I-Premise HighQuality
supervivencia I-Premise HighQuality
a I-Premise HighQuality
un I-Premise HighQuality
año I-Premise HighQuality
, I-Premise HighQuality
38 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
29 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
y I-Premise HighQuality
supervivencia I-Premise HighQuality
a I-Premise HighQuality
dos I-Premise HighQuality
años I-Premise HighQuality
, I-Premise HighQuality
14 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
12 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
fueron I-Premise HighQuality
similares I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
menores I-Premise HighQuality
de I-Premise HighQuality
70 I-Premise HighQuality
años I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
de I-Premise HighQuality
70 I-Premise HighQuality
años I-Premise HighQuality
o I-Premise HighQuality
más I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
índices I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
resultados I-Premise HighQuality
del I-Premise HighQuality
tratamiento I-Premise HighQuality
fueron I-Premise HighQuality
similares. I-Premise HighQuality

En B-Premise HighQuality
ambos I-Premise HighQuality
grupos I-Premise HighQuality
se I-Premise HighQuality
produjeron I-Premise HighQuality
descensos I-Premise HighQuality
equivalentes I-Premise HighQuality
a I-Premise HighQuality
lo I-Premise HighQuality
largo I-Premise HighQuality
del I-Premise HighQuality
tiempo I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
bienestar I-Premise HighQuality
funcional. I-Premise HighQuality

La B-Claim HighQuality
tasa I-Claim HighQuality
de I-Claim HighQuality
respuesta, I-Claim HighQuality
la I-Claim HighQuality
toxicidad I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
supervivencia I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
de I-Claim HighQuality
edad I-Claim HighQuality
avanzada I-Claim HighQuality
con I-Claim HighQuality
CPNM I-Claim HighQuality
en I-Claim HighQuality
buen I-Claim HighQuality
estado I-Claim HighQuality
físico I-Claim HighQuality
que I-Claim HighQuality
reciben I-Claim HighQuality
tratamiento I-Claim HighQuality
a I-Claim HighQuality
base I-Claim HighQuality
de I-Claim HighQuality
platino I-Claim HighQuality
parecen I-Claim HighQuality
ser I-Claim HighQuality
similares I-Claim HighQuality
a I-Claim HighQuality
las I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
más I-Claim HighQuality
jóvenes, I-Claim HighQuality
aunque B-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
de I-Claim HighQuality
70 I-Claim HighQuality
años I-Claim HighQuality
o I-Claim HighQuality
más I-Claim HighQuality
tienen I-Claim HighQuality
más I-Claim HighQuality
comorbilidades I-Claim HighQuality
y I-Claim HighQuality
pueden I-Claim HighQuality
esperar I-Claim HighQuality
más I-Claim HighQuality
leucopenia I-Claim HighQuality
y I-Claim HighQuality
toxicidad I-Claim HighQuality
neuropsiquiátrica. I-Claim HighQuality

La B-Claim HighQuality
edad I-Claim HighQuality
avanzada I-Claim HighQuality
por I-Claim HighQuality
sí I-Claim HighQuality
sola I-Claim HighQuality
no I-Claim HighQuality
debe I-Claim HighQuality
impedir I-Claim HighQuality
un I-Claim HighQuality
tratamiento I-Claim HighQuality
adecuado I-Claim HighQuality
del I-Claim HighQuality
CPNM. I-Claim HighQuality

Investigar O -
el O -
efecto O -
de O -
dos O -
dosis O -
de O -
acetato O -
de O -
megestrol O -
( O -
MA O -
) O -
en O -
comparación O -
con O -
el O -
placebo O -
sobre O -
la O -
calidad O -
de O -
vida O -
( O -
QoL O -
) O -
y O -
el O -
estado O -
nutricional O -
( O -
NS O -
) O -
en O -
pacientes O -
con O -
cáncer O -
avanzado O -
insensible O -
a O -
la O -
endocrina O -
. O -

Doscientos O -
cuarenta O -
pacientes O -
fueron O -
asignados O -
aleatoriamente O -
a O -
MA O -
480 O -
mg/día, O -
MA O -
160 O -
mg/día O -
o O -
placebo O -
equivalente O -
durante O -
12 O -
semanas. O -

El O -
estado O -
nutricional O -
(incluyendo O -
el O -
peso, O -
el O -
grosor O -
de O -
los O -
pliegues O -
de O -
la O -
piel O -
y O -
la O -
circunferencia O -
del O -
brazo) O -
y O -
la O -
calidad O -
de O -
vida O -
(utilizando O -
6 O -
escalas O -
de O -
autoevaluación O -
analógica O -
lineal O -
(LASA)) O -
se O -
evaluaron O -
en O -
el O -
momento O -
de O -
la O -
aleatorización O -
y O -
después O -
de O -
cuatro, O -
ocho O -
y O -
12 O -
semanas. O -

También O -
se O -
utilizó O -
una O -
clasificación O -
de O -
la O -
calidad O -
de O -
vida O -
que O -
incorporaba O -
la O -
calidad O -
de O -
vida O -
y O -
la O -
muerte O -
y O -
que O -
iba O -
de O -
1 O -
= O -
muerto O -
a O -
5 O -
= O -
calidad O -
de O -
vida O -
mucho O -
mejor. O -

Ciento O -
setenta O -
y O -
cuatro O -
pacientes O -
fueron O -
evaluables O -
en O -
la O -
cuarta O -
semana O -
, O -
136 O -
en O -
la O -
octava O -
semana O -
y O -
103 O -
pacientes O -
en O -
la O -
semana O -
12 O -
. O -

Los B-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
AM I-Premise HighQuality
informaron I-Premise HighQuality
de I-Premise HighQuality
una I-Premise HighQuality
mejora I-Premise HighQuality
sustancial I-Premise HighQuality
del I-Premise HighQuality
apetito I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
del I-Premise HighQuality
estado I-Premise HighQuality
de I-Premise HighQuality
ánimo I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
en I-Premise HighQuality
general I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
posiblemente I-Premise HighQuality
de I-Premise HighQuality
menos I-Premise HighQuality
náuseas I-Premise HighQuality
y I-Premise HighQuality
vómitos I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,08 I-Premise HighQuality
) I-Premise HighQuality
que I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
placebo I-Premise HighQuality
, I-Premise HighQuality
según I-Premise HighQuality
una I-Premise HighQuality
prueba I-Premise HighQuality
de I-Premise HighQuality
tendencia I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
observó I-Premise HighQuality
un I-Premise HighQuality
mayor I-Premise HighQuality
beneficio I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
dosis I-Premise HighQuality
más I-Premise HighQuality
alta, I-Premise HighQuality
que I-Premise HighQuality
(a I-Premise HighQuality
diferencia I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
dosis I-Premise HighQuality
más I-Premise HighQuality
baja) I-Premise HighQuality
fue I-Premise HighQuality
significativamente I-Premise HighQuality
mejor I-Premise HighQuality
en I-Premise HighQuality
las I-Premise HighQuality
comparaciones I-Premise HighQuality
por I-Premise HighQuality
pares I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
placebo I-Premise HighQuality
para I-Premise HighQuality
el I-Premise HighQuality
apetito, I-Premise HighQuality
el I-Premise HighQuality
estado I-Premise HighQuality
de I-Premise HighQuality
ánimo I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
en I-Premise HighQuality
general I-Premise HighQuality
(cada I-Premise HighQuality
una I-Premise HighQuality
de I-Premise HighQuality
ellas I-Premise HighQuality
con I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
o I-Premise HighQuality
= I-Premise HighQuality
0,001). I-Premise HighQuality

A B-Premise HighQuality
pesar I-Premise HighQuality
de I-Premise HighQuality
que I-Premise HighQuality
faltaban I-Premise HighQuality
algunos I-Premise HighQuality
datos I-Premise HighQuality
sobre I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida, I-Premise HighQuality
se I-Premise HighQuality
disponía I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
clasificación I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
en I-Premise HighQuality
227 I-Premise HighQuality
( I-Premise HighQuality
95% I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes, I-Premise HighQuality
con I-Premise HighQuality
una I-Premise HighQuality
clasificación I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
significativamente I-Premise HighQuality
mayor I-Premise HighQuality
asociada I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
AM I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,002 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Las B-Premise HighQuality
mejoras I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
se I-Premise HighQuality
produjeron I-Premise HighQuality
pronto, I-Premise HighQuality
en I-Premise HighQuality
un I-Premise HighQuality
plazo I-Premise HighQuality
de I-Premise HighQuality
cuatro I-Premise HighQuality
semanas, I-Premise HighQuality
y I-Premise HighQuality
se I-Premise HighQuality
mantuvieron. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
diferencias I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
las I-Premise HighQuality
mediciones I-Premise HighQuality
del I-Premise HighQuality
NS I-Premise HighQuality
, I-Premise HighQuality
incluido I-Premise HighQuality
el I-Premise HighQuality
peso I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,29 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
efectos I-Premise HighQuality
secundarios I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
terapia I-Premise HighQuality
fueron I-Premise HighQuality
menores I-Premise HighQuality
y I-Premise HighQuality
no I-Premise HighQuality
difirieron I-Premise HighQuality
significativamente I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
tratamientos. I-Premise HighQuality

El B-Claim HighQuality
acetato I-Claim HighQuality
de I-Claim HighQuality
megestrol I-Claim HighQuality
administrado I-Claim HighQuality
a I-Claim HighQuality
480 I-Claim HighQuality
mg/día I-Claim HighQuality
es I-Claim HighQuality
un I-Claim HighQuality
paliativo I-Claim HighQuality
útil I-Claim HighQuality
en I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
avanzado I-Claim HighQuality
insensible I-Claim HighQuality
a I-Claim HighQuality
los I-Claim HighQuality
fármacos I-Claim HighQuality
endocrinos. I-Claim HighQuality

Mejora B-Claim HighQuality
el I-Claim HighQuality
apetito, I-Claim HighQuality
el I-Claim HighQuality
estado I-Claim HighQuality
de I-Claim HighQuality
ánimo I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
en I-Claim HighQuality
general I-Claim HighQuality
de I-Claim HighQuality
estos I-Claim HighQuality
pacientes, I-Claim HighQuality
aunque B-Claim HighQuality
no I-Claim HighQuality
a I-Claim HighQuality
través I-Claim HighQuality
de I-Claim HighQuality
un I-Claim HighQuality
efecto I-Claim HighQuality
directo I-Claim HighQuality
sobre I-Claim HighQuality
el I-Claim HighQuality
estado I-Claim HighQuality
nutricional. I-Claim HighQuality

La B-Claim HighQuality
suramina I-Claim HighQuality
es I-Claim HighQuality
un I-Claim HighQuality
agente I-Claim HighQuality
novedoso I-Claim HighQuality
que I-Claim HighQuality
ha I-Claim HighQuality
demostrado I-Claim HighQuality
pruebas I-Claim HighQuality
preliminares I-Claim HighQuality
de I-Claim HighQuality
actividad I-Claim HighQuality
antitumoral I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
próstata I-Claim HighQuality
refractario I-Claim HighQuality
a I-Claim HighQuality
las I-Claim HighQuality
hormonas I-Claim HighQuality
( I-Claim HighQuality
HRPC I-Claim HighQuality
) I-Claim HighQuality
. I-Claim HighQuality

Se O -
diseñó O -
un O -
ensayo O -
clínico O -
prospectivo O -
y O -
aleatorio O -
para O -
evaluar O -
el O -
dolor O -
y O -
la O -
ingesta O -
de O -
analgésicos O -
opiáceos O -
como O -
sustitutos O -
de O -
la O -
respuesta O -
antitumoral O -
en O -
pacientes O -
con O -
CPDH O -
con O -
dolor O -
significativo O -
dependiente O -
de O -
analgésicos O -
opiáceos. O -

Un O -
ensayo O -
doble O -
ciego, O -
controlado O -
con O -
placebo, O -
aleatorizó O -
a O -
los O -
pacientes O -
para O -
que O -
recibieran O -
un O -
régimen O -
ambulatorio O -
de O -
78 O -
días O -
de O -
suramina O -
más O -
hidrocortisona O -
( O -
HC O -
, O -
40 O -
mg/d O -
) O -
o O -
placebo O -
más O -
HC O -
. O -

La O -
asignación O -
del O -
tratamiento O -
se O -
desenmascaró O -
cuando O -
se O -
produjo O -
la O -
progresión O -
de O -
la O -
enfermedad O -
o O -
la O -
toxicidad O -
limitante O -
de O -
la O -
dosis; O -
a O -
los O -
pacientes O -
con O -
placebo O -
se O -
les O -
permitió O -
cruzar O -
a O -
suramina O -
más O -
HC O -
de O -
etiqueta O -
abierta. O -

Además O -
del O -
dolor O -
y O -
la O -
ingesta O -
de O -
analgésicos O -
opiáceos, O -
se O -
comparó O -
la O -
respuesta O -
del O -
antígeno O -
específico O -
de O -
la O -
próstata O -
(PSA), O -
el O -
tiempo O -
hasta O -
la O -
progresión O -
de O -
la O -
enfermedad, O -
la O -
calidad O -
de O -
vida, O -
el O -
estado O -
de O -
rendimiento O -
y O -
la O -
supervivencia. O -

Las B-Premise HighQuality
reducciones I-Premise HighQuality
medias I-Premise HighQuality
globales I-Premise HighQuality
del I-Premise HighQuality
dolor I-Premise HighQuality
combinado I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
ingesta I-Premise HighQuality
de I-Premise HighQuality
analgésicos I-Premise HighQuality
opiáceos I-Premise HighQuality
fueron I-Premise HighQuality
mayores I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
caso I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
suramina I-Premise HighQuality
más I-Premise HighQuality
HC I-Premise HighQuality
( I-Premise HighQuality
suma I-Premise HighQuality
de I-Premise HighQuality
rangos I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,0001 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
respuesta I-Premise HighQuality
al I-Premise HighQuality
dolor I-Premise HighQuality
se I-Premise HighQuality
logró I-Premise HighQuality
en I-Premise HighQuality
una I-Premise HighQuality
proporción I-Premise HighQuality
mayor I-Premise HighQuality
de I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
suramina I-Premise HighQuality
que I-Premise HighQuality
placebo I-Premise HighQuality
( I-Premise HighQuality
43% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
28% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
=.001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y O -
la B-Premise HighQuality
duración I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
respuesta I-Premise HighQuality
fue I-Premise HighQuality
más I-Premise HighQuality
larga I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
respondieron I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
suramina I-Premise HighQuality
( I-Premise HighQuality
mediana I-Premise HighQuality
, I-Premise HighQuality
240 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
69 I-Premise HighQuality
días I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
=.0027 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

El B-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
progresión I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
fue I-Premise HighQuality
más I-Premise HighQuality
largo I-Premise HighQuality
( I-Premise HighQuality
riesgo I-Premise HighQuality
relativo I-Premise HighQuality
= I-Premise HighQuality
1,5 I-Premise HighQuality
; I-Premise HighQuality
intervalo I-Premise HighQuality
de I-Premise HighQuality
confianza I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
1,2 I-Premise HighQuality
a I-Premise HighQuality
1,9 I-Premise HighQuality
) I-Premise HighQuality
y O -
la B-Premise HighQuality
proporción I-Premise HighQuality
de I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
un I-Premise HighQuality
descenso I-Premise HighQuality
del I-Premise HighQuality
PSA I-Premise HighQuality
superior I-Premise HighQuality
al I-Premise HighQuality
50 I-Premise HighQuality
% I-Premise HighQuality
fue I-Premise HighQuality
mayor I-Premise HighQuality
( I-Premise HighQuality
33 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
16 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,01 I-Premise HighQuality
) I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
suramina I-Premise HighQuality
. I-Premise HighQuality

Ni B-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
ni I-Premise HighQuality
el I-Premise HighQuality
estado I-Premise HighQuality
funcional I-Premise HighQuality
disminuyeron I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
con I-Premise HighQuality
suramina, I-Premise HighQuality
y O -
la B-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
fue I-Premise HighQuality
similar. I-Premise HighQuality

La B-Premise HighQuality
mayoría I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
efectos I-Premise HighQuality
adversos I-Premise HighQuality
fueron I-Premise HighQuality
de I-Premise HighQuality
intensidad I-Premise HighQuality
leve I-Premise HighQuality
o I-Premise HighQuality
moderada I-Premise HighQuality
y I-Premise HighQuality
se I-Premise HighQuality
trataron I-Premise HighQuality
fácilmente I-Premise HighQuality
con I-Premise HighQuality
medicamentos. I-Premise HighQuality

El B-Claim HighQuality
tratamiento I-Claim HighQuality
ambulatorio I-Claim HighQuality
con I-Claim HighQuality
suramina I-Claim HighQuality
más I-Claim HighQuality
HC I-Claim HighQuality
es I-Claim HighQuality
bien I-Claim HighQuality
tolerado I-Claim HighQuality
y I-Claim HighQuality
proporciona I-Claim HighQuality
un I-Claim HighQuality
beneficio I-Claim HighQuality
paliativo I-Claim HighQuality
moderado I-Claim HighQuality
y I-Claim HighQuality
un I-Claim HighQuality
retraso I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
progresión I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
enfermedad I-Claim HighQuality
para I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
CPDH I-Claim HighQuality
sintomático I-Claim HighQuality
. I-Claim HighQuality

Comparar O -
la O -
vinflunina O -
( O -
VFL O -
) O -
con O -
el O -
docetaxel O -
en O -
pacientes O -
con O -
cáncer O -
de O -
pulmón O -
no O -
microcítico O -
( O -
CPNM O -
) O -
en O -
estadio O -
IIIB/IV O -
que O -
han O -
experimentado O -
el O -
fracaso O -
del O -
tratamiento O -
con O -
quimioterapia O -
de O -
primera O -
línea O -
basada O -
en O -
platino O -
. O -

Estudio O -
aleatorio, O -
multicéntrico, O -
de O -
fase O -
III, O -
551 O -
pacientes O -
recibieron O -
vinflunina O -
320 O -
mg/m O -
( O -
2 O -
) O -
o O -
docetaxel O -
75 O -
mg/m O -
( O -
2 O -
) O -
cada O -
21 O -
días O -
hasta O -
la O -
progresión O -
de O -
la O -
enfermedad O -
o O -
toxicidad O -
grave. O -

El O -
criterio O -
de O -
valoración O -
primario O -
fue O -
la O -
supervivencia O -
sin O -
progresión O -
( O -
PFS O -
) O -
. O -

El O -
análisis O -
de O -
no O -
inferioridad O -
se O -
basó O -
en O -
una O -
diferencia O -
del O -
10 O -
% O -
( O -
tasas O -
de O -
error O -
de O -
los O -
tipos O -
I/II O -
: O -
5 O -
% O -
/20 O -
% O -
) O -
. O -

Los O -
criterios O -
de O -
valoración O -
secundarios O -
fueron O -
la O -
tasa O -
de O -
respuesta O -
( O -
ORR O -
) O -
, O -
la O -
duración O -
de O -
la O -
respuesta O -
, O -
la O -
supervivencia O -
global O -
( O -
OS O -
) O -
, O -
el O -
beneficio O -
clínico O -
, O -
la O -
calidad O -
de O -
vida O -
( O -
QOL O -
) O -
y O -
la O -
seguridad O -
. O -

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SLP I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
2,3 I-Premise HighQuality
meses I-Premise HighQuality
para I-Premise HighQuality
cada I-Premise HighQuality
brazo I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
, I-Premise HighQuality
1,004 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,841 I-Premise HighQuality
a I-Premise HighQuality
1,199 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
ORR I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
estable I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SG I-Premise HighQuality
, I-Premise HighQuality
fueron I-Premise HighQuality
del I-Premise HighQuality
4,4 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
5,5 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
del I-Premise HighQuality
36,0 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
39,6 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
del I-Premise HighQuality
6,7 I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
7,2 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
, I-Premise HighQuality
0,973 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,805 I-Premise HighQuality
a I-Premise HighQuality
1,176 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
hay I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
beneficio I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
( I-Premise HighQuality
Functional I-Premise HighQuality
Assessment I-Premise HighQuality
of I-Premise HighQuality
Cancer I-Premise HighQuality
Therapy-Lung I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
efectos I-Premise HighQuality
adversos I-Premise HighQuality
inesperados. I-Premise HighQuality

Grado B-Premise HighQuality
superior I-Premise HighQuality
a I-Premise HighQuality
0 I-Premise HighQuality
( I-Premise HighQuality
vinflunina I-Premise HighQuality
v I-Premise HighQuality
docetaxel I-Premise HighQuality
) I-Premise HighQuality
anemia I-Premise HighQuality
( I-Premise HighQuality
82,1 I-Premise HighQuality
% I-Premise HighQuality
v I-Premise HighQuality
79,8 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
neutropenia I-Premise HighQuality
( I-Premise HighQuality
49,3 I-Premise HighQuality
v I-Premise HighQuality
39,02 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
trombocitopenia I-Premise HighQuality
( I-Premise HighQuality
30,6 I-Premise HighQuality
% I-Premise HighQuality
v I-Premise HighQuality
14,3 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
neutropenia I-Premise HighQuality
febril I-Premise HighQuality
( I-Premise HighQuality
3.3 I-Premise HighQuality
% I-Premise HighQuality
v I-Premise HighQuality
4.7 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
estreñimiento I-Premise HighQuality
( I-Premise HighQuality
39.2 I-Premise HighQuality
% I-Premise HighQuality
v I-Premise HighQuality
11.7 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
fatiga I-Premise HighQuality
( I-Premise HighQuality
36.6 I-Premise HighQuality
% I-Premise HighQuality
v I-Premise HighQuality
33.9 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
reacción I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
lugar I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
inyección I-Premise HighQuality
( I-Premise HighQuality
31.9 I-Premise HighQuality
% I-Premise HighQuality
v I-Premise HighQuality
0.7 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
náuseas I-Premise HighQuality
( I-Premise HighQuality
26.7 I-Premise HighQuality
% I-Premise HighQuality
v I-Premise HighQuality
23.7 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
vómitos I-Premise HighQuality
( I-Premise HighQuality
23.8 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
14,2 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
alopecia I-Premise HighQuality
( I-Premise HighQuality
19,8 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
35,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
estomatitis I-Premise HighQuality
( I-Premise HighQuality
19,4 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
12,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
dolor I-Premise HighQuality
abdominal I-Premise HighQuality
( I-Premise HighQuality
20,1 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
3,6 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
mialgia I-Premise HighQuality
( I-Premise HighQuality
14,7 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
6,6 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
neuropatía I-Premise HighQuality
periférica I-Premise HighQuality
( I-Premise HighQuality
10.7 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
15,0 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
artralgia I-Premise HighQuality
( I-Premise HighQuality
7,0 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
7,7 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
diarrea I-Premise HighQuality
( I-Premise HighQuality
6,2 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
12,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
edema I-Premise HighQuality
( I-Premise HighQuality
1,5 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
5,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
trastornos I-Premise HighQuality
ungueales I-Premise HighQuality
( I-Premise HighQuality
1,1 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
5 I-Premise HighQuality
; I-Premise HighQuality
1 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Este B-Claim HighQuality
estudio I-Claim HighQuality
de I-Claim HighQuality
fase I-Claim HighQuality
III I-Claim HighQuality
de I-Claim HighQuality
no I-Claim HighQuality
inferioridad I-Claim HighQuality
mostró I-Claim HighQuality
puntos I-Claim HighQuality
finales I-Claim HighQuality
de I-Claim HighQuality
eficacia I-Claim HighQuality
similares I-Claim HighQuality
para I-Claim HighQuality
la I-Claim HighQuality
vinflunina I-Claim HighQuality
y I-Claim HighQuality
el I-Claim HighQuality
docetaxel I-Claim HighQuality
. I-Claim HighQuality

A B-Claim HighQuality
pesar I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
mayores I-Claim HighQuality
tasas I-Claim HighQuality
de I-Claim HighQuality
algunos I-Claim HighQuality
efectos I-Claim HighQuality
adversos I-Claim HighQuality
( I-Claim HighQuality
anemia I-Claim HighQuality
, I-Claim HighQuality
dolor I-Claim HighQuality
abdominal I-Claim HighQuality
, I-Claim HighQuality
estreñimiento I-Claim HighQuality
, I-Claim HighQuality
fatiga I-Claim HighQuality
) I-Claim HighQuality
el B-Claim HighQuality
perfil I-Claim HighQuality
de I-Claim HighQuality
toxicidad I-Claim HighQuality
general I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
vinflunina I-Claim HighQuality
fue I-Claim HighQuality
manejable I-Claim HighQuality
. I-Claim HighQuality

Por O -
lo O -
tanto, O -
el B-Claim HighQuality
VFL I-Claim HighQuality
puede I-Claim HighQuality
ser I-Claim HighQuality
otra I-Claim HighQuality
opción I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
segunda I-Claim HighQuality
línea I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
CPNM I-Claim HighQuality
avanzado. I-Claim HighQuality

Este O -
ensayo O -
aleatorio, O -
controlado O -
con O -
placebo O -
y O -
a O -
ciegas, O -
investigó O -
la O -
seguridad O -
y O -
la O -
eficacia O -
de O -
SAMITAL® O -
, O -
una O -
formulación O -
de O -
extractos O -
botánicos O -
altamente O -
estandarizados, O -
en O -
el O -
tratamiento O -
de O -
la O -
mucositis O -
oral O -
( O -
OM O -
) O -
inducida O -
por O -
la O -
quimio/radioterapia O -
en O -
pacientes O -
con O -
cáncer O -
de O -
cabeza O -
y O -
cuello O -
. O -

Los O -
pacientes O -
recibieron O -
SAMITAL® O -
o O -
placebo O -
cuatro O -
veces O -
al O -
día O -
durante O -
un O -
máximo O -
de O -
50 O -
días O -
durante O -
la O -
quimio/radioterapia O -
programada. O -

La O -
gravedad O -
de O -
la O -
OM O -
se O -
controló O -
según O -
una O -
escala O -
de O -
gravedad O -
modificada O -
de O -
la O -
OMS O -
, O -
y O -
las O -
evaluaciones O -
del O -
dolor O -
y O -
la O -
calidad O -
de O -
vida O -
se O -
basaron O -
en O -
el O -
efecto O -
de O -
los O -
síntomas O -
de O -
la O -
OM O -
sobre O -
las O -
actividades O -
diarias O -
relevantes O -
, O -
según O -
una O -
escala O -
visual O -
analógica O -
. O -

Las B-Premise HighQuality
puntuaciones I-Premise HighQuality
medias I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
gravedad I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
OM I-Premise HighQuality
se I-Premise HighQuality
redujeron I-Premise HighQuality
significativamente I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,05 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
línea I-Premise HighQuality
de I-Premise HighQuality
base I-Premise HighQuality
) I-Premise HighQuality
desde I-Premise HighQuality
el I-Premise HighQuality
día I-Premise HighQuality
31 I-Premise HighQuality
hasta I-Premise HighQuality
el I-Premise HighQuality
final I-Premise HighQuality
del I-Premise HighQuality
tratamiento I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
tratados I-Premise HighQuality
con I-Premise HighQuality
SAMITAL® I-Premise HighQuality
( I-Premise HighQuality
n I-Premise HighQuality
= I-Premise HighQuality
20 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observó I-Premise HighQuality
ninguna I-Premise HighQuality
mejora I-Premise HighQuality
significativa I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
placebo I-Premise HighQuality
( I-Premise HighQuality
n I-Premise HighQuality
= I-Premise HighQuality
10 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
reducción I-Premise HighQuality
del I-Premise HighQuality
dolor I-Premise HighQuality
fue I-Premise HighQuality
significativa I-Premise HighQuality
desde I-Premise HighQuality
el I-Premise HighQuality
día I-Premise HighQuality
4 I-Premise HighQuality
hasta I-Premise HighQuality
el I-Premise HighQuality
final I-Premise HighQuality
del I-Premise HighQuality
tratamiento I-Premise HighQuality
con I-Premise HighQuality
SAMITAL® I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
días I-Premise HighQuality
7 I-Premise HighQuality
a I-Premise HighQuality
21 I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
placebo I-Premise HighQuality
. I-Premise HighQuality

SAMITAL® B-Premise HighQuality
también I-Premise HighQuality
mejoró I-Premise HighQuality
significativamente I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida, I-Premise HighQuality
como I-Premise HighQuality
demuestran I-Premise HighQuality
las I-Premise HighQuality
mejoras I-Premise HighQuality
en I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
actividades I-Premise HighQuality
diarias I-Premise HighQuality
relevantes, I-Premise HighQuality
como I-Premise HighQuality
comer, I-Premise HighQuality
beber I-Premise HighQuality
y I-Premise HighQuality
dormir. I-Premise HighQuality

Todos O -
los O -
pacientes O -
de O -
SAMITAL® O -
completaron O -
el O -
periodo O -
de O -
tratamiento, O -
pero O -
ningún O -
receptor O -
de O -
placebo O -
completó O -
el O -
tratamiento. O -

No B-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
efectos I-Premise HighQuality
adversos I-Premise HighQuality
graves I-Premise HighQuality
con I-Premise HighQuality
SAMITAL® I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
absorción I-Premise HighQuality
sistémica I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
principios I-Premise HighQuality
activos I-Premise HighQuality
relevantes I-Premise HighQuality
fue I-Premise HighQuality
indetectable. I-Premise HighQuality

SAMITAL® B-Claim HighQuality
disminuyó I-Claim HighQuality
significativamente I-Claim HighQuality
la I-Claim HighQuality
gravedad I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
OM I-Claim HighQuality
inducida I-Claim HighQuality
por I-Claim HighQuality
la I-Claim HighQuality
quimio/radioterapia I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
cabeza I-Claim HighQuality
y I-Claim HighQuality
cuello, I-Claim HighQuality
sin I-Claim HighQuality
que I-Claim HighQuality
se I-Claim HighQuality
produjeran I-Claim HighQuality
efectos I-Claim HighQuality
adversos I-Claim HighQuality
relacionados I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
tratamiento. I-Claim HighQuality

El B-Claim HighQuality
alivio I-Claim HighQuality
del I-Claim HighQuality
dolor I-Claim HighQuality
duró I-Claim HighQuality
todo I-Claim HighQuality
el I-Claim HighQuality
periodo I-Claim HighQuality
de I-Claim HighQuality
tratamiento, I-Claim HighQuality
y I-Claim HighQuality
las I-Claim HighQuality
mejoras I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
se I-Claim HighQuality
reflejaron I-Claim HighQuality
en I-Claim HighQuality
los I-Claim HighQuality
beneficios I-Claim HighQuality
significativos I-Claim HighQuality
de I-Claim HighQuality
SAMITAL® I-Claim HighQuality
en I-Claim HighQuality
actividades I-Claim HighQuality
como I-Claim HighQuality
beber, I-Claim HighQuality
comer I-Claim HighQuality
y I-Claim HighQuality
hablar. I-Claim HighQuality

Los O -
pacientes O -
que O -
desarrollan O -
un O -
cáncer O -
de O -
próstata O -
resistente O -
a O -
la O -
castración O -
( O -
CRPCa O -
) O -
suelen O -
continuar O -
con O -
la O -
terapia O -
de O -
privación O -
de O -
andrógenos O -
( O -
ADT O -
) O -
. O -

No O -
se O -
ha O -
estudiado O -
bien O -
si O -
estos O -
pacientes O -
deben O -
seguir O -
recibiendo O -
TDA. O -

Se O -
llevó O -
a O -
cabo O -
un O -
ensayo O -
aleatorio O -
multicéntrico O -
para O -
comparar O -
un O -
enfoque O -
intermitente O -
frente O -
a O -
uno O -
continuo O -
de O -
ADT O -
en O -
pacientes O -
con O -
CPRC. O -

La O -
supervivencia O -
global, O -
la O -
calidad O -
de O -
vida O -
relacionada O -
con O -
la O -
salud O -
(QOL) O -
y O -
el O -
coste O -
fueron O -
los O -
principales O -
criterios O -
de O -
valoración. O -

Los O -
pacientes O -
con O -
CPRC O -
fueron O -
aleatorizados O -
2:1 O -
a O -
agonistas O -
de O -
la O -
hormona O -
liberadora O -
de O -
hormona O -
luteinizante O -
( O -
LHRHa O -
) O -
intermitentes O -
o O -
continuos. O -

Se O -
realizó O -
un O -
seguimiento O -
de O -
los O -
pacientes O -
con O -
evaluaciones O -
clínicas, O -
análisis O -
de O -
laboratorio O -
y O -
cuestionarios O -
de O -
calidad O -
de O -
vida O -
( O -
EORTC O -
QLQ-C30 O -
o O -
PROSQOLI O -
) O -
cada O -
dos O -
meses. O -

Si O -
la O -
testosterona O -
sérica O -
se O -
elevaba O -
por O -
encima O -
de O -
los O -
niveles O -
de O -
castrado O -
( O -
1,75 O -
nmol/L O -
) O -
, O -
se O -
reiniciaba O -
la O -
LHRHa O -
. O -

El O -
estudio O -
se O -
diseñó O -
para O -
cerrarse O -
si O -
> O -
50 O -
% O -
de O -
los O -
pacientes O -
necesitaban O -
reiniciar O -
la O -
ADT O -
en O -
el O -
brazo O -
intermitente O -
. O -

Se O -
siguió O -
a O -
31 O -
pacientes O -
con O -
una O -
mediana O -
de O -
seguimiento O -
de O -
26,8 O -
meses, O -
18 O -
en O -
el O -
brazo O -
intermitente O -
y O -
13 O -
en O -
el O -
continuo. O -

Doce O -
de O -
los O -
18 O -
pacientes O -
del O -
brazo O -
intermitente O -
fueron O -
reiniciados O -
con O -
LHRHa O -
en O -
una O -
mediana O -
de O -
tiempo O -
de O -
17,9 O -
meses O -
. O -

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
o I-Premise HighQuality
específica I-Premise HighQuality
del I-Premise HighQuality
cáncer I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
dos I-Premise HighQuality
brazos. I-Premise HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
dos I-Premise HighQuality
brazos I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
0 I-Premise HighQuality
y I-Premise HighQuality
12 I-Premise HighQuality
meses. I-Premise HighQuality

Los B-Premise HighQuality
costes I-Premise HighQuality
medios I-Premise HighQuality
totales I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
24 I-Premise HighQuality
meses I-Premise HighQuality
fueron I-Premise HighQuality
significativamente I-Premise HighQuality
menores I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
brazo I-Premise HighQuality
intermitente I-Premise HighQuality
( I-Premise HighQuality
3135 I-Premise HighQuality
$ I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
8253 I-Premise HighQuality
$ I-Premise HighQuality
canadienses I-Premise HighQuality
, I-Premise HighQuality
P=0,0167 I-Premise HighQuality
) I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
continuo I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
principal I-Premise HighQuality
limitación I-Premise HighQuality
de I-Premise HighQuality
este I-Premise HighQuality
estudio I-Premise HighQuality
es I-Premise HighQuality
el I-Premise HighQuality
reducido I-Premise HighQuality
tamaño I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
muestra. I-Premise HighQuality

Hemos B-Claim HighQuality
observado I-Claim HighQuality
que I-Claim HighQuality
la I-Claim HighQuality
TDA I-Claim HighQuality
intermitente I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
CPRC, I-Claim HighQuality
utilizando I-Claim HighQuality
una I-Claim HighQuality
testosterona I-Claim HighQuality
de I-Claim HighQuality
> I-Claim HighQuality
1,75 I-Claim HighQuality
ngmol/L I-Claim HighQuality
como I-Claim HighQuality
desencadenante I-Claim HighQuality
para I-Claim HighQuality
reiniciar I-Claim HighQuality
la I-Claim HighQuality
LHRHa, I-Claim HighQuality
supone I-Claim HighQuality
un I-Claim HighQuality
ahorro I-Claim HighQuality
sustancial I-Claim HighQuality
de I-Claim HighQuality
costes I-Claim HighQuality
sin I-Claim HighQuality
impacto I-Claim HighQuality
negativo I-Claim HighQuality
en I-Claim HighQuality
los I-Claim HighQuality
resultados I-Claim HighQuality
oncológicos I-Claim HighQuality
y I-Claim HighQuality
de I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida. I-Claim HighQuality

La O -
terapia O -
hormonal O -
para O -
la O -
menopausia O -
se O -
sigue O -
utilizando O -
en O -
la O -
clínica, O -
pero O -
siguen O -
existiendo O -
dudas O -
sobre O -
sus O -
riesgos O -
y O -
beneficios O -
para O -
la O -
prevención O -
de O -
enfermedades O -
crónicas. O -

Informar O -
de O -
una O -
visión O -
global O -
e O -
integrada O -
de O -
los O -
resultados O -
de O -
los O -
2 O -
ensayos O -
de O -
terapia O -
hormonal O -
de O -
la O -
Iniciativa O -
de O -
Salud O -
de O -
la O -
Mujer O -
(WHI) O -
con O -
un O -
seguimiento O -
extendido O -
después O -
de O -
la O -
intervención. O -

Un O -
total O -
de O -
27.347 O -
mujeres O -
posmenopáusicas O -
de O -
entre O -
50 O -
y O -
79 O -
años O -
se O -
inscribieron O -
en O -
40 O -
centros O -
estadounidenses O -
. O -

Las O -
mujeres O -
con O -
el O -
útero O -
intacto O -
recibieron O -
estrógenos O -
equinos O -
conjugados O -
( O -
CEE O -
; O -
0,625 O -
mg/d O -
) O -
más O -
acetato O -
de O -
medroxiprogesterona O -
( O -
MPA O -
; O -
2,5 O -
mg/d O -
) O -
( O -
n O -
= O -
8506 O -
) O -
o O -
placebo O -
( O -
n O -
= O -
8102 O -
) O -
. O -

Las O -
mujeres O -
con O -
histerectomía O -
previa O -
recibieron O -
CEE O -
solo O -
( O -
0,625 O -
mg/d O -
) O -
( O -
n O -
= O -
5310 O -
) O -
o O -
placebo O -
( O -
n O -
= O -
5429 O -
) O -
. O -

La O -
intervención O -
duró O -
una O -
mediana O -
de O -
5,6 O -
años O -
en O -
el O -
ensayo O -
de O -
CEE O -
más O -
MPA O -
y O -
7,2 O -
años O -
en O -
el O -
ensayo O -
de O -
CEE O -
solo, O -
con O -
13 O -
años O -
de O -
seguimiento O -
acumulado O -
hasta O -
el O -
30 O -
de O -
septiembre O -
de O -
2010. O -

Los O -
resultados O -
primarios O -
de O -
eficacia O -
y O -
seguridad O -
fueron O -
la O -
enfermedad O -
coronaria O -
(EC) O -
y O -
el O -
cáncer O -
de O -
mama O -
invasivo, O -
respectivamente. O -

Un O -
índice O -
global O -
incluía O -
también O -
el O -
ictus, O -
la O -
embolia O -
pulmonar, O -
el O -
cáncer O -
colorrectal, O -
el O -
cáncer O -
de O -
endometrio, O -
la O -
fractura O -
de O -
cadera O -
y O -
la O -
muerte. O -

Durante B-Premise HighQuality
la I-Premise HighQuality
fase I-Premise HighQuality
de I-Premise HighQuality
intervención I-Premise HighQuality
de I-Premise HighQuality
CEE I-Premise HighQuality
más I-Premise HighQuality
MPA I-Premise HighQuality
, I-Premise HighQuality
el I-Premise HighQuality
número I-Premise HighQuality
de I-Premise HighQuality
casos I-Premise HighQuality
de I-Premise HighQuality
cardiopatía I-Premise HighQuality
coronaria I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
196 I-Premise HighQuality
para I-Premise HighQuality
CEE I-Premise HighQuality
más I-Premise HighQuality
MPA I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
159 I-Premise HighQuality
para I-Premise HighQuality
placebo I-Premise HighQuality
( I-Premise HighQuality
hazard I-Premise HighQuality
ratio I-Premise HighQuality
[ I-Premise HighQuality
HR I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
1,18 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,95-1,45 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
206 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
155 I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
, I-Premise HighQuality
para I-Premise HighQuality
el I-Premise HighQuality
cáncer I-Premise HighQuality
de I-Premise HighQuality
mama I-Premise HighQuality
invasivo I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
, I-Premise HighQuality
1,24 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
1,01-1,53 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Otros B-Premise HighQuality
riesgos I-Premise HighQuality
fueron I-Premise HighQuality
el I-Premise HighQuality
aumento I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
accidentes I-Premise HighQuality
cerebrovasculares, I-Premise HighQuality
la I-Premise HighQuality
embolia I-Premise HighQuality
pulmonar, I-Premise HighQuality
la I-Premise HighQuality
demencia I-Premise HighQuality
(en I-Premise HighQuality
mujeres I-Premise HighQuality
de I-Premise HighQuality
edad I-Premise HighQuality
≥65 I-Premise HighQuality
años), I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
vesícula I-Premise HighQuality
biliar I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
incontinencia I-Premise HighQuality
urinaria; I-Premise HighQuality
los I-Premise HighQuality
beneficios I-Premise HighQuality
fueron I-Premise HighQuality
la I-Premise HighQuality
disminución I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
fracturas I-Premise HighQuality
de I-Premise HighQuality
cadera, I-Premise HighQuality
la I-Premise HighQuality
diabetes I-Premise HighQuality
y I-Premise HighQuality
los I-Premise HighQuality
síntomas I-Premise HighQuality
vasomotores. I-Premise HighQuality

La B-Premise HighQuality
mayoría I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
riesgos I-Premise HighQuality
y I-Premise HighQuality
beneficios I-Premise HighQuality
se I-Premise HighQuality
disiparon I-Premise HighQuality
después I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
intervención, I-Premise HighQuality
aunque B-Premise HighQuality
persistió I-Premise HighQuality
un I-Premise HighQuality
cierto I-Premise HighQuality
aumento I-Premise HighQuality
del I-Premise HighQuality
riesgo I-Premise HighQuality
de I-Premise HighQuality
cáncer I-Premise HighQuality
de I-Premise HighQuality
mama I-Premise HighQuality
durante I-Premise HighQuality
el I-Premise HighQuality
seguimiento I-Premise HighQuality
acumulado I-Premise HighQuality
( I-Premise HighQuality
434 I-Premise HighQuality
casos I-Premise HighQuality
para I-Premise HighQuality
CEE I-Premise HighQuality
más I-Premise HighQuality
MPA I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
323 I-Premise HighQuality
para I-Premise HighQuality
placebo; I-Premise HighQuality
HR I-Premise HighQuality
, I-Premise HighQuality
1,28 I-Premise HighQuality
[ I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
1,11-1,48 I-Premise HighQuality
] I-Premise HighQuality
) I-Premise HighQuality
. O -

Los B-Premise HighQuality
riesgos I-Premise HighQuality
y I-Premise HighQuality
beneficios I-Premise HighQuality
estuvieron I-Premise HighQuality
más I-Premise HighQuality
equilibrados I-Premise HighQuality
durante I-Premise HighQuality
la I-Premise HighQuality
intervención I-Premise HighQuality
de I-Premise HighQuality
CEE I-Premise HighQuality
solo, I-Premise HighQuality
con I-Premise HighQuality
204 I-Premise HighQuality
casos I-Premise HighQuality
de I-Premise HighQuality
cardiopatía I-Premise HighQuality
coronaria I-Premise HighQuality
para I-Premise HighQuality
CEE I-Premise HighQuality
solo I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
222 I-Premise HighQuality
casos I-Premise HighQuality
para I-Premise HighQuality
placebo I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
, I-Premise HighQuality
0,94 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,78-1,14 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
104 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
135 I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
, I-Premise HighQuality
para I-Premise HighQuality
el I-Premise HighQuality
cáncer I-Premise HighQuality
de I-Premise HighQuality
mama I-Premise HighQuality
invasivo I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
, I-Premise HighQuality
0,79 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,61-1,02 I-Premise HighQuality
) I-Premise HighQuality
; I-Premise HighQuality
acumulativamente I-Premise HighQuality
, I-Premise HighQuality
hubo I-Premise HighQuality
168 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
216 I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
, I-Premise HighQuality
casos I-Premise HighQuality
de I-Premise HighQuality
cáncer I-Premise HighQuality
de I-Premise HighQuality
mama I-Premise HighQuality
diagnosticados I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
, I-Premise HighQuality
0,79 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,65-0,97 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Los O -
resultados O -
de O -
otros O -
resultados O -
fueron O -
similares O -
a O -
los O -
de O -
CEE O -
más O -
MPA O -
. O -

Ninguno O -
de O -
los O -
dos O -
regímenes O -
afectó O -
a O -
la O -
mortalidad O -
por O -
todas O -
las O -
causas. O -

En B-Premise HighQuality
el I-Premise HighQuality
caso I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CEE I-Premise HighQuality
sola, I-Premise HighQuality
las I-Premise HighQuality
mujeres I-Premise HighQuality
más I-Premise HighQuality
jóvenes I-Premise HighQuality
( I-Premise HighQuality
de I-Premise HighQuality
50 I-Premise HighQuality
a I-Premise HighQuality
59 I-Premise HighQuality
años I-Premise HighQuality
) I-Premise HighQuality
tuvieron I-Premise HighQuality
resultados I-Premise HighQuality
más I-Premise HighQuality
favorables I-Premise HighQuality
en I-Premise HighQuality
cuanto I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
mortalidad I-Premise HighQuality
por I-Premise HighQuality
todas I-Premise HighQuality
las I-Premise HighQuality
causas, I-Premise HighQuality
el I-Premise HighQuality
infarto I-Premise HighQuality
de I-Premise HighQuality
miocardio I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
índice I-Premise HighQuality
global I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
nominal I-Premise HighQuality
< I-Premise HighQuality
0,05 I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
tendencia I-Premise HighQuality
por I-Premise HighQuality
edad I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
riesgos I-Premise HighQuality
absolutos I-Premise HighQuality
de I-Premise HighQuality
acontecimientos I-Premise HighQuality
adversos I-Premise HighQuality
( I-Premise HighQuality
medidos I-Premise HighQuality
por I-Premise HighQuality
el I-Premise HighQuality
índice I-Premise HighQuality
global I-Premise HighQuality
) I-Premise HighQuality
por I-Premise HighQuality
cada I-Premise HighQuality
10.000 I-Premise HighQuality
mujeres I-Premise HighQuality
que I-Premise HighQuality
tomaron I-Premise HighQuality
anualmente I-Premise HighQuality
CEE I-Premise HighQuality
más I-Premise HighQuality
AMP I-Premise HighQuality
oscilaron I-Premise HighQuality
entre I-Premise HighQuality
12 I-Premise HighQuality
casos I-Premise HighQuality
de I-Premise HighQuality
exceso I-Premise HighQuality
para I-Premise HighQuality
las I-Premise HighQuality
edades I-Premise HighQuality
de I-Premise HighQuality
50-59 I-Premise HighQuality
años I-Premise HighQuality
y I-Premise HighQuality
38 I-Premise HighQuality
para I-Premise HighQuality
las I-Premise HighQuality
edades I-Premise HighQuality
de I-Premise HighQuality
70-79 I-Premise HighQuality
años I-Premise HighQuality
; I-Premise HighQuality
para I-Premise HighQuality
las I-Premise HighQuality
mujeres I-Premise HighQuality
que I-Premise HighQuality
tomaron I-Premise HighQuality
CEE I-Premise HighQuality
solo I-Premise HighQuality
, I-Premise HighQuality
entre I-Premise HighQuality
19 I-Premise HighQuality
casos I-Premise HighQuality
menos I-Premise HighQuality
para I-Premise HighQuality
las I-Premise HighQuality
edades I-Premise HighQuality
de I-Premise HighQuality
50-59 I-Premise HighQuality
años I-Premise HighQuality
y I-Premise HighQuality
51 I-Premise HighQuality
casos I-Premise HighQuality
de I-Premise HighQuality
exceso I-Premise HighQuality
para I-Premise HighQuality
las I-Premise HighQuality
edades I-Premise HighQuality
de I-Premise HighQuality
70-79 I-Premise HighQuality
años I-Premise HighQuality
. I-Premise HighQuality

Los O -
resultados O -
de O -
calidad O -
de O -
vida O -
tuvieron O -
resultados O -
mixtos O -
en O -
ambos O -
ensayos. O -

La B-Claim HighQuality
terapia I-Claim HighQuality
hormonal I-Claim HighQuality
para I-Claim HighQuality
la I-Claim HighQuality
menopausia I-Claim HighQuality
tiene I-Claim HighQuality
un I-Claim HighQuality
complejo I-Claim HighQuality
patrón I-Claim HighQuality
de I-Claim HighQuality
riesgos I-Claim HighQuality
y I-Claim HighQuality
beneficios I-Claim HighQuality
. I-Claim HighQuality

Los B-Claim HighQuality
resultados I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
intervención I-Claim HighQuality
y I-Claim HighQuality
del I-Claim HighQuality
seguimiento I-Claim HighQuality
posterior I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
intervención I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
2 I-Claim HighQuality
ensayos I-Claim HighQuality
de I-Claim HighQuality
terapia I-Claim HighQuality
hormonal I-Claim HighQuality
del I-Claim HighQuality
WHI I-Claim HighQuality
no I-Claim HighQuality
apoyan I-Claim HighQuality
el I-Claim HighQuality
uso I-Claim HighQuality
de I-Claim HighQuality
esta I-Claim HighQuality
terapia I-Claim HighQuality
para I-Claim HighQuality
la I-Claim HighQuality
prevención I-Claim HighQuality
de I-Claim HighQuality
enfermedades I-Claim HighQuality
crónicas, I-Claim HighQuality
aunque B-Claim HighQuality
es I-Claim HighQuality
adecuada I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
síntomas I-Claim HighQuality
en I-Claim HighQuality
algunas I-Claim HighQuality
mujeres. I-Claim HighQuality

Los O -
supervivientes O -
de O -
cáncer O -
colorrectal O -
corren O -
el O -
riesgo O -
de O -
tener O -
malos O -
resultados O -
en O -
materia O -
de O -
salud O -
debido O -
a O -
estilos O -
de O -
vida O -
poco O -
saludables, O -
pero O -
son O -
pocos O -
los O -
estudios O -
que O -
han O -
desarrollado O -
intervenciones O -
traducibles O -
de O -
cambio O -
de O -
comportamiento O -
en O -
materia O -
de O -
salud. O -

Este O -
estudio O -
tiene O -
como O -
objetivo O -
determinar O -
los O -
efectos O -
de O -
una O -
intervención O -
de O -
cambio O -
de O -
comportamiento O -
de O -
salud O -
múltiple O -
administrada O -
por O -
teléfono O -
( O -
CanChange O -
) O -
en O -
los O -
resultados O -
de O -
salud O -
y O -
comportamiento O -
entre O -
los O -
sobrevivientes O -
de O -
cáncer O -
colorrectal O -
. O -

En O -
este O -
ensayo O -
controlado O -
aleatorio O -
de O -
dos O -
grupos, O -
410 O -
supervivientes O -
de O -
cáncer O -
colorrectal O -
fueron O -
asignados O -
de O -
forma O -
aleatoria O -
a O -
la O -
intervención O -
de O -
entrenamiento O -
de O -
salud O -
( O -
11 O -
sesiones O -
de O -
entrenamiento O -
de O -
salud O -
basadas O -
en O -
la O -
teoría O -
y O -
realizadas O -
por O -
teléfono O -
durante O -
6 O -
meses O -
y O -
centradas O -
en O -
la O -
actividad O -
física, O -
el O -
control O -
del O -
peso, O -
los O -
hábitos O -
dietéticos, O -
el O -
alcohol O -
y O -
el O -
tabaquismo O -
) O -
o O -
a O -
la O -
atención O -
habitual. O -

La O -
evaluación O -
de O -
los O -
resultados O -
primarios O -
( O -
es O -
decir, O -
la O -
actividad O -
física O -
[ O -
Índice O -
de O -
Tiempo O -
Libre O -
de O -
Godin O -
] O -
, O -
la O -
calidad O -
de O -
vida O -
relacionada O -
con O -
la O -
salud O -
[ O -
HRQoL O -
; O -
Short O -
Form-36 O -
] O -
, O -
y O -
la O -
fatiga O -
relacionada O -
con O -
el O -
cáncer O -
[ O -
Functional O -
Assessment O -
of O -
Chronic O -
Illness O -
Therapy O -
Fatigue O -
Scale O -
] O -
) O -
y O -
secundarios O -
( O -
es O -
decir, O -
el O -
índice O -
de O -
masa O -
corporal O -
[ O -
kg/m O -
( O -
2 O -
) O -
] O -
, O -
la O -
dieta O -
y O -
la O -
ingesta O -
de O -
alcohol O -
[ O -
Food O -
Frequency O -
Questionnaire O -
] O -
, O -
y O -
el O -
tabaquismo O -
) O -
se O -
llevaron O -
a O -
cabo O -
al O -
inicio O -
y O -
a O -
los O -
6 O -
y O -
12 O -
meses O -
. O -

A B-Premise HighQuality
los I-Premise HighQuality
12 I-Premise HighQuality
meses, I-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
efectos I-Premise HighQuality
significativos I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
intervención I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
actividad I-Premise HighQuality
física I-Premise HighQuality
moderada I-Premise HighQuality
( I-Premise HighQuality
28,5 I-Premise HighQuality
minutos I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,003 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
el I-Premise HighQuality
índice I-Premise HighQuality
de I-Premise HighQuality
masa I-Premise HighQuality
corporal I-Premise HighQuality
( I-Premise HighQuality
-0,9 I-Premise HighQuality
kg/m I-Premise HighQuality
( I-Premise HighQuality
2 I-Premise HighQuality
) I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
energía I-Premise HighQuality
procedente I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
grasa I-Premise HighQuality
total I-Premise HighQuality
( I-Premise HighQuality
-7,0 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,006 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
energía I-Premise HighQuality
procedente I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
grasa I-Premise HighQuality
saturada I-Premise HighQuality
( I-Premise HighQuality
-2,8 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,016 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
observó I-Premise HighQuality
un I-Premise HighQuality
efecto I-Premise HighQuality
significativo I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
intervención I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
ingesta I-Premise HighQuality
de I-Premise HighQuality
verduras I-Premise HighQuality
( I-Premise HighQuality
0,4 I-Premise HighQuality
raciones I-Premise HighQuality
al I-Premise HighQuality
día; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
meses. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
encontraron I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
o I-Premise HighQuality
12 I-Premise HighQuality
meses I-Premise HighQuality
en I-Premise HighQuality
cuanto I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
CVRS, I-Premise HighQuality
la I-Premise HighQuality
fatiga I-Premise HighQuality
relacionada I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
cáncer, I-Premise HighQuality
la I-Premise HighQuality
ingesta I-Premise HighQuality
de I-Premise HighQuality
fruta, I-Premise HighQuality
fibra I-Premise HighQuality
o I-Premise HighQuality
alcohol, I-Premise HighQuality
o I-Premise HighQuality
el I-Premise HighQuality
tabaquismo. I-Premise HighQuality

La B-Claim HighQuality
intervención I-Claim HighQuality
CanChange I-Claim HighQuality
fue I-Claim HighQuality
eficaz I-Claim HighQuality
para I-Claim HighQuality
mejorar I-Claim HighQuality
la I-Claim HighQuality
actividad I-Claim HighQuality
física, I-Claim HighQuality
los I-Claim HighQuality
hábitos I-Claim HighQuality
dietéticos I-Claim HighQuality
y I-Claim HighQuality
el I-Claim HighQuality
índice I-Claim HighQuality
de I-Claim HighQuality
masa I-Claim HighQuality
corporal I-Claim HighQuality
en I-Claim HighQuality
supervivientes I-Claim HighQuality
de I-Claim HighQuality
cáncer I-Claim HighQuality
colorrectal. I-Claim HighQuality

La O -
intervención O -
es O -
traducible O -
a O -
través O -
de O -
los O -
servicios O -
telefónicos O -
de O -
apoyo O -
e O -
información O -
sobre O -
el O -
cáncer O -
existentes O -
en O -
Australia O -
y O -
otros O -
países. O -

La O -
evaluación O -
de O -
la O -
calidad O -
de O -
vida O -
relacionada O -
con O -
la O -
salud O -
( O -
HRQoL O -
) O -
y O -
la O -
mejora O -
de O -
los O -
síntomas O -
fueron O -
objetivos O -
secundarios O -
planificados O -
de O -
antemano O -
para O -
la O -
población O -
general O -
y O -
los O -
análisis O -
posthoc O -
para O -
los O -
subgrupos O -
con O -
mutación O -
positiva/negativa O -
del O -
receptor O -
del O -
factor O -
de O -
crecimiento O -
epidérmico O -
( O -
EGFR O -
) O -
en O -
IPASS O -
. O -

La O -
CVRS O -
se O -
evaluó O -
mediante O -
la O -
Evaluación O -
Funcional O -
del O -
Tratamiento O -
del O -
Cáncer O -
de O -
Pulmón O -
( O -
FACT-L O -
) O -
y O -
el O -
Índice O -
de O -
Resultados O -
del O -
Ensayo O -
( O -
TOI O -
) O -
; O -
la O -
mejora O -
de O -
los O -
síntomas O -
mediante O -
la O -
Subescala O -
de O -
Cáncer O -
de O -
Pulmón O -
( O -
LCS O -
) O -
. O -

Las O -
mejoras O -
se O -
definen O -
como O -
: O -
6 O -
o O -
más O -
( O -
FACT-L O -
; O -
TOI O -
) O -
, O -
2 O -
o O -
más O -
( O -
LCS O -
) O -
aumento O -
de O -
puntos O -
mantenido O -
durante O -
21 O -
o O -
más O -
días O -
. O -

En O -
general O -
( O -
n O -
= O -
1151/1217 O -
evaluables O -
) O -
, O -
las O -
tasas O -
de O -
mejora O -
de O -
la O -
CVRS O -
fueron O -
significativamente O -
mayores O -
con O -
gefitinib O -
frente O -
a O -
carboplatino/paclitaxel O -
; O -
las O -
tasas O -
de O -
mejora O -
de O -
los O -
síntomas O -
fueron O -
similares O -
para O -
ambos O -
tratamientos O -
. O -

Un B-Premise HighQuality
número I-Premise HighQuality
significativamente I-Premise HighQuality
mayor I-Premise HighQuality
de I-Premise HighQuality
pacientes I-Premise HighQuality
registró I-Premise HighQuality
mejoras I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
CVRS I-Premise HighQuality
y I-Premise HighQuality
los I-Premise HighQuality
síntomas I-Premise HighQuality
con I-Premise HighQuality
gefitinib I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
subgrupo I-Premise HighQuality
con I-Premise HighQuality
mutación I-Premise HighQuality
EGFR I-Premise HighQuality
positiva I-Premise HighQuality
( I-Premise HighQuality
n I-Premise HighQuality
= I-Premise HighQuality
259 I-Premise HighQuality
; I-Premise HighQuality
FACT-L I-Premise HighQuality
70,2 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
44,5 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
odds I-Premise HighQuality
ratio I-Premise HighQuality
, I-Premise HighQuality
3,01 I-Premise HighQuality
[ I-Premise HighQuality
intervalo I-Premise HighQuality
de I-Premise HighQuality
confianza I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
1,79-5,07 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
; I-Premise HighQuality
TOI I-Premise HighQuality
70,2 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
38,3 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
3,96 I-Premise HighQuality
[ I-Premise HighQuality
2,33-6,71 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
; I-Premise HighQuality
LCS I-Premise HighQuality
75,6 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
53.9 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
2,70 I-Premise HighQuality
[ I-Premise HighQuality
1,58-4,62 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
con I-Premise HighQuality
carboplatino/paclitaxel I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
subgrupo I-Premise HighQuality
con I-Premise HighQuality
mutación I-Premise HighQuality
EGFR I-Premise HighQuality
negativa I-Premise HighQuality
( I-Premise HighQuality
n I-Premise HighQuality
= I-Premise HighQuality
169 I-Premise HighQuality
; I-Premise HighQuality
FACT-L I-Premise HighQuality
14,6 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
36,3 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
odds I-Premise HighQuality
ratio I-Premise HighQuality
, I-Premise HighQuality
0.31 I-Premise HighQuality
[ I-Premise HighQuality
0,15-0,65 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,002 I-Premise HighQuality
; I-Premise HighQuality
TOI I-Premise HighQuality
12,4 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
28,8 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
0,35 I-Premise HighQuality
[ I-Premise HighQuality
0,16-0,79 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,011 I-Premise HighQuality
; I-Premise HighQuality
LCS I-Premise HighQuality
20,2 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
47,5 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
0,28 I-Premise HighQuality
[ I-Premise HighQuality
0,14-0,55 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
del I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
el I-Premise HighQuality
empeoramiento I-Premise HighQuality
( I-Premise HighQuality
meses I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
FACT-L I-Premise HighQuality
fue I-Premise HighQuality
más I-Premise HighQuality
larga I-Premise HighQuality
con I-Premise HighQuality
gefitinib I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
carboplatino/paclitaxel I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
población I-Premise HighQuality
global I-Premise HighQuality
( I-Premise HighQuality
8,3 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
2,5 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
subgrupo I-Premise HighQuality
con I-Premise HighQuality
mutación I-Premise HighQuality
EGFR I-Premise HighQuality
positiva I-Premise HighQuality
( I-Premise HighQuality
15,6 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
3,0 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
similar I-Premise HighQuality
para I-Premise HighQuality
ambos I-Premise HighQuality
tratamientos I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
subgrupo I-Premise HighQuality
con I-Premise HighQuality
mutación I-Premise HighQuality
EGFR I-Premise HighQuality
negativa I-Premise HighQuality
( I-Premise HighQuality
1,4 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
1,4 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
del I-Premise HighQuality
tiempo I-Premise HighQuality
de I-Premise HighQuality
mejora I-Premise HighQuality
con I-Premise HighQuality
gefitinib I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
8 I-Premise HighQuality
días I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
tumores I-Premise HighQuality
con I-Premise HighQuality
mutación I-Premise HighQuality
EGFR I-Premise HighQuality
positiva I-Premise HighQuality
que I-Premise HighQuality
mejoraron I-Premise HighQuality
. I-Premise HighQuality

Los B-Claim HighQuality
criterios I-Claim HighQuality
de I-Claim HighQuality
valoración I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
CVRS I-Claim HighQuality
y I-Claim HighQuality
los I-Claim HighQuality
síntomas I-Claim HighQuality
fueron I-Claim HighQuality
coherentes I-Claim HighQuality
con I-Claim HighQuality
los I-Claim HighQuality
resultados I-Claim HighQuality
de I-Claim HighQuality
eficacia I-Claim HighQuality
del I-Claim HighQuality
IPASS I-Claim HighQuality
y I-Claim HighQuality
favorecieron I-Claim HighQuality
a I-Claim HighQuality
gefitinib I-Claim HighQuality
en I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
tumores I-Claim HighQuality
con I-Claim HighQuality
mutación I-Claim HighQuality
EGFR I-Claim HighQuality
positiva I-Claim HighQuality
y I-Claim HighQuality
a I-Claim HighQuality
carboplatino/paclitaxel I-Claim HighQuality
en I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
tumores I-Claim HighQuality
con I-Claim HighQuality
mutación I-Claim HighQuality
EGFR I-Claim HighQuality
negativa. I-Claim HighQuality

En B-Claim HighQuality
un I-Claim HighQuality
ensayo I-Claim HighQuality
clínico I-Claim HighQuality
aleatorizado I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
pulmón I-Claim HighQuality
no I-Claim HighQuality
microcítico I-Claim HighQuality
avanzado I-Claim HighQuality
( I-Claim HighQuality
NSCLC I-Claim HighQuality
) I-Claim HighQuality
, I-Claim HighQuality
la I-Claim HighQuality
infusión I-Claim HighQuality
con I-Claim HighQuality
adenosina I-Claim HighQuality
5'-trifosfato I-Claim HighQuality
( I-Claim HighQuality
ATP I-Claim HighQuality
) I-Claim HighQuality
inhibió I-Claim HighQuality
la I-Claim HighQuality
pérdida I-Claim HighQuality
de I-Claim HighQuality
peso I-Claim HighQuality
corporal I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
. I-Claim HighQuality

En O -
el O -
presente O -
artículo, O -
se O -
informa O -
de O -
los O -
efectos O -
del O -
ATP O -
en O -
la O -
composición O -
corporal, O -
la O -
ingesta O -
de O -
energía O -
y O -
el O -
gasto O -
energético O -
como O -
medidas O -
de O -
resultado O -
secundarias O -
en O -
los O -
mismos O -
pacientes. O -

Los O -
pacientes O -
con O -
CPNM O -
, O -
estadio O -
IIIB O -
o O -
IV O -
, O -
fueron O -
asignados O -
al O -
azar O -
para O -
recibir O -
10 O -
infusiones O -
intravenosas O -
de O -
30 O -
horas O -
de O -
ATP O -
cada O -
2 O -
a O -
4 O -
semanas O -
o O -
sin O -
ATP O -
. O -

Se O -
evaluaron O -
la O -
masa O -
grasa O -
( O -
FM O -
) O -
, O -
la O -
masa O -
libre O -
de O -
grasa O -
( O -
FFM O -
) O -
y O -
el O -
área O -
muscular O -
del O -
brazo O -
a O -
intervalos O -
de O -
4 O -
semanas O -
durante O -
28 O -
semanas O -
. O -

Se O -
evaluaron O -
la O -
ingesta O -
de O -
alimentos, O -
la O -
masa O -
celular O -
corporal O -
(MCC) O -
y O -
el O -
gasto O -
energético O -
en O -
reposo O -
(GEC) O -
a O -
intervalos O -
de O -
8 O -
semanas O -
durante O -
16 O -
semanas. O -

Se O -
comprobó O -
la O -
significación O -
estadística O -
de O -
las O -
diferencias O -
entre O -
grupos O -
mediante O -
un O -
análisis O -
de O -
covarianza O -
de O -
medidas O -
repetidas. O -

Se O -
asignaron O -
al O -
azar O -
58 O -
pacientes O -
( O -
28 O -
ATP O -
, O -
30 O -
control O -
) O -
. O -

No B-Premise HighQuality
se I-Premise HighQuality
encontró I-Premise HighQuality
ningún I-Premise HighQuality
cambio I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
composición I-Premise HighQuality
corporal I-Premise HighQuality
durante I-Premise HighQuality
el I-Premise HighQuality
período I-Premise HighQuality
de I-Premise HighQuality
seguimiento I-Premise HighQuality
de I-Premise HighQuality
28 I-Premise HighQuality
semanas I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
ATP I-Premise HighQuality
, I-Premise HighQuality
mientras I-Premise HighQuality
que I-Premise HighQuality
, I-Premise HighQuality
por I-Premise HighQuality
4 I-Premise HighQuality
semanas I-Premise HighQuality
, I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
perdió I-Premise HighQuality
0,6 I-Premise HighQuality
kg I-Premise HighQuality
de I-Premise HighQuality
FM I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,004 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
0,5 I-Premise HighQuality
kg I-Premise HighQuality
de I-Premise HighQuality
FFM I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,02 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
1,8 I-Premise HighQuality
% I-Premise HighQuality
de I-Premise HighQuality
área I-Premise HighQuality
muscular I-Premise HighQuality
del I-Premise HighQuality
brazo I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,02 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
0,6 I-Premise HighQuality
% I-Premise HighQuality
de I-Premise HighQuality
BCM I-Premise HighQuality
/ I-Premise HighQuality
kg I-Premise HighQuality
de I-Premise HighQuality
peso I-Premise HighQuality
corporal I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,054 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
disminuyó I-Premise HighQuality
568 I-Premise HighQuality
KJ I-Premise HighQuality
/ I-Premise HighQuality
d I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
ingesta I-Premise HighQuality
de I-Premise HighQuality
energía I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,0001 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

El B-Premise HighQuality
apetito I-Premise HighQuality
también I-Premise HighQuality
se I-Premise HighQuality
mantuvo I-Premise HighQuality
estable I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
ATP, I-Premise HighQuality
pero I-Premise HighQuality
disminuyó I-Premise HighQuality
significativamente I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,0004 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
REE I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
ATP I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
control. I-Premise HighQuality

La B-Claim HighQuality
inhibición I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
pérdida I-Claim HighQuality
de I-Claim HighQuality
peso I-Claim HighQuality
mediante I-Claim HighQuality
infusiones I-Claim HighQuality
de I-Claim HighQuality
ATP I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
CPNM I-Claim HighQuality
avanzado I-Claim HighQuality
se I-Claim HighQuality
atribuye I-Claim HighQuality
a I-Claim HighQuality
que I-Claim HighQuality
se I-Claim HighQuality
contrarresta I-Claim HighQuality
la I-Claim HighQuality
pérdida I-Claim HighQuality
de I-Claim HighQuality
tejidos I-Claim HighQuality
metabólicamente I-Claim HighQuality
activos I-Claim HighQuality
e I-Claim HighQuality
inactivos I-Claim HighQuality
. I-Claim HighQuality

Estos B-Premise HighQuality
efectos I-Premise HighQuality
se I-Premise HighQuality
atribuyen I-Premise HighQuality
en I-Premise HighQuality
parte I-Premise HighQuality
al I-Premise HighQuality
mantenimiento I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
ingesta I-Premise HighQuality
de I-Premise HighQuality
energía. I-Premise HighQuality

Evaluar O -
si O -
el O -
tratamiento O -
con O -
docetaxel O -
como O -
agente O -
único O -
daría O -
lugar O -
a O -
una O -
mayor O -
supervivencia O -
que O -
el O -
mejor O -
tratamiento O -
de O -
apoyo O -
en O -
pacientes O -
con O -
cáncer O -
de O -
pulmón O -
no O -
microcítico O -
que O -
habían O -
sido O -
tratados O -
previamente O -
con O -
quimioterapia O -
basada O -
en O -
platino. O -

Los O -
puntos O -
finales O -
secundarios O -
incluyeron O -
la O -
evaluación O -
de O -
la O -
respuesta O -
(sólo O -
en O -
el O -
brazo O -
de O -
docetaxel), O -
la O -
toxicidad O -
y O -
la O -
calidad O -
de O -
vida. O -

Los O -
pacientes O -
con O -
estados O -
de O -
rendimiento O -
de O -
0 O -
a O -
2 O -
y O -
cáncer O -
de O -
pulmón O -
no O -
microcítico O -
en O -
estadio O -
IIIB/IV O -
con O -
lesiones O -
medibles O -
o O -
evaluables O -
fueron O -
elegibles O -
para O -
entrar O -
en O -
el O -
estudio O -
si O -
habían O -
sido O -
sometidos O -
a O -
uno O -
o O -
más O -
regímenes O -
de O -
quimioterapia O -
con O -
platino O -
y O -
si O -
tenían O -
parámetros O -
hematológicos O -
y O -
bioquímicos O -
adecuados O -
. O -

Se O -
excluyeron O -
si O -
tenían O -
metástasis O -
cerebrales O -
sintomáticas O -
o O -
si O -
habían O -
sido O -
tratados O -
previamente O -
con O -
paclitaxel O -
. O -

Los O -
pacientes O -
fueron O -
estratificados O -
por O -
el O -
estado O -
de O -
rendimiento O -
y O -
la O -
mejor O -
respuesta O -
a O -
la O -
quimioterapia O -
con O -
cisplatino O -
y O -
luego O -
fueron O -
asignados O -
al O -
azar O -
al O -
tratamiento O -
con O -
docetaxel O -
100 O -
mg/m O -
( O -
2 O -
) O -
( O -
49 O -
pacientes O -
) O -
o O -
75 O -
mg/m O -
( O -
2 O -
) O -
( O -
55 O -
pacientes O -
) O -
o O -
al O -
mejor O -
cuidado O -
de O -
apoyo O -
. O -

Los O -
pacientes O -
de O -
ambos O -
brazos O -
fueron O -
evaluados O -
cada O -
3 O -
semanas. O -

Ciento O -
cuatro O -
pacientes O -
( O -
103 O -
de O -
los O -
cuales O -
eran O -
elegibles O -
para O -
entrar O -
en O -
el O -
estudio O -
) O -
estaban O -
bien O -
equilibrados O -
para O -
los O -
factores O -
de O -
pronóstico O -
. O -

De O -
los O -
84 O -
pacientes O -
con O -
lesiones O -
medibles, O -
seis O -
( O -
7 O -
. O -

1 O -
% O -
) O -
lograron O -
respuestas O -
parciales O -
( O -
tres O -
pacientes O -
en O -
cada O -
nivel O -
de O -
dosis O -
) O -
. O -

El B-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
progresión I-Premise HighQuality
fue I-Premise HighQuality
mayor I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
docetaxel I-Premise HighQuality
que I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
mejor I-Premise HighQuality
tratamiento I-Premise HighQuality
de I-Premise HighQuality
apoyo I-Premise HighQuality
( I-Premise HighQuality
10,6 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
6,7 I-Premise HighQuality
semanas I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
<0,001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
al I-Premise HighQuality
igual I-Premise HighQuality
que I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
( I-Premise HighQuality
7,0 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
4,6 I-Premise HighQuality
meses I-Premise HighQuality
; I-Premise HighQuality
prueba I-Premise HighQuality
de I-Premise HighQuality
rango I-Premise HighQuality
logarítmico I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
=0,047 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
diferencia I-Premise HighQuality
fue I-Premise HighQuality
más I-Premise HighQuality
significativa I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
docetaxel I-Premise HighQuality
75 I-Premise HighQuality
mg/m I-Premise HighQuality
( I-Premise HighQuality
2 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
correspondientes I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
mejor I-Premise HighQuality
tratamiento I-Premise HighQuality
de I-Premise HighQuality
apoyo I-Premise HighQuality
( I-Premise HighQuality
7,5 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
4,6 I-Premise HighQuality
meses I-Premise HighQuality
; I-Premise HighQuality
prueba I-Premise HighQuality
de I-Premise HighQuality
rango I-Premise HighQuality
logarítmico I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
=0,010 I-Premise HighQuality
; I-Premise HighQuality
supervivencia I-Premise HighQuality
a I-Premise HighQuality
un I-Premise HighQuality
año I-Premise HighQuality
, I-Premise HighQuality
37 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
11 I-Premise HighQuality
% I-Premise HighQuality
; I-Premise HighQuality
prueba I-Premise HighQuality
de I-Premise HighQuality
chi I-Premise HighQuality
( I-Premise HighQuality
2 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
=0,003 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
produjo I-Premise HighQuality
neutropenia I-Premise HighQuality
febril I-Premise HighQuality
en I-Premise HighQuality
11 I-Premise HighQuality
pacientes I-Premise HighQuality
tratados I-Premise HighQuality
con I-Premise HighQuality
docetaxel I-Premise HighQuality
100 I-Premise HighQuality
mg/m I-Premise HighQuality
( I-Premise HighQuality
2 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
tres I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
cuales I-Premise HighQuality
murieron, I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
un I-Premise HighQuality
paciente I-Premise HighQuality
tratado I-Premise HighQuality
con I-Premise HighQuality
docetaxel I-Premise HighQuality
75 I-Premise HighQuality
mg/m I-Premise HighQuality
( I-Premise HighQuality
2 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
toxicidad I-Premise HighQuality
no I-Premise HighQuality
hematológica I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
3 I-Premise HighQuality
ó I-Premise HighQuality
4, I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
excepción I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
diarrea, I-Premise HighQuality
se I-Premise HighQuality
produjo I-Premise HighQuality
en I-Premise HighQuality
una I-Premise HighQuality
proporción I-Premise HighQuality
similar I-Premise HighQuality
tanto I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
docetaxel I-Premise HighQuality
como I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
de I-Premise HighQuality
mejor I-Premise HighQuality
tratamiento I-Premise HighQuality
de I-Premise HighQuality
apoyo. I-Premise HighQuality

El B-Claim HighQuality
tratamiento I-Claim HighQuality
con I-Claim HighQuality
docetaxel I-Claim HighQuality
se I-Claim HighQuality
asocia I-Claim HighQuality
a I-Claim HighQuality
una I-Claim HighQuality
prolongación I-Claim HighQuality
significativa I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
supervivencia, I-Claim HighQuality
y O -
a B-Claim HighQuality
una I-Claim HighQuality
dosis I-Claim HighQuality
de I-Claim HighQuality
75 I-Claim HighQuality
mg/m I-Claim HighQuality
( I-Claim HighQuality
2 I-Claim HighQuality
), I-Claim HighQuality
los I-Claim HighQuality
beneficios I-Claim HighQuality
del I-Claim HighQuality
tratamiento I-Claim HighQuality
con I-Claim HighQuality
docetaxel I-Claim HighQuality
superan I-Claim HighQuality
los I-Claim HighQuality
riesgos. I-Claim HighQuality

Se O -
ha O -
demostrado O -
que O -
los O -
programas O -
de O -
recuperación O -
mejorada O -
( O -
ERP O -
) O -
reducen O -
la O -
duración O -
de O -
la O -
estancia O -
hospitalaria O -
( O -
LOS O -
) O -
y O -
las O -
complicaciones O -
en O -
la O -
cirugía O -
colorrectal O -
. O -

No O -
está O -
claro O -
si O -
los O -
ERP O -
tienen O -
los O -
mismos O -
beneficios O -
en O -
la O -
cirugía O -
de O -
resección O -
hepática O -
abierta, O -
y O -
se O -
carece O -
de O -
ensayos O -
clínicos O -
aleatorios. O -

Los O -
pacientes O -
consecutivos O -
programados O -
para O -
una O -
resección O -
hepática O -
abierta O -
fueron O -
asignados O -
aleatoriamente O -
a O -
un O -
grupo O -
de O -
ERP O -
o O -
a O -
la O -
atención O -
estándar O -
. O -

Los O -
criterios O -
de O -
valoración O -
primarios O -
fueron O -
el O -
tiempo O -
hasta O -
el O -
alta O -
médica O -
("MFD") O -
y O -
la O -
estancia O -
en O -
el O -
hospital. O -

Los O -
criterios O -
de O -
valoración O -
secundarios O -
fueron O -
la O -
morbilidad O -
postoperatoria, O -
las O -
puntuaciones O -
de O -
dolor, O -
la O -
tasa O -
de O -
reingreso, O -
la O -
mortalidad, O -
la O -
calidad O -
de O -
vida O -
(QoL) O -
y O -
la O -
satisfacción O -
del O -
paciente. O -

Los O -
elementos O -
de O -
la O -
ERP O -
incluían O -
una O -
mayor O -
educación O -
preoperatoria, O -
carga O -
preoperatoria O -
de O -
carbohidratos O -
por O -
vía O -
oral, O -
fluidoterapia O -
postoperatoria O -
dirigida O -
a O -
objetivos, O -
movilización O -
temprana O -
y O -
fisioterapia. O -

Ambos O -
grupos O -
recibieron O -
anestesia O -
normalizada O -
con O -
analgesia O -
epidural. O -

El O -
análisis O -
incluyó O -
a O -
46 O -
pacientes O -
en O -
el O -
grupo O -
de O -
ERP O -
y O -
a O -
45 O -
en O -
el O -
grupo O -
de O -
atención O -
estándar. O -

La B-Premise HighQuality
mediana I-Premise HighQuality
del I-Premise HighQuality
tiempo I-Premise HighQuality
de I-Premise HighQuality
MFD I-Premise HighQuality
se I-Premise HighQuality
redujo I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
ERP I-Premise HighQuality
( I-Premise HighQuality
3 I-Premise HighQuality
días I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
6 I-Premise HighQuality
días I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
atención I-Premise HighQuality
estándar I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0-001 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
al I-Premise HighQuality
igual I-Premise HighQuality
que I-Premise HighQuality
la I-Premise HighQuality
LOS I-Premise HighQuality
( I-Premise HighQuality
4 I-Premise HighQuality
días I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
7 I-Premise HighQuality
días I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0-001 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
ERP I-Premise HighQuality
redujo I-Premise HighQuality
significativamente I-Premise HighQuality
la I-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
complicaciones I-Premise HighQuality
médicas I-Premise HighQuality
( I-Premise HighQuality
7 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
27% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0-020 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
pero B-Premise HighQuality
no I-Premise HighQuality
las I-Premise HighQuality
complicaciones I-Premise HighQuality
quirúrgicas I-Premise HighQuality
( I-Premise HighQuality
15 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
11% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0-612 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
los I-Premise HighQuality
reingresos I-Premise HighQuality
( I-Premise HighQuality
4 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
0% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0-153 I-Premise HighQuality
) I-Premise HighQuality
o I-Premise HighQuality
la I-Premise HighQuality
mortalidad I-Premise HighQuality
( I-Premise HighQuality
ambos I-Premise HighQuality
2% I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0-987 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
a I-Premise HighQuality
lo I-Premise HighQuality
largo I-Premise HighQuality
de I-Premise HighQuality
28 I-Premise HighQuality
días I-Premise HighQuality
fue I-Premise HighQuality
significativamente I-Premise HighQuality
mejor I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
ERP I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0-002 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
satisfacción I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes. I-Premise HighQuality

Los B-Claim HighQuality
ERP I-Claim HighQuality
para I-Claim HighQuality
la I-Claim HighQuality
cirugía I-Claim HighQuality
de I-Claim HighQuality
resección I-Claim HighQuality
hepática I-Claim HighQuality
abierta I-Claim HighQuality
son I-Claim HighQuality
seguros I-Claim HighQuality
y I-Claim HighQuality
eficaces I-Claim HighQuality
. I-Claim HighQuality

Los B-Claim HighQuality
pacientes I-Claim HighQuality
tratados I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
ERP I-Claim HighQuality
se I-Claim HighQuality
recuperaron I-Claim HighQuality
más I-Claim HighQuality
rápido, I-Claim HighQuality
fueron I-Claim HighQuality
dados I-Claim HighQuality
de I-Claim HighQuality
alta I-Claim HighQuality
antes I-Claim HighQuality
y I-Claim HighQuality
tuvieron I-Claim HighQuality
menos I-Claim HighQuality
complicaciones I-Claim HighQuality
médicas I-Claim HighQuality
y I-Claim HighQuality
una I-Claim HighQuality
mejor I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida. I-Claim HighQuality

Aunque O -
el O -
deterioro O -
cognitivo O -
inducido O -
por O -
la O -
quimioterapia O -
es O -
común O -
entre O -
las O -
pacientes O -
con O -
cáncer O -
de O -
mama, O -
las O -
pruebas O -
de O -
intervenciones O -
eficaces O -
para O -
abordar O -
los O -
déficits O -
cognitivos O -
son O -
limitadas. O -

Este O -
ensayo O -
controlado O -
aleatorio O -
examinó O -
la O -
viabilidad O -
y O -
la O -
eficacia O -
preliminar O -
de O -
un O -
programa O -
de O -
Meditación O -
con O -
Sonido O -
Tibetano O -
( O -
TSM O -
) O -
para O -
mejorar O -
la O -
función O -
cognitiva O -
y O -
la O -
calidad O -
de O -
vida O -
en O -
pacientes O -
con O -
cáncer O -
de O -
mama O -
. O -

Se O -
reclutaron O -
47 O -
pacientes O -
con O -
cáncer O -
de O -
mama O -
( O -
edad O -
media O -
de O -
56,3 O -
años O -
) O -
, O -
que O -
estaban O -
en O -
el O -
estadio O -
I-III O -
en O -
el O -
momento O -
del O -
diagnóstico O -
, O -
entre O -
6 O -
y O -
60 O -
meses O -
después O -
de O -
la O -
quimioterapia O -
, O -
y O -
que O -
informaron O -
de O -
un O -
deterioro O -
cognitivo O -
al O -
inicio O -
del O -
estudio O -
. O -

Los O -
participantes O -
fueron O -
asignados O -
al O -
azar O -
a O -
dos O -
sesiones O -
semanales O -
de O -
TSM O -
durante O -
6 O -
semanas O -
o O -
a O -
un O -
grupo O -
de O -
control O -
en O -
lista O -
de O -
espera. O -

Las O -
evaluaciones O -
neuropsicológicas O -
se O -
completaron O -
al O -
inicio O -
y O -
un O -
mes O -
después O -
del O -
tratamiento. O -

Medidas O -
de O -
autoinforme O -
de O -
la O -
función O -
cognitiva O -
( O -
Evaluación O -
Funcional O -
de O -
la O -
Terapia O -
del O -
Cáncer O -
( O -
FACT O -
) O -
-Cog O -
) O -
, O -
la O -
calidad O -
de O -
vida O -
( O -
SF-36 O -
) O -
, O -
los O -
síntomas O -
depresivos O -
( O -
Escala O -
de O -
Depresión O -
del O -
Centro O -
de O -
Estudios O -
Epidemiológicos O -
) O -
, O -
las O -
alteraciones O -
del O -
sueño O -
( O -
Índice O -
de O -
Calidad O -
del O -
Sueño O -
de O -
Pittsburgh O -
) O -
, O -
la O -
fatiga O -
( O -
Inventario O -
Breve O -
de O -
Fatiga O -
) O -
y O -
la O -
espiritualidad O -
( O -
FACT-Sp O -
) O -
se O -
completaron O -
al O -
inicio O -
, O -
al O -
final O -
del O -
tratamiento O -
y O -
1 O -
mes O -
después O -
. O -

En B-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control, I-Premise HighQuality
las I-Premise HighQuality
mujeres I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
TSM I-Premise HighQuality
obtuvieron I-Premise HighQuality
mejores I-Premise HighQuality
resultados I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
prueba I-Premise HighQuality
de I-Premise HighQuality
memoria I-Premise HighQuality
verbal I-Premise HighQuality
( I-Premise HighQuality
Prueba I-Premise HighQuality
de I-Premise HighQuality
Aprendizaje I-Premise HighQuality
Verbal I-Premise HighQuality
Auditivo I-Premise HighQuality
Rey I-Premise HighQuality
ensayo I-Premise HighQuality
1 I-Premise HighQuality
) I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,06 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
tarea I-Premise HighQuality
de I-Premise HighQuality
memoria I-Premise HighQuality
a I-Premise HighQuality
corto I-Premise HighQuality
plazo I-Premise HighQuality
y I-Premise HighQuality
velocidad I-Premise HighQuality
de I-Premise HighQuality
procesamiento I-Premise HighQuality
( I-Premise HighQuality
Símbolo I-Premise HighQuality
de I-Premise HighQuality
Dígitos I-Premise HighQuality
) I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,09 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
manifestaron I-Premise HighQuality
una I-Premise HighQuality
mejora I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
función I-Premise HighQuality
cognitiva I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,06 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
capacidades I-Premise HighQuality
cognitivas I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,08 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
salud I-Premise HighQuality
mental I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,04 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
espiritualidad I-Premise HighQuality
( I-Premise HighQuality
p I-Premise HighQuality
= I-Premise HighQuality
0,05 I-Premise HighQuality
) I-Premise HighQuality
al I-Premise HighQuality
final I-Premise HighQuality
del I-Premise HighQuality
tratamiento, I-Premise HighQuality
pero I-Premise HighQuality
no I-Premise HighQuality
un I-Premise HighQuality
mes I-Premise HighQuality
después I-Premise HighQuality
. I-Premise HighQuality

Este B-Claim HighQuality
ensayo I-Claim HighQuality
controlado I-Claim HighQuality
aleatorio I-Claim HighQuality
reveló I-Claim HighQuality
que I-Claim HighQuality
el I-Claim HighQuality
programa I-Claim HighQuality
TSM I-Claim HighQuality
parece I-Claim HighQuality
ser I-Claim HighQuality
una I-Claim HighQuality
intervención I-Claim HighQuality
factible I-Claim HighQuality
y I-Claim HighQuality
aceptable I-Claim HighQuality
y I-Claim HighQuality
puede I-Claim HighQuality
estar I-Claim HighQuality
asociado I-Claim HighQuality
con I-Claim HighQuality
mejoras I-Claim HighQuality
a I-Claim HighQuality
corto I-Claim HighQuality
plazo I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
función I-Claim HighQuality
cognitiva I-Claim HighQuality
objetiva I-Claim HighQuality
y I-Claim HighQuality
subjetiva, I-Claim HighQuality
así I-Claim HighQuality
como I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
salud I-Claim HighQuality
mental I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
espiritualidad I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
mama I-Claim HighQuality
. I-Claim HighQuality

La B-Claim HighQuality
elección I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
reconstrucción I-Claim HighQuality
después I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
gastrectomía I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
importancia I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
función I-Claim HighQuality
del I-Claim HighQuality
reservorio I-Claim HighQuality
restante I-Claim HighQuality
es I-Claim HighQuality
un I-Claim HighQuality
tema I-Claim HighQuality
de I-Claim HighQuality
controversia I-Claim HighQuality
. I-Claim HighQuality

Para O -
ampliar O -
los O -
criterios O -
de O -
elección O -
del O -
tratamiento O -
, O -
realizamos O -
un O -
ensayo O -
clínico O -
prospectivo O -
aleatorio O -
para O -
determinar O -
el O -
impacto O -
de O -
varios O -
procedimientos O -
de O -
gastrectomía O -
en O -
la O -
calidad O -
de O -
vida O -
. O -

Los O -
pacientes O -
consecutivos O -
( O -
n O -
= O -
64 O -
) O -
elegibles O -
para O -
la O -
cirugía O -
curativa O -
del O -
cáncer O -
gástrico O -
fueron O -
aleatorizados O -
para O -
someterse O -
a O -
una O -
gastrectomía O -
total O -
( O -
n O -
= O -
31 O -
) O -
o O -
subtotal O -
( O -
n O -
= O -
13 O -
) O -
o O -
a O -
la O -
implantación O -
de O -
una O -
bolsa O -
yeyunal O -
en O -
forma O -
de O -
S O -
( O -
n O -
= O -
20 O -
) O -
como O -
sustituto O -
gástrico O -
. O -

La O -
evaluación O -
de O -
la O -
calidad O -
de O -
vida O -
se O -
basó O -
en O -
una O -
batería O -
de O -
cuestionarios O -
que O -
abarcaban O -
aspectos O -
generales O -
y O -
específicos O -
de O -
la O -
vida O -
. O -

Los O -
pacientes O -
fueron O -
evaluados O -
por O -
uno O -
de O -
los O -
dos O -
psiquiatras O -
que O -
no O -
conocían O -
la O -
afiliación O -
de O -
los O -
pacientes O -
al O -
grupo. O -

Las O -
evaluaciones O -
se O -
realizaron O -
en O -
tres O -
ocasiones: O -
durante O -
la O -
semana O -
anterior O -
a O -
la O -
cirugía O -
y O -
3 O -
y O -
12 O -
meses O -
después O -
de O -
la O -
intervención O -
quirúrgica O -
. O -

Las B-Premise HighQuality
tasas I-Premise HighQuality
de I-Premise HighQuality
complicaciones I-Premise HighQuality
y I-Premise HighQuality
mortalidad I-Premise HighQuality
postoperatorias I-Premise HighQuality
fueron I-Premise HighQuality
similares I-Premise HighQuality
en I-Premise HighQuality
todos I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
tratamiento, I-Premise HighQuality
con I-Premise HighQuality
pocas I-Premise HighQuality
complicaciones I-Premise HighQuality
graves. I-Premise HighQuality

Independientemente B-Premise HighQuality
del I-Premise HighQuality
tipo I-Premise HighQuality
de I-Premise HighQuality
tratamiento, I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
presentaban I-Premise HighQuality
síntomas I-Premise HighQuality
alimentarios I-Premise HighQuality
y I-Premise HighQuality
limitaciones I-Premise HighQuality
funcionales I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
vida I-Premise HighQuality
cotidiana, I-Premise HighQuality
mientras B-Premise HighQuality
que I-Premise HighQuality
su I-Premise HighQuality
bienestar I-Premise HighQuality
mental I-Premise HighQuality
mejoró I-Premise HighQuality
tras I-Premise HighQuality
la I-Premise HighQuality
cirugía. I-Premise HighQuality

Los B-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
se I-Premise HighQuality
sometieron I-Premise HighQuality
a I-Premise HighQuality
una I-Premise HighQuality
gastrectomía I-Premise HighQuality
subtotal I-Premise HighQuality
obtuvieron I-Premise HighQuality
los I-Premise HighQuality
mejores I-Premise HighQuality
resultados, I-Premise HighQuality
especialmente I-Premise HighQuality
en I-Premise HighQuality
lo I-Premise HighQuality
que I-Premise HighQuality
respecta I-Premise HighQuality
a I-Premise HighQuality
las I-Premise HighQuality
quejas I-Premise HighQuality
de I-Premise HighQuality
diarrea. I-Premise HighQuality

Los B-Premise HighQuality
pacientes I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
se I-Premise HighQuality
les I-Premise HighQuality
administró I-Premise HighQuality
un I-Premise HighQuality
sustituto I-Premise HighQuality
gástrico I-Premise HighQuality
después I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
gastrectomía I-Premise HighQuality
no I-Premise HighQuality
mostraron I-Premise HighQuality
diferencias I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
sólo I-Premise HighQuality
se I-Premise HighQuality
sometieron I-Premise HighQuality
a I-Premise HighQuality
una I-Premise HighQuality
gastrectomía I-Premise HighQuality
total I-Premise HighQuality
. I-Premise HighQuality

Concluimos B-Claim HighQuality
que, I-Claim HighQuality
a I-Claim HighQuality
pesar I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
importantes I-Claim HighQuality
consecuencias I-Claim HighQuality
desfavorables I-Claim HighQuality
que I-Claim HighQuality
siguen I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
gastrectomía, I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
se I-Claim HighQuality
recuperan I-Claim HighQuality
con I-Claim HighQuality
una I-Claim HighQuality
mejora I-Claim HighQuality
del I-Claim HighQuality
estado I-Claim HighQuality
mental. I-Claim HighQuality

Una B-Claim HighQuality
reconstrucción I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
bolsa I-Claim HighQuality
después I-Claim HighQuality
de I-Claim HighQuality
una I-Claim HighQuality
gastrectomía I-Claim HighQuality
total I-Claim HighQuality
no I-Claim HighQuality
mejora I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
, I-Claim HighQuality
pero O -
una B-Claim HighQuality
gastrectomía I-Claim HighQuality
subtotal I-Claim HighQuality
tiene I-Claim HighQuality
ventajas I-Claim HighQuality
que I-Claim HighQuality
deben I-Claim HighQuality
ser I-Claim HighQuality
consideradas I-Claim HighQuality
cuando I-Claim HighQuality
el I-Claim HighQuality
procedimiento I-Claim HighQuality
es I-Claim HighQuality
clínicamente I-Claim HighQuality
factible I-Claim HighQuality
. I-Claim HighQuality

Evaluar O -
el O -
efecto O -
de O -
la O -
epoetina O -
alfa O -
sobre O -
la O -
calidad O -
de O -
vida O -
( O -
QOL O -
) O -
en O -
pacientes O -
con O -
tumores O -
sólidos O -
y O -
anemia O -
leve O -
a O -
moderada O -
que O -
reciben O -
quimioterapia O -
basada O -
en O -
platino O -
en O -
relación O -
con O -
las O -
normas O -
de O -
la O -
población O -
. O -

En O -
el O -
estudio O -
original, O -
los O -
pacientes O -
( O -
n O -
= O -
316 O -
) O -
con O -
niveles O -
de O -
hemoglobina O -
( O -
Hb O -
) O -
< O -
o O -
=12,1 O -
g/dl O -
fueron O -
asignados O -
al O -
azar O -
2:1 O -
para O -
recibir O -
epoetina O -
alfa O -
en O -
una O -
dosis O -
de O -
10.000 O -
U O -
tres O -
veces O -
por O -
semana O -
s.c. O -
o O -
el O -
mejor O -
cuidado O -
de O -
apoyo O -
( O -
BSC O -
) O -
para O -
comparar O -
los O -
efectos O -
sobre O -
el O -
uso O -
de O -
transfusiones O -
, O -
la O -
respuesta O -
hematológica O -
y O -
la O -
CdV O -
( O -
medida O -
por O -
la O -
Evaluación O -
Funcional O -
de O -
la O -
Terapia O -
del O -
Cáncer-Anemia O -
[ O -
FACT-An O -
] O -
y O -
la O -
Escala O -
Analógica O -
Lineal O -
del O -
Cáncer O -
[ O -
CLAS O -
] O -
) O -
. O -

Los O -
datos O -
sobre O -
la O -
calidad O -
de O -
vida O -
de O -
este O -
ensayo, O -
ya O -
publicados, O -
se O -
volvieron O -
a O -
analizar O -
aquí O -
en O -
relación O -
con O -
las O -
normas O -
de O -
la O -
población. O -

Las O -
puntuaciones O -
medias O -
de O -
la O -
calidad O -
de O -
vida O -
inicial O -
fueron O -
similares O -
entre O -
los O -
grupos. O -

Al O -
finalizar O -
el O -
estudio, O -
las O -
puntuaciones O -
medias O -
de O -
la O -
CLAS, O -
la O -
FACT-An, O -
la O -
subescala O -
de O -
anemia O -
de O -
la O -
FACT-An O -
y O -
la O -
subescala O -
de O -
fatiga O -
de O -
la O -
FACT-An O -
fueron O -
significativamente O -
mayores O -
en O -
los O -
pacientes O -
que O -
recibieron O -
epoetina O -
alfa O -
que O -
en O -
los O -
tratados O -
con O -
BSC. O -

En O -
comparación O -
con O -
las O -
normas O -
de O -
la O -
población, O -
ambos O -
grupos O -
presentaban O -
un O -
deterioro O -
de O -
la O -
calidad O -
de O -
vida O -
al O -
inicio O -
del O -
estudio. O -

Las B-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
medias I-Premise HighQuality
de I-Premise HighQuality
cambio I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
desde I-Premise HighQuality
el I-Premise HighQuality
inicio I-Premise HighQuality
hasta I-Premise HighQuality
el I-Premise HighQuality
final I-Premise HighQuality
del I-Premise HighQuality
estudio I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
epoetina I-Premise HighQuality
alfa I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
BSC I-Premise HighQuality
fueron I-Premise HighQuality
de I-Premise HighQuality
3,17 I-Premise HighQuality
puntos I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
FACT-Total, I-Premise HighQuality
de I-Premise HighQuality
9,90 I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
subescala I-Premise HighQuality
FACT-An I-Premise HighQuality
de I-Premise HighQuality
Fatiga I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
7,30 I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
subescala I-Premise HighQuality
FACT-An I-Premise HighQuality
de I-Premise HighQuality
Anemia. I-Premise HighQuality

Esto B-Premise HighQuality
fue I-Premise HighQuality
equivalente I-Premise HighQuality
a I-Premise HighQuality
correcciones I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
déficits I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
atribuibles I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
epoetina I-Premise HighQuality
alfa I-Premise HighQuality
del I-Premise HighQuality
97,3% I-Premise HighQuality
, I-Premise HighQuality
el I-Premise HighQuality
40,7% I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
38,0% I-Premise HighQuality
para I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
subescalas I-Premise HighQuality
FACT-General, I-Premise HighQuality
FACT-An I-Premise HighQuality
Fatiga I-Premise HighQuality
y I-Premise HighQuality
FACT-An I-Premise HighQuality
Anemia I-Premise HighQuality
, I-Premise HighQuality
respectivamente, I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
BSC I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
observó I-Premise HighQuality
un I-Premise HighQuality
beneficio I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
algo I-Premise HighQuality
mayor I-Premise HighQuality
para I-Premise HighQuality
las I-Premise HighQuality
subescalas I-Premise HighQuality
FACT-An I-Premise HighQuality
Fatiga I-Premise HighQuality
y I-Premise HighQuality
FACT-An I-Premise HighQuality
Anemia I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
subconjunto I-Premise HighQuality
de I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
niveles I-Premise HighQuality
de I-Premise HighQuality
Hb I-Premise HighQuality
basales I-Premise HighQuality
> I-Premise HighQuality
10,5 I-Premise HighQuality
g/dl I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
pacientes I-Premise HighQuality
de I-Premise HighQuality
este I-Premise HighQuality
estudio I-Premise HighQuality
presentaban I-Premise HighQuality
un I-Premise HighQuality
deterioro I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
las I-Premise HighQuality
normas I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
población. I-Premise HighQuality

El B-Claim HighQuality
tratamiento I-Claim HighQuality
temprano I-Claim HighQuality
con I-Claim HighQuality
epoetina I-Claim HighQuality
alfa I-Claim HighQuality
para I-Claim HighQuality
corregir I-Claim HighQuality
la I-Claim HighQuality
anemia I-Claim HighQuality
mejoró I-Claim HighQuality
la I-Claim HighQuality
CdV I-Claim HighQuality
de I-Claim HighQuality
forma I-Claim HighQuality
estadísticamente I-Claim HighQuality
significativa I-Claim HighQuality
y I-Claim HighQuality
clínicamente I-Claim HighQuality
significativa I-Claim HighQuality
, I-Claim HighQuality
y I-Claim HighQuality
las I-Claim HighQuality
mejoras I-Claim HighQuality
fueron I-Claim HighQuality
mayores I-Claim HighQuality
en I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
niveles I-Claim HighQuality
basales I-Claim HighQuality
de I-Claim HighQuality
Hb I-Claim HighQuality
> I-Claim HighQuality
10,5 I-Claim HighQuality
g/dl I-Claim HighQuality
. I-Claim HighQuality

Observar O -
el O -
efecto O -
del O -
régimen O -
integral O -
de O -
la O -
medicina O -
china O -
( O -
CM O -
) O -
como O -
terapia O -
de O -
mantenimiento O -
( O -
MT O -
) O -
en O -
el O -
tiempo O -
hasta O -
la O -
progresión O -
( O -
TTP O -
) O -
y O -
la O -
calidad O -
de O -
vida O -
( O -
QOL O -
) O -
de O -
los O -
pacientes O -
con O -
cáncer O -
de O -
pulmón O -
no O -
microcítico O -
avanzado O -
( O -
NSCLC O -
) O -
. O -

El O -
estudio O -
fue O -
un O -
ensayo O -
clínico O -
prospectivo, O -
aleatorio O -
y O -
controlado. O -

Cincuenta O -
pacientes O -
no O -
progresivos O -
con O -
CPNM O -
avanzado O -
que O -
respondieron O -
a O -
la O -
terapia O -
de O -
primera O -
línea O -
fueron O -
distribuidos O -
aleatoriamente O -
en O -
el O -
grupo O -
de O -
prueba O -
( O -
25 O -
casos O -
, O -
tratados O -
con O -
un O -
régimen O -
integral O -
de O -
CM O -
: O -
goteo O -
intravenoso O -
de O -
la O -
preparación O -
de O -
hierbas O -
chinas O -
, O -
la O -
administración O -
oral O -
de O -
la O -
decocción O -
de O -
hierbas O -
chinas O -
, O -
y O -
la O -
aplicación O -
de O -
puntos O -
) O -
y O -
el O -
grupo O -
de O -
control O -
[ O -
25 O -
casos O -
, O -
tratados O -
con O -
uno O -
de O -
los O -
tres O -
regímenes O -
de O -
quimioterapia O -
de O -
mantenimiento O -
de O -
un O -
solo O -
agente O -
: O -
pemetrexed O -
( O -
500 O -
mg/m2 O -
, O -
día O -
1 O -
) O -
, O -
docetaxel O -
( O -
75 O -
mg/m2 O -
, O -
día O -
1 O -
) O -
, O -
y O -
gemcitabina O -
( O -
1000 O -
mg/mi O -
, O -
día O -
1 O -
y O -
día O -
8 O -
) O -
en O -
la O -
proporción O -
de O -
1:1 O -
] O -
. O -

Cada O -
ciclo O -
constaba O -
de O -
21 O -
días. O -

Los O -
ciclos O -
se O -
repitieron O -
hasta O -
que O -
la O -
enfermedad O -
progresó, O -
o O -
se O -
produjeron O -
reacciones O -
tóxicas O -
o O -
adversas O -
intolerables, O -
o O -
los O -
pacientes O -
se O -
negaron O -
a O -
continuar O -
el O -
tratamiento. O -

El O -
criterio O -
de O -
valoración O -
primario O -
fue O -
el O -
TTP O -
y O -
el O -
secundario, O -
la O -
calidad O -
de O -
vida. O -

La O -
calidad O -
de O -
vida O -
se O -
evaluó O -
mediante O -
el O -
cuestionario O -
de O -
calidad O -
de O -
vida O -
QLQ-LC43 O -
de O -
la O -
Organización O -
Europea O -
para O -
la O -
Investigación O -
y O -
el O -
Tratamiento O -
del O -
Cáncer O -
( O -
EORTC O -
QLQ-LC43 O -
) O -
. O -

Se O -
han O -
analizado O -
estadísticamente O -
el O -
TTP O -
de O -
cincuenta O -
pacientes O -
y O -
la O -
CdV O -
de O -
43 O -
pacientes. O -

( O -
1 O -
) O -
El B-Premise HighQuality
TTP I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
prueba I-Premise HighQuality
se I-Premise HighQuality
prolongó I-Premise HighQuality
durante I-Premise HighQuality
23 I-Premise HighQuality
días I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
, I-Premise HighQuality
con I-Premise HighQuality
una I-Premise HighQuality
diferencia I-Premise HighQuality
insignificante I-Premise HighQuality
( I-Premise HighQuality
87 I-Premise HighQuality
días I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
64 I-Premise HighQuality
días I-Premise HighQuality
, I-Premise HighQuality
P=0,063 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

( O -
2 O -
) O -
Las B-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
dominios I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
EORTC I-Premise HighQuality
QLQ-LC43 I-Premise HighQuality
fueron I-Premise HighQuality
significativamente I-Premise HighQuality
mejores I-Premise HighQuality
desde I-Premise HighQuality
el I-Premise HighQuality
punto I-Premise HighQuality
de I-Premise HighQuality
vista I-Premise HighQuality
estadístico I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
prueba I-Premise HighQuality
que I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,05 I-Premise HighQuality
) I-Premise HighQuality
excepto B-Premise HighQuality
las I-Premise HighQuality
funciones I-Premise HighQuality
cognitivas I-Premise HighQuality
y I-Premise HighQuality
sociales I-Premise HighQuality
, I-Premise HighQuality
los I-Premise HighQuality
síntomas I-Premise HighQuality
de I-Premise HighQuality
disfagia I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
dolor I-Premise HighQuality
en I-Premise HighQuality
otras I-Premise HighQuality
partes I-Premise HighQuality
. I-Premise HighQuality

( O -
1 O -
) O -
El B-Claim HighQuality
régimen I-Claim HighQuality
integral I-Claim HighQuality
de I-Claim HighQuality
CM I-Claim HighQuality
como I-Claim HighQuality
MT I-Claim HighQuality
tuvo I-Claim HighQuality
una I-Claim HighQuality
eficacia I-Claim HighQuality
equivalente I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
TTP I-Claim HighQuality
cuando I-Claim HighQuality
se I-Claim HighQuality
comparó I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
régimen I-Claim HighQuality
de I-Claim HighQuality
quimioterapia I-Claim HighQuality
de I-Claim HighQuality
mantenimiento I-Claim HighQuality
con I-Claim HighQuality
un I-Claim HighQuality
solo I-Claim HighQuality
agente I-Claim HighQuality
. I-Claim HighQuality

Era B-Claim HighQuality
ventajoso I-Claim HighQuality
respecto I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
mejora I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida. I-Claim HighQuality

( O -
2 O -
) O -
Es B-Claim HighQuality
necesario I-Claim HighQuality
ampliar I-Claim HighQuality
el I-Claim HighQuality
tamaño I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
muestra I-Claim HighQuality
para I-Claim HighQuality
confirmar I-Claim HighQuality
aún I-Claim HighQuality
más I-Claim HighQuality
la I-Claim HighQuality
eficacia I-Claim HighQuality
terapéutica I-Claim HighQuality
del I-Claim HighQuality
régimen I-Claim HighQuality
integral I-Claim HighQuality
de I-Claim HighQuality
CM I-Claim HighQuality
como I-Claim HighQuality
MT I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
CPNM I-Claim HighQuality
avanzado I-Claim HighQuality
. I-Claim HighQuality

La O -
proctocolectomía O -
restauradora O -
con O -
anastomosis O -
ileal O -
( O -
IPAA O -
) O -
es O -
el O -
procedimiento O -
quirúrgico O -
estándar O -
para O -
la O -
colitis O -
ulcerosa O -
( O -
CU O -
) O -
y O -
la O -
poliposis O -
adenomatosa O -
familiar O -
( O -
PAF O -
) O -
. O -

Aunque O -
las O -
técnicas O -
mínimamente O -
invasivas O -
se O -
han O -
aplicado O -
cada O -
vez O -
más, O -
todavía O -
no O -
se O -
dispone O -
de O -
pruebas O -
claras O -
de O -
la O -
superioridad O -
de O -
los O -
procedimientos O -
laparoscópicos O -
de O -
bolsa. O -

El O -
objetivo O -
del O -
ensayo O -
LapConPouch O -
fue O -
comparar O -
la O -
eficacia O -
del O -
procedimiento O -
de O -
bolsa O -
ileoanal O -
laparoscópica O -
( O -
LAP O -
) O -
frente O -
al O -
convencional O -
( O -
CON O -
) O -
en O -
pacientes O -
sometidos O -
a O -
proctocolectomía O -
restauradora O -
electiva O -
. O -

El O -
ensayo O -
se O -
diseñó O -
como O -
un O -
ensayo O -
controlado, O -
aleatorizado O -
y O -
preoperatorio O -
en O -
un O -
solo O -
centro, O -
utilizando O -
un O -
diseño O -
de O -
superioridad O -
paralelo O -
de O -
dos O -
grupos. O -

Los O -
pacientes O -
programados O -
para O -
una O -
proctocolectomía O -
reparadora O -
por O -
PAF O -
o O -
por O -
CU O -
fueron O -
elegibles O -
para O -
participar. O -

Los O -
pacientes O -
y O -
los O -
evaluadores O -
de O -
resultados O -
no O -
conocían O -
la O -
asignación O -
de O -
grupos. O -

El O -
criterio O -
de O -
valoración O -
primario O -
se O -
definió O -
como O -
la O -
cantidad O -
de O -
pérdida O -
de O -
sangre O -
. O -

Los O -
análisis O -
estadísticos O -
fueron O -
exploratorios, O -
ya O -
que O -
el O -
ensayo O -
tuvo O -
que O -
interrumpirse O -
prematuramente. O -

Un O -
total O -
de O -
42 O -
pacientes O -
( O -
21 O -
LAP O -
( O -
50,0 O -
% O -
) O -
; O -
21 O -
CON O -
( O -
50,0 O -
% O -
) O -
) O -
fueron O -
aleatorizados O -
. O -

El B-Premise HighQuality
ensayo I-Premise HighQuality
tuvo I-Premise HighQuality
que I-Premise HighQuality
interrumpirse I-Premise HighQuality
prematuramente I-Premise HighQuality
debido I-Premise HighQuality
a I-Premise HighQuality
que I-Premise HighQuality
el I-Premise HighQuality
reclutamiento I-Premise HighQuality
de I-Premise HighQuality
pacientes I-Premise HighQuality
fue I-Premise HighQuality
insuficiente. I-Premise HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
cantidad I-Premise HighQuality
de I-Premise HighQuality
pérdida I-Premise HighQuality
de I-Premise HighQuality
sangre I-Premise HighQuality
entre I-Premise HighQuality
ambos I-Premise HighQuality
grupos: I-Premise HighQuality
LAP I-Premise HighQuality
261,5 I-Premise HighQuality
± I-Premise HighQuality
195,4 I-Premise HighQuality
ml I-Premise HighQuality
, I-Premise HighQuality
CON I-Premise HighQuality
228,1 I-Premise HighQuality
± I-Premise HighQuality
119,5 I-Premise HighQuality
ml I-Premise HighQuality
. I-Premise HighQuality

Los O -
criterios O -
de O -
valoración O -
secundarios O -
difieren O -
en O -
ambos O -
grupos. O -

La B-Claim HighQuality
cirugía I-Claim HighQuality
laparoscópica I-Claim HighQuality
fue I-Claim HighQuality
superior I-Claim HighQuality
en I-Claim HighQuality
cuanto I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
longitud I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
incisión I-Claim HighQuality
cutánea; I-Claim HighQuality
en O -
cambio, O -
el B-Claim HighQuality
enfoque I-Claim HighQuality
convencional I-Claim HighQuality
fue I-Claim HighQuality
superior I-Claim HighQuality
en I-Claim HighQuality
cuanto I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
duración I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
operación. I-Claim HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
discrepancias I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
duración I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
estancia I-Premise HighQuality
hospitalaria, I-Premise HighQuality
el I-Premise HighQuality
dolor I-Premise HighQuality
postoperatorio, I-Premise HighQuality
la I-Premise HighQuality
función I-Premise HighQuality
intestinal I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
entre I-Premise HighQuality
ambos I-Premise HighQuality
enfoques. I-Premise HighQuality

La O -
tasa O -
de O -
conversión O -
del O -
enfoque O -
LAP O -
al O -
CON O -
fue O -
del O -
23,8%. O -

No B-Claim HighQuality
hubo I-Claim HighQuality
diferencias I-Claim HighQuality
con I-Claim HighQuality
respecto I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
pérdida I-Claim HighQuality
de I-Claim HighQuality
sangre I-Claim HighQuality
entre I-Claim HighQuality
el I-Claim HighQuality
grupo I-Claim HighQuality
LAP I-Claim HighQuality
y I-Claim HighQuality
el I-Claim HighQuality
grupo I-Claim HighQuality
CON I-Claim HighQuality
. I-Claim HighQuality

El B-Claim HighQuality
enfoque I-Claim HighQuality
LAP I-Claim HighQuality
es I-Claim HighQuality
factible I-Claim HighQuality
para I-Claim HighQuality
la I-Claim HighQuality
proctocolectomía I-Claim HighQuality
restauradora I-Claim HighQuality
, I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
IPAA I-Claim HighQuality
parece I-Claim HighQuality
al I-Claim HighQuality
menos I-Claim HighQuality
tan I-Claim HighQuality
segura I-Claim HighQuality
como I-Claim HighQuality
la I-Claim HighQuality
cirugía I-Claim HighQuality
CON I-Claim HighQuality
. I-Claim HighQuality

La O -
ventaja O -
más O -
evidente O -
de O -
la O -
técnica O -
mínimamente O -
invasiva O -
es O -
la O -
mejora O -
de O -
la O -
cosmética. O -

Este O -
análisis O -
de O -
los O -
resultados O -
de O -
un O -
ensayo O -
aleatorio O -
y O -
controlado O -
que O -
evalúa O -
los O -
efectos O -
del O -
tratamiento O -
con O -
epoetina O -
alfa O -
( O -
EPO O -
) O -
sobre O -
las O -
necesidades O -
de O -
transfusión, O -
la O -
hemoglobina O -
( O -
Hb O -
) O -
y O -
la O -
calidad O -
de O -
vida O -
( O -
QOL O -
) O -
en O -
pacientes O -
con O -
cáncer O -
que O -
reciben O -
quimioterapia O -
basada O -
en O -
el O -
platino O -
se O -
realizó O -
para O -
evaluar O -
el O -
efecto O -
del O -
nivel O -
inicial O -
de O -
Hb O -
en O -
los O -
resultados O -
del O -
estudio O -
. O -

Los O -
pacientes O -
con O -
niveles O -
de O -
Hb O -
< O -
o O -
=12,1 O -
g/dl O -
fueron O -
aleatorizados O -
2:1 O -
para O -
recibir O -
EPO O -
, O -
10.000 O -
U O -
tres O -
veces O -
por O -
semana O -
s.c. O -
o O -
el O -
mejor O -
cuidado O -
de O -
apoyo O -
( O -
BSC O -
) O -
hasta O -
4 O -
semanas O -
después O -
de O -
su O -
último O -
ciclo O -
de O -
quimioterapia O -
. O -

Para O -
este O -
análisis, O -
se O -
estratificó O -
a O -
los O -
pacientes O -
según O -
el O -
nivel O -
inicial O -
de O -
Hb O -
( O -
< O -
o O -
=9,7 O -
g/dl O -
, O -
> O -
9,7 O -
g/dl O -
a O -
< O -
o O -
=10,5 O -
g/dl O -
, O -
> O -
10,5 O -
g/dl O -
a O -
< O -
o O -
=11,3 O -
g/dl O -
, O -
y O -
> O -
11,3 O -
g/dl O -
a O -
< O -
o O -
=12,1 O -
g/dl O -
) O -
y O -
se O -
volvieron O -
a O -
analizar O -
los O -
resultados O -
del O -
estudio. O -

Un B-Premise HighQuality
número I-Premise HighQuality
significativamente I-Premise HighQuality
menor I-Premise HighQuality
de I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
EPO I-Premise HighQuality
que I-Premise HighQuality
con I-Premise HighQuality
BSC I-Premise HighQuality
con I-Premise HighQuality
niveles I-Premise HighQuality
iniciales I-Premise HighQuality
de I-Premise HighQuality
Hb I-Premise HighQuality
> I-Premise HighQuality
9,7 I-Premise HighQuality
g/dl I-Premise HighQuality
a I-Premise HighQuality
< I-Premise HighQuality
o I-Premise HighQuality
=12,1 I-Premise HighQuality
g/dl I-Premise HighQuality
requirieron I-Premise HighQuality
transfusiones I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
EPO I-Premise HighQuality
mantuvo I-Premise HighQuality
los I-Premise HighQuality
niveles I-Premise HighQuality
de I-Premise HighQuality
Hb I-Premise HighQuality
a I-Premise HighQuality
lo I-Premise HighQuality
largo I-Premise HighQuality
del I-Premise HighQuality
estudio I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
niveles I-Premise HighQuality
de I-Premise HighQuality
Hb I-Premise HighQuality
> I-Premise HighQuality
11,3 I-Premise HighQuality
g/dl I-Premise HighQuality
a I-Premise HighQuality
< I-Premise HighQuality
o I-Premise HighQuality
=12,1 I-Premise HighQuality
g/dl I-Premise HighQuality
, I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
una I-Premise HighQuality
disminución I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
BSC I-Premise HighQuality
. I-Premise HighQuality

Para B-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
niveles I-Premise HighQuality
basales I-Premise HighQuality
de I-Premise HighQuality
Hb I-Premise HighQuality
> I-Premise HighQuality
10,5 I-Premise HighQuality
g/dl I-Premise HighQuality
, I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
se I-Premise HighQuality
midieron I-Premise HighQuality
los I-Premise HighQuality
cambios I-Premise HighQuality
medios I-Premise HighQuality
desde I-Premise HighQuality
el I-Premise HighQuality
punto I-Premise HighQuality
de I-Premise HighQuality
partida I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
última I-Premise HighQuality
evaluación I-Premise HighQuality
mediante I-Premise HighQuality
las I-Premise HighQuality
evaluaciones I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
Escala I-Premise HighQuality
Analógica I-Premise HighQuality
Lineal I-Premise HighQuality
del I-Premise HighQuality
Cáncer I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
energía I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
general, I-Premise HighQuality
así I-Premise HighQuality
como I-Premise HighQuality
mediante I-Premise HighQuality
la I-Premise HighQuality
Evaluación I-Premise HighQuality
Funcional I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
Terapia I-Premise HighQuality
del I-Premise HighQuality
Cáncer I-Premise HighQuality
( I-Premise HighQuality
FACT I-Premise HighQuality
) I-Premise HighQuality
-Fatiga I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
subescala I-Premise HighQuality
FACT-Anemia I-Premise HighQuality
, I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
fueron I-Premise HighQuality
significativamente I-Premise HighQuality
mayores I-Premise HighQuality
con I-Premise HighQuality
EPO I-Premise HighQuality
que I-Premise HighQuality
con I-Premise HighQuality
BSC I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
CdV I-Premise HighQuality
disminuyó I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
BSC I-Premise HighQuality
, I-Premise HighQuality
y O -
las B-Premise HighQuality
disminuciones I-Premise HighQuality
medias I-Premise HighQuality
en I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
CdV I-Premise HighQuality
fueron I-Premise HighQuality
mayores I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
de I-Premise HighQuality
BSC I-Premise HighQuality
con I-Premise HighQuality
niveles I-Premise HighQuality
basales I-Premise HighQuality
de I-Premise HighQuality
Hb I-Premise HighQuality
> I-Premise HighQuality
10,5 I-Premise HighQuality
g/dl I-Premise HighQuality
, I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
general I-Premise HighQuality
de I-Premise HighQuality
BSC I-Premise HighQuality
. I-Premise HighQuality

En B-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
que I-Claim HighQuality
reciben I-Claim HighQuality
quimioterapia I-Claim HighQuality
basada I-Claim HighQuality
en I-Claim HighQuality
platino I-Claim HighQuality
y I-Claim HighQuality
con I-Claim HighQuality
niveles I-Claim HighQuality
de I-Claim HighQuality
Hb I-Claim HighQuality
basales I-Claim HighQuality
> I-Claim HighQuality
10,5 I-Claim HighQuality
g/dl I-Claim HighQuality
, I-Claim HighQuality
la I-Claim HighQuality
intervención I-Claim HighQuality
temprana I-Claim HighQuality
con I-Claim HighQuality
EPO I-Claim HighQuality
reduce I-Claim HighQuality
las I-Claim HighQuality
transfusiones I-Claim HighQuality
, I-Claim HighQuality
mantiene I-Claim HighQuality
el I-Claim HighQuality
nivel I-Claim HighQuality
de I-Claim HighQuality
Hb I-Claim HighQuality
, I-Claim HighQuality
y I-Claim HighQuality
mantiene I-Claim HighQuality
o I-Claim HighQuality
mejora I-Claim HighQuality
la I-Claim HighQuality
CdV I-Claim HighQuality
. I-Claim HighQuality

Este B-Claim HighQuality
estudio I-Claim HighQuality
apoya I-Claim HighQuality
los I-Claim HighQuality
efectos I-Claim HighQuality
positivos I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
intervención I-Claim HighQuality
temprana I-Claim HighQuality
cuando I-Claim HighQuality
se I-Claim HighQuality
analiza I-Claim HighQuality
según I-Claim HighQuality
el I-Claim HighQuality
valor I-Claim HighQuality
inicial I-Claim HighQuality
de I-Claim HighQuality
Hb I-Claim HighQuality
. I-Claim HighQuality

Se B-Claim HighQuality
desconoce I-Claim HighQuality
hasta I-Claim HighQuality
qué I-Claim HighQuality
punto I-Claim HighQuality
la I-Claim HighQuality
quimioterapia I-Claim HighQuality
puede I-Claim HighQuality
aliviar I-Claim HighQuality
los I-Claim HighQuality
síntomas I-Claim HighQuality
relacionados I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
tumor, I-Claim HighQuality
mejorar I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
y I-Claim HighQuality
prolongar I-Claim HighQuality
la I-Claim HighQuality
supervivencia I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
gástrico, I-Claim HighQuality
a I-Claim HighQuality
pesar I-Claim HighQuality
del I-Claim HighQuality
amplio I-Claim HighQuality
uso I-Claim HighQuality
de I-Claim HighQuality
esta I-Claim HighQuality
modalidad I-Claim HighQuality
de I-Claim HighQuality
tratamiento. I-Claim HighQuality

El O -
objetivo O -
de O -
este O -
estudio O -
era O -
estimar O -
la O -
ganancia O -
en O -
cantidad O -
y O -
calidad O -
de O -
vida O -
que O -
produce O -
la O -
quimioterapia O -
en O -
estos O -
pacientes O -
. O -

Entre O -
enero O -
de O -
1991 O -
y O -
febrero O -
de O -
1995, O -
61 O -
pacientes O -
con O -
cáncer O -
gástrico O -
fueron O -
asignados O -
aleatoriamente O -
a O -
quimioterapia O -
además O -
de O -
los O -
mejores O -
cuidados O -
de O -
apoyo O -
o O -
a O -
los O -
mejores O -
cuidados O -
de O -
apoyo. O -

En O -
este O -
último O -
grupo O -
se O -
permitió O -
la O -
quimioterapia O -
si O -
las O -
medidas O -
de O -
apoyo O -
no O -
conducían O -
a O -
la O -
paliación O -
. O -

La O -
quimioterapia O -
fue O -
el O -
régimen O -
ELF, O -
consistente O -
en O -
5-fluorouracilo, O -
leucovorina O -
y O -
etopósido, O -
o, O -
en O -
los O -
pacientes O -
de O -
edad O -
avanzada O -
y O -
con O -
bajo O -
rendimiento, O -
un O -
régimen O -
de O -
5-fluorouracilo/leucovorina O -
( O -
FLv O -
) O -
. O -

La O -
calidad O -
de O -
vida O -
se O -
evaluó O -
con O -
el O -
instrumento O -
EORTC-QLQ-C30 O -
. O -

Más B-Premise HighQuality
pacientes I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
quimioterapia I-Premise HighQuality
( I-Premise HighQuality
45 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
14/31 I-Premise HighQuality
) I-Premise HighQuality
tuvieron I-Premise HighQuality
una I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
mejorada I-Premise HighQuality
o I-Premise HighQuality
prolongada I-Premise HighQuality
durante I-Premise HighQuality
un I-Premise HighQuality
periodo I-Premise HighQuality
mínimo I-Premise HighQuality
de I-Premise HighQuality
4 I-Premise HighQuality
meses I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
mejores I-Premise HighQuality
cuidados I-Premise HighQuality
de I-Premise HighQuality
apoyo I-Premise HighQuality
( I-Premise HighQuality
20 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
6/30 I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,05 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
observó I-Premise HighQuality
una I-Premise HighQuality
diferencia I-Premise HighQuality
similar I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
evaluación I-Premise HighQuality
del I-Premise HighQuality
médico I-Premise HighQuality
tratante I-Premise HighQuality
sobre I-Premise HighQuality
si I-Premise HighQuality
el I-Premise HighQuality
paciente I-Premise HighQuality
había I-Premise HighQuality
mejorado I-Premise HighQuality
subjetivamente I-Premise HighQuality
o I-Premise HighQuality
seguía I-Premise HighQuality
estando I-Premise HighQuality
bien I-Premise HighQuality
durante I-Premise HighQuality
al I-Premise HighQuality
menos I-Premise HighQuality
4 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
17/31 I-Premise HighQuality
, I-Premise HighQuality
55 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
6/30 I-Premise HighQuality
, I-Premise HighQuality
20 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,01 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
fue I-Premise HighQuality
mayor I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
quimioterapia I-Premise HighQuality
( I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
8 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
5 I-Premise HighQuality
meses I-Premise HighQuality
) I-Premise HighQuality
aunque B-Premise HighQuality
la I-Premise HighQuality
diferencia I-Premise HighQuality
no I-Premise HighQuality
fue I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativa I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,12 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Sin B-Premise HighQuality
embargo, I-Premise HighQuality
tras I-Premise HighQuality
las I-Premise HighQuality
correcciones I-Premise HighQuality
por I-Premise HighQuality
desequilibrios I-Premise HighQuality
en I-Premise HighQuality
las I-Premise HighQuality
características I-Premise HighQuality
previas I-Premise HighQuality
al I-Premise HighQuality
tratamiento, I-Premise HighQuality
el I-Premise HighQuality
tratamiento I-Premise HighQuality
con I-Premise HighQuality
quimioterapia I-Premise HighQuality
se I-Premise HighQuality
asoció I-Premise HighQuality
con I-Premise HighQuality
un I-Premise HighQuality
beneficio I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,003 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Además, B-Premise HighQuality
el I-Premise HighQuality
tiempo I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
ajustado I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
progresión I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
fueron I-Premise HighQuality
más I-Premise HighQuality
largos I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asignados I-Premise HighQuality
al I-Premise HighQuality
azar I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
quimioterapia I-Premise HighQuality
( I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
5 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
2 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,03 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Los B-Claim HighQuality
resultados I-Claim HighQuality
muestran I-Claim HighQuality
que I-Claim HighQuality
la I-Claim HighQuality
quimioterapia I-Claim HighQuality
puede I-Claim HighQuality
aumentar I-Claim HighQuality
la I-Claim HighQuality
cantidad I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
en I-Claim HighQuality
el I-Claim HighQuality
cáncer I-Claim HighQuality
gástrico I-Claim HighQuality
avanzado. I-Claim HighQuality

Sin B-Claim HighQuality
embargo, I-Claim HighQuality
el I-Claim HighQuality
número I-Claim HighQuality
de I-Claim HighQuality
pacientes I-Claim HighQuality
que I-Claim HighQuality
se I-Claim HighQuality
benefician I-Claim HighQuality
del I-Claim HighQuality
tratamiento I-Claim HighQuality
es I-Claim HighQuality
todavía I-Claim HighQuality
bastante I-Claim HighQuality
limitado. I-Claim HighQuality

La B-Claim HighQuality
colectomía I-Claim HighQuality
asistida I-Claim HighQuality
por I-Claim HighQuality
laparoscopia I-Claim HighQuality
( I-Claim HighQuality
LAC I-Claim HighQuality
) I-Claim HighQuality
ha I-Claim HighQuality
surgido I-Claim HighQuality
como I-Claim HighQuality
la I-Claim HighQuality
estrategia I-Claim HighQuality
quirúrgica I-Claim HighQuality
mínimamente I-Claim HighQuality
invasiva I-Claim HighQuality
preferida I-Claim HighQuality
para I-Claim HighQuality
las I-Claim HighQuality
enfermedades I-Claim HighQuality
del I-Claim HighQuality
colon I-Claim HighQuality
. I-Claim HighQuality

Se B-Claim HighQuality
desconocen I-Claim HighQuality
la I-Claim HighQuality
seguridad I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
eficacia I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
CAV I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
colon, I-Claim HighQuality
así O -
como O -
la B-Claim HighQuality
naturaleza I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
magnitud I-Claim HighQuality
de I-Claim HighQuality
cualquier I-Claim HighQuality
beneficio I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
( I-Claim HighQuality
QOL I-Claim HighQuality
) I-Claim HighQuality
resultante I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
CAV I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
colon. I-Claim HighQuality

Comparar O -
los O -
resultados O -
de O -
la O -
calidad O -
de O -
vida O -
a O -
corto O -
plazo O -
después O -
de O -
la O -
LAC O -
frente O -
a O -
la O -
colectomía O -
abierta O -
para O -
el O -
cáncer O -
de O -
colon. O -

Ensayo O -
controlado O -
multicéntrico O -
y O -
aleatorizado O -
( O -
Clinical O -
Outcomes O -
of O -
Surgical O -
Therapy O -
[ O -
COST O -
] O -
) O -
. O -

Entre O -
septiembre O -
de O -
1994 O -
y O -
febrero O -
de O -
1999, O -
37 O -
de O -
48 O -
centros O -
proporcionaron O -
datos O -
para O -
el O -
componente O -
de O -
calidad O -
de O -
vida O -
del O -
ensayo O -
para O -
449 O -
pacientes O -
consecutivos O -
con O -
cáncer O -
de O -
colon O -
clínicamente O -
resecable. O -

Puntuaciones O -
en O -
la O -
Escala O -
de O -
Sintomatología O -
( O -
SDS O -
) O -
, O -
Índice O -
de O -
Calidad O -
de O -
Vida O -
, O -
y O -
una O -
escala O -
de O -
calificación O -
global O -
de O -
un O -
solo O -
ítem O -
a O -
los O -
2 O -
días O -
, O -
2 O -
semanas O -
y O -
2 O -
meses O -
del O -
postoperatorio O -
; O -
duración O -
del O -
uso O -
de O -
analgésicos O -
postoperatorios O -
en O -
el O -
hospital O -
; O -
y O -
duración O -
de O -
la O -
estancia O -
. O -

De O -
449 O -
pacientes, O -
428 O -
proporcionaron O -
datos O -
sobre O -
la O -
calidad O -
de O -
vida. O -

En B-Premise HighQuality
un I-Premise HighQuality
análisis I-Premise HighQuality
por I-Premise HighQuality
intención I-Premise HighQuality
de I-Premise HighQuality
tratar I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
que I-Premise HighQuality
se I-Premise HighQuality
compararon I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
intensidad I-Premise HighQuality
del I-Premise HighQuality
dolor I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SDS, I-Premise HighQuality
el I-Premise HighQuality
resumen I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SDS, I-Premise HighQuality
el I-Premise HighQuality
resumen I-Premise HighQuality
del I-Premise HighQuality
índice I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
escala I-Premise HighQuality
de I-Premise HighQuality
calificación I-Premise HighQuality
global I-Premise HighQuality
en I-Premise HighQuality
cada I-Premise HighQuality
punto I-Premise HighQuality
temporal, I-Premise HighQuality
la I-Premise HighQuality
única I-Premise HighQuality
diferencia I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativa I-Premise HighQuality
observada I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
fue I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
escala I-Premise HighQuality
de I-Premise HighQuality
calificación I-Premise HighQuality
global I-Premise HighQuality
a I-Premise HighQuality
las I-Premise HighQuality
2 I-Premise HighQuality
semanas I-Premise HighQuality
del I-Premise HighQuality
postoperatorio. I-Premise HighQuality

Las B-Premise HighQuality
puntuaciones I-Premise HighQuality
medias I-Premise HighQuality
( I-Premise HighQuality
mediana I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
escala I-Premise HighQuality
de I-Premise HighQuality
valoración I-Premise HighQuality
global I-Premise HighQuality
a I-Premise HighQuality
las I-Premise HighQuality
2 I-Premise HighQuality
semanas I-Premise HighQuality
del I-Premise HighQuality
postoperatorio I-Premise HighQuality
fueron I-Premise HighQuality
de I-Premise HighQuality
76,9 I-Premise HighQuality
( I-Premise HighQuality
80 I-Premise HighQuality
) I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
LAC I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
74,4 I-Premise HighQuality
( I-Premise HighQuality
75 I-Premise HighQuality
) I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
colectomía I-Premise HighQuality
abierta I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,009 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Durante B-Premise HighQuality
su I-Premise HighQuality
estancia I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
hospital, I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asignados I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
CAV I-Premise HighQuality
necesitaron I-Premise HighQuality
menos I-Premise HighQuality
días I-Premise HighQuality
de I-Premise HighQuality
analgésicos I-Premise HighQuality
parenterales I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
asignados I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
colectomía I-Premise HighQuality
abierta I-Premise HighQuality
( I-Premise HighQuality
media I-Premise HighQuality
[ I-Premise HighQuality
mediana I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
3,2 I-Premise HighQuality
[ I-Premise HighQuality
3 I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
4,0 I-Premise HighQuality
[ I-Premise HighQuality
4 I-Premise HighQuality
] I-Premise HighQuality
días I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
< I-Premise HighQuality
0,001 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
analgésicos I-Premise HighQuality
orales I-Premise HighQuality
( I-Premise HighQuality
media I-Premise HighQuality
[ I-Premise HighQuality
mediana I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
1,9 I-Premise HighQuality
[ I-Premise HighQuality
1 I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
2,2 I-Premise HighQuality
[ I-Premise HighQuality
2 I-Premise HighQuality
] I-Premise HighQuality
días I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,03 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Sólo B-Claim HighQuality
se I-Claim HighQuality
encontraron I-Claim HighQuality
beneficios I-Claim HighQuality
mínimos I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
CdV I-Claim HighQuality
a I-Claim HighQuality
corto I-Claim HighQuality
plazo I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
colon I-Claim HighQuality
en I-Claim HighQuality
comparación I-Claim HighQuality
con I-Claim HighQuality
la I-Claim HighQuality
colectomía I-Claim HighQuality
abierta I-Claim HighQuality
estándar. I-Claim HighQuality

Hasta B-Claim HighQuality
que I-Claim HighQuality
los I-Claim HighQuality
ensayos I-Claim HighQuality
en I-Claim HighQuality
curso I-Claim HighQuality
establezcan I-Claim HighQuality
que I-Claim HighQuality
la I-Claim HighQuality
LAC I-Claim HighQuality
es I-Claim HighQuality
tan I-Claim HighQuality
eficaz I-Claim HighQuality
como I-Claim HighQuality
la I-Claim HighQuality
colectomía I-Claim HighQuality
abierta I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
prevención I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
recurrencia I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
muerte I-Claim HighQuality
por I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
colon I-Claim HighQuality
, I-Claim HighQuality
este I-Claim HighQuality
procedimiento I-Claim HighQuality
no I-Claim HighQuality
debe I-Claim HighQuality
ofrecerse I-Claim HighQuality
a I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
colon I-Claim HighQuality
. I-Claim HighQuality

El B-Claim HighQuality
impacto I-Claim HighQuality
del I-Claim HighQuality
hipertiroidismo I-Claim HighQuality
subclínico I-Claim HighQuality
prolongado I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
no I-Claim HighQuality
está I-Claim HighQuality
claro. I-Claim HighQuality

Por O -
lo O -
tanto O -
, O -
se O -
evaluó O -
la O -
calidad O -
de O -
vida O -
en O -
pacientes O -
con O -
carcinoma O -
diferenciado O -
de O -
tiroides O -
( O -
DTC O -
) O -
en O -
la O -
terapia O -
de O -
tiroxina O -
supresora O -
de O -
TSH O -
como O -
un O -
modelo O -
para O -
el O -
hipertiroidismo O -
subclínico O -
y O -
se O -
investigó O -
si O -
la O -
restauración O -
al O -
eutiroidismo O -
afecta O -
a O -
la O -
calidad O -
de O -
vida O -
. O -

Se O -
realizó O -
un O -
ensayo O -
prospectivo, O -
a O -
ciegas, O -
controlado O -
con O -
placebo O -
y O -
aleatorizado O -
de O -
6 O -
meses O -
de O -
duración O -
con O -
dos O -
grupos O -
paralelos. O -

Veinticuatro O -
sujetos O -
con O -
antecedentes O -
de O -
carcinoma O -
diferenciado O -
de O -
tiroides O -
con O -
> O -
10 O -
años O -
de O -
tratamiento O -
supresor O -
de O -
la O -
TSH O -
con O -
L-tiroxina O -
completaron O -
el O -
estudio O -
. O -

La O -
dosis O -
de O -
L-tiroxina O -
se O -
sustituyó O -
por O -
la O -
medicación O -
del O -
estudio O -
que O -
contenía O -
L-tiroxina O -
o O -
L-tiroxina O -
más O -
placebo O -
. O -

La O -
medicación O -
se O -
tituló O -
para O -
establecer O -
la O -
continuación O -
de O -
la O -
supresión O -
de O -
la O -
TSH O -
(grupo O -
de O -
baja O -
TSH) O -
y O -
el O -
eutiroidismo O -
(grupo O -
eutiroideo). O -

Ambos O -
grupos O -
estaban O -
formados O -
por O -
12 O -
pacientes. O -

Se O -
evaluó O -
la O -
calidad O -
de O -
vida O -
mediante O -
cinco O -
cuestionarios O -
validados. O -

En O -
la O -
línea O -
de O -
base O -
, O -
el O -
cuestionario O -
de O -
trastornos O -
somáticos O -
( O -
SDQ O -
) O -
indicó O -
más O -
disfunción O -
somática O -
en O -
los O -
pacientes O -
en O -
comparación O -
con O -
los O -
valores O -
de O -
referencia O -
, O -
mientras O -
que O -
la O -
puntuación O -
de O -
la O -
depresión O -
( O -
HADS O -
) O -
reveló O -
una O -
mejor O -
puntuación O -
que O -
el O -
grupo O -
de O -
referencia O -
. O -

Todos O -
los O -
demás O -
parámetros O -
de O -
calidad O -
de O -
vida O -
eran O -
normales. O -

En O -
la O -
línea O -
de O -
base, O -
no O -
se O -
observaron O -
diferencias O -
significativas O -
entre O -
los O -
grupos O -
de O -
bajo O -
TSH O -
y O -
de O -
eutiroidismo. O -

Después B-Premise HighQuality
de I-Premise HighQuality
6 I-Premise HighQuality
meses, I-Premise HighQuality
ninguno I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
parámetros I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
baja I-Premise HighQuality
HTA I-Premise HighQuality
era I-Premise HighQuality
diferente I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
valores I-Premise HighQuality
iniciales. I-Premise HighQuality

En B-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
eutiroideo I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
motivación I-Premise HighQuality
mejoró I-Premise HighQuality
significativamente I-Premise HighQuality
( I-Premise HighQuality
Índice I-Premise HighQuality
de I-Premise HighQuality
Fatiga I-Premise HighQuality
Multidimensional-20 I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,003 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
aunque B-Premise HighQuality
este I-Premise HighQuality
parámetro I-Premise HighQuality
no I-Premise HighQuality
difirió I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
referencia I-Premise HighQuality
al I-Premise HighQuality
inicio I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
observó I-Premise HighQuality
un I-Premise HighQuality
probable I-Premise HighQuality
empeoramiento I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
limitaciones I-Premise HighQuality
de I-Premise HighQuality
rol I-Premise HighQuality
como I-Premise HighQuality
consecuencia I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
problemas I-Premise HighQuality
físicos I-Premise HighQuality
( I-Premise HighQuality
Short I-Premise HighQuality
Form-36 I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,050 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observó I-Premise HighQuality
ninguna I-Premise HighQuality
mejora I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
del I-Premise HighQuality
SDQ. I-Premise HighQuality

En B-Claim HighQuality
resumen, I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
DTC I-Claim HighQuality
y I-Claim HighQuality
con I-Claim HighQuality
hipertiroidismo I-Claim HighQuality
subclínico I-Claim HighQuality
de I-Claim HighQuality
larga I-Claim HighQuality
duración I-Claim HighQuality
en I-Claim HighQuality
general I-Claim HighQuality
está I-Claim HighQuality
preservada. I-Claim HighQuality

La B-Claim HighQuality
restauración I-Claim HighQuality
del I-Claim HighQuality
eutiroidismo I-Claim HighQuality
en I-Claim HighQuality
general I-Claim HighQuality
no I-Claim HighQuality
afecta I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
. I-Claim HighQuality

La O -
mayoría O -
de O -
los O -
pacientes O -
con O -
glioblastoma O -
son O -
mayores O -
de O -
60 O -
años, O -
pero O -
las O -
directrices O -
de O -
tratamiento O -
se O -
basan O -
en O -
ensayos O -
realizados O -
en O -
pacientes O -
de O -
hasta O -
70 O -
años. O -

Realizamos O -
un O -
ensayo O -
aleatorio O -
para O -
evaluar O -
el O -
tratamiento O -
paliativo O -
óptimo O -
en O -
pacientes O -
de O -
60 O -
años O -
o O -
más O -
con O -
glioblastoma O -
. O -

Se O -
reclutaron O -
pacientes O -
con O -
glioblastoma O -
recién O -
diagnosticado O -
en O -
Austria, O -
Dinamarca, O -
Francia, O -
Noruega, O -
Suecia, O -
Suiza O -
y O -
Turquía. O -

Fueron O -
asignados O -
mediante O -
un O -
programa O -
de O -
aleatorización O -
generado O -
por O -
ordenador O -
, O -
estratificado O -
por O -
centro O -
, O -
a O -
recibir O -
temozolomida O -
( O -
200 O -
mg/m O -
( O -
2 O -
) O -
en O -
los O -
días O -
1-5 O -
de O -
cada O -
28 O -
días O -
durante O -
un O -
máximo O -
de O -
seis O -
ciclos O -
) O -
, O -
radioterapia O -
hipofraccionada O -
( O -
34-0 O -
Gy O -
administrados O -
en O -
fracciones O -
de O -
3-4 O -
Gy O -
durante O -
2 O -
semanas O -
) O -
, O -
o O -
radioterapia O -
estándar O -
( O -
60-0 O -
Gy O -
administrados O -
en O -
fracciones O -
de O -
2-0 O -
Gy O -
durante O -
6 O -
semanas O -
) O -
. O -

Los O -
pacientes O -
y O -
el O -
personal O -
del O -
estudio O -
conocían O -
la O -
asignación O -
del O -
tratamiento. O -

El O -
criterio O -
de O -
valoración O -
principal O -
fue O -
la O -
supervivencia O -
global. O -

Los O -
análisis O -
se O -
realizaron O -
por O -
intención O -
de O -
tratar. O -

Este O -
ensayo O -
está O -
registrado O -
con O -
el O -
número O -
ISRCTN81470623. O -

Se O -
inscribieron O -
342 O -
pacientes, O -
de O -
los O -
cuales O -
291 O -
fueron O -
aleatorizados O -
en O -
tres O -
grupos O -
de O -
tratamiento O -
( O -
temozolomida O -
n=93 O -
, O -
radioterapia O -
hipofraccionada O -
n=98 O -
, O -
radioterapia O -
estándar O -
n=100 O -
) O -
y O -
51 O -
de O -
ellos O -
fueron O -
aleatorizados O -
en O -
sólo O -
dos O -
grupos O -
( O -
temozolomida O -
n=26 O -
, O -
radioterapia O -
hipofraccionada O -
n=25 O -
) O -
. O -

En B-Premise HighQuality
la I-Premise HighQuality
aleatorización I-Premise HighQuality
de I-Premise HighQuality
tres I-Premise HighQuality
grupos, I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
radioterapia I-Premise HighQuality
estándar, I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
fue I-Premise HighQuality
significativamente I-Premise HighQuality
mayor I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
temozolomida I-Premise HighQuality
( I-Premise HighQuality
8-3 I-Premise HighQuality
meses I-Premise HighQuality
[ I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
7-1-9-5 I-Premise HighQuality
; I-Premise HighQuality
n=93 I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
6-0 I-Premise HighQuality
meses I-Premise HighQuality
[ I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
5-1-6-8 I-Premise HighQuality
; I-Premise HighQuality
n=100 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
hazard I-Premise HighQuality
ratio I-Premise HighQuality
[ I-Premise HighQuality
HR I-Premise HighQuality
] I-Premise HighQuality
0-70 I-Premise HighQuality
; I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
0-52-0-93 I-Premise HighQuality
, I-Premise HighQuality
p=0-01 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
pero I-Premise HighQuality
no I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
radioterapia I-Premise HighQuality
hipofraccionada I-Premise HighQuality
( I-Premise HighQuality
7-5 I-Premise HighQuality
meses I-Premise HighQuality
[ I-Premise HighQuality
6-5-8-6 I-Premise HighQuality
; I-Premise HighQuality
n=98 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
HR I-Premise HighQuality
0-85 I-Premise HighQuality
[ I-Premise HighQuality
0-64-1-12 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
p=0-24 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Para B-Premise HighQuality
todos I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
temozolomida I-Premise HighQuality
o I-Premise HighQuality
radioterapia I-Premise HighQuality
hipofraccionada I-Premise HighQuality
( I-Premise HighQuality
n=242 I-Premise HighQuality
) I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
fue I-Premise HighQuality
similar I-Premise HighQuality
( I-Premise HighQuality
8-4 I-Premise HighQuality
meses I-Premise HighQuality
[ I-Premise HighQuality
7-3-9-4 I-Premise HighQuality
; I-Premise HighQuality
n=119 I-Premise HighQuality
] I-Premise HighQuality
vs I-Premise HighQuality
7-4 I-Premise HighQuality
meses I-Premise HighQuality
[ I-Premise HighQuality
6-4-8-4 I-Premise HighQuality
; I-Premise HighQuality
n=123 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
HR I-Premise HighQuality
0-82 I-Premise HighQuality
, I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
0-63-1-06 I-Premise HighQuality
; I-Premise HighQuality
p=0-12 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Para B-Premise HighQuality
los I-Premise HighQuality
mayores I-Premise HighQuality
de I-Premise HighQuality
70 I-Premise HighQuality
años, I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
fue I-Premise HighQuality
mejor I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
temozolomida I-Premise HighQuality
y I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
radioterapia I-Premise HighQuality
hipofraccionada I-Premise HighQuality
que I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
radioterapia I-Premise HighQuality
estándar I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
temozolomida I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
radioterapia I-Premise HighQuality
estándar I-Premise HighQuality
0-35 I-Premise HighQuality
[ I-Premise HighQuality
0-21-0-56 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0-0001 I-Premise HighQuality
; I-Premise HighQuality
HR I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
radioterapia I-Premise HighQuality
hipofraccionada I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
estándar I-Premise HighQuality
0-59 I-Premise HighQuality
[ I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
0-37-0-93 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
p=0-02 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
pacientes I-Premise HighQuality
tratados I-Premise HighQuality
con I-Premise HighQuality
temozolomida I-Premise HighQuality
que I-Premise HighQuality
tenían I-Premise HighQuality
metilación I-Premise HighQuality
del I-Premise HighQuality
promotor I-Premise HighQuality
de I-Premise HighQuality
MGMT I-Premise HighQuality
del I-Premise HighQuality
tumor I-Premise HighQuality
tuvieron I-Premise HighQuality
una I-Premise HighQuality
supervivencia I-Premise HighQuality
significativamente I-Premise HighQuality
mayor I-Premise HighQuality
que I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
no I-Premise HighQuality
tenían I-Premise HighQuality
metilación I-Premise HighQuality
del I-Premise HighQuality
promotor I-Premise HighQuality
de I-Premise HighQuality
MGMT I-Premise HighQuality
( I-Premise HighQuality
9-7 I-Premise HighQuality
meses I-Premise HighQuality
[ I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
8-0-11-4 I-Premise HighQuality
] I-Premise HighQuality
vs I-Premise HighQuality
6-8 I-Premise HighQuality
meses I-Premise HighQuality
[ I-Premise HighQuality
5-9-7-7 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
HR I-Premise HighQuality
0-56 I-Premise HighQuality
[ I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
0-34-0-93 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
p=0-02 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
pero I-Premise HighQuality
no I-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
diferencias I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
tenían I-Premise HighQuality
el I-Premise HighQuality
promotor I-Premise HighQuality
de I-Premise HighQuality
MGMT I-Premise HighQuality
metilado I-Premise HighQuality
y I-Premise HighQuality
no I-Premise HighQuality
metilado I-Premise HighQuality
tratados I-Premise HighQuality
con I-Premise HighQuality
radioterapia I-Premise HighQuality
( I-Premise HighQuality
HR I-Premise HighQuality
0-97 I-Premise HighQuality
[ I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
0-69-1-38 I-Premise HighQuality
] I-Premise HighQuality
; I-Premise HighQuality
p=0-81 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Como O -
era O -
de O -
esperar, O -
los B-Premise HighQuality
acontecimientos I-Premise HighQuality
adversos I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
3-4 I-Premise HighQuality
más I-Premise HighQuality
comunes I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
temozolomida I-Premise HighQuality
fueron I-Premise HighQuality
la I-Premise HighQuality
neutropenia I-Premise HighQuality
( I-Premise HighQuality
n=12 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
trombocitopenia I-Premise HighQuality
( I-Premise HighQuality
n=18 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
notificaron I-Premise HighQuality
infecciones I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
3-5 I-Premise HighQuality
en I-Premise HighQuality
todos I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
aleatorización I-Premise HighQuality
en I-Premise HighQuality
18 I-Premise HighQuality
pacientes I-Premise HighQuality
. I-Premise HighQuality

Dos B-Premise HighQuality
pacientes I-Premise HighQuality
tuvieron I-Premise HighQuality
infecciones I-Premise HighQuality
mortales I-Premise HighQuality
( I-Premise HighQuality
uno I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
temozolomida I-Premise HighQuality
y I-Premise HighQuality
otro I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
radioterapia I-Premise HighQuality
estándar I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
uno I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
temozolomida I-Premise HighQuality
con I-Premise HighQuality
trombocitopenia I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
2 I-Premise HighQuality
murió I-Premise HighQuality
por I-Premise HighQuality
complicaciones I-Premise HighQuality
después I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
cirugía I-Premise HighQuality
por I-Premise HighQuality
una I-Premise HighQuality
hemorragia I-Premise HighQuality
gastrointestinal I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
radioterapia I-Claim HighQuality
estándar I-Claim HighQuality
se I-Claim HighQuality
asoció I-Claim HighQuality
con I-Claim HighQuality
malos I-Claim HighQuality
resultados, I-Claim HighQuality
especialmente I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
mayores I-Claim HighQuality
de I-Claim HighQuality
70 I-Claim HighQuality
años. I-Claim HighQuality

Tanto B-Claim HighQuality
la I-Claim HighQuality
temozolomida I-Claim HighQuality
como I-Claim HighQuality
la I-Claim HighQuality
radioterapia I-Claim HighQuality
hipofraccionada I-Claim HighQuality
deben I-Claim HighQuality
considerarse I-Claim HighQuality
como I-Claim HighQuality
opciones I-Claim HighQuality
de I-Claim HighQuality
tratamiento I-Claim HighQuality
estándar I-Claim HighQuality
en I-Claim HighQuality
los I-Claim HighQuality
pacientes I-Claim HighQuality
ancianos I-Claim HighQuality
con I-Claim HighQuality
glioblastoma I-Claim HighQuality
. I-Claim HighQuality

El B-Claim HighQuality
estado I-Claim HighQuality
de I-Claim HighQuality
metilación I-Claim HighQuality
del I-Claim HighQuality
promotor I-Claim HighQuality
MGMT I-Claim HighQuality
podría I-Claim HighQuality
ser I-Claim HighQuality
un I-Claim HighQuality
marcador I-Claim HighQuality
predictivo I-Claim HighQuality
útil I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
beneficio I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
temozolomida I-Claim HighQuality
. I-Claim HighQuality

Evaluar O -
la O -
diferencia O -
de O -
eficacia, O -
efectos O -
secundarios O -
y O -
calidad O -
de O -
vida O -
en O -
pacientes O -
con O -
cáncer O -
de O -
pulmón O -
no O -
microcítico O -
avanzado O -
(CPNM) O -
tratados O -
con O -
oxaliplatino O -
más O -
vinorelbina O -
o O -
cisplatino O -
más O -
vinorelbina. O -

Los O -
pacientes O -
elegibles O -
fueron O -
asignados O -
aleatoriamente O -
al O -
grupo O -
NL O -
( O -
oxaliplatino O -
+ O -
vinorelbina O -
) O -
y O -
al O -
grupo O -
NP O -
( O -
cisplatino O -
+ O -
vinorelbina O -
) O -
en O -
una O -
proporción O -
de O -
2:1 O -
. O -

En O -
el O -
grupo O -
NL O -
, O -
70 O -
casos O -
evaluables O -
fueron O -
tratados O -
con O -
oxaliplatino O -
130 O -
mg/m O -
( O -
2 O -
) O -
i.v O -
. O -

el O -
día O -
2 O -
, O -
y O -
vinorelbina O -
25 O -
mg/m O -
( O -
2 O -
) O -
i.v O -
. O -

los O -
días O -
1 O -
y O -
8 O -
en O -
21 O -
días O -
por O -
ciclo O -
. O -

En O -
el O -
grupo O -
NP O -
, O -
32 O -
casos O -
evaluables O -
fueron O -
tratados O -
con O -
cisplatino O -
80 O -
mg/m O -
( O -
2 O -
) O -
i.v O -
. O -

dividido O -
a O -
2 O -
- O -
3 O -
días O -
de O -
dosificación O -
, O -
21 O -
días O -
por O -
ciclo O -
, O -
y O -
vinorelbina O -
administrada O -
por O -
la O -
misma O -
forma O -
que O -
en O -
el O -
grupo O -
NL O -
. O -

Se O -
observó O -
la O -
tasa O -
de O -
respuesta, O -
el O -
tiempo O -
hasta O -
la O -
progresión O -
(TTP), O -
la O -
supervivencia O -
a O -
un O -
año, O -
los O -
efectos O -
secundarios O -
y O -
la O -
calidad O -
de O -
vida. O -

La B-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
respuesta I-Premise HighQuality
fue I-Premise HighQuality
del I-Premise HighQuality
35,7 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
43,8 I-Premise HighQuality
% I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,4 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
mediana I-Premise HighQuality
del I-Premise HighQuality
TTP I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
4,7 I-Premise HighQuality
meses I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
5,5 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,6 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
a I-Premise HighQuality
un I-Premise HighQuality
año I-Premise HighQuality
fue I-Premise HighQuality
del I-Premise HighQuality
38,5 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
al I-Premise HighQuality
58,6 I-Premise HighQuality
% I-Premise HighQuality
( I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,07 I-Premise HighQuality
) I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
NL I-Premise HighQuality
y I-Premise HighQuality
NP I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
toxicidad I-Premise HighQuality
neurosensorial I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
I-II I-Premise HighQuality
fue I-Premise HighQuality
significativamente I-Premise HighQuality
más I-Premise HighQuality
frecuente I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
NL I-Premise HighQuality
que I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
NP I-Premise HighQuality
( I-Premise HighQuality
68,4 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
36,4 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,0017 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Sin B-Premise HighQuality
embargo, I-Premise HighQuality
la I-Premise HighQuality
granulocitopenia I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
I-II I-Premise HighQuality
fue I-Premise HighQuality
significativamente I-Premise HighQuality
menor I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
NL I-Premise HighQuality
que I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
NP I-Premise HighQuality
( I-Premise HighQuality
49,4 I-Premise HighQuality
% I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
70,6 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,037 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
estadísticas I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
dos I-Premise HighQuality
grupos I-Premise HighQuality
en I-Premise HighQuality
cuanto I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida. I-Premise HighQuality

Debido B-Claim HighQuality
a I-Claim HighQuality
su I-Claim HighQuality
buena I-Claim HighQuality
eficacia I-Claim HighQuality
y I-Claim HighQuality
tolerabilidad, I-Claim HighQuality
el I-Claim HighQuality
régimen I-Claim HighQuality
NL I-Claim HighQuality
ofreció I-Claim HighQuality
un I-Claim HighQuality
nuevo I-Claim HighQuality
candidato I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
del I-Claim HighQuality
CPNM I-Claim HighQuality
avanzado. I-Claim HighQuality

El O -
restablecimiento O -
de O -
la O -
inervación O -
sensorial O -
puede O -
ser O -
un O -
complemento O -
útil O -
en O -
la O -
reconstrucción O -
de O -
cabeza O -
y O -
cuello O -
con O -
colgajo O -
libre, O -
pero, O -
hasta O -
ahora, O -
no O -
se O -
ha O -
demostrado O -
que O -
mejore O -
los O -
resultados O -
de O -
la O -
reconstrucción O -
mamaria. O -

El O -
estudio O -
anterior O -
de O -
los O -
autores O -
demostró O -
una O -
mejora O -
objetiva O -
de O -
la O -
sensibilidad O -
en O -
un O -
grupo O -
de O -
pacientes O -
de O -
reconstrucción O -
mamaria O -
con O -
colgajo O -
musculocutáneo O -
del O -
recto O -
abdominal O -
transverso O -
(TRAM) O -
inervado O -
en O -
comparación O -
con O -
los O -
colgajos O -
no O -
inervados. O -

Este O -
estudio O -
comparó O -
los O -
resultados O -
calificados O -
por O -
las O -
pacientes O -
de O -
la O -
reconstrucción O -
mamaria O -
TRAM O -
libre O -
en O -
colgajos O -
inervados O -
versus O -
no O -
inervados O -
. O -

Veintisiete O -
mujeres O -
fueron O -
aleatorizadas O -
prospectivamente O -
para O -
someterse O -
a O -
una O -
reconstrucción O -
mamaria O -
con O -
colgajo O -
TRAM O -
libre O -
inervado O -
o O -
no O -
inervado O -
. O -

Para O -
los O -
colgajos O -
inervados, O -
el O -
nervio O -
intercostal O -
T10 O -
se O -
cosechó O -
con O -
el O -
colgajo O -
TRAM O -
y O -
se O -
neurotizó O -
al O -
nervio O -
sensorial O -
T4 O -
en O -
el O -
sitio O -
receptor. O -

Se O -
administraron O -
tres O -
herramientas O -
de O -
resultados O -
validadas O -
después O -
de O -
la O -
cirugía: O -
el O -
Medical O -
Outcomes O -
Study O -
36-Item O -
Short O -
Form O -
Health O -
Survey O -
, O -
el O -
Body O -
Image O -
after O -
Breast O -
Cancer O -
Questionnaire O -
y O -
el O -
Functional O -
Assessment O -
of O -
Cancer O -
Therapy-Breast O -
. O -

Los B-Premise HighQuality
resultados I-Premise HighQuality
se I-Premise HighQuality
correlacionaron I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
resultados I-Premise HighQuality
de I-Premise HighQuality
sensibilidad I-Premise HighQuality
objetiva I-Premise HighQuality
comunicados I-Premise HighQuality
anteriormente. I-Premise HighQuality

Dieciocho O -
de O -
27 O -
mujeres O -
devolvieron O -
sus O -
cuestionarios O -
una O -
media O -
de O -
48 O -
meses O -
después O -
de O -
la O -
reconstrucción O -
con O -
colgajo O -
TRAM O -
libre. O -

El O -
análisis O -
demográfico O -
no O -
reveló O -
diferencias O -
significativas O -
en O -
cuanto O -
a O -
la O -
edad O -
de O -
las O -
pacientes, O -
la O -
altura, O -
el O -
tabaquismo, O -
la O -
radioterapia O -
y O -
la O -
reconstrucción O -
del O -
complejo O -
areola-pezón O -
entre O -
los O -
grupos O -
de O -
pacientes O -
aleatorios. O -

Hubo B-Premise HighQuality
una I-Premise HighQuality
mejora I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativa I-Premise HighQuality
en I-Premise HighQuality
las I-Premise HighQuality
tres I-Premise HighQuality
medidas I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
fueron I-Premise HighQuality
aleatorizados I-Premise HighQuality
para I-Premise HighQuality
recibir I-Premise HighQuality
colgajos I-Premise HighQuality
TRAM I-Premise HighQuality
libres I-Premise HighQuality
inervados I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
los I-Premise HighQuality
que I-Premise HighQuality
recibieron I-Premise HighQuality
colgajos I-Premise HighQuality
no I-Premise HighQuality
inervados I-Premise HighQuality
. I-Premise HighQuality

Este B-Claim HighQuality
estudio I-Claim HighQuality
demuestra I-Claim HighQuality
que I-Claim HighQuality
la I-Claim HighQuality
inervación I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
colgajos I-Claim HighQuality
TRAM I-Claim HighQuality
libres I-Claim HighQuality
utilizados I-Claim HighQuality
para I-Claim HighQuality
la I-Claim HighQuality
reconstrucción I-Claim HighQuality
mamaria I-Claim HighQuality
no I-Claim HighQuality
sólo I-Claim HighQuality
mejora I-Claim HighQuality
la I-Claim HighQuality
sensibilidad, I-Claim HighQuality
sino I-Claim HighQuality
que I-Claim HighQuality
también I-Claim HighQuality
tiene I-Claim HighQuality
un I-Claim HighQuality
efecto I-Claim HighQuality
positivo I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
calificada I-Claim HighQuality
por I-Claim HighQuality
las I-Claim HighQuality
pacientes. I-Claim HighQuality

A O -
pesar O -
de O -
las O -
mejoras O -
en O -
las O -
técnicas O -
quirúrgicas O -
, O -
la O -
incontinencia O -
urinaria O -
( O -
IU O -
) O -
no O -
es O -
infrecuente O -
después O -
de O -
la O -
prostatectomía O -
radical O -
( O -
PR O -
) O -
, O -
y O -
puede O -
empeorar O -
dramáticamente O -
la O -
calidad O -
de O -
vida O -
( O -
QoL O -
) O -
. O -

Determinar O -
el O -
beneficio O -
de O -
comenzar O -
a O -
realizar O -
ejercicios O -
para O -
los O -
músculos O -
del O -
suelo O -
pélvico O -
( O -
PFME O -
) O -
30 O -
días O -
antes O -
de O -
la O -
RP O -
y O -
de O -
continuar O -
con O -
los O -
PFME O -
en O -
el O -
postoperatorio O -
para O -
la O -
recuperación O -
temprana O -
de O -
la O -
continencia O -
. O -

Se O -
diseñó O -
un O -
estudio O -
aleatorio O -
y O -
prospectivo. O -

Se O -
incluyeron O -
hombres O -
con O -
cáncer O -
de O -
próstata O -
localizado O -
( O -
PCa O -
) O -
que O -
se O -
sometieron O -
a O -
una O -
prostatectomía O -
radical O -
retropúbica O -
( O -
RRP O -
) O -
abierta O -
en O -
nuestro O -
departamento O -
de O -
urología O -
. O -

Los O -
pacientes O -
fueron O -
asignados O -
aleatoriamente O -
a O -
iniciar O -
la O -
EPF O -
antes O -
de O -
la O -
operación O -
y O -
a O -
continuar O -
en O -
el O -
postoperatorio O -
( O -
grupo O -
activo O -
: O -
A O -
) O -
o O -
a O -
iniciar O -
la O -
EPF O -
sólo O -
en O -
el O -
postoperatorio O -
( O -
grupo O -
de O -
control O -
: O -
B O -
) O -
. O -

La O -
medida O -
de O -
resultado O -
primaria O -
fue O -
la O -
continencia O -
autodeclarada O -
tras O -
la O -
cirugía. O -

Las O -
medidas O -
de O -
resultado O -
secundarias O -
fueron O -
evaluadas O -
por O -
el O -
grado O -
de O -
IU O -
basado O -
en O -
una O -
prueba O -
de O -
almohadillas O -
de O -
24 O -
horas O -
e O -
instrumentos O -
de O -
calidad O -
de O -
vida O -
( O -
Sociedad O -
Internacional O -
de O -
Continencia O -
[ O -
ICS O -
] O -
formulario O -
corto O -
masculino O -
[ O -
SF O -
] O -
) O -
. O -

De O -
los O -
143 O -
hombres O -
evaluados O -
para O -
el O -
estudio, O -
118 O -
fueron O -
asignados O -
aleatoriamente O -
a O -
iniciar O -
la O -
EMSP O -
antes O -
de O -
la O -
operación O -
y O -
continuar O -
después O -
de O -
la O -
misma O -
(grupo O -
A, O -
n=59) O -
o O -
a O -
iniciar O -
la O -
EMSP O -
después O -
de O -
la O -
operación O -
(grupo O -
B, O -
n=59). O -

Después B-Premise HighQuality
de I-Premise HighQuality
1 I-Premise HighQuality
mes, I-Premise HighQuality
el I-Premise HighQuality
44,1% I-Premise HighQuality
( I-Premise HighQuality
26 I-Premise HighQuality
de I-Premise HighQuality
59 I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
eran I-Premise HighQuality
continentes I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
A I-Premise HighQuality
, I-Premise HighQuality
mientras I-Premise HighQuality
que I-Premise HighQuality
el I-Premise HighQuality
20,3% I-Premise HighQuality
( I-Premise HighQuality
12 I-Premise HighQuality
de I-Premise HighQuality
59 I-Premise HighQuality
) I-Premise HighQuality
lo I-Premise HighQuality
eran I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
B I-Premise HighQuality
( I-Premise HighQuality
p=0,018 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

A B-Premise HighQuality
los I-Premise HighQuality
3 I-Premise HighQuality
meses, I-Premise HighQuality
el I-Premise HighQuality
59,3% I-Premise HighQuality
( I-Premise HighQuality
35 I-Premise HighQuality
de I-Premise HighQuality
59 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
37,3% I-Premise HighQuality
( I-Premise HighQuality
22 I-Premise HighQuality
de I-Premise HighQuality
59 I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
eran I-Premise HighQuality
continente I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
A I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
B I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
( I-Premise HighQuality
p=0,028 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
puntuación I-Premise HighQuality
media I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
SF I-Premise HighQuality
masculina I-Premise HighQuality
del I-Premise HighQuality
ICS I-Premise HighQuality
mostró I-Premise HighQuality
mejores I-Premise HighQuality
resultados I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
A I-Premise HighQuality
que I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
B I-Premise HighQuality
tanto I-Premise HighQuality
a I-Premise HighQuality
1 I-Premise HighQuality
mes I-Premise HighQuality
( I-Premise HighQuality
14,6 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
18,3 I-Premise HighQuality
) I-Premise HighQuality
como I-Premise HighQuality
a I-Premise HighQuality
3 I-Premise HighQuality
meses I-Premise HighQuality
( I-Premise HighQuality
8,1 I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
12,2 I-Premise HighQuality
) I-Premise HighQuality
después I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
RP I-Premise HighQuality
( I-Premise HighQuality
p=0,002 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

En B-Premise HighQuality
los I-Premise HighQuality
análisis I-Premise HighQuality
de I-Premise HighQuality
regresión I-Premise HighQuality
logística I-Premise HighQuality
ajustados I-Premise HighQuality
por I-Premise HighQuality
edad, I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
que I-Premise HighQuality
realizaron I-Premise HighQuality
una I-Premise HighQuality
PFME I-Premise HighQuality
preoperatoria I-Premise HighQuality
tenían I-Premise HighQuality
un I-Premise HighQuality
riesgo I-Premise HighQuality
0,41 I-Premise HighQuality
veces I-Premise HighQuality
menor I-Premise HighQuality
de I-Premise HighQuality
sufrir I-Premise HighQuality
incontinencia I-Premise HighQuality
un I-Premise HighQuality
mes I-Premise HighQuality
después I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
RP I-Premise HighQuality
y I-Premise HighQuality
un I-Premise HighQuality
riesgo I-Premise HighQuality
0,38 I-Premise HighQuality
veces I-Premise HighQuality
menor I-Premise HighQuality
de I-Premise HighQuality
sufrir I-Premise HighQuality
incontinencia I-Premise HighQuality
tres I-Premise HighQuality
meses I-Premise HighQuality
después I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
RP I-Premise HighQuality
( I-Premise HighQuality
p≤0,001 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

El B-Claim HighQuality
PFME I-Claim HighQuality
preoperatorio I-Claim HighQuality
puede I-Claim HighQuality
mejorar I-Claim HighQuality
la I-Claim HighQuality
continencia I-Claim HighQuality
temprana I-Claim HighQuality
y I-Claim HighQuality
los I-Claim HighQuality
resultados I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
después I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
RP I-Claim HighQuality
. I-Claim HighQuality

Se B-Claim HighQuality
necesitan I-Claim HighQuality
más I-Claim HighQuality
estudios I-Claim HighQuality
para I-Claim HighQuality
corroborar I-Claim HighQuality
nuestros I-Claim HighQuality
resultados. I-Claim HighQuality

El O -
papel O -
de O -
la O -
quimioterapia O -
en O -
pacientes O -
con O -
CPNM O -
avanzado O -
y O -
ECOG O -
PS2 O -
sigue O -
siendo O -
controvertido O -
. O -

Evaluamos O -
4 O -
dosis O -
de O -
docetaxel O -
de O -
3 O -
semanas O -
para O -
identificar O -
una O -
dosis O -
menos O -
tóxica O -
y O -
clínicamente O -
efectiva. O -

Setenta O -
y O -
tres O -
pacientes O -
con O -
CPNM O -
en O -
estadio O -
III O -
( O -
22 O -
% O -
) O -
( O -
no O -
aptos O -
para O -
cirugía/radioterapia O -
radical O -
) O -
y O -
IV O -
( O -
78 O -
% O -
) O -
fueron O -
asignados O -
al O -
azar O -
para O -
recibir O -
4 O -
dosis O -
de O -
docetaxel O -
cada O -
3 O -
semanas O -
, O -
durante O -
4 O -
ciclos O -
: O -
brazo O -
( O -
A O -
) O -
40 O -
mg/m O -
( O -
2 O -
) O -
( O -
n=17 O -
) O -
, O -
brazo O -
( O -
B O -
) O -
50 O -
mg/m O -
( O -
2 O -
) O -
( O -
n=17 O -
) O -
, O -
brazo O -
( O -
C O -
) O -
60 O -
mg/m O -
( O -
2 O -
) O -
( O -
n=19 O -
) O -
, O -
brazo O -
( O -
D O -
) O -
50 O -
mg/m O -
( O -
2 O -
) O -
escalados O -
en O -
10 O -
mg/m O -
( O -
2 O -
) O -
hasta O -
un O -
máximo O -
de O -
70 O -
mg/m O -
( O -
2 O -
) O -
( O -
n=19 O -
) O -
. O -

Criterios O -
de O -
valoración O -
primarios: O -
dosis O -
máxima O -
tolerada, O -
RR, O -
duración O -
de O -
la O -
respuesta, O -
mejora O -
de O -
los O -
síntomas, O -
toxicidad O -
y O -
calidad O -
de O -
vida. O -

Criterio O -
de O -
valoración O -
secundario: O -
supervivencia O -
global O -
(SG). O -

Las O -
características O -
de O -
los O -
pacientes O -
y O -
de O -
la O -
enfermedad O -
estaban O -
bien O -
equilibradas. O -

La O -
mediana O -
de O -
edad O -
era O -
de O -
67 O -
años O -
( O -
rango O -
45-81 O -
) O -
, O -
había O -
32 O -
hombres O -
y O -
41 O -
mujeres O -
, O -
subtipo O -
de O -
histología O -
: O -
escamoso/adenocarcinoma/mixto/NOS=42 O -
% O -
/49 O -
% O -
/4 O -
% O -
/5 O -
% O -
. O -

Siete O -
pacientes O -
no O -
recibieron O -
ningún O -
tratamiento O -
debido O -
al O -
deterioro O -
del O -
PS O -
o O -
a O -
la O -
muerte. O -

El O -
50 O -
% O -
de O -
los O -
pacientes O -
del O -
brazo O -
D O -
, O -
que O -
recibieron O -
más O -
de O -
un O -
ciclo, O -
recibieron O -
una O -
escalada O -
de O -
dosis O -
. O -

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
estadísticas I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
número I-Premise HighQuality
de I-Premise HighQuality
ciclos I-Premise HighQuality
administrados I-Premise HighQuality
( I-Premise HighQuality
brazos I-Premise HighQuality
A I-Premise HighQuality
, I-Premise HighQuality
B I-Premise HighQuality
y I-Premise HighQuality
D I-Premise HighQuality
: I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
2 I-Premise HighQuality
ciclos I-Premise HighQuality
y I-Premise HighQuality
brazo I-Premise HighQuality
C I-Premise HighQuality
: I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
3 I-Premise HighQuality
ciclos I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
no I-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
RR I-Premise HighQuality
: I-Premise HighQuality
brazo I-Premise HighQuality
A=6 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
brazo I-Premise HighQuality
B=6 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
brazo I-Premise HighQuality
C=10 I-Premise HighQuality
% I-Premise HighQuality
y I-Premise HighQuality
brazo I-Premise HighQuality
D=0 I-Premise HighQuality
% I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
neutropenia I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
trombocitopenia I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
3/4 I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
cuatro I-Premise HighQuality
brazos. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
tasa I-Premise HighQuality
de I-Premise HighQuality
hospitalización, I-Premise HighQuality
las I-Premise HighQuality
transfusiones I-Premise HighQuality
de I-Premise HighQuality
sangre, I-Premise HighQuality
la I-Premise HighQuality
administración I-Premise HighQuality
de I-Premise HighQuality
antibióticos I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
toxicidad I-Premise HighQuality
no I-Premise HighQuality
hematológica. I-Premise HighQuality

Calidad O -
de O -
vida: O -
no O -
hay O -
diferencias O -
en O -
las O -
puntuaciones O -
totales O -
entre O -
el O -
inicio O -
y O -
los O -
ciclos O -
1-4. O -

Hubo B-Premise HighQuality
una I-Premise HighQuality
disminución I-Premise HighQuality
significativa I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
puntuaciones I-Premise HighQuality
de I-Premise HighQuality
dolor I-Premise HighQuality
desde I-Premise HighQuality
la I-Premise HighQuality
línea I-Premise HighQuality
de I-Premise HighQuality
base I-Premise HighQuality
hasta I-Premise HighQuality
los I-Premise HighQuality
ciclos I-Premise HighQuality
2 I-Premise HighQuality
y I-Premise HighQuality
3 I-Premise HighQuality
( I-Premise HighQuality
p=0,025 I-Premise HighQuality
y I-Premise HighQuality
p=0,002 I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
SG I-Premise HighQuality
( I-Premise HighQuality
p=0,992 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
meses I-Premise HighQuality
fueron I-Premise HighQuality
de I-Premise HighQuality
61 I-Premise HighQuality
, I-Premise HighQuality
86 I-Premise HighQuality
, I-Premise HighQuality
88 I-Premise HighQuality
y I-Premise HighQuality
97 I-Premise HighQuality
días I-Premise HighQuality
y I-Premise HighQuality
del I-Premise HighQuality
29 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
33 I-Premise HighQuality
% I-Premise HighQuality
, I-Premise HighQuality
21 I-Premise HighQuality
% I-Premise HighQuality
y I-Premise HighQuality
26 I-Premise HighQuality
% I-Premise HighQuality
para I-Premise HighQuality
los I-Premise HighQuality
brazos I-Premise HighQuality
A I-Premise HighQuality
, I-Premise HighQuality
B I-Premise HighQuality
, I-Premise HighQuality
C I-Premise HighQuality
y I-Premise HighQuality
D I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
. I-Premise HighQuality

La B-Claim HighQuality
eficacia I-Claim HighQuality
clínica I-Claim HighQuality
del I-Claim HighQuality
docetaxel I-Claim HighQuality
se I-Claim HighQuality
observó I-Claim HighQuality
en I-Claim HighQuality
todos I-Claim HighQuality
los I-Claim HighQuality
niveles I-Claim HighQuality
de I-Claim HighQuality
dosis. I-Claim HighQuality

Los B-Claim HighQuality
niveles I-Claim HighQuality
de I-Claim HighQuality
dosis I-Claim HighQuality
más I-Claim HighQuality
altos I-Claim HighQuality
no I-Claim HighQuality
se I-Claim HighQuality
asociaron I-Claim HighQuality
a I-Claim HighQuality
un I-Claim HighQuality
aumento I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
toxicidades, I-Claim HighQuality
del I-Claim HighQuality
uso I-Claim HighQuality
de I-Claim HighQuality
antibióticos I-Claim HighQuality
intravenosos I-Claim HighQuality
o I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
tasas I-Claim HighQuality
de I-Claim HighQuality
hospitalización. I-Claim HighQuality

Sin O -
embargo, O -
la B-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
observada I-Premise HighQuality
es I-Premise HighQuality
más I-Premise HighQuality
corta I-Premise HighQuality
que I-Premise HighQuality
los I-Premise HighQuality
datos I-Premise HighQuality
históricos I-Premise HighQuality
y I-Premise HighQuality
no I-Premise HighQuality
apoyan I-Premise HighQuality
una I-Premise HighQuality
mayor I-Premise HighQuality
evaluación I-Premise HighQuality
de I-Premise HighQuality
estas I-Premise HighQuality
dosis I-Premise HighQuality
de I-Premise HighQuality
docetaxel I-Premise HighQuality
como I-Premise HighQuality
agente I-Premise HighQuality
único I-Premise HighQuality
en I-Premise HighQuality
esta I-Premise HighQuality
población. I-Premise HighQuality

Los O -
análogos O -
de O -
la O -
somatostatina O -
están O -
indicados O -
para O -
el O -
control O -
de O -
los O -
síntomas O -
en O -
pacientes O -
con O -
tumores O -
neuroendocrinos O -
gastroenteropancreáticos O -
( O -
NETs O -
) O -
. O -

La O -
capacidad O -
de O -
los O -
análogos O -
de O -
la O -
somatostatina O -
para O -
controlar O -
el O -
crecimiento O -
de O -
los O -
NETs O -
metastásicos O -
bien O -
diferenciados O -
es O -
objeto O -
de O -
debate. O -

Realizamos O -
un O -
estudio O -
de O -
fase O -
IIIB, O -
doble O -
ciego O -
y O -
controlado O -
con O -
placebo O -
en O -
pacientes O -
con O -
TNE O -
de O -
intestino O -
medio O -
bien O -
diferenciados. O -

La O -
hipótesis O -
era O -
que O -
la O -
octreotida O -
LAR O -
prolonga O -
el O -
tiempo O -
de O -
progresión O -
del O -
tumor O -
y O -
la O -
supervivencia. O -

Los O -
pacientes O -
sin O -
tratamiento O -
fueron O -
asignados O -
aleatoriamente O -
a O -
placebo O -
o O -
a O -
octreotida O -
LAR O -
30 O -
mg O -
por O -
vía O -
intramuscular O -
en O -
intervalos O -
mensuales O -
hasta O -
la O -
progresión O -
del O -
tumor O -
o O -
la O -
muerte. O -

El O -
criterio O -
de O -
valoración O -
primario O -
de O -
la O -
eficacia O -
fue O -
el O -
tiempo O -
hasta O -
la O -
progresión O -
del O -
tumor. O -

Los O -
criterios O -
de O -
valoración O -
secundarios O -
fueron O -
el O -
tiempo O -
de O -
supervivencia O -
y O -
la O -
respuesta O -
tumoral. O -

Este O -
informe O -
se O -
basa O -
en O -
67 O -
progresiones O -
tumorales O -
y O -
16 O -
muertes O -
observadas O -
en O -
85 O -
pacientes O -
en O -
el O -
momento O -
del O -
análisis O -
intermedio O -
previsto. O -

La B-Premise HighQuality
mediana I-Premise HighQuality
del I-Premise HighQuality
tiempo I-Premise HighQuality
hasta I-Premise HighQuality
la I-Premise HighQuality
progresión I-Premise HighQuality
del I-Premise HighQuality
tumor I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
octreotida I-Premise HighQuality
LAR I-Premise HighQuality
y I-Premise HighQuality
placebo I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
14,3 I-Premise HighQuality
y I-Premise HighQuality
6 I-Premise HighQuality
meses I-Premise HighQuality
, I-Premise HighQuality
respectivamente I-Premise HighQuality
( I-Premise HighQuality
hazard I-Premise HighQuality
ratio I-Premise HighQuality
[ I-Premise HighQuality
HR I-Premise HighQuality
] I-Premise HighQuality
= I-Premise HighQuality
0,34 I-Premise HighQuality
; I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,20 I-Premise HighQuality
a I-Premise HighQuality
0,59 I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
.000072 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Tras B-Premise HighQuality
6 I-Premise HighQuality
meses I-Premise HighQuality
de I-Premise HighQuality
tratamiento, I-Premise HighQuality
se I-Premise HighQuality
observó I-Premise HighQuality
una I-Premise HighQuality
enfermedad I-Premise HighQuality
estable I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
66,7% I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
octreotida I-Premise HighQuality
LAR I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
37,2% I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
del I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
placebo. I-Premise HighQuality

Los O -
tumores O -
funcionalmente O -
activos O -
e O -
inactivos O -
respondieron O -
de O -
forma O -
similar. O -

El B-Premise HighQuality
efecto I-Premise HighQuality
más I-Premise HighQuality
favorable I-Premise HighQuality
se I-Premise HighQuality
observó I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
con I-Premise HighQuality
baja I-Premise HighQuality
carga I-Premise HighQuality
tumoral I-Premise HighQuality
hepática I-Premise HighQuality
y I-Premise HighQuality
tumor I-Premise HighQuality
primario I-Premise HighQuality
resecado I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
observaron I-Premise HighQuality
siete I-Premise HighQuality
y I-Premise HighQuality
nueve I-Premise HighQuality
muertes I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
octreotida I-Premise HighQuality
LAR I-Premise HighQuality
y I-Premise HighQuality
placebo I-Premise HighQuality
, I-Premise HighQuality
respectivamente. I-Premise HighQuality

El B-Premise HighQuality
HR I-Premise HighQuality
para I-Premise HighQuality
la I-Premise HighQuality
supervivencia I-Premise HighQuality
global I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
0,81 I-Premise HighQuality
( I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
CI I-Premise HighQuality
, I-Premise HighQuality
0,30 I-Premise HighQuality
a I-Premise HighQuality
2,18 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Octreotide B-Claim HighQuality
LAR I-Claim HighQuality
alarga I-Claim HighQuality
significativamente I-Claim HighQuality
el I-Claim HighQuality
tiempo I-Claim HighQuality
hasta I-Claim HighQuality
la I-Claim HighQuality
progresión I-Claim HighQuality
del I-Claim HighQuality
tumor I-Claim HighQuality
en I-Claim HighQuality
comparación I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
placebo I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
NETs I-Claim HighQuality
de I-Claim HighQuality
intestino I-Claim HighQuality
medio I-Claim HighQuality
funcionalmente I-Claim HighQuality
activos I-Claim HighQuality
e I-Claim HighQuality
inactivos. I-Claim HighQuality

Debido B-Premise HighQuality
al I-Premise HighQuality
bajo I-Premise HighQuality
número I-Premise HighQuality
de I-Premise HighQuality
muertes I-Premise HighQuality
observadas, I-Premise HighQuality
el I-Premise HighQuality
análisis I-Premise HighQuality
de I-Premise HighQuality
supervivencia I-Premise HighQuality
no I-Premise HighQuality
fue I-Premise HighQuality
confirmatorio. I-Premise HighQuality

En B-Claim HighQuality
el I-Claim HighQuality
contexto I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
enfermedades I-Claim HighQuality
físicas I-Claim HighQuality
crónicas, I-Claim HighQuality
como I-Claim HighQuality
el I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
mama, I-Claim HighQuality
la I-Claim HighQuality
depresión I-Claim HighQuality
se I-Claim HighQuality
asocia I-Claim HighQuality
con I-Claim HighQuality
una I-Claim HighQuality
mayor I-Claim HighQuality
morbilidad, I-Claim HighQuality
períodos I-Claim HighQuality
más I-Claim HighQuality
largos I-Claim HighQuality
de I-Claim HighQuality
hospitalización I-Claim HighQuality
y I-Claim HighQuality
una I-Claim HighQuality
mayor I-Claim HighQuality
discapacidad I-Claim HighQuality
general. I-Claim HighQuality

Por B-Claim HighQuality
lo I-Claim HighQuality
tanto, I-Claim HighQuality
es I-Claim HighQuality
esencial I-Claim HighQuality
un I-Claim HighQuality
diagnóstico I-Claim HighQuality
rápido I-Claim HighQuality
y I-Claim HighQuality
un I-Claim HighQuality
tratamiento I-Claim HighQuality
eficaz. I-Claim HighQuality

Varios O -
estudios O -
pequeños O -
han O -
establecido O -
la O -
eficacia O -
de O -
los O -
antidepresivos O -
tricíclicos O -
( O -
ATC O -
) O -
en O -
este O -
contexto O -
, O -
y O -
los O -
inhibidores O -
selectivos O -
de O -
la O -
recaptación O -
de O -
serotonina O -
( O -
ISRS O -
) O -
parecen O -
ser O -
una O -
opción O -
terapéutica O -
alternativa O -
debido O -
a O -
su O -
eficacia O -
establecida O -
y O -
mejor O -
perfil O -
de O -
tolerabilidad O -
. O -

Se O -
trata O -
de O -
un O -
estudio O -
multicéntrico. O -

Estudio O -
doble O -
ciego O -
de O -
grupos O -
paralelos O -
en O -
el O -
que O -
179 O -
mujeres O -
con O -
cáncer O -
de O -
mama O -
fueron O -
asignadas O -
al O -
azar O -
a O -
un O -
tratamiento O -
con O -
el O -
ISRS O -
paroxetina O -
( O -
20-40 O -
mg/día O -
) O -
, O -
o O -
el O -
ATC O -
, O -
amitriptilina O -
( O -
75-150 O -
mg/día O -
) O -
. O -

Después B-Premise HighQuality
de I-Premise HighQuality
8 I-Premise HighQuality
semanas I-Premise HighQuality
de I-Premise HighQuality
tratamiento, I-Premise HighQuality
la I-Premise HighQuality
sintomatología I-Premise HighQuality
depresiva I-Premise HighQuality
había I-Premise HighQuality
mejorado I-Premise HighQuality
notablemente I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
un I-Premise HighQuality
grado I-Premise HighQuality
similar I-Premise HighQuality
en I-Premise HighQuality
ambos I-Premise HighQuality
grupos I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
Escala I-Premise HighQuality
de I-Premise HighQuality
Calificación I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
Depresión I-Premise HighQuality
de I-Premise HighQuality
Montgomery I-Premise HighQuality
Asberg. I-Premise HighQuality

Las B-Premise HighQuality
escalas I-Premise HighQuality
de I-Premise HighQuality
impresión I-Premise HighQuality
clínica I-Premise HighQuality
global I-Premise HighQuality
( I-Premise HighQuality
CGI I-Premise HighQuality
) I-Premise HighQuality
de I-Premise HighQuality
mejora I-Premise HighQuality
global I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
evaluación I-Premise HighQuality
global I-Premise HighQuality
del I-Premise HighQuality
paciente I-Premise HighQuality
indicaron I-Premise HighQuality
que I-Premise HighQuality
los I-Premise HighQuality
pacientes I-Premise HighQuality
mejoraron I-Premise HighQuality
de I-Premise HighQuality
forma I-Premise HighQuality
mínima I-Premise HighQuality
a I-Premise HighQuality
considerable I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
punto I-Premise HighQuality
final I-Premise HighQuality
del I-Premise HighQuality
estudio: I-Premise HighQuality
un I-Premise HighQuality
cambio I-Premise HighQuality
de I-Premise HighQuality
moderado/leve I-Premise HighQuality
a I-Premise HighQuality
límite I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
escala I-Premise HighQuality
de I-Premise HighQuality
gravedad I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
enfermedad I-Premise HighQuality
CGI I-Premise HighQuality
. I-Premise HighQuality

También B-Claim HighQuality
se I-Claim HighQuality
observó I-Claim HighQuality
una I-Claim HighQuality
mejora I-Claim HighQuality
constante I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
en I-Claim HighQuality
ambos I-Claim HighQuality
grupos. I-Claim HighQuality

No B-Premise HighQuality
hubo I-Premise HighQuality
diferencias I-Premise HighQuality
clínicamente I-Premise HighQuality
significativas I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
grupos. I-Premise HighQuality

En B-Premise HighQuality
total, I-Premise HighQuality
47 I-Premise HighQuality
( I-Premise HighQuality
53,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
pacientes I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
paroxetina I-Premise HighQuality
y I-Premise HighQuality
53 I-Premise HighQuality
( I-Premise HighQuality
59,6 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
pacientes I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
amitriptilina I-Premise HighQuality
tuvieron I-Premise HighQuality
experiencias I-Premise HighQuality
adversas, I-Premise HighQuality
las I-Premise HighQuality
más I-Premise HighQuality
comunes I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
cuales I-Premise HighQuality
fueron I-Premise HighQuality
los I-Premise HighQuality
efectos I-Premise HighQuality
secundarios I-Premise HighQuality
bien I-Premise HighQuality
conocidos I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
medicamentos I-Premise HighQuality
antidepresivos I-Premise HighQuality
o I-Premise HighQuality
la I-Premise HighQuality
quimioterapia I-Premise HighQuality
. I-Premise HighQuality

Los B-Premise HighQuality
efectos I-Premise HighQuality
anticolinérgicos I-Premise HighQuality
fueron I-Premise HighQuality
casi I-Premise HighQuality
dos I-Premise HighQuality
veces I-Premise HighQuality
más I-Premise HighQuality
frecuentes I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
amitriptilina I-Premise HighQuality
( I-Premise HighQuality
19,1 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
paroxetina I-Premise HighQuality
( I-Premise HighQuality
11,4 I-Premise HighQuality
% I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Este O -
estudio O -
ha O -
demostrado O -
que O -
la B-Claim HighQuality
paroxetina I-Claim HighQuality
es I-Claim HighQuality
una I-Claim HighQuality
alternativa I-Claim HighQuality
adecuada I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
amitriptilina I-Claim HighQuality
para I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
depresión I-Claim HighQuality
en I-Claim HighQuality
pacientes I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
mama I-Claim HighQuality
. I-Claim HighQuality

En O -
los O -
pacientes O -
con O -
cáncer O -
anorrectal, O -
un O -
efecto O -
secundario O -
agudo O -
de O -
la O -
quimiorradioterapia O -
es O -
la O -
toxicidad O -
gastrointestinal, O -
que O -
a O -
menudo O -
impide O -
la O -
administración O -
del O -
tratamiento. O -

Basándose O -
en O -
ensayos O -
anteriores, O -
el O -
acetato O -
de O -
octreotida O -
se O -
recomienda O -
ampliamente O -
para O -
el O -
control O -
de O -
la O -
diarrea O -
inducida O -
por O -
la O -
quimioterapia. O -

Sin O -
embargo, O -
se O -
desconoce O -
la O -
eficacia O -
de O -
la O -
octreotida O -
para O -
prevenir O -
o O -
controlar O -
la O -
diarrea O -
inducida O -
por O -
la O -
radiación O -
y O -
la O -
quimiorradiación. O -

Se O -
diseñó O -
un O -
ensayo O -
aleatorizado, O -
doble O -
ciego O -
y O -
controlado O -
con O -
placebo O -
para O -
determinar O -
la O -
eficacia O -
del O -
acetato O -
de O -
octreotida O -
de O -
acción O -
prolongada O -
( O -
LAO O -
) O -
en O -
la O -
prevención O -
de O -
la O -
aparición O -
de O -
diarrea O -
aguda O -
en O -
pacientes O -
sometidos O -
a O -
quimiorradioterapia O -
por O -
cáncer O -
rectal O -
o O -
anal O -
. O -

Entre O -
4 O -
y O -
7 O -
días O -
antes O -
del O -
inicio O -
de O -
la O -
radioterapia O -
, O -
los O -
pacientes O -
recibieron O -
una O -
dosis O -
de O -
30 O -
mg O -
de O -
LAO O -
( O -
109 O -
pacientes O -
) O -
o O -
de O -
placebo O -
( O -
106 O -
pacientes O -
) O -
mediante O -
inyección O -
intramuscular O -
. O -

Se O -
administró O -
una O -
segunda O -
dosis O -
el O -
día O -
22 O -
( O -
+/-3 O -
días O -
) O -
de O -
la O -
radioterapia O -
. O -

Un O -
total O -
de O -
215 O -
pacientes O -
fueron O -
incluidos O -
en O -
el O -
análisis O -
final. O -

El O -
criterio O -
de O -
valoración O -
primario O -
fue O -
la O -
incidencia O -
de O -
diarrea O -
aguda O -
de O -
grado O -
2-4; O -
los O -
criterios O -
de O -
valoración O -
secundarios O -
incluyeron O -
el O -
cumplimiento O -
del O -
tratamiento, O -
la O -
utilización O -
de O -
recursos O -
médicos, O -
la O -
función O -
intestinal O -
informada O -
por O -
el O -
paciente O -
y O -
la O -
calidad O -
de O -
vida O -
( O -
QoL O -
) O -
. O -

Las O -
pruebas O -
estadísticas O -
fueron O -
de O -
una O -
o O -
dos O -
caras, O -
según O -
se O -
especifique. O -

Tras B-Premise HighQuality
una I-Premise HighQuality
mediana I-Premise HighQuality
de I-Premise HighQuality
seguimiento I-Premise HighQuality
de I-Premise HighQuality
9,64 I-Premise HighQuality
meses, I-Premise HighQuality
las I-Premise HighQuality
tasas I-Premise HighQuality
de I-Premise HighQuality
incidencia I-Premise HighQuality
de I-Premise HighQuality
diarrea I-Premise HighQuality
aguda I-Premise HighQuality
de I-Premise HighQuality
grado I-Premise HighQuality
2-4 I-Premise HighQuality
fueron I-Premise HighQuality
similares I-Premise HighQuality
en I-Premise HighQuality
ambos I-Premise HighQuality
grupos I-Premise HighQuality
( I-Premise HighQuality
49 I-Premise HighQuality
% I-Premise HighQuality
de I-Premise HighQuality
placebo I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
44 I-Premise HighQuality
% I-Premise HighQuality
de I-Premise HighQuality
LAO I-Premise HighQuality
; I-Premise HighQuality
P I-Premise HighQuality
= I-Premise HighQuality
0,21 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
diferencias I-Premise HighQuality
de I-Premise HighQuality
tratamiento I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
administración I-Premise HighQuality
de I-Premise HighQuality
quimioterapia I-Premise HighQuality
o I-Premise HighQuality
radiación, I-Premise HighQuality
la I-Premise HighQuality
utilización I-Premise HighQuality
de I-Premise HighQuality
recursos I-Premise HighQuality
médicos, I-Premise HighQuality
la I-Premise HighQuality
función I-Premise HighQuality
intestinal I-Premise HighQuality
informada I-Premise HighQuality
por I-Premise HighQuality
el I-Premise HighQuality
paciente I-Premise HighQuality
o I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida. I-Premise HighQuality

En B-Claim HighQuality
este I-Claim HighQuality
estudio, I-Claim HighQuality
el I-Claim HighQuality
uso I-Claim HighQuality
profiláctico I-Claim HighQuality
de I-Claim HighQuality
LAO I-Claim HighQuality
no I-Claim HighQuality
previno I-Claim HighQuality
la I-Claim HighQuality
incidencia I-Claim HighQuality
ni I-Claim HighQuality
redujo I-Claim HighQuality
la I-Claim HighQuality
gravedad I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
diarrea I-Claim HighQuality
y I-Claim HighQuality
no I-Claim HighQuality
tuvo I-Claim HighQuality
un I-Claim HighQuality
impacto I-Claim HighQuality
notable I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
función I-Claim HighQuality
intestinal I-Claim HighQuality
o I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
informada I-Claim HighQuality
por I-Claim HighQuality
los I-Claim HighQuality
pacientes. I-Claim HighQuality

Una O -
proporción O -
significativa O -
de O -
pacientes O -
desarrolla O -
incontinencia O -
urinaria O -
al O -
principio O -
de O -
la O -
prostatectomía O -
radical. O -

Se O -
ha O -
comprobado O -
que O -
la O -
reconstrucción O -
posterior O -
de O -
los O -
tejidos O -
de O -
soporte O -
reduce O -
la O -
incontinencia O -
en O -
las O -
series O -
de O -
prostatectomía O -
laparoscópica O -
abierta O -
y O -
convencional O -
. O -

Investigar O -
si O -
nuestra O -
versión O -
de O -
una O -
reconstrucción O -
musculofascial O -
posterior O -
reducirá O -
la O -
incontinencia O -
precoz O -
y O -
tendrá O -
un O -
efecto O -
beneficioso O -
en O -
la O -
calidad O -
de O -
vida O -
( O -
QoL O -
) O -
de O -
las O -
pacientes. O -

Ciento O -
siete O -
pacientes O -
consecutivos O -
sometidos O -
a O -
prostatectomía O -
radical O -
laparoscópica O -
primaria O -
asistida O -
por O -
robot O -
( O -
RALP O -
) O -
realizada O -
por O -
un O -
único O -
cirujano O -
en O -
una O -
institución O -
oncológica O -
de O -
referencia O -
terciaria O -
fueron O -
asignados O -
alternativamente O -
( O -
no O -
aleatorizados O -
) O -
a O -
los O -
grupos O -
de O -
intervención O -
( O -
n=53 O -
) O -
o O -
de O -
control O -
( O -
n=54 O -
) O -
. O -

RALP O -
con O -
reconstrucción O -
del O -
rafe O -
fibroso O -
medio O -
( O -
MFRR O -
) O -
seguido O -
de O -
la O -
formación O -
de O -
la O -
anastomosis O -
uretrovesical O -
( O -
grupo O -
de O -
intervención O -
) O -
frente O -
a O -
la O -
anastomosis O -
estándar O -
sin O -
reconstrucción O -
posterior O -
( O -
grupo O -
de O -
control O -
) O -
. O -

Las O -
mediciones O -
incluyeron O -
la O -
incontinencia O -
al O -
inicio O -
y O -
a O -
intervalos O -
de O -
3 O -
meses; O -
la O -
calidad O -
de O -
vida O -
medida O -
por O -
un O -
cuestionario O -
simple, O -
el O -
cuestionario O -
de O -
la O -
Organización O -
Europea O -
para O -
la O -
Investigación O -
y O -
el O -
Tratamiento O -
del O -
Cáncer O -
( O -
EORTC O -
) O -
Quality O -
of O -
Life-Core O -
30 O -
( O -
QLQ-C30 O -
) O -
y O -
el O -
Módulo O -
de O -
Cáncer O -
de O -
Próstata O -
( O -
PR25 O -
) O -
antes O -
de O -
la O -
operación O -
y O -
a O -
los O -
6 O -
meses O -
después O -
del O -
procedimiento; O -
las O -
características O -
del O -
tumor; O -
el O -
tiempo O -
de O -
la O -
operación; O -
la O -
puntuación O -
de O -
preservación O -
de O -
la O -
fascia; O -
la O -
duración O -
del O -
sondaje; O -
y O -
la O -
fuga O -
anastomótica O -
en O -
el O -
cistograma. O -

Para B-Premise HighQuality
los I-Premise HighQuality
grupos I-Premise HighQuality
de I-Premise HighQuality
intervención I-Premise HighQuality
y I-Premise HighQuality
de I-Premise HighQuality
control, I-Premise HighQuality
respectivamente, I-Premise HighQuality
la I-Premise HighQuality
duración I-Premise HighQuality
media I-Premise HighQuality
del I-Premise HighQuality
catéter I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
11,74 I-Premise HighQuality
días I-Premise HighQuality
y I-Premise HighQuality
12,74 I-Premise HighQuality
días I-Premise HighQuality
( I-Premise HighQuality
p=0,451 I-Premise HighQuality
) I-Premise HighQuality
; I-Premise HighQuality
la I-Premise HighQuality
fuga I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
cistograma I-Premise HighQuality
estuvo I-Premise HighQuality
presente I-Premise HighQuality
en I-Premise HighQuality
seis I-Premise HighQuality
y I-Premise HighQuality
ocho I-Premise HighQuality
casos I-Premise HighQuality
( I-Premise HighQuality
p=0,28 I-Premise HighQuality
) I-Premise HighQuality
; I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
incontinencia I-Premise HighQuality
( I-Premise HighQuality
cualquier I-Premise HighQuality
pérdida I-Premise HighQuality
involuntaria I-Premise HighQuality
de I-Premise HighQuality
orina I-Premise HighQuality
) I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
3 I-Premise HighQuality
meses I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
75% I-Premise HighQuality
y I-Premise HighQuality
69% I-Premise HighQuality
( I-Premise HighQuality
p=0,391 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
meses I-Premise HighQuality
fue I-Premise HighQuality
de I-Premise HighQuality
51% I-Premise HighQuality
y I-Premise HighQuality
43% I-Premise HighQuality
( I-Premise HighQuality
p=0,686 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Sólo B-Premise HighQuality
se I-Premise HighQuality
produjo I-Premise HighQuality
retención I-Premise HighQuality
urinaria I-Premise HighQuality
en I-Premise HighQuality
un I-Premise HighQuality
caso I-Premise HighQuality
( I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
control I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

El B-Premise HighQuality
porcentaje I-Premise HighQuality
de I-Premise HighQuality
casos I-Premise HighQuality
que I-Premise HighQuality
volvieron I-Premise HighQuality
a I-Premise HighQuality
la I-Premise HighQuality
línea I-Premise HighQuality
de I-Premise HighQuality
base I-Premise HighQuality
en I-Premise HighQuality
todos I-Premise HighQuality
los I-Premise HighQuality
dominios I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
( I-Premise HighQuality
excepto I-Premise HighQuality
el I-Premise HighQuality
insomnio I-Premise HighQuality
) I-Premise HighQuality
fue I-Premise HighQuality
similar I-Premise HighQuality
a I-Premise HighQuality
los I-Premise HighQuality
6 I-Premise HighQuality
meses I-Premise HighQuality
entre I-Premise HighQuality
los I-Premise HighQuality
dos I-Premise HighQuality
grupos I-Premise HighQuality
. I-Premise HighQuality

Se B-Premise HighQuality
identificaron I-Premise HighQuality
como I-Premise HighQuality
limitaciones I-Premise HighQuality
significativas I-Premise HighQuality
el I-Premise HighQuality
corto I-Premise HighQuality
seguimiento, I-Premise HighQuality
la I-Premise HighQuality
falta I-Premise HighQuality
de I-Premise HighQuality
cegamiento I-Premise HighQuality
y I-Premise HighQuality
las I-Premise HighQuality
probables I-Premise HighQuality
pequeñas I-Premise HighQuality
diferencias I-Premise HighQuality
en I-Premise HighQuality
nuestro I-Premise HighQuality
método I-Premise HighQuality
de I-Premise HighQuality
MFRR I-Premise HighQuality
realizado I-Premise HighQuality
en I-Premise HighQuality
comparación I-Premise HighQuality
con I-Premise HighQuality
otros I-Premise HighQuality
estudios. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
observaron I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
ninguna I-Premise HighQuality
de I-Premise HighQuality
las I-Premise HighQuality
medidas I-Premise HighQuality
de I-Premise HighQuality
resultado I-Premise HighQuality
analizadas. I-Premise HighQuality

La B-Claim HighQuality
reconstrucción I-Claim HighQuality
posterior I-Claim HighQuality
del I-Claim HighQuality
complejo I-Claim HighQuality
musculofascial I-Claim HighQuality
no I-Claim HighQuality
parece I-Claim HighQuality
mejorar I-Claim HighQuality
la I-Claim HighQuality
incontinencia I-Claim HighQuality
urinaria I-Claim HighQuality
precoz I-Claim HighQuality
tras I-Claim HighQuality
la I-Claim HighQuality
RALP I-Claim HighQuality
. I-Claim HighQuality

En O -
el O -
ensayo O -
Gynecologic O -
Cancer O -
Intergroup O -
International O -
Collaboration O -
on O -
Ovarian O -
Neoplasms O -
7 O -
( O -
ICON7 O -
) O -
, O -
bevacizumab O -
mejoró O -
la O -
supervivencia O -
libre O -
de O -
progresión O -
en O -
pacientes O -
con O -
cáncer O -
de O -
ovario O -
cuando O -
se O -
utilizó O -
en O -
combinación O -
con O -
quimioterapia O -
de O -
primera O -
línea O -
y O -
como O -
tratamiento O -
de O -
continuación O -
con O -
un O -
solo O -
fármaco O -
durante O -
18 O -
ciclos O -
. O -

En O -
un O -
análisis O -
preliminar O -
de O -
un O -
subgrupo O -
de O -
pacientes O -
de O -
alto O -
riesgo O -
, O -
también O -
hubo O -
una O -
mejora O -
en O -
la O -
supervivencia O -
global O -
. O -

Este O -
estudio O -
tiene O -
como O -
objetivo O -
describir O -
los O -
resultados O -
de O -
la O -
calidad O -
de O -
vida O -
relacionada O -
con O -
la O -
salud O -
( O -
QoL O -
) O -
de O -
ICON7 O -
. O -

ICON7 O -
es O -
un O -
ensayo O -
aleatorio, O -
multicéntrico O -
y O -
abierto O -
de O -
fase O -
3. O -

Entre O -
el O -
18 O -
de O -
diciembre O -
de O -
2006 O -
y O -
el O -
16 O -
de O -
febrero O -
de O -
2009, O -
tras O -
una O -
intervención O -
quirúrgica O -
destinada O -
a O -
eliminar O -
la O -
enfermedad, O -
las O -
mujeres O -
con O -
cáncer O -
de O -
ovario O -
epitelial O -
en O -
estadio O -
I-IV O -
de O -
alto O -
riesgo O -
de O -
la O -
Federación O -
Internacional O -
de O -
Ginecología O -
y O -
Obstetricia O -
(FIGO) O -
fueron O -
asignadas O -
aleatoriamente O -
( O -
1:1 O -
) O -
por O -
programa O -
informático O -
y O -
aleatorización O -
en O -
bloque O -
a O -
recibir O -
seis O -
ciclos O -
de O -
quimioterapia O -
estándar O -
( O -
total O -
18 O -
semanas O -
) O -
con O -
carboplatino O -
( O -
área O -
bajo O -
la O -
curva O -
5 O -
o O -
6 O -
) O -
y O -
paclitaxel O -
( O -
175 O -
mg/m O -
( O -
2 O -
) O -
) O -
solo O -
o O -
con O -
bevacizumab O -
( O -
7-5 O -
mg/kg O -
) O -
administrado O -
por O -
vía O -
intravenosa O -
con O -
la O -
quimioterapia O -
y O -
continuado O -
como O -
fármaco O -
único O -
después O -
( O -
total O -
54 O -
semanas O -
) O -
. O -

El O -
criterio O -
de O -
valoración O -
primario O -
de O -
la O -
calidad O -
de O -
vida O -
fue O -
la O -
calidad O -
de O -
vida O -
global O -
del O -
cuestionario O -
de O -
calidad O -
de O -
vida O -
30 O -
de O -
la O -
Organización O -
Europea O -
para O -
la O -
Investigación O -
y O -
el O -
Tratamiento O -
del O -
Cáncer O -
en O -
la O -
semana O -
54, O -
analizada O -
mediante O -
ANOVA O -
y O -
ajustada O -
a O -
la O -
puntuación O -
inicial. O -

Los O -
análisis O -
fueron O -
por O -
intención O -
de O -
tratar. O -

El O -
ensayo O -
ICON7 O -
ha O -
completado O -
el O -
reclutamiento O -
y O -
sigue O -
en O -
seguimiento. O -

Este O -
estudio O -
está O -
registrado O -
con O -
el O -
número O -
ISRCTN91273375. O -

Se O -
asignaron O -
aleatoriamente O -
764 O -
mujeres O -
al O -
grupo O -
de O -
quimioterapia O -
estándar O -
y O -
764 O -
al O -
grupo O -
de O -
bevacizumab O -
. O -

Al O -
inicio O -
del O -
estudio, O -
684 O -
( O -
90% O -
) O -
de O -
las O -
mujeres O -
del O -
grupo O -
de O -
quimioterapia O -
estándar O -
y O -
691 O -
( O -
90% O -
) O -
de O -
las O -
del O -
grupo O -
de O -
bevacizumab O -
habían O -
completado O -
los O -
cuestionarios O -
de O -
calidad O -
de O -
vida. O -

En O -
la O -
semana O -
54, O -
502 O -
( O -
66 O -
% O -
) O -
mujeres O -
del O -
grupo O -
de O -
bevacizumab O -
y O -
388 O -
( O -
51 O -
% O -
) O -
mujeres O -
del O -
grupo O -
de O -
quimioterapia O -
estándar O -
proporcionaron O -
datos O -
de O -
calidad O -
de O -
vida O -
. O -

En B-Premise HighQuality
general, I-Premise HighQuality
la I-Premise HighQuality
puntuación I-Premise HighQuality
media I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
global I-Premise HighQuality
mejoró I-Premise HighQuality
durante I-Premise HighQuality
la I-Premise HighQuality
quimioterapia I-Premise HighQuality
en I-Premise HighQuality
7-2 I-Premise HighQuality
puntos I-Premise HighQuality
( I-Premise HighQuality
SD I-Premise HighQuality
24-4 I-Premise HighQuality
) I-Premise HighQuality
cuando I-Premise HighQuality
se I-Premise HighQuality
analizaron I-Premise HighQuality
todas I-Premise HighQuality
las I-Premise HighQuality
mujeres I-Premise HighQuality
con I-Premise HighQuality
datos I-Premise HighQuality
al I-Premise HighQuality
inicio I-Premise HighQuality
y I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
semana I-Premise HighQuality
18 I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
puntuación I-Premise HighQuality
media I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
global I-Premise HighQuality
a I-Premise HighQuality
las I-Premise HighQuality
54 I-Premise HighQuality
semanas I-Premise HighQuality
fue I-Premise HighQuality
mayor I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
quimioterapia I-Premise HighQuality
estándar I-Premise HighQuality
que I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
de I-Premise HighQuality
bevacizumab I-Premise HighQuality
( I-Premise HighQuality
76-1 I-Premise HighQuality
[ I-Premise HighQuality
SD I-Premise HighQuality
18-2 I-Premise HighQuality
] I-Premise HighQuality
frente I-Premise HighQuality
a I-Premise HighQuality
69-7 I-Premise HighQuality
[ I-Premise HighQuality
19-1 I-Premise HighQuality
] I-Premise HighQuality
puntos I-Premise HighQuality
; I-Premise HighQuality
diferencia I-Premise HighQuality
6-4 I-Premise HighQuality
puntos I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
3-7-9-0 I-Premise HighQuality
, I-Premise HighQuality
p I-Premise HighQuality
< I-Premise HighQuality
0-0001 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

El B-Claim HighQuality
tratamiento I-Claim HighQuality
de I-Claim HighQuality
continuación I-Claim HighQuality
con I-Claim HighQuality
bevacizumab I-Claim HighQuality
parece I-Claim HighQuality
estar I-Claim HighQuality
asociado I-Claim HighQuality
a I-Claim HighQuality
una I-Claim HighQuality
disminución I-Claim HighQuality
pequeña I-Claim HighQuality
pero I-Claim HighQuality
clínicamente I-Claim HighQuality
significativa I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
CdV I-Claim HighQuality
en I-Claim HighQuality
comparación I-Claim HighQuality
con I-Claim HighQuality
el I-Claim HighQuality
tratamiento I-Claim HighQuality
estándar I-Claim HighQuality
para I-Claim HighQuality
las I-Claim HighQuality
mujeres I-Claim HighQuality
con I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
ovario I-Claim HighQuality
. I-Claim HighQuality

La O -
compensación O -
entre O -
la O -
prolongación O -
de O -
la O -
supervivencia O -
libre O -
de O -
progresión O -
y O -
la O -
calidad O -
de O -
ese O -
periodo O -
de O -
tiempo O -
debe O -
tenerse O -
en O -
cuenta O -
en O -
la O -
práctica O -
clínica O -
a O -
la O -
hora O -
de O -
tomar O -
decisiones O -
de O -
tratamiento O -
. O -

Se O -
examinaron O -
los O -
mecanismos O -
de O -
mediación O -
de O -
una O -
intervención O -
de O -
ejercicio O -
en O -
grupo O -
de O -
12 O -
semanas O -
sobre O -
la O -
calidad O -
de O -
vida O -
( O -
QoL O -
) O -
de O -
los O -
supervivientes O -
de O -
cáncer O -
para O -
informar O -
sobre O -
el O -
desarrollo O -
de O -
futuras O -
intervenciones O -
de O -
ejercicio. O -

Doscientos O -
nueve O -
supervivientes O -
de O -
cáncer O -
≥ O -
3 O -
meses O -
después O -
del O -
tratamiento O -
( O -
57 O -
% O -
cáncer O -
de O -
mama O -
) O -
de O -
49,5 O -
( O -
± O -
10,4 O -
) O -
años O -
de O -
edad O -
fueron O -
asignados O -
a O -
ejercicio O -
físico O -
( O -
n O -
= O -
147 O -
) O -
o O -
a O -
control O -
en O -
lista O -
de O -
espera O -
( O -
n O -
= O -
62 O -
) O -
. O -

La O -
calidad O -
de O -
vida, O -
la O -
fatiga, O -
el O -
malestar O -
emocional, O -
la O -
actividad O -
física, O -
la O -
autoeficacia O -
general O -
y O -
el O -
dominio O -
se O -
evaluaron O -
al O -
inicio O -
y O -
después O -
de O -
la O -
intervención O -
mediante O -
cuestionarios. O -

Se O -
llevó O -
a O -
cabo O -
un O -
análisis O -
de O -
trayectorias O -
utilizando O -
Mplus O -
para O -
explorar O -
si O -
la O -
mejora O -
de O -
la O -
actividad O -
física, O -
la O -
autoeficacia O -
general O -
y O -
el O -
dominio O -
mediaban O -
los O -
efectos O -
del O -
ejercicio O -
sobre O -
la O -
fatiga O -
y O -
la O -
angustia O -
y, O -
en O -
consecuencia, O -
la O -
calidad O -
de O -
vida. O -

La B-Premise HighQuality
intervención I-Premise HighQuality
se I-Premise HighQuality
asoció I-Premise HighQuality
con I-Premise HighQuality
un I-Premise HighQuality
aumento I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
actividad I-Premise HighQuality
física I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
0,46 I-Premise HighQuality
, I-Premise HighQuality
intervalo I-Premise HighQuality
de I-Premise HighQuality
confianza I-Premise HighQuality
( I-Premise HighQuality
IC I-Premise HighQuality
) I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
0,14 I-Premise HighQuality
; I-Premise HighQuality
0,59 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
autoeficacia I-Premise HighQuality
general I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
2,41 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
0,35 I-Premise HighQuality
; I-Premise HighQuality
4,73 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
dominio I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
1,75 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
0,36 I-Premise HighQuality
; I-Premise HighQuality
2,78 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Además O -
, O -
la B-Premise HighQuality
intervención I-Premise HighQuality
tuvo I-Premise HighQuality
tanto I-Premise HighQuality
un I-Premise HighQuality
efecto I-Premise HighQuality
directo I-Premise HighQuality
sobre I-Premise HighQuality
la I-Premise HighQuality
fatiga I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-1,09 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
-2,12 I-Premise HighQuality
; I-Premise HighQuality
0,01 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
como I-Premise HighQuality
un I-Premise HighQuality
efecto I-Premise HighQuality
indirecto I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-0,54 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
-1,00 I-Premise HighQuality
; I-Premise HighQuality
-0,21 I-Premise HighQuality
) I-Premise HighQuality
a I-Premise HighQuality
través I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
actividad I-Premise HighQuality
física I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-0,29 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
-0,64 I-Premise HighQuality
; I-Premise HighQuality
-0,07 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
autoeficacia I-Premise HighQuality
general I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-0,25 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
-0,61 I-Premise HighQuality
; I-Premise HighQuality
-0,05 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

La B-Premise HighQuality
intervención I-Premise HighQuality
tuvo I-Premise HighQuality
un I-Premise HighQuality
efecto I-Premise HighQuality
directo I-Premise HighQuality
casi I-Premise HighQuality
significativo I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
reducción I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
angustia I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-1,32 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
-2,68 I-Premise HighQuality
; I-Premise HighQuality
0,11 I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
y I-Premise HighQuality
un I-Premise HighQuality
efecto I-Premise HighQuality
indirecto I-Premise HighQuality
significativo I-Premise HighQuality
a I-Premise HighQuality
través I-Premise HighQuality
del I-Premise HighQuality
aumento I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
autoeficacia I-Premise HighQuality
general I-Premise HighQuality
y I-Premise HighQuality
el I-Premise HighQuality
dominio I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-1,06 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
-1,89 I-Premise HighQuality
; I-Premise HighQuality
-0,38 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

Las B-Premise HighQuality
reducciones I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
fatiga I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-1,33 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
=-1,85 I-Premise HighQuality
; I-Premise HighQuality
-0,83 I-Premise HighQuality
) I-Premise HighQuality
y I-Premise HighQuality
la I-Premise HighQuality
angustia I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
-0,86 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
-1,25 I-Premise HighQuality
; I-Premise HighQuality
-0,52 I-Premise HighQuality
) I-Premise HighQuality
se I-Premise HighQuality
asociaron I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
mejora I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
. I-Premise HighQuality

Además O -
, O -
el B-Premise HighQuality
aumento I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
actividad I-Premise HighQuality
física I-Premise HighQuality
se I-Premise HighQuality
asoció I-Premise HighQuality
directamente I-Premise HighQuality
con I-Premise HighQuality
la I-Premise HighQuality
mejora I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
CdV I-Premise HighQuality
( I-Premise HighQuality
β I-Premise HighQuality
= I-Premise HighQuality
3,37 I-Premise HighQuality
, I-Premise HighQuality
IC I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
= I-Premise HighQuality
1,01 I-Premise HighQuality
; I-Premise HighQuality
5,54 I-Premise HighQuality
) I-Premise HighQuality
. I-Premise HighQuality

El B-Claim HighQuality
efecto I-Claim HighQuality
beneficioso I-Claim HighQuality
del I-Claim HighQuality
ejercicio I-Claim HighQuality
físico I-Claim HighQuality
en I-Claim HighQuality
grupo I-Claim HighQuality
sobre I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
estuvo I-Claim HighQuality
mediado I-Claim HighQuality
por I-Claim HighQuality
el I-Claim HighQuality
aumento I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
actividad I-Claim HighQuality
física, I-Claim HighQuality
la I-Claim HighQuality
autoeficacia I-Claim HighQuality
general I-Claim HighQuality
y I-Claim HighQuality
el I-Claim HighQuality
dominio, I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
consiguiente I-Claim HighQuality
reducción I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
fatiga I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
angustia. I-Claim HighQuality

Además B-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
actividad I-Claim HighQuality
física, I-Claim HighQuality
las I-Claim HighQuality
futuras I-Claim HighQuality
intervenciones I-Claim HighQuality
deberían I-Claim HighQuality
centrarse I-Claim HighQuality
en I-Claim HighQuality
la I-Claim HighQuality
autoeficacia I-Claim HighQuality
y I-Claim HighQuality
el I-Claim HighQuality
dominio. I-Claim HighQuality

Esto B-Claim HighQuality
puede I-Claim HighQuality
conducir I-Claim HighQuality
a I-Claim HighQuality
la I-Claim HighQuality
reducción I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
angustia I-Claim HighQuality
y I-Claim HighQuality
la I-Claim HighQuality
fatiga I-Claim HighQuality
, I-Claim HighQuality
y I-Claim HighQuality
por I-Claim HighQuality
lo I-Claim HighQuality
tanto I-Claim HighQuality
la I-Claim HighQuality
mejora I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
de I-Claim HighQuality
los I-Claim HighQuality
sobrevivientes I-Claim HighQuality
de I-Claim HighQuality
cáncer I-Claim HighQuality
. I-Claim HighQuality

Evaluar O -
si O -
la O -
omisión O -
de O -
la O -
radioterapia O -
( O -
RT O -
) O -
postoperatoria O -
en O -
mujeres O -
con O -
cáncer O -
de O -
mama O -
de O -
"bajo O -
riesgo" O -
con O -
ganglios O -
axilares O -
negativos O -
[ O -
tamaño O -
del O -
tumor O -
inferior O -
a O -
5 O -
cm O -
( O -
T0-2 O -
) O -
aunque O -
los O -
criterios O -
de O -
elegibilidad O -
reducen O -
aún O -
más O -
el O -
tamaño O -
elegible O -
a O -
un O -
máximo O -
de O -
3 O -
cm O -
] O -
tratadas O -
mediante O -
cirugía O -
conservadora O -
de O -
la O -
mama O -
y O -
terapia O -
endocrina O -
mejora O -
la O -
calidad O -
de O -
vida O -
y O -
es O -
más O -
rentable O -
. O -

Se O -
realizó O -
un O -
ensayo O -
clínico O -
controlado O -
y O -
aleatorizado, O -
utilizando O -
un O -
método O -
de O -
minimización O -
equilibrado O -
por O -
centro, O -
grado O -
de O -
cáncer, O -
edad, O -
invasión O -
linfovascular O -
y O -
terapia O -
endocrina O -
preoperatoria. O -

Clínicas O -
de O -
cáncer O -
de O -
mama O -
en O -
centros O -
oncológicos O -
del O -
Reino O -
Unido O -
. O -

Las O -
pacientes O -
de O -
edad O -
≥ O -
65 O -
años O -
fueron O -
elegibles O -
siempre O -
que O -
sus O -
cánceres O -
de O -
mama O -
se O -
consideraran O -
de O -
bajo O -
riesgo O -
de O -
recurrencia O -
local O -
, O -
fueran O -
adecuadas O -
para O -
la O -
cirugía O -
de O -
conservación O -
de O -
la O -
mama O -
, O -
estuvieran O -
recibiendo O -
terapia O -
endocrina O -
y O -
estuvieran O -
dispuestas O -
y O -
fueran O -
capaces O -
de O -
dar O -
su O -
consentimiento O -
informado O -
. O -

El O -
tratamiento O -
estándar O -
de O -
la O -
irradiación O -
mamaria O -
completa O -
postoperatoria O -
o O -
la O -
omisión O -
de O -
la O -
RT O -
. O -

La O -
calidad O -
de O -
vida O -
fue O -
la O -
principal O -
medida O -
de O -
resultado, O -
junto O -
con O -
la O -
ansiedad O -
y O -
la O -
depresión O -
y O -
la O -
rentabilidad. O -

Las O -
medidas O -
de O -
resultado O -
secundarias O -
fueron O -
las O -
tasas O -
de O -
recidiva O -
y O -
supervivencia O -
, O -
y O -
la O -
morbilidad O -
relacionada O -
con O -
el O -
tratamiento O -
. O -

El O -
método O -
principal O -
de O -
recogida O -
de O -
datos O -
fue O -
un O -
cuestionario, O -
completado O -
en O -
casa O -
con O -
una O -
enfermera O -
de O -
investigación O -
en O -
cuatro O -
ocasiones O -
durante O -
15 O -
meses, O -
y O -
luego O -
por O -
cuestionario O -
postal O -
a O -
los O -
3 O -
y O -
5 O -
años O -
después O -
de O -
la O -
cirugía. O -

La O -
hipotética O -
mejora O -
de O -
la O -
calidad O -
de O -
vida O -
global O -
con O -
la O -
omisión O -
de O -
la O -
RT O -
no O -
se O -
observó O -
en O -
los O -
dominios O -
de O -
resumen O -
de O -
las O -
escalas O -
de O -
la O -
Organización O -
Europea O -
para O -
la O -
Investigación O -
en O -
el O -
Tratamiento O -
del O -
Cáncer O -
( O -
EORTC O -
) O -
. O -

Se O -
observaron O -
algunas O -
diferencias O -
dentro O -
de O -
las O -
subescalas O -
de O -
los O -
cuestionarios O -
de O -
la O -
EORTC O -
, O -
y O -
los O -
datos O -
cualitativos O -
obtenidos O -
mediante O -
preguntas O -
abiertas O -
añadidas O -
por O -
el O -
equipo O -
del O -
ensayo O -
también O -
aportaron O -
información O -
sobre O -
el O -
impacto O -
del O -
tratamiento. O -

Las O -
diferencias O -
fueron O -
más O -
evidentes O -
poco O -
después O -
de O -
la O -
hora O -
de O -
finalización O -
de O -
la O -
RT O -
. O -

La B-Premise HighQuality
RT I-Premise HighQuality
se I-Premise HighQuality
asoció I-Premise HighQuality
entonces I-Premise HighQuality
con I-Premise HighQuality
un I-Premise HighQuality
aumento I-Premise HighQuality
de I-Premise HighQuality
los I-Premise HighQuality
síntomas I-Premise HighQuality
mamarios I-Premise HighQuality
y I-Premise HighQuality
con I-Premise HighQuality
una I-Premise HighQuality
mayor I-Premise HighQuality
fatiga I-Premise HighQuality
( I-Premise HighQuality
autodeclarada I-Premise HighQuality
) I-Premise HighQuality
, I-Premise HighQuality
pero I-Premise HighQuality
con I-Premise HighQuality
menores I-Premise HighQuality
niveles I-Premise HighQuality
de I-Premise HighQuality
insomnio I-Premise HighQuality
y I-Premise HighQuality
efectos I-Premise HighQuality
secundarios I-Premise HighQuality
endocrinos I-Premise HighQuality
. I-Premise HighQuality

Estas B-Premise HighQuality
diferencias I-Premise HighQuality
estadísticamente I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
los I-Premise HighQuality
síntomas I-Premise HighQuality
mamarios I-Premise HighQuality
persistieron I-Premise HighQuality
hasta I-Premise HighQuality
5 I-Premise HighQuality
años I-Premise HighQuality
después I-Premise HighQuality
de I-Premise HighQuality
la I-Premise HighQuality
RT I-Premise HighQuality
[la I-Premise HighQuality
diferencia I-Premise HighQuality
media I-Premise HighQuality
, I-Premise HighQuality
la I-Premise HighQuality
RT I-Premise HighQuality
fue I-Premise HighQuality
5,27 I-Premise HighQuality
unidades I-Premise HighQuality
mayor I-Premise HighQuality
que I-Premise HighQuality
la I-Premise HighQuality
no I-Premise HighQuality
RT I-Premise HighQuality
, I-Premise HighQuality
intervalo I-Premise HighQuality
de I-Premise HighQuality
confianza I-Premise HighQuality
( I-Premise HighQuality
IC I-Premise HighQuality
) I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
% I-Premise HighQuality
de I-Premise HighQuality
1,46 I-Premise HighQuality
a I-Premise HighQuality
9,07 I-Premise HighQuality
] I-Premise HighQuality
, I-Premise HighQuality
con I-Premise HighQuality
tendencias I-Premise HighQuality
similares I-Premise HighQuality
, I-Premise HighQuality
aunque I-Premise HighQuality
no I-Premise HighQuality
significativas I-Premise HighQuality
, I-Premise HighQuality
en I-Premise HighQuality
el I-Premise HighQuality
insomnio I-Premise HighQuality
. I-Premise HighQuality

No B-Premise HighQuality
se I-Premise HighQuality
encontraron I-Premise HighQuality
diferencias I-Premise HighQuality
significativas I-Premise HighQuality
en I-Premise HighQuality
la I-Premise HighQuality
medida I-Premise HighQuality
global I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida, I-Premise HighQuality
ya I-Premise HighQuality
que I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
sin I-Premise HighQuality
RT I-Premise HighQuality
tenía I-Premise HighQuality
0,36 I-Premise HighQuality
unidades I-Premise HighQuality
más I-Premise HighQuality
de I-Premise HighQuality
calidad I-Premise HighQuality
de I-Premise HighQuality
vida I-Premise HighQuality
que I-Premise HighQuality
el I-Premise HighQuality
grupo I-Premise HighQuality
con I-Premise HighQuality
RT I-Premise HighQuality
(IC I-Premise HighQuality
del I-Premise HighQuality
95 I-Premise HighQuality
%: I-Premise HighQuality
-5,09 I-Premise HighQuality
a I-Premise HighQuality
5,81). I-Premise HighQuality

La B-Claim HighQuality
RT I-Claim HighQuality
de I-Claim HighQuality
mama I-Claim HighQuality
es I-Claim HighQuality
bien I-Claim HighQuality
tolerada I-Claim HighQuality
por I-Claim HighQuality
la I-Claim HighQuality
mayoría I-Claim HighQuality
de I-Claim HighQuality
las I-Claim HighQuality
pacientes I-Claim HighQuality
de I-Claim HighQuality
cáncer I-Claim HighQuality
de I-Claim HighQuality
mama I-Claim HighQuality
de I-Claim HighQuality
edad I-Claim HighQuality
avanzada I-Claim HighQuality
sin I-Claim HighQuality
perjudicar I-Claim HighQuality
su I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
general I-Claim HighQuality
relacionada I-Claim HighQuality
con I-Claim HighQuality
la I-Claim HighQuality
salud I-Claim HighQuality
( I-Claim HighQuality
HRQoL I-Claim HighQuality
) I-Claim HighQuality
. I-Claim HighQuality

Aunque O -
la O -
CVRS O -
debe O -
tenerse O -
siempre O -
en O -
cuenta O -
a O -
la O -
hora O -
de O -
determinar O -
el O -
tratamiento, O -
nuestros B-Claim HighQuality
resultados I-Claim HighQuality
muestran I-Claim HighQuality
que I-Claim HighQuality
la I-Claim HighQuality
adición I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
RT I-Claim HighQuality
no I-Claim HighQuality
perjudica I-Claim HighQuality
la I-Claim HighQuality
calidad I-Claim HighQuality
de I-Claim HighQuality
vida I-Claim HighQuality
en I-Claim HighQuality
general. I-Claim HighQuality

Es B-Claim HighQuality
necesario I-Claim HighQuality
elaborar I-Claim HighQuality
más I-Claim HighQuality
modelos I-Claim HighQuality
económicos I-Claim HighQuality
sobre I-Claim HighQuality
los I-Claim HighQuality
costes I-Claim HighQuality
y I-Claim HighQuality
las I-Claim HighQuality
consecuencias I-Claim HighQuality
a I-Claim HighQuality
largo I-Claim HighQuality
plazo I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
omisión I-Claim HighQuality
de I-Claim HighQuality
la I-Claim HighQuality
RT. I-Claim HighQuality

